ESCMID Global 2025 - Programme

Friday, 11 April 2025 Challenges in identification and relevance of slow-growing pathogens

Chairs Kerrie Davies (Leeds, United Kingdom)
Yann Dumont (Nancy, France)

SP1
08:30 - 10:30 Hall 0
W0009 08:30 Sampling and culturing anaerobesHugo Cruz (Porto,
Special Session
Portugal)
Antimicrobial Stewardship in Different Scenarios W0010 08:50 I have an anaerobe: what is it and does it
matter?Kathleen Boiten (Groningen, Netherlands)
Chairs Murat Akova (Ankara, Türkiye)
Andre Fuchs (Augsburg, Germany) W0011 09:10 Actinomyces in clinical samples: when is it worth the
Maddalena Giannella (Bologna, Italy) trouble?Eija Inkeri Könönen (Turku, Finland)
Angela Huttner (Geneva, Switzerland) W0012 09:30 Nocardiosis: when to test and how to manage
Benedikt Huttner (Geneva, Switzerland) results?David Lebeaux (Paris, France)
Jose Ramon Pano-Pardo (Zaragoza, Spain)
Galadriel Pellejero-Sagastizábal (Zaragoza, Spain) Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI),
Holger Rohde (Hamburg, Germany) ESCMID Study Group for Clostridioides difficile (ESGCD)
Oana Sandulescu (Bucharest, Romania)
Jeroen Schouten (Nijmegen, Netherlands)
EW004
Valentijn Schweitzer (Utrecht, Netherlands) 08:30 - 10:30 Hall 6
Thomas Tängdén (Uppsala, Sweden)
Suzanne Van Asten (Nijmegen, Netherlands) Educational Session
Dafna Yahav (Ramat-Gan, Israel)
A hard nut to crack in HIV

Co-organised with: ESCMID Education Subcommittee

W0013 08:30 Viral reservoir: what a physician should knowIvailo
Alexiev (Sofia, Bulgaria)
EW001
08:30 - 10:30 Hall 2 W0014 08:50 Non-suppressible viraemia during HIV-1 therapy: a
challenge for cliniciansJose Arribas (Madrid, Spain)
Educational Session
W0015 09:10 Chronic vascular and pulmonary disease and HIV:
Surgical site infections: principles and practice in the era of multidrug what can we do about it?Susanne Dam Poulsen
resistance (Copenhagen, Denmark)
Chairs Gabriel Birgand (Nantes, France) W0016 09:30 Opportunistic infections: most common and most
Efthymia Giannitsioti (Athens, Greece) deadlyMilena Stevanovikj (Sopje, North Macedonia,
Republic of)
Co-organised with: Euroguidelines in Central and Eastern Europe Network
Group
W0001 08:30 Evolving antimicrobial resistance: do we need a
change in surgical antimicrobial prophylaxis?Camilla
Rodrigues (Mumbai, India) EW005
W0002 08:50 Role of decolonisation and bowel decontamination in
08:30 - 10:30 Hall 8

regions of overwhelming multidrug Educational Session

resistancePrasannakumar Palanikumar (Vellore,
India) Diagnostic parasitology in the XXIst century: is microscopy “+” still useful?
W0003 09:10 Screening for MDR GNR coloniSation: is there Chairs Miriam José Álvarez-Martínez (Barcelona, Spain)
evidence for prophylaxisElisabeth Presterl (Vienna, Caroline Rönnberg (Stockholm, Sweden)
Austria)
W0004 09:30 Perioperative prophylaxis in special populations in
the era of MDRDivyashree Shanthamurthy (Mumbai, W0017 08:30 Artificial Intelligence for the diagnosis of parasitic
India) infectionsBobbi Pritt (Rochester, United States)
W0018 08:50 Histopathology of parasitic infectionsRichard
Bradbury (Townsville, Australia)
EW002
08:30 - 10:30 Hall 3
W0019 09:10 Molecular diagnosis vs. microscopy in the diagnosis
Educational Session of parasitic infectionsSitara Sr Ajjampur (Vellore,
India)
Demystifying pharmacokinetics and population pharmacokinetics: a toolkit W0020 09:30 Paleoparasitology: what diagnostic tools?Ayman El-
for non-experts Badry (Cairo, Egypt)
Chairs Shampa Das (Liverpool, United Kingdom) Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)
João Paulo Telles (Sao Paulo, Brazil)

EW006
08:30 - 10:30 Hall 9
W0005 08:30 Pharmacokinetics 101: navigating the basics for
optimal dosingLinda Aulin (Leiden, Netherlands) Educational Session
W0006 08:50 The ABCs of population pharmacokinetic Vaccine hesitancy: from issues to solutions through developing
modelsErwin Dreesen (Leuven, Belgium) communication skills
W0007 09:10 Looking into the crystal ball: exploring the fabulous Chairs Monia Chemais (Soignies, Belgium)
world of PK-PD simulationsVincent Aranzana-Climent Petar Velikov (Sofia, Bulgaria)
(Poitiers, France)
W0008 09:30 Decoding population pharmacokinetic papers:
interpreting, comparing and discussing resultsIris K.
Minichmayr (Vienna, Austria) W0021 08:30 Vaccine hesitancy and its consequencesNoni
Macdonald (Halifax, Canada)
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
W0022 08:50 Why are patients and parents hesitant about
vaccination?Eve Dube (Quebec City, Canada)
EW003 W0023 09:10 Using social media to deal with vaccine
08:30 - 10:30 Hall 5
hesitancyMuge Cevik (St Andrews, United Kingdom)
Educational Session W0024 09:30 Strengthening vaccine confidence in patients and
parentsTba
ESCMID Global 2025 - Programme
Co-organised with: ESCMID Vaccine Study Group (EVASG)
ME012
11:00 - 12:00 Hall 9
SP2
11:00 - 12:00 Hall 0
Meet-the-Expert
Special Session
How to understand infectious disease risks in changing climates
Principles of systematic reviews (with and without meta-analysis)
Chairs Chiara Iaria (Palermo, Italy)
Miranda Langendam (Amsterdam, Netherlands) M0035 11:00 Kimberly Fornace (Singapore, Singapore)
Blin Nagavci (Gjakove, Kosovo)
Mical Paul (Haifa, Israel) M0036 11:12 Rachel Lowe (Barcelona, Spain)
Luigia Scudeller (Pavia, Italy)
SP3
13:30 - 14:30 Hall 0

Co-organised with: ESCMID Education Subcommittee Special Session

Top five mistakes in Infection prevention and control

ME007
11:00 - 12:00 Hall 2 Chairs Maeve Doyle (Waterford, Ireland)
Barbara Juliane Holzknecht (Copenhagen, Denmark)
Meet-the-Expert David Ong (Zoetermeer, Netherlands)
Arjana Tambic Andrasevic (Zagreb, Croatia)
How to interpret resistance patterns from antibiograms

Co-organised with: ESCMID Education Subcommittee

M0025 11:00 Tommaso Giani (Florence, Italy)
M0026 11:12 Diaz Lorena (Santiago, Chile)
ME013
13:30 - 14:30 Hall 2

Meet-the-Expert
ME008
11:00 - 12:00 Hall 3
Orthopaedic implant infections: new approaches for improved outcomes
Meet-the-Expert

Children are not just small adults: interactive paediatric cases

M0037 13:30 Marjan Wouthuyzen-Bakker (Groningen,
Netherlands)
M0027 11:00 Julie Toubiana (Paris, France) M0038 13:42 Trisha Peel (Melbourne, Australia)
M0028 11:12 Sanjay Patel (Winchester, United Kingdom) Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG),
ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID
Study Group for Infectious Diseases of the Brain (ESGIB)
ME009
11:00 - 12:00 Hall 5

ME014
Meet-the-Expert
13:30 - 14:30 Hall 3

How to practise WHO Guidelines for the prevention of bloodstream infections Meet-the-Expert
and other intravascular catheter infections
Timing of antimicrobials in sepsis and septic shock - the sooner the better?

M0029 11:00 Kushlani Jayatilleke (Battaramulla, Sri Lanka)

M0030 11:12 Walter Zingg (Zurich, Switzerland) M0039 13:30 Laura Evans (Seattle, United States)
M0040 13:42 Evangelos Giamarellos-Bourboulis (Athens, Greece)
Co-organised with: ESCMID Study Group for Bloodstream Infections,
ME010
11:00 - 12:00 Hall 6 Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci
and Staphylococcal Diseases (ESGS)
Meet-the-Expert

Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional ME015
experience 13:30 - 14:30 Hall 5

Meet-the-Expert

PrEP in Europe: Current gaps and solutions

M0031 11:00 Ecaterina Noroc (Chisinau, Moldova, Republic of)
M0032 11:12 Fakhriddin Nizamov (Almaty, Kazakhstan)
Co-organised with: Euroguidelines in Central and Eastern Europe Network
Group, United Nations International Children's Emergency Fund (UNICEF) M0041 13:30 Teymur Noori (Stockholm, Sweden)
M0042 13:42 Milosz Parczewski (Szczecin, Poland)
Co-organised with: European AIDS Clinical Society (EACS)
ME011
11:00 - 12:00 Hall 8

Meet-the-Expert ME016
13:30 - 14:30 Hall 6
Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare Meet-the-Expert

Short regimens for treating drug-susceptible and drug-resistant tuberculosis:

Insights from guidelines
M0033 11:00 Jaime Esteban (Madrid, Spain)
M0034 11:12 Philippe Morand (Paris, France)
Co-organised with: ESCMID Study Group for Implant-associated Infections
(ESGIAI), ESCMID Study Group for Mycobacterial Infections (ESGMYC) M0043 13:30 Daria Podlekareva (Copenhagen, Denmark)
ESCMID Global 2025 - Programme
M0044 13:42 Raquel Duarte (Porto, Portugal)
Co-organised with: European Respiratory Society (ERS) M0053 14:45 Luigia Scudeller (Pavia, Italy)
M0054 14:57 Blin Nagavci (Gjakove, Kosovo)
ME017 Co-organised with: ESCMID Guidelines Subcommittee
13:30 - 14:30 Hall 8

Meet-the-Expert
ME022
How to navigate Risk Communication in Public Health
14:45 - 15:45 Hall 6

Meet-the-Expert

Multidisciplinary management of bone and joint infections: is there a recipe

M0045 13:30 Christina Rolfheim-Bye (Oslo, Norway) for success?

M0046 13:42 Marius Gilbert (Brussels, Belgium)

Co-organised with: ESCMID Study Group for Public Health Microbiology
(ESGPHM) M0055 14:45 Natividad Benito (Barcelona, Spain)
M0056 14:57 Tiziana Ascione (Naples, Italy)
ME018 Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)
13:30 - 14:30 Hall 9

Meet-the-Expert
ME023
Do we need antiviral stewardship in immunocompromised hosts? role of cell-
14:45 - 15:45 Hall 8

mediated immunity Meet-the-Expert

How to manage and prevent travellers' diarrhoea

M0047 13:30 Michelle Yong (Melbourne, Australia)

M0048 13:42 Genovefa Papanicolaou (New York, United States) M0057 14:45 Tinja Laaveri (Helsinki, Finland)
M0058 14:57 David Tribble (Bethesda, United States)
SP4
14:45 - 15:45 Hall 0

ME024
Special Session 14:45 - 15:45 Hall 9

Science Slam - How to Communicate Science with Clarity Meet-the-Expert

Chairs Mary Horgan (Dublin, Ireland) How to diagnose and treat infectious complications in critically ill patients
Jaroslav Hrabak (Plzen, Czech Republic) receiving ECMO support
Nina Khanna (Basel, Switzerland)
Preeti Malani (Ann Arbor, United States)
Emily G. Mcdonald (Montreal, Canada)
Joshua Nosanchuk (Bronx, United States)
M0059 14:45 Jordi Riera (Barcelona, Spain)
Jesús Rodríguez-Baño (Seville, Spain)
M0060 14:57 Giacomo Grasselli (Besana In Brianza, Italy)
Co-organised with: European Extracorporeal Life Support Organization
(EuroELSO)
Co-organised with: ESCMID Education Subcommittee

SP5
ME019
14:45 - 15:45 Hall 2 16:15 - 18:15 Hall 0

Special Session
Meet-the-Expert
Multidisciplinary approach to early sepsis management
Healthcare-associated CNS infections
Chairs Markus Bald (Lüdenscheid, Germany)
Aleksandra Davidovic (Luedenscheid, Germany)
Charalambos Dokos (Lüdenscheid, Germany)
M0049 14:45 Diederik Van De Beek (Amsterdam, Netherlands)
M0050 14:57 Alexandra Mailles (Paris, France)
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain Co-organised with: ESCMID Education Subcommittee
(ESGIB)

EW025
16:15 - 18:15 Hall 2
ME020
14:45 - 15:45 Hall 3
Educational Session
Meet-the-Expert
AMR surveillance: current challenges and new perspectives
Translation of gut microbiome data to clinical practice: a guide for clinicians Chair Tomislav Mestrovic (Varazdin, Croatia)

M0051 14:45 Aycan Gundogdu (Kayseri, Türkiye) W0061 16:15 The essentials of GRAM project: data sources,
methodology and challenges in estimating AMR
M0052 14:57 Niranjan Nagarajan (Singapore, Singapore) burdenAuthia Gray (Washington, United States)
Co-organised with: ESCMID Study Group for Host and Microbiota Interaction W0062 16:35 Networks for surveillance of AMR in animal
(ESGHAMI) pathogensLucie Collineau (Lyon, France)
W0063 16:55 Transition to genomic-based methodology for
ME021 surveillance and outbreak detection to effectively
14:45 - 15:45 Hall 5
combact AMRCamilla Wiuff Coia (Copenhagen,
Meet-the-Expert Denmark)
W0064 17:15 Implementing and running hospital-wide genomic
How to make sense out of guidelines and scientific evidence surveillance of pathogensAlexander Mellmann
(Münster, Germany)
ESCMID Global 2025 - Programme
Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group Suzanne Van Asten (Nijmegen, Netherlands)
for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for
Veterinary Microbiology (ESGVM)

W0077 16:15 The impact of diabetes and host-pathogen interaction

EW026 and gut microbiomeReinout Van Crevel (Nijmegen,
16:15 - 18:15 Hall 3
Netherlands)
Educational Session W0078 16:35 Diabetes and invasive fungal infectionsJochem Buil
(Nijmegen, Netherlands)
New insights into antifungal agents and resistance
W0079 16:55 Viral infections and diabetes: is there a
Chairs Anuradha Chowdhary (New Delhi, India) connection?Malin Flodström-Tullberg (Stockholm,
Jon Salmanton-Garcia (Cologne, Germany) Sweden)
W0080 17:15 Pathogenesis of diabetic wound infectionTba

W0065 16:15 Emerging resistance in Candida tropicalisSharon

EW030
Chen (Sydney, Australia) 16:15 - 18:15 Hall 9
W0066 16:35 Mechanisms of resistance in Candida glabrataDavid Educational Session
Perlin (Nutley, United States)
W0067 16:55 Surveillance of resistance in Aspergillus Primer on infection prevention and control: the crucial support by clinical
speciesMaiken Cavling Arendrup (Copenhagen, microbiology
Denmark) Chairs Nico Tom Mutters (Bonn, Germany)
W0068 17:15 Environmental surveillance for antifungal Margreet C. Vos (Rotterdam, Netherlands)
resistanceEveline Snelders (Wageningen,
Netherlands)
W0081 16:15 Microbial fundamentals: building blocks of infection
EW027 prevention and controlLaurence Armand-Lefevre
16:15 - 18:15 Hall 5
(Paris, France)
Educational Session W0082 16:35 Optimising environmental sampling in infection
control: rational use of the microbiology
Going Viral! Phage Therapy Clinical rounds laboratoryJohn E. Coia (Esbjerg, Denmark)
Chairs Gregory German (Maple, Canada) W0083 16:55 The crucial role of molecular typing in infection
Ameneh Khatami (Sydney, Australia) controlStefanie Kampmeier (Würzburg, Germany)
W0084 17:15 How can we link diagnostic and antibiotic
stewardship?Constantinos Tsioutis (Nicosia, Cyprus)
W0069 16:15 Clinical cases and lessons from the STAMP Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI),
protocolHolly Sinclair (Nsw, Australia) EUCIC Steering Committee
W0070 16:35 Difficult cases treated with phagesGhady Haidar
(Pittsburgh, United States)
W0071 16:55 Challenging osteoarticular cases treated with
Saturday, 12 April 2025
phagesTristan Ferry (Lyon, France)
W0072 17:15 Treating urinary tract infections with phages: dream
or reality?Saima Aslam (San Diego, United States)
SY036
Co-organised with: ESCMID Study Group for Non-traditional Antibacterial 08:30 - 10:30 Hall 15

Therapy (ESGNTA) 2-hour Symposium

The quality of antibiotics used in the communities of LMICs

EW028
16:15 - 18:15 Hall 6 Chairs Thi Thuy Nga Do (Ha Noi, Vietnam)
Christina Obiero (Kilifi, Kenya)
Educational Session

Addressing infection challenges in immunocompromised patients: a case-

based exploration S0105 08:30 The quality of antibiotics and their potential impact on
Chairs Maddalena Giannella (Bologna, Italy) patient outcome and AMRPaul Newton (Oxford,
Asma Nasim (Karachi, Pakistan) United Kingdom)
S0106 09:00 Community antibiotic access and use in Sub-Sahara
AfricaSamuel Afari-Asiedu (Kintampo, Ghana)
W0073 16:15 Challenges in managing gastrointestinal infections in S0107 09:30 Encountered challenges and reflections on
patients with primary immunodeficiencyEffrossyni conducting multi-country medicine quality
Gkrania-Klotsas (Cambridge, United Kingdom) studiesNoudy Sengxeu (Vientiane Capital, Lao
People's democratic republic)
W0074 16:35 Respiratory infections in patients receiving CAR-T
cells or bispecific monoclonal antibodiesGemma S0108 10:00 Confusion in appearance of common used antibiotics
Reynolds (Heidelberg, Australia) in LMICsHeiman Wertheim (Nijmegen, Netherlands)
W0075 16:55 Mycobacterial infections in patients with HIV
infectionGraeme Ayton Meintjes (Observatory, South
SY031
Africa) 08:30 - 10:30 Hall 6

W0076 17:15 Breakthrough fungal infections in haematopoietic 2-hour Symposium

cancer and in stem cell transplantationDimitrios P.
Kontoyiannis (Houston, Tx, United States) To screen or not to screen prior to transplant?
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), Chairs Laura Alicia Barcan (Buenos Aires, Argentina)
International Immunocompromised Host Society (ICHS) Oscar Len (Barcelona, Spain)

EW029
16:15 - 18:15 Hall 8
S0085 08:30 HHV-8 ScreeningAlessandra Mularoni (Palermo,
Educational Session Italy)
S0086 09:00 TB screening and prevention in endemic
Impact of diabetes on infectious diseases: what should we know? regionsRubina Naqvi (Karachi, Pakistan)
Chairs Mark G. J. De Boer (Leiden, Netherlands) S0087 09:30 Screening for and prevention of chagas in
ESCMID Global 2025 - Programme
immunocompromised hostsMarcelo Victor Radisic G. Wang
(Buenos Aires, Argentina) E0031 In vitro investigations of ceftazidime-avibactam and
S0088 10:00 Screening of lung donors for MolicutesMichael G Ison fosfomycin against carbapenemase-producing
(Derwood (MD), United States) Enterobacterales clinical isolatesM. Martens*
(Hamburg, Germany), F.M. Docobo-Perez, C. Sauco
Carballo, J. Rodriguez-Baño, S. Marchand, L.
EF003 Keomany, I. Portillo-Calderon, M. Gianella, S.
08:30 - 09:30 Arena 1
Ambretti, B. Secci, S.G. Wicha
ePoster Flash Session E0032 In vivo activity and PK of the novel siderophore-
cephalosporin AR-2126 in a lethal lung infection
On the frontiers of vaccine driven prevention model in mice infected with a carbapenem-resistant
Chair Maria Ganczak (Zielona Gora, Poland) Pseudomonas aeruginosa following subcutaneous
administrationW. Wicha* (Bruck An Der Leitha,
Austria), S. Paukner
E0033 Synergistic Potency Unveiled: β-Lactam and β-
E0021 Changes in dose interval can impact T cell responses
Lactamase Inhibitor Combination against
but not antibody levels in individuals receiving the
modified vaccinia Ankara Mpox vaccineJ. Parsons*
Mycobacterium abscessus with Dual Action of β-
Lactamase Inhibition and Multi-Target Receptor
(Liverpool, United Kingdom), K. Subramaniam, L.
InactivationE. Shin* (Cleveland, United States), K.M.
Turtle, S. Dobson, L. Goodwin, C. Jones, T. Jones, P.
Shellman, A. Uriel, S. Jones, A. Otter, S. Laidlaw, M. Dousa, C.R. Bethel, M. Nantongo, S.M. Holland, E.J.
Carroll Rubin, J.B. Bulitta, K. Barry, R.A. Bonomo
E0034 Pharmacokinetic/pharmacodynamic evaluation of
E0022 A phase 1 study with an innovative approach for an
benzoxaborole MRX-5 in mouse pneumonia model
HIV-1 prophylactic vaccineP. Garbes* (Newark,
with Mycobacterium abscessus infectionW. Wang*
United States), C. Chang, H. Wraight, R. Norton, S.
Ouyang, S. Shen, H. Gao, D. Montefiori, J. Heptinstall, (Foster City, United States), S. Liu, B. Rimal, Y. Xu, Q.
S. Sawant, G. Tomaras, J. Zhu, K. Braz Gomes, M. Dai, G. Lamichhane
Giffear, K. Damjanoska, J. Li E0035 Pharmacokinetic/pharmacodynamic modelling of
immune response and meropenem activity in
E0023 A Pragmatic Randomized Trial to Evaluate Bivalent
immunocompetent and neutropenic mouse lung
RSV Prefusion F Protein–based Vaccine Effectiveness
infection modelsR. Saporta* (Uppsala, Sweden), N.
for Preventing RSV Hospitalizations in Older Adults
(DAN-RSV): Rationale & Trial DesignM. Lassen*
Tassi, O. Ticha, V. Biordi, A. Ginosyan, I. Loryan, E.I.
(Copenhagen, Denmark), S. Christensen, N. Nielsen, I. Bekeredjian-Ding, B. Kerscher, L.E. Friberg
Johansen, K. Skaarup, D. Modin, B. Claggett, C. E0036 Implementation of a model-based nomogram for
Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. amoxicillin precision dosing in patients suspected of
Lindholm, L. Køber, S. Solomon, J. Jensen, C. Martel, infective endocarditis: preliminary results of the
C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, B. NOMOBA-AMX multicentre studyP. Le Turnier*
Gessner, N. Aliabadi, E. Begier, T. Biering-Sørensen (Cayenne, French Guiana), S. Jamard, A. Lorleac'h, C.
E0024 Six-month Immunogenicity of mRNA-1345 RSV
Deschanvres, F. Andry, A. Coste, P. Danneels, T.
Vaccine in Adults Aged ≥60 YearsM. Desai*
Guimard, P. Gicquel, H. Harrabi, N. Issa, J.B. Lainé, R.
(Cambridge, United States), E. Comstock, L. Lan, A. Lamberet, A. Le Bot, M. Maillet, P. Petitgas, V. Rabier,
Kapoor, J. Goswami, F. Priddy, R. Das S. Sunder, J.M. Turmel, D. Boutoille, C. Delaunay, M.
Grégoire, A.G. Leroy, M. Wargny, R. Bellouard
E0025 Comparative Immune Responses to Homologous and
E0037 No time to waste: hospital-wide assessment of IV-
Heterologous SARS-CoV-2 Vaccination Using DNA
vial and line residuals and impact on target
and Protein PlatformsS. Prieto Martin Gil* (Madrid,
attainment.D. Vanneste* (Leuven, Belgium), M.
Spain), S. Prieto Martín Gil, M. López Siles, J.A.
Infantes Lorenzo, E. Lorente, D. Fousteris, B. Cano Gijsen, W. Zhang, O. Elkayal, V. Caubergs, J. Wauters,
Castaño, A. Tajuelo, D. López, V. Mas Lloret, E. Gato, S. Desmet, E. Dreesen, I. Spriet
A. Pérez, M.J. Mcconnell E0038 Population pharmacokinetic modelling of colistin in
critically-ill patients on sustained low-efficiency
E0026 Quantitative correlates of protection against SARS-
dialysis: implications for dose selectionD. Fuhs*
CoV-2 variants using individual-level reconstructed
antibody kineticsT. Russell* (London, United
(Parkville, Australia), A. Boonyasiri, T. Naorungroj, L.
Kingdom), E.C. Wall, A.J. Kucharski, J. Hellewell, O. Wang, J. Wang, R. Ratanarat, J. Li, R. Nation, T.
Hague, H. Townsley, J. Gahir, M. Shawe-Taylor, D. Visanu, C. Landersdorfer
Greenwood, R. Harvey, M.Y. Wu, D.L. Bauer, E.J. Carr
E0027 Effectiveness of the 2023-24 seasonal influenza SY034
vaccine in UK healthcare workers: results from the 08:30 - 10:30 Hall 10
SIREN prospective cohort studyL. Mcgeoch* 2-hour Symposium
(London, United Kingdom), S. Foulkes, H. Whitaker, K.
Munro, J. Khawam, D. Sparkes, A. Charlett, C. Brown, Endoscopy: infection risks and mitigation
A. Atti, J. Islam, S. Hopkins, N. Andrews, V. Hall
Chairs Elisabeth Presterl (Vienna, Austria)
E0028 Immunogenicity and safety of second COVID-19 Gordon Ramage (Glasgow, United Kingdom)
booster and Influenza vaccination coadministrationI.
Wagenhäuser* (Würzburg, Germany), J. Reusch, J.
Mees, A. Gabel, N. Petri, M. Krone
E0029 The degree of immunization against the Measles S0097 08:30 Should we be concerned about infection from
virus of the infant population in Sibiu county, contaminated endoscopes?Claire Aumeran
RomaniaS. Cristea* (Sibiu, Romania), C. Grigore (Clermont-Ferrand, France)
S0098 09:00 Prevention of multidrug-resistant infections from
contaminated duodenoscopesMargreet C. Vos
EF004 (Rotterdam, Netherlands)
08:30 - 09:30 Arena 3
S0099 09:30 Understanding the causes of medical device
ePoster Flash Session contamination: it is all biofilm!Roberto Rusconi (Milan,
Italy)
Pharmacology from bench to the bedside
S0100 10:00 Does the European medical Device Regulation bring
Chair Alina Karoline Nussbaumer-Pröll (Wien, Österreich, us safer duodenoscopes?Markus Hell (Salzburg,
Austria) Austria)
Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study
Group for Nosocomial Infections (ESGNI)
E0030 Enterococcus faecalis impairs Escherichia coli
response to antibiotics in a dual-species intracellular
infection modelF. Van Bambeke* (Brussels, Belgium),
ESCMID Global 2025 - Programme

OS002 people living with HIVRaimonda Matulionyte (Vilnius,

08:30 - 10:30 Hall 11
Lithuania)
2-hour Oral Session S0103 09:30 Integration of HIV and TB care to improve patient
outcome in resource-limited settingsAkaki Abutidze
Translating metagenomics into clinical practice (Tbilisi, Georgia)
Chairs Benjamin Peter Howden (Parkville (Victoria), S0104 10:00 How researchers can influence policy and practice in
Australia) HIV/TB careJens D. Lundgren (Copenhagen,
Paula Mölling (Örebro, Sweden) Denmark)
Co-organised with: ESCMID Study Group for Mycobacterial Infections
(ESGMYC), Euroguidelines in Central and Eastern Europe Network Group
O0011 Nanopore metagenomic sequencing for rapid
bloodstream infection diagnostics evaluated in a
prospective observational studyH.L. Nielsen* EW041
(Aalborg, Denmark), C. Thygesen, K.K. Søgaard, A.B.
08:30 - 10:30 Hall 13

Sørensen, S.M. Karst, A.L. Krarup, M. Albertsen Educational Session

O0012 Interpretative Criteria for Adjudicating Clinical
Significance to Next-Generation Sequencing Results RSV infections: diagnosis, surveillance and treatment in the advent of
from Bronchial-alveolar Lavage and Bronchial vaccines
Wash.J. Alexander* (Orlando, United States), A. Chairs Monika Redlberger-Fritz (Vienna, Austria)
Charles Makeda Semret (Montreal, Canada)
O0013 Implementing same-day respiratory metagenomic
diagnostics in paediatric intensive careR. Hammond*
(London, United Kingdom), A. Kopec, J. Brown, J. W0126 08:30 Costs of RSV infection, compared to other
Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B. respiratory virusesBarbara Rath (Besançon, France)
Snell, J. Breuer
W0127 08:50 Virology and host interactions of RSVPeter
O0014 Detection of pathogenic microorganisms using Openshaw (London, United Kingdom)
metagenomic next-generation sequencing in ICU
patients with ongoing antibiotic therapyT. W0128 09:10 RSV surveillance in the EU/EEA in the vaccine
Schroeder* (Nuertingen, Germany), M. Eliwi Alsaffan, eraEeva Broberg (Solna, Sweden)
A. Dervishi, P. Kawaletz, H. Stäudle W0129 09:30 RSV fusion inhibitors and monoclonals: current
O0015 Analysis of metagenomic pathogen detection status and future developmentsLouis Bont (Utrecht,
compared to conventional diagnostics: clinical usage Netherlands)
and relevance for patient outcomesE. Siegel* (Mainz, Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV),
Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C. International Society for Influenza and other Respiratory Viruses (ISIRV)
Hamm, D. Teschner, O. Kriege, D. Grimm, I.
Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S.
Hagge, S. Vieira-Silva, T. Sparwasser EW042
O0016 Same-day pan-microbial metagenomics for
08:30 - 10:30 Hall 14

personalized therapy and pathogen surveillance on Educational Session

the intensive care unit: a single-centre prospective
studyL.B. Snell* (London, United Kingdom), A. Traumatic wound infections: diagnosis and treatment options
Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D. Chairs Amparo Fernández-Rodríguez (Madrid, Spain)
Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W. Veroniek Saegeman (Sint-Niklaas, Belgium)
Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J.
Whitehorn, G. Nebbia
O0017 Evaluation of the diagnostic efficacy of targeted next-
W0130 08:30 Multidrug-resistant infections after trauma in
generation sequencing in the detection of pathogens
warzoneShehan Hettiaratchy (Hampton, United
in bronchoalveolar lavage fluid from patients with
Kingdom)
lower respiratory tract infections in ICUB. Ran*
(Taiyuan, China), Y. Liu, X. Wu, X. Lin, X. Li, Q. Zhan, C. W0131 08:50 Fungal infections during natural disastersAnuradha
Wang, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. Chowdhary (New Delhi, India)
Zhang, J. Hao, L. Jin, Z. Huang W0132 09:10 Bacteriophage therapy for multidrug-resistant wound
O0018 Prognostic and diagnostic value of Next-generation infections in traumaTristan Ferry (Lyon, France)
sequencing in female reproductive tract infection and W0133 09:30 Infection of burn woundsNur Benzonana (Istanbul,
HPV persistenceC. Peng* (Shiyan, China), S. Qi, C. Türkiye)
Jiachang, P. Chunyan, W. Taiquan, X. Xianru, Y.
Jianying, Y. Qirong, Z. Pengyuan, L. Jun Co-organised with: ESCMID Study Group for Forensic and Postmortem
Microbiology (ESGFOR), ESCMID Study Group for Non-traditional
O0019 A promising approach to rapid, non-culture diagnosis Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades
of invasive fungal infections (IFIs) by targeted next- Infecciosas Microbiología Clinica), International Society of Antimicrobial
generation sequencing (tNGS)M.H. Nguyen* Chemotherapy (ISAC)
(Pittsburgh, United States), H. Badrane, B.A. Stevens,
S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B.
Hao, E. Driscoll, W. Maynard, C. Clancy SY037
O0020 Implementation of Clinical Metagenomics in France:
08:30 - 10:30 Hall 16

Insights from a Five-Years StudyM. Dutkiewicz* 2-hour Symposium

(Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul,
S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Unveiling the challenges: nosocomial infections in ECMO-supported patients
Caméléna, J. Le Goff, M. Salmona Chairs Antonios Katsounas (Bochum, Germany)
Jordi Riera (Barcelona, Spain)

SY035
08:30 - 10:30 Hall 12

2-hour Symposium S0109 08:30 Source of infection and pathogensChristian Eckmann

(Hannover, Germany)
Barriers to TB/HIV elimination in low- and high-incidence settings S0110 09:00 Prophylaxis and empiric treatmentGiacomo Grasselli
Chair Daria Podlekareva (Copenhagen, Denmark) (Besana In Brianza, Italy)
S0111 09:30 Diagnostic criteria and definitionsGraeme Maclaren
(Singapore, Singapore)
S0101 08:30 HIV and TB epidemic: the storm hasn’t subsided S0112 10:00 Microbial filmsMarta Hernández-Meneses
yetTetiana Koval (Poltava, Ukraine) (Barcelona, Spain)
S0102 09:00 Approaches for latent and active TB screening in Co-organised with: European Extracorporeal Life Support Organization
ESCMID Global 2025 - Programme
(EuroELSO)
O0001 Decoding the role of blaCPE-carrying plasmids on
wings: A holistic view using the One Health
EW039 approachS.A. Martínez-Álvarez* (Logrono, Spain),
08:30 - 10:30 Hall 2
P. Châtre, T. Cardona-Cabrera, P. François, U.
Educational Session Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C.
Torres
Are urinary tract infections still the same? O0002 A novel isolation room model leveraging culture-
Chairs Suzanne Geerlings (Amsterdam, Netherlands) independent Hi-C metagenomics for tracking
Agnes Maria Sonnevend (Pécs, Hungary) antimicrobial resistance transmission between
patients and hospital environmental reservoirsV.
Koh* (Singapore, Singapore), R. Cabrera, J. Chua,
J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M.
W0118 08:30 Update on paediatric UTI Michael Buettcher (Luzern, Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng
Switzerland)
O0003 Deciphering the pathogenic potentials and
W0119 08:50 Diagnosis and treatment of UTI in the era of epidemiological identities of Staphylococcus
antimicrobial resistanceJennifer Kranz (Aachen, pseudintermedius colonizing companion dogs in
Germany) Sao PauloI.B. Moses* (Sao Paulo, Brazil), L. Sartori,
W0120 09:10 Can UTI be prevented?Chris Harding (Newcastle D.A. Henriques, M.M. Marini, F.M. Lima, R.X.
Upon Tyne, United Kingdom) Espinosa, I. Orlandino Da Silva, F.F. Santos, L.
Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales
W0121 09:30 Fungal and parasitic infections of the urinary
tractGladys Mbwanji (Mwanza, Tanzania, United O0004 Recent progress towards integrated surveillance of
republic of) antimicrobial resistance in FranceL. Collineau*
(Lyon, France), S. Bareille, G. Birgand, L. Lacmago,
B. Lange, O. Lemenand, C. Chauvin
EW040
08:30 - 10:30 Hall 3 O0005 Exploring the plasmidome of 3rd generation
cephalosporin-resistant Enterobacterales in wild
Educational Session birds: Insights into horizontal gene transfer and
AMR disseminationB. Timmer* (Debrecen,
OPAT: from aged wine to new vintage Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas-
Chairs Birgit Koch (Rotterdam, Netherlands) Kiss, L. Laczkó, G. Kardos
Sonia Luque (Barcelona, Spain) O0006 Emergence of mobile colistin resistance in
Klebsiella at human-animal-environment interface
in BangladeshS. Rahman* (Oxford, United
Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R.
W0122 08:30 OPAT: principles, practice and checklistsCharlotte Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T.
Quintens (Leuven, Belgium) Walsh, R. Farzana
W0123 08:50 COPAT: complex outpatient parenteral antimicrobial O0007 Unveiling the invisible: antimicrobial resistance
therapy Ronald Andrew Seaton (Glasgow, United genes and pathogenic microbial diversity in sewage
Kingdom) of North India's largest industrial hub, A
W0124 09:10 Antimicrobial stability and other challenges for OPAT metagenomic perspectiveI. Singh* (Chandigarh,
practice? Mark Gilchrist (London, United Kingdom) India), R. Sharma, A. Arora, B. Mohan, N. Taneja
W0125 09:30 New OPAT safety and efficacy data to guide O0008 Culturomics as a tool for ONE HEALTH approach:
practiceMatthew Rawlins (Murdoch, Australia) Unveiling the role of unknown microorganisms as
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), antibiotic resistance carriers in wastewater
Society of Infectious Diseases Pharmacists (SIDP) samplesE. Ouranou* (Heraklion, Greece), A.
Psaroulaki, D. Chochlakis, M. Malliarou, K.
Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos
EW038 O0009 One Health intervention impacts on antibiotic
08:30 - 11:30 Hall 4
resistance in Denmark, England and Senegal: A
Educational Session mathematical model comparisonG. Knight*
(London, United Kingdom), R. Booton, J.V.
EUCAST Educational Workshop Robotham, K. Aluzaite, D. Belay, J. Guitian, M.
Chairs Marlene Amara (Le Chesnay Cedex, France) Dione, E. Emes
Alasdair P. Macgowan (Bristol, United Kingdom) O0010 Clinically important sequence types and resistance
genes in Enterobacteriaceae from coastal
environments and gullsV. Silva* (Lisbon, Portugal),
M. Quintelas, M. Caniça, R. Rivière, P. Poeta, G.
W0113 08:30 EUCAST updateSören G. Gatermann (Bochum, Igrejas
Germany)
W0114 08:50 Setting clinical breakpoints, assessing
evidenceAnouk Edwina Muller (The Hague, SY032
Netherlands)
08:30 - 10:30 Hall 7

W0115 09:10 Benzylpenicillin susceptibility testing of S. 2-hour Symposium

pneumoniae by disk diffusionGunnar Kahlmeter
New insights into Candida pathogenesis
(Tävelsås, Sweden)
Chairs Aleksandra Barac (Belgrade, Serbia)
W0116 09:30 What to do when there are no breakpointsBarbara
Joshua Nosanchuk (Bronx, United States)
Juliane Holzknecht (Copenhagen, Denmark)
W0117 09:50 Detection of resistance mechanismsChristian Giske
(Stockholm, Sweden)
Co-organised with: EUCAST Steering Committee S0089 08:30 Insights into the evolution of Candida under
antifungal pressureAttila Gacser (Szeged, Hungary)
S0090 09:00 How do Candida extracellular vesicles modify
OS001 virulence during disease?Leonardo Nimrichter (Rio
08:30 - 10:30 Hall 5
De Janeiro, Brazil)
2-hour Oral Session S0091 09:30 The commensal to pathogen transition: kind to
killerIlse D. Jacobsen (Jena, Germany)
One Health means resistance everywhere
S0092 10:00 Fungal-bacterial interactions: who wins?Rebecca Hall
Chairs Alessandra Carattoli (Rome, Italy) (Canterbury, United Kingdom)
Prasannakumar Palanikumar (Vellore, India)
ESCMID Global 2025 - Programme

SY033 Aragão, C. Palos, C. Mimoso, I. Neves, M.J. Janeiro,

08:30 - 10:30 Hall 8
J.A. Paiva
2-hour Symposium

Single-cell approaches to dissect cellular phenotypic heterogeneity of EF006

bacterial pathogen populations. 09:30 - 10:30 Arena 4

Chairs Christian Stephan Lentz (Tromsø, Norway) ePoster Flash Session

Annelies Zinkernagel (Zurich, Switzerland)
Emerging developments in antifungal pharmacology
Chair Roger Brüggemann (Nijmegen, Netherlands)
S0093 08:30 Adaptive evolution and phenotypic heterogeneity of
bacterial pathogens during infectionsChristoph Ernst
(Cologne, Germany) E0048 NATURE-US: the natural history of antifungal failure
S0094 09:00 Single-cell imaging and heterogeneity in antimicrobial in invasive candidiasisL. Ostrosky-Zeichner*
resistanceStefano Pagliara (Exeter, United Kingdom) (Houston, United States), P.G. Pappas, M.H. Miceli,
A. Spec, C.Z. Grimes, F. Lewis, M. Mammadova, E.
S0095 09:30 Single-cell RNAseq and heterogeneity in bacterial McKie, M. Middle, M. Kordalewska, D.S. Perlin, D.P.
transcriptionAnna Kuchina (Seattle, United States) Kontoyiannis, O.A. Cornely, J. Vazquez, D. Angulo
S0096 10:00 Dissecting the function of individual bacteria in their E0049 The antidepressant vortioxetine enhances
spatial contextKnut Drescher (Basel, Switzerland) resistance toward multiple azolesS. Rizzo* (Rome,
Italy), M. Cacaci, V. Di Pilato, S. Di Bella, U. Albert, B.
Posteraro, M. Sanguinetti, F. Bugli, R. Torelli
SY043
09:30 - 10:30 Hall 1
E0050 Enhancing Isavuconazole Pharmacokinetics: A
1-hour Symposium Comprehensive Population (PPK) Model from Three
Phase 3 Trials and Covariate ExplorationD. Amit*
Year in infection control (Chicago, United States), A. Desai, L. Kovanda
Chairs Nico Tom Mutters (Bonn, Germany) E0051 Identification of efflux inhibitors for Candida
Ermira Tartari (Msida, Malta) albicans through a drug repurposing strategyD.
Marques* (Lisbon, Portugal), S. Santos Costa, L.
Rodrigues
E0052 Clinical outcomes of micafungin 100 mg vs. 150 mg
S0134 09:30 Andrew James Stewardson (Melbourne, Victoria, daily for the treatment of Candida auris fungemiaJ.
Australia) Hou* (Chicago, Il, United States), Y. Wang, R.
S0135 10:00 Kalisvar Marimuthu (Singapore, Singapore) Burgos, L. Danziger, E. Drwiega
E0053 Resolution of clinical signs in adults with invasive
candidiasis and/or candidaemia treated with
EF005
09:30 - 10:30 Arena 2 rezafungin or caspofungin: ReSTORE and STRIVE
trial pooled analysisG.R. Thompson* (Davis,
ePoster Flash Session California, United States), A. Soriano, M. Bassetti,
P.M. Honore, J. Vazquez, S. Dickerson, O.A. Cornely
It's all in the blood
E0054 Ibrexafungerp is effective in treatment of patients
Chair Colin R. Mackenzie (Neuss, Germany) with candidiasis, including candidaemia, caused by
Candida auris: a multicentre, open-label study
(CARES)M.H. Miceli* (Ann Arbor, United States),
T.F. Patterson, D. Juneja, G.R. Thompson Ill, P.
E0039 Limited delayed incubation of blood culture bottles
Vergidis, A. Spec, T.J. Walsh, D. Angulo, J. Breedt,
has limited effect on yield and time-to-positivityL.
N. Yaddanapudi, R.S. Siebert, E. McKie, F. Lewis, M.
Hardy* (Antwerp, Belgium), A.S. Heroes, E. Middle, M. Hoenigl
Genbrugge, B. Gleeson, C. Ferreyra, T. Vermoesen, E.
Corsmit, B. De Smet E0055 High-dose isavuconazole therapy is well-tolerated
and significantly improves survival in a fruit fly
E0040 Unnecessary clinical interventions due to blood
model of invasive mucormycosisS. Wurster*
culture contamination in a large Canadian hospital
(Houston, United States), N.D. Albert, N.P.
networkC. Hall* (Hamilton, Canada), C. Fuller, S.
Wiederhold, R.E. Lewis, D.P. Kontoyiannis
Ramondino, C. Main
E0056 Pharmacokinetics, pharmacodynamics, safety, and
E0042 Clinical microbiology laboratory consultancy to
efficacy of innovative dosing schedules of liposomal
optimize blood culture workflow: Analysis of resultsC.
amphotericin B for treatment of experimental
Magri* (Rome, Italy), C. Magrì, G. Menchinelli, D. invasive pulmonary aspergillosis in persistently
Squitieri, B. Fiori, M. Cacaci, B. Posteraro, G. De neutropenic rabbitsR. Petraitiene* (New York,
Angelis, M. Sanguinetti United States), E. Naing, A. Garcia, V. Zigmantaite,
E0043 Comparison of Syndromic Sepsis Panel and Standard R. Grigaleviciute, A. Pockevicius, M. Zimmerman,
Blood Culture Results: Contribution to Patient A.H. Groll, T.J. Walsh, V. Petraitis
ManagementS. Buyukberber* (Ankara, Türkiye), S.
Aydogan, B. Dinc, N. Coplu, S. Turan, S.S. Yakin, H.
Dal, T. Kayan FO050
E0044 Predicting blood culture positivity using machine
11:00 - 12:00 Arena 1

learning with complete blood and differential counts Open Forum

in a tertiary care hospital of TurkiyeÖ. Türkmen
Recen* (Izmir, Türkiye), M. Kıplapınar, H. Özdemir, S. HIV: a global ethical Conundrum
Kurutepe, H. Gazi Chair Seif Al-Abri (Muscat, Oman)
E0045 Performance of direct pathogen and β-lactamase
detection workflow using MALDI-TOF MS from
positive blood culture specimensK. Kosai* (Nagasaki,
F0147 11:00 HIV, from key population to general population: a
Japan), Y. Kawamoto, K. Yanagihara
Pandora's BoxSyed Faisal Mahmood (Karachi,
E0046 Waiting for follow-up blood cultures is not always Pakistan)
necessary for diagnosis of central line-associated
F0148 11:10 Ethical considerations in preventing mother-to-child
bloodstream infectionsL. Van Balen* (Maastricht,
HIV transmission Glory Alexander (Bangalore, India)
Netherlands), R. Koeck
F0149 11:20 HIV drug trials in Africa: ethical concernsShah Reena
E0047 Economic and health gains associated with the
(Nairobi, Kenya)
adoption of the 2-hour phenotypic antimicrobial
susceptibility testing in patients with bloodstream F0150 11:30 HIV-related stigma and discrimination in the
infection in EuropeC. Pina-Vaz* (Oporto, Portugal), F. healthcare settingTeymur Noori (Stockholm,
ESCMID Global 2025 - Programme
Sweden) infections and plasmid epidemiology in England: A
Co-organised with: ESCMID Ethics Advisory Committee (EEAC) pilot studyD. Nagy* (Oxford, United Kingdom), N.
Stoesser, S. Lipworth, V. Pennetta, G. Rodger, K.
Hopkins, C. Jones, T. Neksus Study Group, S.
Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L.
EF014
11:00 - 12:00 Arena 2
Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown
ePoster Flash Session
EF015
Infection control and prevention around the World 11:00 - 12:00 Arena 3
Chair Divyashree Shanthamurthy (Mumbai, India) ePoster Flash Session

Advances in the diagnosis and treatment of skin, bone, and joint infections
E0092 WHO Global Survey on Infection Prevention and Chair Norma Jung (Köln, Germany)
Control Minimum Requirements: Laying the
Foundation for 2030 Global TargetsP. Bischoff*
(Geneva, Switzerland), S. Tomczyk, G. Satta, E.
Tartari, A. Meinen, P. Rogers, L. Cihambanya, C.R. E0101 Potential benefits of PET-CT in the management of
Ana Paula, I. Hewedy, Z. Li, P. Ramon-Pardo, A. Singh, bone and joint infections in infective endocarditis: a
B. Allegranzi retrospective analysis from the Mayo ClinicF. Petri*
(Milan, Italy), F. Borgonovo, O.K. Mahmoud, R.
E0093 Healthcare-associated infections in african intensive Igwilo-Alaneme, T. Matsuo, S. El Zein, D. De Simone,
care units: A muliticentre prospective cohort studyB. A. Gori, E. Berbari
Gaye* (Dakar, Senegal), N. Madani, J. Ben Khlil, A.
Ben Souissi, B. Seydina Alouine, G.F. Otiobanda, R.M. E0102 Synovial fluid microRNA biomarkers enable
Hamidi, M.S. Chaibou, P.A. Leye, L. Oualili, T. accurate diagnosis of periprosthetic joint
Dendane, K. Abidi, M. Bouaziz, R. Ammar, M. infectionB.J.H. Frank* (Vienna, Austria), T.
Elombila, W. Naija, M. Kahloul, R. Herch, R. Toumi, E. Krammer, J. Pfeiffer-Vogel, T. Nguyen, A.
Ennouri, M. Boussarsar, N. Ben Mrad, A. Soumare, Diendorfer, M. Hackl, J. Hofstaetter
T.M. Diop, N. Brahmi, A. Ben Jazia, H. Ben Ghezala, E0103 Diagnostic accuracy of 16S rDNA PCR, multiplex
A.A. Messadi, H. Fredj, A. Mokline, S. Abdellatif, T. PCR and metagenomic Next-Generation
Badis, L. Messaoud, A. Bouzid, S. Feki, H. Sequencing in periprosthetic joint infections: a
Cheikhrouhou, A. Hachimi, B. Khemlich, F.Y. Bah, A.B. systematic review and meta-analysisF. Olearo*
Faye, L. Ouanes Besbes, Z. Hammouda, M.S. (Hamburg, Germany), S. El Zein, E. Portillo M, A.
Mebazaa, S. Elatrous, S. Ayed, W. Sellami, A. Ben Zapf, H. Rohde, E.F. Berbari, M. Wouthuyzen-Bakker
Amri, M. Ferjani, O. Bouhamed, N. Hajjem, H. Daddy, E0104 Comparison of microbiology, management and
M. Gagara Mayaou, B. Marou Soumana, B. Diallo, B. outcome between patients with native and with
Gafsi, F. Ben Salem, E. Milli, B. Idali, T. Merhabene, N. post-surgical vertebral osteomyelitis: a 7-year
Ben Slimane, F. Kaaniche Medhioub, R. Allala, C. retrospective studyG. Franceschi* (Modena, Italy),
Kaddour, N. Baffoun, R. Hammami, H. Allouche, H. M. Pellegrino, M. Del Monte, A. Bedini, L. Benassi,
Ghadhoune, S. Soui, H. Hmouda, R. Ben Dabebiss, A. A. Soffritti, A. Tili, E. Dema, M. Palmisani, A. Veroni,
Sidibe, N. Diani, N. Benmouhoub, M.S. Ado Zakari, O. G. Pavesi, M. Cristina
Mamane Nassirou, O. Bachar Loukoumi, A. Ben Fraj,
H. Jaoua, K. Ben Fadhl, T. Abdoulaye, T. Bagouma, H. E0105 Cefiderocol real-life use in bone and joint infection:
Arfaoui, O. Kaabachi, O. Nasri, C. Ben Massoud, M. a retrospective French multicenter studyA. Diarra*
Niandou, M. Nanzir Sanoussi, H. Bassama, A. Jebri, H. (Tourcoing, France), V. Delastours, A. Bleibtreu, H.
Ben Fradj, A. Hafyene, N. Soraa, O. Kechini, A. Felhi, Wille, N. Sayre, N. Rouzic, K. Jaffal, I. Strachinaru, B.
R. Abouqal, Y. Coulibaly Valentin, M. Bermejo, P. Gazeau, A. Baldolli, B.
Lefevre, A. Asquier, J. Courjon, R. Larcher, L.
E0094 Epidemiology of community-acquired versus Escaut, L. Deconinck, N. Taar, V. Dacquet, T. Ferry,
hospital-acquired sepsis in acute hospitals in Ireland - I. Eberl, M. Degrendel, P. Patoz, P.Y. Tortai, O.
2016-2022.E. Liddy* (Dublin, Ireland), A. Vellinga, D. Robineau, E. Senneville
Amin
E0106 Real-Life Experience with Dalbavancin as
E0095 Epidemiology of Central Line-Associated Suppressive Antibiotic Treatment in orthopaedic
Bloodstream Infections (CLABSIs) in a Network of implant-related infections.R. Escudero-Sánchez*
Ten Hospitals across Greece: A 30-Month (Madrid, Spain), S. De La Villa Martínez, A. Rico
Surveillance Study – GRIPP-SNF NetworkI. Kopsidas* Nieto, M. Sanchez-Somolinos, M. Tasias Pitarch, M.
(Neo Psychiko, Greece), E. Kourkouni, G.C. Tsopela, Salaver Lletí, M. Correa Ballester, R. Blanez
D. Kousi, A. Moutou, P. Varda, P. Pantelidou, A. Hernández, E. Calabuig Muñoz, M. Montero Alonso,
Karaiiskou, D. Kaitelidou, T. Zaoutis, A. Koutsoukou L. Guio Carrion, J. Gomez Junyent, M.L. Sorli, F.
E0096 Characterisation of plasmids disseminating antibiotic Braojos Sanchez, A. Muñoz Gomez, M.J. Nuñez
resistance in Klebsiella pneumoniae isolates from Oranto, E. Baos Muñoz, R. Manzano Lorenzo, J.
Pretoria, South AfricaT. Govender* (Pretoria, South Perez-Somarribas Moreno, J.M. Barbero Allende,
Africa), A. Moultrie, M. Moodley, J. Featherston, M. M.J. Garcia Pais, F.J. Martínez Marco, A. Galeote
Mohlamonyane, J. Pitout, T. Hamiwe, T. Lentswe, S. Rivas, B. De La Torre Escuredo, J. Cobo
Liknaitzky, K. Salvador-Oke, A. Smith, I. Arshad, M. E0107 Short or Long Antibiotic Regimes in Orthopaedics:
Said, M. Ehlers, M. Kock the SOLARIO multicentre randomised controlled
E0097 Transmission dynamics of carbapenemase- trialM. Dudareva* (Oxford, United Kingdom), M.
producing bacteria between hospital and household Scarborough, M. Mcnally, M. Kumin, C.
settings in BeninK. Sintondji* (Abomey-Calavi, Benin), Scarborough, W. Vach, J. Ferguson
V. Dougnon, B. Legba, B.G. Hougbenou, K. Fabiyi, H. E0108 Clinical and Antibacterial Diversity of
Koudokpon, A. Dalsgaard, Y.M.G. Hounmanou Staphylococcal Phenotypes in Skin and Soft Tissue
E0098 Evaluating the impact of a rapid screening test for Infections: A Resource-Limited Country
carbapenem-resistant organisms in Brazilian Perspective.F. Zeeshan* (Karachi, Pakistan), A.
intensive care units.M. Salomão* (Sao Paulo Sp, Naeem, F. Uddin
Brazil), B. De Almeida Lessa Castro, C. Loredana P. A. E0109 Discrepancy between clinical-radiological diagnosis
M. Bezerra, E. Lino Dos Santos Junior, C. Lee Luna and surgical confirmation in 62 patients undergoing
Fernandes, A. Pereira Funari, S. Bollinger, F. C. Lessa, fasciotomy for suspected necrotizing fasciitis: a 11-
G. Mahon, M. Westercamp, M. Chiarastelli Salomao year retrospective study.F. Romani* (Modena,
E0099 Genomic Insights into the Rapid Rise of Italy), A. Bedini, A. Spadoni, G. Manzini, G.
Pseudomonas aeruginosa ST463: A High-Risk Franceschi, B. Fontana, M. Sarti, C. Mussini
Clone's Adaptive Strategy in ChinaX. Dong*
(Hangzhou, China)
EF016
E0100 Nanopore long-read only genome assembly for public 11:00 - 12:00 Arena 4
health surveillance of Enterobacterales bloodstream
ESCMID Global 2025 - Programme
ePoster Flash Session combination for the management of multi-drug
resistant E.coli on peritonitis in a pediatric liver
Rising threats: antimicrobial resistance in STIs transplant recipientR. Morales Junior* (Cincinnati,
Chair Marcos Rust (Feldkirch, Austria) United States), V. Juodinis, C. Donini, J. Sampaio
O0075 Early oral antibiotic treatment in patients with post-
neurosurgical brain abscesses caused by
Cutibacterium acnes – a case seriesM. Karolyi*
E0110 Important rise of antibiotic resistance of (Vienna, Austria), D. Stahl, E. Pawelka, S. Omid, A.
Mycoplasma genitalium, a sexually transmitted Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fischoeder,
pathogen, in a French University hospitalF. Doucet M. Ortler, C. Wenisch
Populaire* (Clamart, France), W. Ben Nejma, C.
Benet, M. Grimaldi, I. Kansau, S. Pozzi-Gaudin, C. O0076 Meropenem-vaborbactam as intrathecal-sparing
Guillet-Caruba, N. Bourgeois-Nicolaos therapy for the treatment of carbapenem-resistant K.
pneumoniae shunt-related ventriculitis: two case
E0111 Molecular characterization of antimicrobial reports.G. Giuliano* (Siena, Italy), M. Sambo, P.
resistance and genotyping of Mycoplasma Castellani, S. Benedetti, F. Tarantino, M. Tumbarello
genitalium positive samples of the Lisbon area,
PortugalM. Barros* (Lisbon, Portugal), F. Pereira, L.
Rodrigues SY047
E0112 Antimicrobial Resistance in Mycoplasma
11:00 - 12:00 Hall 11

genitalium: Surveillance and Management in São 1-hour Symposium

Paulo, BrazilV. Passarelli* (São Paulo, Brazil), F.
Goldemberg, A. Freitas, C. Picone, C. Lazari, G. How long should contact isolation precautions be continued?
Carnevale, M. Thomazella, S. Chamarelli, D. Chairs Cansu Cimen (Oldenburg, Germany)
Gennari, C. Pedrozo, G. Hughes, S. Costa Kyriaki Tryfinopoulou (Heraklion, Greece)
E0113 Impact of genotypic substitutions on treatment
failure for Mycoplasma genitalium infectionN.B.
Bana* (Milan, Italy), A. Nava, D. Fanti, C. Vismara, G.
Cavazza, E. Di Gennaro, F. Peracchi, L. Rezzonico, A. S0141 11:00 Contact isolation in patients with MDR organisms:
Mulè, L. Denti, M. Puoti, R. Rossotti Why, when, where?Gabriel Birgand (Nantes, France)
E0114 Macrolide-resistant Mycoplasma genitalium: an S0142 11:30 Is discontinuation of contact precautions associated
emerging threat to public health?J. Ciscar Soriano* with an increase in infections?Daniel Diekema
(València, Spain), J. Ciscar-Soriano, M.D. Gómez- (Harpswell, United States)
Ruiz, A. Valentín-Martín, A. Hernández-Cabezas, Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI),
J.L. Lopez-Hontangas EUCIC Steering Committee, Multidisciplinary Joint Committee Infection
E0115 Comparison of carbapenem MIC in wild-type, MDR Control UEMS
and XDR Neisseria gonorrhoeae isolatesJ.
Brousseau* (Paris, France), A. Braille, M. Mainardis,
ME048
F. Meunier, M. Mérimèche, F. Caméléna, B. Berçot 11:00 - 12:00 Hall 12
E0116 Unsettling surge in antimicrobial resistance
Meet-the-Expert
patterns of Neisseria gonorrhoeae - A study from
national reference centre in India.D. Sharma* (Delhi, Cut a long story short: choosing NGS platforms
India), S. Muralidhar, N. Joshi
E0117 Surveillance of Neisseria gonorrhoeae antimicrobial
resistance rate and treatment regimes in Singapore
from 2014 to 2024M. Giovanni* (Singapore, M0143 11:00 Etienne Ruppe (Paris, France)
Singapore), A.L. Tan, B.K.W. Yeo, M.T.W. Chio, S.S.
M0144 11:12 Stefan Green (Chicago, United States)
Goh, S.T. Koh, Y.E. Tan
E0118 Molecular surveillance results of N. gonorrhoeae in
KoreaK.H. Roh* (Goyang, Korea, Republic of), C. OS011
Liu, Y.H. Suh, H. Lee, K. Lee 11:00 - 12:00 Hall 13

1-hour Oral Session

KN044
11:00 - 12:00 Hall 1 Around the lab in 80 ways: a journey through innovative therapeutics
Chairs Zuzanna Drulis-Kawa (Wroclaw, Poland)
Keynote Lecture
Helena Zemlickova (Prague, Czech Republic)
Asia: an AMR Hot Zone
Chairs Giulia De Angelis (Rome, Italy)
Robert Leo Skov (Copenhagen, Denmark) O0077 In vivo expression of an mRNA encoded multi-
mechanistic mAb combination against
Staphylococcus aureus and protection in a disease
modelC. Tkaczyk* (Gaithersburg, United States), N.
K0136 11:00 David L. Paterson (Singapore, Singapore) Michael, P. Mun Mun, T. George, S. Martin, G. Adam,
M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark,
L. Ashley, D. Antonio, S. Bret
OS010
11:00 - 12:00 Hall 10 O0078 Hijacking intrinsic resistance in Mycobacterium
abscessusG. Phelps* (Memphis, United States), S.
1-hour Case Session
Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E.
Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L.
Antimicrobial drugs in action
Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O.
Chairs Katy Jeannot (Besançon, France) Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A.
Timothy R. Walsh (Oxford, United Kingdom) Iverson, J.W. Rosch, B. Schulthess, P. Geeleher, S.
Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander,
R. Lee
O0072 In vivo cefiderocol resistance due to cirA modification O0079 Tripartite bacteriophage-based strategy to combat
during treatmentE. Carretto* (Reggio Emilia, Italy), P. human clinical pathogensP. Kalatzis* (Copenhagen,
Pini, R. Farzana, C. Bedogni, R. Marrollo, P. Nardini, Denmark), R. Ibarra-Chávez, H. Sampson, S.
M. Bardaro, N.C. Facciolongo, S. Mezzadri, T. Walsh Michniewski, A. Shen, M. Ford, B. Petersen, P.
Worning, P. Klement, H.P. Calum, U.M. Singh, A.
O0073 Long-term outcomes in dalbavancin-treated patients Millard, M. Clokie, T. Sicheritz-Pontén
with vascular graft infection.A. Specklin* (Reims,
France), T. Noël, M. Bonnet, A. Duprey, M. Hentzien O0080 Eosin Y and Ceragenin combinations for enhanced
antimicrobial photodynamic therapyY. Tekintas*
O0074 Aztreonam, ceftazidime/avibactam, and tigecycline
ESCMID Global 2025 - Programme
(Cigli, Türkiye), P.B. Savage, M. Ucuncu Clèries-Rovira, A. Padullés, N. Sabé Fernández, M.
O0081 Identification of compounds capable of removing Tuset, O. Len
established bacterial biofilmsT. Inzana* (Brookville, O0090 Prediction of BK Polyomavirus nephropathy in kidney
United States), A. Gates, W. Weng, J. Cusumano, Y.J. transplantation by measuring neutralizing responses
Lee, N. Vogelaar in a large cohort of donor and recipientsM. Solis*
(Strasbourg, France), W. Fardi, I. Benotmane, F.
Gallais, S. Caillard, S. Fafi-Kremer
ME049
11:00 - 12:00 Hall 14 O0091 Dengue in solid organ transplant recipientsS.I.
Galian* (Buenos Aires, Argentina), N. Pujato, N.S.
Meet-the-Expert Nolis, R. Del Grosso, P. Lopez, G. Aballay, M. Agustin,
G. Werber
How to perform clinical trials in mycoses?

SY045
11:00 - 12:00 Hall 2
M0145 11:00 Monica Slavin (Melbourne, Australia) 1-hour Symposium
M0146 11:12 Nkechi Azie (Barrington, United States)
What happens following TB infection?
Co-organised with: ESCMID Fungal Infection Study Group (EFISG)
Chairs Catherine Ong (Singapore, Singapore)
Sean Wasserman (London, United Kingdom)
OS012
11:00 - 12:00 Hall 15

1-hour Oral Session

S0137 11:00 Post-TB disease: burden and treatment
Climate Impact and One Health Approaches Against Infectious Diseases strategiesDeborah Chong (London, United Kingdom)
Chair Chadia Wannous (Paris, France) S0138 11:30 TB sequelae and fungal infectionHelmut Salzer (Linz,
Austria)
Co-organised with: ESCMID Study Group for Mycobacterial Infections
(ESGMYC), CPAnet
O0082 Airborne Threats: Pollution, Climate, and Respiratory
Infections in a Pyrenean setting: The Andorran
hospital based respiratory perspectiveC. Royo- YIA
Cebrecos* (Andorra, Andorra), N. Duran Torralbo, D. 11:00 - 12:00 Hall 3
Vilanova Gonzalez, M. Clusas Antolin, L. Trapero Awards
O0083 Effects of climate change on Aedes aegypti
abundance and dengue transmissionL. Geng* Young Investigator Award Session
(Singapore, Singapore) Chair Emmanuelle Cambau (Paris, France)
O0084 Impact of climate variables on Crimean-Congo
hemorrhagic fever in Iran, Iraq, Kazakhstan, and
RussiaM. Fereidouni* (Jahrom, Iran, Islamic Republic
of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. A001 11:00 Deciphering the pathogenic traits and
Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. epidemiological identities of Staphylococcus
Alhilfi, M. Keshtkar-Jahromi pseudintermedius: an emerging and underestimated
zoonotic pathogenIkechukwu Benjamin Moses
O0085 Successful public health and one health response to a (Abakaliki, Nigeria)
high pathogenicity avian influenza outbreak in poultry
farms in Victoria, Australia: implications for future A002 11:12 Drugs for Vector-borne Infections: Facts and
planningE. Athan* (Geelong, Australia), A. Hussain, K. FibrillationsXin Hui Chan (Oxford, United Kingdom)
Blaney, L. Cardamone, N. Clarke, M. Hayes, M. A003 11:24 Duke criteria for the diagnosis of infective
Muleme, B. Mcnamara, E. Jalil, S. Holwill, C.K. Lim, H. endocarditis in clinical practice: are we there yet?
O'brien, E. Layton, A. Fidao, S. Salmon, R. Kinnear Matthaios Papadimitriou Olivgeris (Sion, Switzerland)
O0086 Turning disease surveillance into reality: Using A004 11:36 Finding a place for observational studies in infectious
metagenomic sequencing with piggery diseases researchAnthony Bai (Kingston, Canada)
wastewaterM. Muralidhar* (St Lucia, Australia), L. A005 11:48 Clearing fungal fog in viral storms: deciphering
Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni influenza- and COVID-19-associated pulmonary
aspergillosisSimon Feys (Leuven, Belgium)

OS013
11:00 - 12:00 Hall 16
SY046
1-hour Oral Session 11:00 - 12:00 Hall 5

1-hour Symposium
Viral challenges in organ transplantation
Chairs Ghady Haidar (Pittsburgh, United States) New frontiers in bacterial pathogenesis
Cristiana Oprea (Bucharest, Romania) Chairs Silvio Daniel Brugger (Zurich, Switzerland)
Abdou Hachani (Melbourne, Australia)

O0087 Evaluation of an individualized CMV prevention

strategy guided by post-transplant CMV-specific cell- S0139 11:00 Bacterial infections and cellular immunityCharlotte
mediated immunity in intermediate-risk kidney Odendall (London, United Kingdom)
transplant recipientsI. Rodríguez-Goncer* (Madrid,
Spain), J.M. Caso, M. Fernández-Ruiz, E. González, N. S0140 11:20 Immuno-metabolism in bacterial diseasesTania Wong
Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan, (New York, United States)
L.M. Allende, E. Paz-Artal, A. Andrés, F. López-
Medrano, J.M. Aguado, I. Rodríguez-Góncer
OS007
O0088 Real-world Use of Letermovir Prophylaxis for 11:00 - 12:00 Hall 6
Cytomegalovirus (CMV) Prevention in Non-kidney 1-hour Oral Session
Transplant RecipientsA. Mughrabi* (Rochester,
Minnesota, United States), B. Bisono-Garcia, S. New developements in prophylaxis and treatment of COVID-19
Chesdachai, N. Ranganath, R. Razonable
Chairs Gülsen Özkaya Sahin (Lund, Sweden)
O0089 Real-world administration of maribavir beyond the Snjezana Zidovec Lepej (Zagreb, Croatia)
eight weeks established in the clinical trialD.
Martínez-Simón* (Barcelona, Spain), C. Ribera-Puig,
M. Bodro, D. Campany, J. Esperalba, I. Los Arcos, P.
ESCMID Global 2025 - Programme
O0057 Ensitrelvir for the prevention of COVID-19 among Corbacho-Loarte, S. De La Fuente-Herranz, J. Cobo
household contacts: key subgroup analyses of a Soriano, J. Urbano, M. Martín Martín, J.A. Pérez-
randomized, double-blinded, placebo controlled Molina
post-exposure prophylaxis study, SCORPIO-PEPF. O0069 Two cases of septic osteoarthritis of Cutibacterium
Hayden* (Virginia, United States), N. Ohmagari, acnes detected by 16S rRNA gene sequencing in
T.W. Clark, M. Shinkai, A.F. Luetkemeyer, P. Sax, immunocompetent adolescentsH. Okuno* (Osaka,
W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, Japan), K. Shiota, K. Amo
C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S.
Lacey, G. Ichihashi, T. Uehara O0070 A UK case of Melioidosis with osteomyelitis two years
after geographical exposureC. Darlow* (Liverpool,
O0058 Efficacy of nirmatrelvir/ritonavir on overall COVID- United Kingdom), L. Swithenbank, R. Taggart, V.
19 related symptoms in immunocompromised adult Owen, N. Wong, S. Woolley, W.D. Harrison, L.
participants from the EPIC-IC trialR. Mokgokong* Ratcliffe, J. Lewis
(Tadworth, United Kingdom), P. Cislo, E. Tudone, E.
Weinstein, J.C. Cappelleri O0071 When Infection Masquerades as Malignancy: A Case
of Disseminated Mycobacterium fortuitum complex
O0059 COVID-19 patients benefitting from remdesivir for infection with Mixed Osteoblastic and Osteolytic
improved survival: a neural network-based Lesions and Lymphadenopathy in Anti-IFN-γ
approach.T.F. Aiello* (Barcelona, Spain), C. Teijón- Immunodeficiency SyndromeN. Hiranburana*
Lumbreras, C. Garcia-Vidal, M. Chumbita, M. (Bangkok, Thailand), S. Khahakaew, K.
Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó- Meesilpavikkai, M. Satja, G. Suwanpimolkul
Gallo, A. Gallardo-Pizarro, A. Martinez-Urrea, R.
Méndez, E. Calbo, M. Ballestero-Tellez, G. Cuesta-
Chasco, M. Marcos, A. Soriano
LB001
O0060 Efficacy and safety of sotrovimab vs oral antivirals 11:00 - 12:00 Hall 9

in omicron waves: a retrospective analysisC. 1-hour Oral Session

Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P.
Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N. Advances in vaccine effectiveness for viral respiratory infections
Coppola Chair Jean Paul Stahl (Corenc, France)
O0061 Pharmacokinetics and immunogenicity of AZD7442
(Tixagevimab/Cilgavimab) in hospitalised COVID-19
patients: results from the DisCoVeRy trialC.
Massonnaud* (Paris, France), M. Hites, N. Peiffer- L0001 Immunogenicity of JN.1- and KP.2-encoding mRNA
Smadja, T.H.L. Han, G. Carcelain, F. Mentré, F. Ader COVID-19 vaccines against JN.1 SARS-CoV-2
sublineages in adult participantsA. Figueroa*
(Cambridge, United States), D. Edwards, K. Johnson,
OS008 D. Motefiori, B. Girard, S. Hack, X. Cao, E. De Windt
11:00 - 12:00 Hall 7
L0002 JN.1-adapted vaccine effectiveness against COVID-19
1-hour Oral Session hospitalisation in Europe: a test-negative case-control
study using id.DRIVEH.R. Volkman* (New York,
Advancing Malaria Research: From Molecular Insights to Clinical Challenges United States), L. De Munter, J.L. Nguyen, T.M.P.
Chairs Kamruddin Ahmed (Kota Kinabalu, Malaysia) Tran, C. Marques, E. Mesfun-Kap, L. Choi, L. Drikite,
Giri Shan Rajahram (Kota Kinabalu, Malaysia) S. Valluri, J.V. Hernandez-Villena, J. Yang, I. Casas, E.
Martro, B. Gruner, G. Icardi, A. Mira-Iglesias, C.M.
Oñoro López, O. Pares-Badell, A. Orrico-Sanchez, S.
Otero-Romero, A. Riva, A. Torres, F. Martinon Torres,
O0062 Influence of second blood meals on Plasmodium L. Jodar, J.M. Mclaughlin, K. Bollaerts
vivax development and infectivity in mosquitoesS. L0003 Real-world effectiveness of 20-valent pneumococcal
Bantuchai* (Bangkok, Thailand), W. Nguitragool, J. conjugate vaccine among adults ≥65 years of age in
Sattabongkot, C. Kumpitak the United StatesA. Miles* (New York, United States),
O0064 Severe imported Plasmodium falciparum malaria with J.T. Vietri, S. Rosenstock, H. Li, J. Vojicic, L.R. Grant,
hyperparasitaemia: evaluation of predictors for A. Randall, B.D. Gessner, P. Balmer, A. Cane, P.
critical diseaseT. Lingscheid* (Berlin, Germany), J. Peyrani
Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E. L0004 Safety and immunogenicity of the MERS vaccine,
Sander, M. Ramharter, F. Kurth ChAdOx1 MERS, in older adults with and without prior
O0065 The current status of Plasmodium falciparum ChAdOx1 exposureD. Jenkin* (Oxford, United
chloroquine resistance transporter gene (K76T) and Kingdom), E. Sheehan, R. Huq, T. Lambe, S. Gilbert,
Plasmodium falciparum multi-drug resistance gene 1 A.M. Collins, M.N. Ramasamy, A. Mujati, R. Kenneil,
(N86Y) in CameroonM. Fru* (Buea, Cameroon) N. Marchevsky, I. Haeusler, E. Vannaxay, N. Ebrahimi,
O0066 SOFA score vs WHO severity criteria to guide S. Batawi, F. Cappuccini, R. White, L.S. Ortega, O.
antimalarial treatment - 10 years of imported malaria Mazur, H.T. Belhadef, B. Stoilova, D. Pulido-Gomez, H.
cases in a UK tertiary centre reviewed.E. Savory* Zhang, K. Conlin, M. Voysey, A. Hyder-Wright, L.
(Cambridge, United Kingdom), M. Routledge, B. Mclellan, O. Hamilton, V. Simpson, J. Court, N.
Warne, E. Moore, D. Sparkes Murphy, M. Farrar, P. Saunderson
L0005 Vaccination in pregnancy with RSVpreF elicits IgG,
IgA and total secretory antibody responses in milk of
OS009 lactating individualsJ. Atwell* (New York, United
11:00 - 12:00 Hall 8
States), R. Powell, X. Yang, C. Decarlo, A. Fox, R. Fan,
1-hour Case Session S. Uppal, J. Deese, M. Vichnin, E. Gonzalez, B.
Gessner
Osteoarticular uninvited guests
Chairs Tiziana Ascione (Naples, Italy)
SY051
Jaime Esteban (Madrid, Spain) 13:30 - 14:30 Hall 1

1-hour Symposium

O0067 Antibiotic-refractory oligoarthritis in an adolescent Year in infectious diseases

caused by Borrelia bavariensis in CroatiaN. Krajcar* Chairs Nur Benzonana (Istanbul, Türkiye)
(Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak Evelina Tacconelli (Verona, Italy)
Pažur, S. Roglić, R. Beck, G. Tešović
O0068 Progression of vertebral echinococcosis despite
radiotherapy treatmentM. González-Sanz* (Madrid,
Spain), O. Martín, A. Romero-Alegría, M. Belhassen, S0151 13:30 Yoav Keynan (Winnipeg, Canada)
S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman, S0152 14:00 Elisa Cordero Matia (Seville, Spain)
B. Monge Maillo, C. Crespillo-Andújar, M.D.
ESCMID Global 2025 - Programme

SY053 hematopoietic cell transplant (HCT) recipients

13:30 - 14:30 Hall 16
receiving meropenem (MER) or
1-hour Symposium piperacillin/tazobactam (P/T)E. Dubberke* (Saint
Louis, United States), M. Schroeder, H. Sappington,
Developing guidelines with AI tools: are they ready for prime time? G. Lampen, K. Reske, T. Hink, V. Joachimstaler, E.
Chairs Miranda Langendam (Amsterdam, Netherlands) Jeremy, M. Keller, A. Bristol, C. Le, S. Connelly, M.
Blin Nagavci (Gjakove, Kosovo) Moenk, V. Wacher, M. Kaleko, J. Kuti, M. Olsen
E0146 Standardized gastrointestinal cytomegalovirus
(CMV) tissue quantitative-nucleic-acid testing
(QNAT) compared to immunohistochemistry in
S0155 13:30 The PROs and CONs of using AI tools for developing allogeneic hematopoietic cell transplant (HCT)
guidelinesHolger Schuenemann (Milano, Italy) recipientsS. De Aragón De La Cruz* (Basel,
S0156 14:00 AI in action: validated tools for speeding up your Switzerland), C.S. Walti, N. Khanna, K. Leuzinger,
systematic reviews and how to use themSara J.P. Halter, H.H. Hirsch, K. Nägele, J. Passweg, J.
Fernandez (Oslo, Norway) Vosbeck
Co-organised with: ESCMID Guidelines Subcommittee E0147 Real-life experience with maribavir for the
treatment of cytomegalovirus infection in
hematological patients.J. Boan Perez* (Madrid,
SY052 Spain), J.M. Sánchez-Pina, C. Aizpurúa, I.
13:30 - 14:30 Hall 2
Rodríguez-Goncer, F. López-Medrano, R. San-Juan,
1-hour Symposium M. Fernández-Ruiz, E. Aparicio, M. Lizasoaín, J.M.
Caro-Teller, J. Martínez, M. Calbacho, J.M. Aguado
Exploring children's role in infection spread
Chairs Angelika Berger
EF022
Sanjay Patel (Winchester, United Kingdom) 13:30 - 14:30 Arena 2

ePoster Flash Session

S0153 13:30 Are children really super-spreaders of respiratory Syndromic testing is still coming of age
viruses?Emmanuel André (Leuven, Belgium) Chair Tommaso Giani (Florence, Italy)
S0154 14:00 Should schools be closed at the start of the next
pandemic?Vittoria Colizza (Paris, France)
Co-organised with: European Society of Paedriatic Infectious Diseases E0148 Bacterial infections of the central nervous system:
(ESPID) addressing the diagnostic gap in non- community-
acquired meningitisG. Menchinelli* (Rome, Italy), M.
Cacaci, D. Squitieri, B. Fiori, T. D'inzeo, G. De Angelis,
EF021
13:30 - 14:30 Arena 1 B. Posteraro, M. Sanguinetti
E0149 Epidemiological surveillance of central nervous
ePoster Flash Session
system infections through a rapid syndromic testing
platformM. Rey* (Barcelona, Spain), L. Pau, C.
Infections in hemato-oncological hosts: from bacterial to viral
Miravet, A. Molins, G. Hansen, M. Juanola-Falgarona
Chair Genovefa Papanicolaou (New York, United States)
E0150 Impact of Syndromic Panel Implementation on
Meningitis/Encephalitis Diagnosis, Antimicrobial Use,
Costs, and Hospital Stay in a Regional Australian
E0139 Vancomycin-resistant Enterococcus faecium HospitalS. Subedi* (Brisbane, Australia), P. Harris, D.
bloodstream infection in patients with Paterson
hematological malignancy and stem cell transplant: E0151 Performance evaluation of the NxTAG® GPP Panel
a case-control studyJ. Fung* (Vancouver, Canada), for the detection of gastrointestinal pathogens by
K. Aldhaheri, C. Nishi, J. Lau, A. Mah, A. Wright, R. comparison with current routine methods in Nantes
Stubbins, M. Charles, S. Belga University Hospital.S. Gibaud* (Nantes, France), L.
E0140 Bacteremia secondary to urinary tract infection in Castain, S. Hartuis, C. Hervochon, B.M. Imbert, P.
oncology patients: risk factors and impact of Lepape, S. Corvec
multidrug-resistant Gram-negative bacilli.I. Grafia* E0152 Correct discrimination of Monkeypox virus clades by
(Barcelona, Spain), A. Moll, S.J. Santillá, C. Rodrigo, fast syndromic testingS. Reister* (Hilden, Germany),
E. Lillo, M. Garcia De Herreros, N. López, A. Soriano, L. Peñarrubia, M. Juanola-Falgarona, G. Pueyo, S.
M. Espasa, D. Marco, S. Fernández, J. Marco- Jiménez-Guzmán, R. Diaz-Hernández, E. Padilla-
Hernández, C. Zamora, J. Padrosa, L. Llavata, M. Cámara, J. Michel, A. Puyskens, F. Van Deursen, D.
Viladot, A. Tuca, P. Puerta-Alcalde Lueerssen
E0141 Rectal carriage of multidrug-resistant organisms E0153 Managing a Mycoplasma pneumoniae Outbreak:
and subsequent bloodstream infections in Impact of Syndromic Panels on Antimicrobial
hematologic patients undergoing hematopoietic Prescriptions in Pediatric EmergenciesL. Brusca*
stem cell transplantation or chimeric antigen (Barcelona, Spain), L. Brusca-Vidao, M. Pallarés-
receptor T-cell therapyC. Charalampidis* (Athens, Borrás, G. Santillana-Cernuda, M. Ballestero-Tellez,
Greece), I. Konstantellos, P. Kazakou, K. Gkirkas, I. A. Boronat, J. Perez
Lazana, C. Chatzidimitriou, A. Zormpa, E. E0154 Performance of BIOFIRE® FILMARRAY® Pneumonia
Mastrostamati, I. Grigoropoulos, D. Kavatha, S. plus in general population, solid organ transplant
Tsiodras, P. Tsirigotis, K. Thomas recipients and patients with hematologic
E0143 The RUSTIC Study: Respiratory Virus Infection in a malignancies – Interim analysisR. Riccardi* (Bologna,
Contemporary Longitudinal Cohort of Patients with Italy), M. Rinaldi, G. Ceccarelli, C. Campoli, C. Tondi,
Haematological MalignancyB. Teh* (Melbourne, M. Casarini, B. Miani, G. Nigrisoli, S. Ambretti, P.
Australia), V.G. Hall, A. Liu, K.Y. Yong, Z. Andrews, Viale, M. Giannella
P. Kinsella, N. Laundy, J. Wolfe, L. Cooley, M.K. E0155 Impact of the molecular rapid diagnostic panel
Yong, M.A. Slavin testing in adjustment of antimicrobial therapy in
E0144 Viral respiratory infections in patients with febrile neutropenic patients with bacteremiaS.
hematological diseases over 10 years: epidemiology Chantharasut* (Bangkok, Thailand), M.
and impact on disease severityP. Bono* (Milan, Chayakulkeeree, W. Kamolvit, A. Jitmuang, I.
Italy), A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, Thaipisuttikul
F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N. E0156 BacteREVEAL: Analytical performance and
Hejazifar, C. Biassoni, G. Giacomel, A. Valzano, M.R. contribution of BioFire® BCID2 and Vitek®
Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti,
A. Callegaro, C. Alteri REVEALTM in intensive care patients with Gram-
negative bloodstream infectionsC. Roger* (Nimes,
E0145 Safety and tolerability of SYN-004 in allogeneic France), L. Oudiane, M. Benyahia, F. Salipante, A.
ESCMID Global 2025 - Programme
Dubois, L. Muller, J.P. Lavigne, A. Pantel
E0166 Gfa, a novel integron-born fosfomycin resistance
mechanismN. Kieffer* (Madrid, Spain), L. Ortiz-
EF023 Miravalles, A. Hipolito, J.A. Escudero
13:30 - 14:30 Arena 3
E0167 Regulons of RamA, RarA and SoxS mediated
ePoster Flash Session tigecycline resistance and oxidative stress among in
vitro tigecycline resistant evolution trajectory of
Effective microbiology for the management of sepsis Klebsiella pneumoniae.X. Wang* (Beijing, China), J.
Chair Maurizio Sanguinetti (Rome, Italy) Kuai, Y. Zhao
E0168 Assessing the impact of altered penicillin binding
proteins on susceptibility to novel antimicrobials
among clinical isolates of carbapenemase-producing
E0157 Molecular epidemiology of Klebsiella bloodstream Escherichia colC. Tellapragada* (Stockholm,
infection-causing isolates across England using Sweden), P. Jonsson, C. Giske
Nanopore longread-only sequencing: An interim
analysis of the NEKSUS studyD. Nagy* (Oxford, E0170 Enterococcus faecalis penicillin-binding protein-4
United Kingdom), N. Stoesser, S. Lipworth, V. sequence differences based on penicillin minimum
Pennetta, K. Hopkins, G. Rodger, R. Moran, C. Jones, inhibitory concentrationO. Funk* (Brooklyn, United
T. Neksus Study Group, S. Hopkins, D. Crook, A.S. States), A. Kozlenkov, C. Toro Chacon, J. Azzouzi, S.
Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Brown, J. Cusumano
Williams, R. Hope, C.S. Brown E0171 Uncommon genomic rearrangements drive
E0158 Investigating seasonality of antibiotic resistance vancomycin resistance in vanB-positive
associated with E. coli and Klebsiella pneumoniae Enterococcus faeciumK. Xanthopoulou* (Cologne,
bloodstream infectionsS. Lipworth* (Oxford, United Germany), J. Mellüh, R. Arazo Del Pino, L.
Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. Casselmann, V. Persy, T. Burgwinkel, E. Gieraths, L.
Sanderson, C. Beck, R. Hope, C. Brown, K. Turner Maus, A. Klimka, P.G. Higgins
E0159 Sensitivity of a host-protein test for microbiologically E0172 Heteroresistance in Enterococcus faecalis:
confirmed bacterial infectionsR. Navon* (Tirat prevalence and mechanistic insights across clinically
Carmel, Israel), E. Reiner, O. Shaham, A. Neuberger, relevant antibioticsS. Heidarian* (Uppsala, Sweden),
S. Shiber, S. Halabi, A. Epstein, T. Zalut, S. Motov, T.P. S. Lohsen, A. Guliaev, K. Hjort, S. Satola, D. I.
Aufderheide Andersson
E0160 Comparative genomics of Klebsiella pneumoniae E0173 Side effects of rifampicin resistance: transcriptome
from gut colonisation and bloodstream infections modulation by rpoB mutations in Staphylococcus
reveal novel genetic associationsM. Hetland* aureusM. Roch* (Geneva, Switzerland), R. Sierra, C.
(Stavanger, Norway), K.L. Wyres, H.B. Cooper, A. Colomer Winter, F. Bezrukov, O. Panasenko, A.
Correia, M.A. Winkler, A. Fostervold, N. Raffelsberger, Guisolon, U. Von Ah, M. Villanueva, P. Redder, K.
A. Sundsfjord, Ø. Samuelsen, K.E. Holt, I.H. Löhr Kline, J. Prados, W.L. Kelley
E0161 Conventional microbiology vs. conventional E0174 Novel continuous experimental evolution
microbiology + nucleic acid-based multiplex real-time methodology revealing rapid resistance development
polymerase chain reaction (MPCR) test kit in septic and cross-resistanceT. Echelmeyer* (Greifswald,
shock: results of a matched cohort studyG. Sanlidag Germany), M. Ellmann, S.E. Heiden, M. Schwabe, H.
Isbilen* (Izmir, Türkiye), G. Şanlıdağ İşbi̇len, B. Akkul, Fickenscher, G. Maschkowitz, D. Nurjadi, R.
C. Tol, D. Akyol Seyhan, H. Sipahi, Ş. Aydemir, F. Çilli, Podschun, K. Schaufler, E. Eger
B. Arda, O.R. Sipahi
E0162 Contribution of Escherichia coli microbiological OS018
factors to the presentation as sepsis/septic shock in 13:30 - 14:30 Hall 11
patients with bacteraemia: a matched case-control 1-hour Oral Session
studyN. Maldonado* (Seville, Spain), I. López-
Hernández, L.E. López-Cortes, P.M. Martínez Pérez- Battling the Spore: C. difficile epidemiology and management
Crespo, A. García-Montaner, M. Alcade-Rico, A.
Sousa-Dominguez, A. Jover-Sáenz, J. Goikoetxea, Á. Chairs Nicolas Benech (Lyon, France)
Pulido-Navazo, C. Labayru Echeverría, A.I. Aller- Fidelma Fitzpatrick (Dublin, Ireland)
García, L. Boix-Palop, A. Del Arco-Jiménez, A.
Smithson-Amat, J.M. Sánchez-Calvo, C. Natera-
Kindelán, J.M. Reguera Iglesias, C. Armiñanzas- O0124 Molecular epidemiology and antimicrobial resistome
Castillo, F. Galán-Sánchez, A. Bahamonde, I. Gea- of Clostridioides difficile from private and public
Lázaro, J. Fernández-Suárez, I. Pérez-Camacho, T. healthcare settings in three provinces in South
Marrodán-Ciordia, B. Becerril-Carral, Á. Pascual- AfricaH. Shirinda* (Pretoria, South Africa), A.M.
Hernández, J. Rodríguez-Baño Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M.
E0163 Simplified and rapid bacterial identification with Ehlers
antimicrobial resistance detection in bacteremia by O0125 Screening for Clostridioides difficile colonization at
on-chip multiplexed LAMP.C. Treille* (Saclay, admission and during hospitalizationN. Khanafer*
France), K. Perez-Toralla, H. Boutal, X. Garcia (Lyon, France), S. Bennia, G. Martin-Gaujard, L.
Velasquez, L. Pommies, S. Simon, H. Volland Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin,
E0164 Community-onset bloodstream infection among P. Vanhems
people with opioid use disorders: A twenty-year O0126 Revolutionizing CDI treatment: Are shorter antibiotic
population-based cohort study in Queensland, regimens the futureM. Duricek* (Prague, Czech
Australia.K. Laupland* (Herston, Australia), A. Republic), J. Benes, K. Halmova
Stewart, F. Edwards, P. Harris, S. Coulter
O0127 Extended-pulsed fidaxomicin versus conventional
E0165 Microbiological diagnosis tools for primary and dosing in patients at high risk of recurrence of
secondary abdominal aortic infections requiring Clostridioides difficile infectionE. Rubio-Martín*
surgeryS. Soueges* (Lyon, France), A. Blanco, A. (Seville, Spain), R. Escudero-Sánchez, Á. Gutiérrez
Souche, C. Triffault-Fillit, M. Arsicot, M. Wan, N. Della- Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Díaz
Schiava, U. Huvelle, A. Millon, F. Valour Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez
Caballero, A.M. Rodríguez Benavente, S. De La Villa,
J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez
EF024
13:30 - 14:30 Arena 4 Gómez, E. Calabuig, M. Tasias, R. Blanes, M.Á. López
Zúñiga, J. Rodríguez Granger, P. Merino Amador, A.
ePoster Flash Session Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G.
Maestro De La Calle, J. Mateo Flores, J.B. Pérez
A never-ending evolution of antimicrobial resistance Gilaberte, R.M. Martínez Álvarez, F. Martínez García,
Chair Antonio Oliver (Palma De Mallorca, Spain) N. Cobos-Trigueros, J. Llenas-García, M. Solivella-
Rodríguez, L. Ramos Merino, B. Castelo López, M.M.
ESCMID Global 2025 - Programme
Montero, D. Echeverría-Esnal, J. López-Contreras, P. O0136 Utilizing a weighted-incidence syndromic
Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. antibiogram to evaluate antimicrobial therapies and
Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, resistance trends in community-acquired infections
A. Muriel García, S. Moreno Guillén, J. Cobo in a community teaching hospitalV. Huang*
O0128 Gut phageome profiling in Clostridioides difficile (Glendale, United States), T. Pham, A. Vogler, H.
infection and faecal microbiota transplantationC. Chhen, C. Vandenberg
Chen* (Lausanne, Switzerland), T. Pillonel, J. Schaer, O0137 Capturing days of therapy per days of service as a
G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galpérine stewardship tool to identify outliers in prescribing
broad-spectrum antimicrobials in the hospital
settingA. Hopkins* (Livingston, United States), A.
OS019 Farkas, S. Tamirisa, G. Severance, A. Yassin, E. Jaime
13:30 - 14:30 Hall 12
O0138 Timing of Novel β-Lactams vs. Alternatives in
1-hour Oral Session Hospitalized Patients with Gram-Negative Infections:
Line of Therapy (LoT) Analysis Preliminary findingsE.
Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Yucel* (Rahway, United States), J. Min, Y. Wang, M.
Potential Vendetti, Y. Emre, R.K. Shields
Chairs Mauricio Farfan (Santiago, Chile)
Eija Inkeri Könönen (Turku, Finland)
ME054
13:30 - 14:30 Hall 3

Meet-the-Expert
O0129 Multi-omics integrated analysis revealed the key role
of Fusobacterium periodonticum in colorectal How antimicrobial tolerance impacts polymicrobial biofilm-associated
tumorigenesis by decanoic acid promoting neutrophil infections
chemotaxis.X. Chu* (Beijing, China), Q. Yang
O0130 Exploring the respiratory microbiome in COPD
patients: The role of Haemophilus spp. in disease
pathogenesisP. Camps-Massa* (Barcelona, Spain), L. M0157 13:30 Hans Steenackers (Leuven, Belgium)
Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara- M0158 13:42 Brian Conlon (Chapel Hill, United States)
Nuñez, F. Tubau, J. Burgos, M. Lopez, A. González-
Díaz, C. Ardanuy, M. Dominguez, S. Santos, S. Martí
O0131 Using the in vitro MiGut system to simulate the OS017
ulcerative colitis microbiome and post-antibiotic 13:30 - 14:30 Hall 5

recovery supported by a pre-defined consortium of 1-hour Case Session

microbesI. Moura* (Leeds, United Kingdom), W.
Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Bad bacteria
Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M. Chairs Maristela P. Freire (Sao Paulo, Brazil)
Wilcox, N. Kapur, A. Buckley Siegbert Rieg (Freiburg, Germany)
O0132 Functional characterization of the Brazilian Yanomami
microbiome along an urbanization gradient: Insights
into the impacts of Westernization on human
healthM. Thorp* (Gent, Belgium), C. Callewaert, B. De O0119 Vancomycin Dependent Enterococci: An evolutionary
Pessemier, D. Good, E. Allen-Vercoe, L. Paulino, L. dead end or the ultimate evolution of a superbugR.
Vereecke Gupta (bagga)* (London, Canada), A. Cabrera, A.
Kanyua, F. Almutawa, J. Delport, K. Kavanoor Sridhar
O0133 Colonization resistance of the intestinal microbiota to
multidrug-resistant bacteria?K. Villageois-Tran* O0120 Whipple's disease: one of medicine's great
(Bobigny, France), C. Emavivie, H. Skerdi, E.N. Saad, imitatorsS. Kesavan* (Nottingham, United Kingdom),
M. Julie, E. Ruppé F. Heard, S. Kesevan, E. Hart, V. Fleming, C. Santos,
R. Thomson
O0121 Phage Therapy as a Rescue Treatment for Recurrent
ME055 Pseudomonas aeruginosa Bentall InfectionV.
13:30 - 14:30 Hall 14
Eiferman* (Paris, France), P.A. Vion, B. Rached, C.
Meet-the-Expert Granger, N. Hammoudi, A. Bleibtreu
O0122 A clinical case of Legionella longbeachae pneumonia
Long acting injectables to treat and prevent infections: an example from HIV
featuring unique epidemiological features in a major
field
italian hospitalS. Guerriero* (Rome, Italy), M. La
Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del
Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti,
C. Torti
M0159 13:30 Monica Gandhi (Salt Lake City, United States)
O0123 Francisella tularensis – First autochthonous case in
M0160 13:42 Pedro Cahn (Buenos Aires, Argentina) the UKG. Vanstone* (Truro, United Kingdom), A.
Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques
Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam,
OS020
13:30 - 14:30 Hall 15 A. Ainarozidou
1-hour Oral Session
ME061
How to evaluate AMS programs 14:45 - 15:45 Hall 3

Chairs Esther Calbo (Terrassa, Spain) Meet-the-Expert

Sabiha Essack (Durban, South Africa)
How to use large language models and machine learning for improving One
Health

O0134 Preference-based instrumental variables for

estimating the causal effects of antibiotic prescribing
decisions in common infections: Assessing potential M0170 14:45 Javier Fernández (Oviedo, Spain)
validity using CPRD dataN. Nguyen* (Oxford, United
Kingdom), K. Pouwels, J.V. Robotham, S. Yu, S. M0171 14:57 Nicolas Radomski (Teramo, Italy)
Wordsworth Co-organised with: ESCMID Food- and Water-borne Infections Study Group
O0135 Novel antibiotic spectrum metrics to quantify the (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM),
impact of antimicrobial stewardship: a multicentre Portuguese Society of Microbiology (SPM)
studyB. Moshy* (London, United Kingdom), R.
Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah,
B. Gemma, I. Balakrishnan
ESCMID Global 2025 - Programme

FO063 studyS. Lant* (Liverpool, United Kingdom), R.

14:45 - 15:45 Arena 1
Mehta, M.L. Brito Ferreira, C. Soares, R. Medialdea
Open Forum Carrera, M. Tulius, P. Brasil, C. Miguelote, A.
Henriques Souza, M. Ellul, M. Griffiths, M.M. Jardim
Science communication in a noisy world: podcasting and social media in Rodrigues, R. Braga, L. Pamplona, C. Spitz, F.
ID/CM Militao, A. Rosala Hallas, G. Burnside, R. Vivancos,
Chair Emily G. Mcdonald (Montreal, Canada) S. Leonhard, L. Rodrigues De Mendonça-Vieira, B.
Jacobs, C. Brito, P. Sequiera, D. Brown, L. Turtle, R.
Franca, A. Bispo, T. Solomon
E0206 Challenges in managing Central nervous system
F0174 14:45 The ID:IOTS guide to creating a successful CM/ID infections: Battling the Unknown Enemy, West Nile
podcast"Callum Mutch (Edinburgh, United Kingdom) virus vs unknown etiologyC. Marin* (Bucharest,
F0175 14:55 Using social media for CM/ID educationScott Jake Romania), A. Paun, E. Nedu, S. Tetradov, S. Lazar,
(Oakland, United States) M. Nica, G. Tardei, I.A. Condurache, S.A. Florescu,
S.M. Ruta, C.P. Popescu
F0176 15:05 Podcasting and social media for antimicrobial
stewardship and pharmacyErin Mccreary E0207 Spatial and temporal profiling of the immune
(Pittsburgh, United States) responses induced by Japanese encephalitis virus
in a mouse modelZ. Ou* (Shenzhen, China), Z.
Co-organised with: CMI Communications Board of Editors
Wang, Q. Chen, X. He, P. Ren, J. Li, G. Cheng
E0208 Intrathecal immunoglobulin synthesis in tick-borne
EF029 encephalitisS. Grygorczuk* (Bialystok, Poland), P.
14:45 - 15:45 Arena 2
Czupryna, D. Martonik, J. Dunaj-Małyszko, J.
ePoster Flash Session Adamczuk, A. Parfieniuk-Kowerda, J. Osada, A.
Moniuszko-Malinowska
Vaccination uptake-challenges and opportunities E0209 B and T cell responses to Tick-borne Encephalitis
Chair Joanne M. Langley (Halifax, Canada) VirusN. Mayola Danes* (Stockholm, Sweden), R.
Varnaitė, N. Mayola Danés, K. Blom, H.G. Ljunggren,
S. Gredmark-Russ
E0210 Enterovirus infections in pediatric central nervous
E0196 Psychological Predictors of Influenza Vaccination
system (CNS) diseases: molecular epidemiology
Intent Among Healthcare Workers in BulgariaP.
and neuroimaging insightsD. Sharma* (Chandigarh,
Velikov* (Sofia, Bulgaria), V. Rangelova, Y. Axentieva, India), R. Pathania, P. Bhattacharya, M. Gautam, A.
Y. Tcholakov, V. Borisova-Nenovа, D. Ivanov, A. Bansal, S. Vyas, A. Ghosh, K. Goyal, M. P Singh
Zasheva, A. Hori
E0211 Neuroimaging findings and their correlation with
E0197 Determinants of COVID-19 vaccine uptake in patients
autopsy findings: Prospective study on Rabies
with hematologic malignancies: a nationwide cohort
encephalitisM. Mohata* (New Delhi, India), V. Suri,
studyQ. Hofsink* (Amsterdam, Netherlands), T.
P. Singh, G.K. Mohi, A. Bhalla, R. Mohindra, R.K.
Osmenaj, B.I. Lissenberg-Witte, S. Hahné, J. Soni, K. Gupta
Heijmans, I.S. Nijhof, A. Goorhuis, M.D. Hazenberg,
C.E. Rutten, S. Haggenburg, P. Den Tex, A. E0212 Toxoplasma gondii IgG Screening and Central
Dinmohamed, J. Kemmeren, H. De Melker, S. Van Nervous System Complications among People with
Den Hof HIV in the Combination Antiretroviral Therapy EraT.
Ou* (New Taipei City, Taiwan, China), T.Y. Tsai, S.H.
E0199 Inequality in vaccine uptake among children in
Huang, T.Y. Wu, W.D. Liu, H.Y. Sun, K.Y. Lin, C.C.
Denmark in the national childhood vaccination
Hung
programmeA.C.M. Breschel* (Copenhagen,
Denmark), A.V. Søndergaard, S.K. Nørgaard, B.
Søborg, P.H. Andersend
EF031
E0200 Prevalence and associated factors of parental refusal 14:45 - 15:45 Arena 4

rates for routine immunisation: A cross-sectional ePoster Flash Session

study in Peshawar, Khyber Pakhtunkhwa, Pakistan-
2024M. Hakim* (Hayat Abad Peshawar Kp Pakistan, AMS around the world: know your data!
Pakistan) Chair Eoghan De Barra (Dublin, Ireland)
E0201 Shingles Prevalence, Vaccine Awareness, and
Acceptance in People Living with HIVD. Yaman*
(Izmir, Türkiye), D. Akdağ, M. Taşbakan, H. Pullukçu,
D. Gökengin E0213 Duration of antibiotic treatment for respiratory tract
infections in primary care.C. Llor* (Barcelona, Spain),
E0202 Tick-borne encephalitis vaccine uptake,
M.P. Hansen, J. Lykkegaard, J.K. Olsen, B.H.
effectiveness, and impact in Sweden, 2018−2022A.
Lindberg, I.K. Rebnord, R. Radzeviciene, L.
Palmborg* (Stockholm, Sweden), F. Angulo, P.
Jaruseviciene, P.T. Lundgren, P. Bruno, A. Kowalczyk,
Zhang, A. Pilz, J. Stark, M. Jennifer, L. Jodar
C. Lionis
E0203 Monkeypox (mpox) vaccination willingness and
E0214 Antibiotic prescribing for common acute infections in
determinants among people living with HIV (PLWH) in
Pakistan - an analysis using IQVIA prescriber
turkeyC. Boşnak* (Altındağ, Türkiye), T.K. Şahin, E.
healthcare surveysN. Nguyen* (Oxford, United
Erul, M.Ç. Sönmezer, A.Ç. Inkaya, S. Ünal
Kingdom), K. Pouwels, M. Sharland, S. Mangla, A.
Cook, M. Thorn, P. Stephens
EF030 E0215 Antibiotic prescribing for common acute infections in
14:45 - 15:45 Arena 3
Egypt - an analysis using IQVIA prescriber healthcare
ePoster Flash Session surveysN. Nguyen* (Oxford, United Kingdom), S.
Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels,
Viruses crossing the blood-brain barrier M. Sharland
E0216 Population based analysis of the impact of Japan's
AMR national action plan and the COVID-19
pandemic on antimicrobial prescriptionR. Koizumi*
E0204 Clinical characteristics and outcome of Herpes (Tokyo, Japan), S. Tsuzuki, Y. Asai, K. Aoyagi, N.
simplex virus type 1 and varicella zoster virus Ohmagari
encephalitis: A prospective population-based
E0217 Quality of antibiotic prescribing in Portuguese
cohort studyL. Duerlund* (Aarhus, Denmark), L.
hospitals: a snapshot of the first National
Larsen, M. Storgaard, H. Mens, L. Weise, M.P.G. Antimicrobial Prescribing Survey.C. Palos* (Lisbon,
Jepsen, B.R. Hansen, H.R. Von Lüttichau, C.Ø. Portugal), C. Ierano, R. James, J.A. Paiva, K. Thursky,
Andersen, H. Nielsen, J. Bodilsen P. Sousa
E0205 Arbovirus associated neurological disease in adults E0218 Evaluating the impact on 28-day mortality of different
and children in Brazil: a multicentre case-control
ESCMID Global 2025 - Programme
empiric AWaRe antibiotic treatment strategies for Staphylococcus aureus nasal colonisation statusD.
hospital-acquired infections across different hospital Aggarwal* (London, United Kingdom), K.L. Bellis, B.
settings.C. Lim* (Oxford, United Kingdom), K.B. Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E.
Pouwels, D. Limmathurotsakul, Q. Gu, D.E. Eyre, A.S. Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry,
Walker, M. Sharland, B.S. Cooper M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L.
E0219 Update on WHO's Global antibiotic use surveillance Sarkane, J. Brennan, S. Duthie, E. Johnson, M.
system (GLASS-AMU)B. Huttner* (Geneva, Juhasz, S. Irvine, A. Mcmahon, A. Van Tonder, E. Di
Switzerland), A. Muller, M. Escher, V. Ivanoska, D. Angelantonio, A. Butterworth, J.A. Geoghegan, J.
Tong Danesh, J. Parkhill, S.J. Peacock, E. Harrison
E0220 Harmonisation trajectory of Global-Point Prevalence O0186 Development of a Staphylococcus aureus human
Survey (Global-PPS) and WHO-PPSA. Versporten* nasal colonisation modelA. Hachani* (Melbourne,
(Antwerp, Belgium), A. Muller, M. Escher, I. Pauwels, Australia), B. Tran, E. Cho, R. Guérillot, B. Howden, T.
D. Tong, A. Boven, V. Ivanovska, B. Huttner, E. Vlieghe Stinear, E. Vincan
E0221 Implementation of prospective audit and feedback O0187 Selection-free, virulence gene promoter-controlled
strategy in intensive care units: Analysis of CRISPR interference system for in vivo pathogenesis
antimicrobial prescription patterns in a Guatemalan study of Staphylococcus aureus - A proof of
tertiary care hospitalN. Sandoval* (Guatemala, conceptR. Miah* (Tromsø, Norway), M. Johannessen,
Guatemala), G. Ozaeta, G. Reyes, K. Carrascosa M. Kjos, C. Lentz
O0188 Placebo-controlled study of competitive exclusion
using Lactococcus lactis to reduce transmission of
KN056 LA-MRSA from pigs to humansB. Duim* (Utrecht,
14:45 - 15:45 Hall 1
Netherlands), A. Vlasblom, A. Rittscher-Fogg, R.
Keynote Lecture Rattigan, L. Wajda, D. Crespo-Piazuelo, M.
Broekhuizen-Stins, L. Portengen, G. Van Eijden, C.
Defending against dengue: global epidemiology and strategies for prevention Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A.
and control Zomer, J. Wagenaar
Chairs Anu Kantele (Helsinki, Finland) O0189 Rifampicin-induced Staphylococcus aureus persister
Carlos Seas (Lima, Peru) formation is driven by CodY and oxidative stress
levelN. Pordone* (Lyon, France), J. Guillemot, K.
Rodriguez, N. Personnic, E. Botelho-Nevers, P.O.
Verhoeven
K0161 14:45 Fernanda Boulos (São Paulo, Brazil)

SY059
OS026 14:45 - 15:45 Hall 13
14:45 - 15:45 Hall 11
1-hour Symposium
1-hour Oral Session
Value-based syndromic diagnostics in medical microbiology: Pro / Con
Carbapenem resistance Gram-negatives, what's new in treatment? debate
Chairs Matteo Bassetti (Genova, Italy) Chairs Hege Vangstein Aamot (Lørenskog, Norway)
Maria Milagro Montero (Barcelona, Spain) Eric Claas (Leiden, Netherlands)

O0180 Ceftriaxone sulbactam disodium EDTA S0166 14:45 Pro: clinical benefit and potential for improved patient
combination(CSE) as a treatment option for outcomesKirstine K. Søgaard (Aalborg, Denmark)
carbapenem resistant gram negative bacilli - to be
S0167 15:15 Con: limitations, costs, and possible overuse of
or not to be?Y. Verma* (Hisar, India), K. Narang, D.
syndromic panelsGilbert Greub (Lausanne,
Bandlish, C. Sharma
Switzerland)
O0181 Sulbactam-durlobactam as an effective alternative
Co-organised with: ESCMID Study Group for Genomic and Molecular
option against NDM-producing Escherichia coli
Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française
including cefiderocol and aztreonam-avibactam-
resistant isolates in SwizterlandC. Le Terrier*
(Fribourg, Switzerland), P. Nordmann, A. Delaval, L.
SY060
Poirel 14:45 - 15:45 Hall 14
O0182 Optimising Difficult-to-treat Gram-negative 1-hour Symposium
Bacterial Infection Outcomes with Personalised
Fosfomycin-Based Combination Therapy Guided by We need to talk about toilets…
in vitro Antibiotic Combination TestingT. Lim*
(Singapore, Singapore), J.Q. Teo, J.J.Y. Ho, T.G. Chairs Stephanie J. Dancer (Glasgow, United Kingdom)
Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W. Juliette Severin (Rotterdam, Netherlands)
Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa
O0183 Management of infections caused by ST308 New
Dehli metallo-ß-lactamase-producing S0168 14:45 Infection risks from sanitation engineeringDavey
Pseudomonas aeruginosa with in vitro-guided Jones (Bangor, United Kingdom)
combination antibiotic therapyJ. Teo* (Singapore, S0169 15:15 Ventilation in toilets: how can we improve it?Michael
Singapore), J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, Gormley (Edinburgh, United Kingdom)
T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa
Co-organised with: ESCMID Food- and Water-borne Infections Study Group
O0184 In vitro activity of cefepime/enmetazobactam (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)
against clinical isolates of Enterobacterales in
Portugal: A multicentre retrospective studyH. Cruz*
(Porto, Portugal), C. Chaves, L. Carneiro
OS028
14:45 - 15:45 Hall 15

1-hour Oral Session

OS027
14:45 - 15:45 Hall 12
Unlocking the potential of the human microbiome for clinical diagnostics
1-hour Oral Session
Chairs John W. A. Rossen (Groningen, Netherlands)
Staphylococcus aureus: colonisation, virulence, and persistence Maria Vehreschild (Frankfurt Am Main, Germany)
Chair Stefano Giulieri (Melbourne, Australia)

O0190 Deep learning-enhanced wellness scores: Advancing

gut microbiome-based health predictionsO.
O0185 The nasal microbiome redefines and predicts
ESCMID Global 2025 - Programme
Nalbantoglu* (Kayseri, Türkiye), A. Gundogdu, B.H. O0175 Strong Alignment Between National Standard
Ermis Treatment Guidelines and WHO AWaRe Book
O0191 Comparison of Second-Generation and Third- Recommendations for Primary Care Pediatric
Generation Sequencing technologies for 16S rRNA InfectionsD. Dona* (Padova, Italy), D. Donà, G.
amplicon-based gut microbiome analysisE. Rubio Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S.
García* (Barcelona, Spain), E. Rubio-García, A. Mathur, M. Sharland, S.M.R. Esposito
Pulgarin, R. López-Aladid, L. Martínez-Priego, N. O0176 Correlation between antibiotic consumption and
Palau, A. Mendoza, R. Isanta, A. Montalban, J.L. digestive colonization with multidrug-resistant
Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. Enterobacterales in a paediatric haematology
Reig, C. Casals-Pascual departmentS. Frigui Ep Oueslati* (Tunis, Tunisia), N.
O0192 Donor for fecal microbiota transplantation: a Fitouri, S. Frigui, Y. Chebbi, I. Fezaa, M. Ouederni, C.
challenging research.B.S. Orena* (Milan, Italy), M.F. Drira, W. Achour
Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E. O0177 Interleukin-6 as a diagnostic biomarker for sepsis in
Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A. neonates, children and pregnant women – a real-
Callegaro, L. Cariani world cohort studySean Olann Whelan (Dublin,
O0193 Antibiotic resistance genes diversity and Ireland)
antimicrobial effects in the vaginal microbiome during O0178 Impact of rapid diagnostic stewardship interventions
pregnancyN. Boutouchent* (Rouen, France), S. to reduce blood culture utilization in a pediatric
Kennedy medical centerE. Vaugon* (Los Angeles, United
O0194 Distinct gut microbiota and metabolic profiles in brain States), C. Costales, T. Barter, L. Posch, E. Orgel, J.
tumor patients: Bridging microbial insights to CNS Dien Bard
oncologyA. Gundogdu* (Kayseri, Türkiye), O.U. O0179 Infective endocarditis: A Decade of Experience at a
Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F. Tertiary Pediatric Care CentreM. De Luca* (Rome,
Kelestimur, U. Ture Italy), R. Iacobelli, S. Samperi, S. Mercadante, L.
Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò
Carducci, P. Bernaschi, A. Rizza, L. Lancella, L. Galletti
ME062
14:45 - 15:45 Hall 16

Meet-the-Expert EW071
16:15 - 18:15 Hall 15

Untangling the web: antimicrobial dose adjustments in renal impairment Educational Session

The rare art of writing scientific articles: from conception to submission

Chairs Marlieke De Kraker (Geneva, Switzerland)
M0172 14:45 Claire Roger (Nimes, France) Mical Paul (Haifa, Israel)
M0173 14:57 Isabel Spriet (Leuven, Belgium)
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG),
ESCMID Study Group for Critically Ill Patients (ESGCIP) W0205 16:15 Expressing yourself correctly: writing tipsAngela
Huttner (Geneva, Switzerland)
W0206 16:35 Constructing your manuscript for an original
SY057
14:45 - 15:45 Hall 2
articleJesús Rodríguez-Baño (Seville, Spain)
1-hour Symposium W0207 16:55 The use of artificial intelligence tools for writing
articles: what to do and not to doErlangga Yusuf
Macrolides in community-acquired pneumonia: therapeutic necessity or path (Rotterdam, Netherlands)
to overuse? W0208 17:15 Selecting the best journal for my manuscriptAndre
Chairs Marc J.M. Bonten (Utrecht, Netherlands) Kalil (Omaha, United States)
Karin Thursky (Carlton, Australia) Co-organised with: CMI Board of Editors

SY069
S0162 14:45 Pro: maximising outcomes with evidence-based 16:15 - 18:15 Hall 16
useEvangelos Giamarellos-Bourboulis (Athens,
Greece) 2-hour Symposium
S0163 15:15 Con: the risks of routine (over)useAurélien Dinh Controlled human infection models
(Garches, France)
Chairs Frederick Hayden (Charlottesville, United States)
Nikolai Siemens (Greifswald, Germany)
SY058
14:45 - 15:45 Hall 4

1-hour Symposium S0197 16:15 Updates on the dengue human infection

modelKirsten Lyke (Baltimore, United States)
Top papers in transplant ID
S0198 16:45 CHIM in endemic countriesMelissa Kapulu (Kilifi,
Chairs Nicolas Mueller (Zurich, Switzerland) Kenya)
Alessandra Mularoni (Palermo, Italy)
S0199 17:15 Controlled human infection models of parasitic
infectionsMeta Roestenberg (Leiden, Netherlands)
S0200 17:45 Controlled human infection models of non-typhoidal
S0164 14:45 Top 10 papers in infections in SOTPatricia Munoz SalmonellaMalick Gibani (London, United Kingdom)
(Madrid, Spain)
Co-organised with: British Infection Association (BIA)
S0165 15:15 Top 10 paper in infections in HCT and cellular
therapyJoshua Hill (Seattle, United States)
EF033
16:15 - 17:15 Arena 2

OS025
14:45 - 15:45 Hall 5 ePoster Flash Session

1-hour Oral Session Current treatment options for invasive fungal infections

Bacterial battles: a paediatric perspective on infections and interventions Chair Andreas H. Groll (Münster, Germany)
Chairs Angelika Berger
Julie Toubiana (Paris, France)
E0232 The paediatric European Confederation of Clinical
Mycology (ECMM) Quality (paed-EQUAL) Score for
ESCMID Global 2025 - Programme
the management of candidaemia in children and Villavicencio* (Taguig, Philippines), M.C. Hufano, R.R.
neonatesZ.D. Pana* (Nicosia, Cyprus), A.H. Groll, A. Gabunada, Z. Alano
Bal, R. Sprute, F. Carlesse, S. Mellinghoff, S. Butzer,
D. Ludwig-Bettin, K. Mehler, J. Stemler, D. Seidel, A.
Marek, U. Ristau-Schäfer, O. Cornely SY067
16:15 - 18:15 Hall 11
E0233 Prevalence rate, species distribution and antifungal
susceptibility of bloodstream infections caused by 2-hour Symposium
rare yeasts of the Saccharomycetales order
documented in 28 Brazilian medical centersC. STIs: an ongoing crisis
Palamin Buonafine* (São Paulo, Brazil), C.P. Chairs Dagmar Heuer (Berlin, Germany)
Buonafine, A.E. Dos Santos, L.M. Favarello, R.C. Tomislav Mestrovic (Varazdin, Croatia)
Cognialli, V.R. Aquino, C.B. Agnelli, A.V. Mendes, T.
Guimaraes, T.C. Sukiennik, F. Carlesse, P.T. Castro,
C.C. Baqueiro, E.C. Francisco, A.L. Colombo
S0189 16:15 STI treatment options are running out due to
E0234 Rezafungin showed high in vitro activity and very
AMRMagnus Unemo (Örebro, Sweden)
low resistance rate against a collection of yeasts
causing fungaemia in patients admitted to a tertiary S0190 16:45 Genomic surveillance of Neisseria gonorrhoeae
hospital in Madrid from 2014 to 2024J. Guinea* strainsPetra Wolffs (Maastricht, Netherlands)
(Madrid, Spain), P. Escribano, A. Gomez, A. Burillo, S0191 17:15 Evolutionary insights into syphilis and Treponema
P. Muñoz pallidumMathew Beale (Hinxton, United Kingdom)
E0235 Posaconazole Drug-Drug Interaction Potential is S0192 17:45 Challenges in chlamydial STI infectionsCecile Bebear
Similar Across BodyweightR.E. Wrishko* (Rahway, (Bordeaux, France)
United States), P. Kothare, T.J. Bateman, M.G.
Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie
Johnson, A. Stoch
E0236 Phase 2, open-label, non-comparative clinical trial
evaluating the safety and efficacy of posaconazole SY068
in paediatric patients 2 to <18 years old with 16:15 - 18:15 Hall 12
invasive aspergillosisH. Kang* (Seoul, Korea, 2-hour Symposium
Republic of), A.C. Arrieta, C. Dhooge, A. Kelemen,
M. Macías-Parra, L. Aranda, Y.V. Dinikina, I. Kassis, Tick-borne encephalitis: contemporary diagnosis and management
S. Cesaro, T. Mackey, A. Shepherd, A.K. Shah, H.
Chairs Joanna Maria Zajkowska (Białystok, Poland)
Waskin, M.G. Johnson
Dace Zavadska (Riga, Latvia)
E0237 Activity of manogepix against a worldwide
collection of mould isolates from 2023M. Winkler*
(North Liberty, United States), S. Edeker, A. Klauer,
P. Rhomberg, M. Castanheira S0193 16:15 Tick-borne encephalitis: immune response and
E0239 Candida auris displays an inoculum effect with clinical experienceSara Gredmark Russ (Stockholm,
multiple antifungal drug classesR. Ben-Ami* (Tel Sweden)
Aviv, Israel), R. Shadhan, A. Novikov, N. Mizrahi S0194 16:45 TBE immune responses and vaccine
E0240 In vitro olorofim activity against Aspergillus spp effectivenessKarin Stiasny (Vienna, Austria)
clinical isolates collected as part as two national S0195 17:15 NS1 antibodies: diagnostics and screening of
surveys on azole resistance conducted in Spain seroprevalence of TBE virus infectionGerhard
(ASPEIN II and III)J. Guinea* (Madrid, Spain), P. Dobler (Munich, Germany)
Escribano, J. Moraga, A. Gomez, P. Muñoz S0196 17:45 Treatment for TBE: where do we stand?Daniel
Ruzek (Brno, Czech Republic)
EF034
16:15 - 17:15 Arena 4
LB006
ePoster Flash Session 16:15 - 18:15 Hall 13

2-hour Oral Session

Surgical site infections: epidemiology, risk factors, and prevention strategies
Chair Trisha Peel (Melbourne, Australia) The Trial Run: recent trials on S. aureus bacteraemia management
Chairs Julia Anna Bielicki (London, United Kingdom)
Vance Fowler (Durham, United States)
E0241 Incidence of Surgical Site Infections (SSIs) from the
automated patient-based surveillance system,
SPICMI, FranceP. Astagneau* (Paris, France), B. L0031 16:15 Introduction, Julia Anna Bielicki (London, United
Nkoumazok, N. Benhajkassen, I. Arnaud, D. Verjat- Kingdom), Vance Fowler (Durham, United States)
Trannoy, J. Auraix, K. Lebascle
L0032 16:20 Description of SNAP trial
E0242 Beta-lactam versus non-beta-lactam antimicrobial
prophylaxis and its association with the surgical site L0033 16:30 Benzylpenicillin versus (flu)cloxacillin for the
infection rate, a nationwide cohort study with 348 treatment of penicillin-susceptible Staphylococcus
793 patientsS. Largiadèr* (Lucerne, Switzerland), D. aureus bacteraemia: a randomised controlled trial of
Berthod, A. Widmer, N. Troillet, C. Perdrieu, S. the S. aureus network adaptive platform (SNAP)S.
Harbarth, R. Sommerstein Tong* (Melbourne, Australia), S. Aureus Network
Adaptive Platform Trial Group
E0245 Cutibacterium species in Neurosurgical Infections:
Not Such a "Cute" Pathogen After AllJ. Donnelly* L0034 16:45 Cefazolin versus (flu)cloxacillin for the treatment of
(Dublin, Ireland), B. Dinesh, S. O'donnell penicillin-resistant, methicillin-susceptible
Staphylococcus aureus bacteraemia: a randomised
E0246 The polymicrobial nature of wound infections in an controlled trial within the S. aureus network adaptive
emergency orthopaedic ward in Northern Nigeria - platform (SNAP)J. Davis* (Newcastle, Australia), S.
implications for treatment and patient outcomeK. Aureus Network Adaptive Platform Trial Group
Cook* (Oxford, United Kingdom), F.S. Mohd, M.Y.
Ahmad, A. Aliyu, K. Iregbu, C. Achi, T. Walsh, K. Sands L0035 17:00 Cloxacillin versus cefazolin for methicillin-susceptible
Staphylococcus aureus bacteraemia (CloCeBa): a
E0247 Efficacy of Octenidine Dihydrochloride Versus randomised, controlled, non-inferiority trialX.
Chlorhexidine Gluconate Solutions in Reducing Lescure* (Paris, France), F. Vandenesch, X. Duval, S.
Surgical-Site Infections in Total Hip and Knee Tubiana, C. Burdet, N. Saïdani, A. Lemaignien, E.
Arthroplasty: A Comparative AnalysisA. Abialevich* Canoui, L. Surgers, M. Esposito Farese, V. Le Moing,
(Beer Sheva, Israel), V. Benkovich, G. Benkovich P. Tattevin
E0249 Impact on rates of surgical site infection of requiring L0036 17:15 Trial DiscussionJulia Anna Bielicki (London, United
pre-authorization of surgical antibiotic prophylaxis Kingdom)
choice and post-operative antibiotic dosesC.M.
L0037 17:30 Trial DiscussionVance Fowler (Durham, United
ESCMID Global 2025 - Programme
States) Kretschmer, B. Dave, T. Maddison, S. Hopkins, S.
L0038 17:45 Open Discussion and Q&A Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison

SY064
OS032
16:15 - 18:15 Hall 14 16:15 - 18:15 Hall 2

2-hour Oral Session 2-hour Symposium

Unraveling respiratory viruses, 2025 PK/PD to avoid emergence of resistance?

Chairs Eeva Broberg (Solna, Sweden) Chairs Anne-Grete Märtson (Leiden, Netherlands)
Florian Krammer (New York, United States) Joseph Meletiadis (Athens, Greece)

O0222 Human metapneumovirus infections in hospitalized S0177 16:15 PK/PD and antibacterial therapyDolors Soy-Muner
adults compared to respiratory syncytial virus and (Barcelona, Spain)
influenza infections over ten years in FranceP. S0178 16:45 PK/PD and antifungal therapyRoger Brüggemann
Loubet* (Nimes, France), S. Guitton, R. Simon, L. (Nijmegen, Netherlands)
Lefrancois, L.B. Luong Nguyen, P. Vanhems, F. S0179 17:15 PK/PD and antiviral therapyJoe Standing (London,
Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. United Kingdom)
Lagathu, V. Foulogne, N. Houhou-Fidhou, A.S.
L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay S0180 17:45 PK/PD considerations in anthelminthic
treatmentJennifer Keiser (Allschwil, Switzerland)
O0223 Unveiling animal susceptibility to influenza viruses
(H1N1(pdm09) and H5N1 HPAIV) using animal-
derived respiratory organoidsF. Tarrés-Freixas*
EW070
(Bellaterra, Spain), G. Ceada, N. Navarro, M. Pérez- 16:15 - 18:15 Hall 3
Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Educational Session
Moreno, C. López, J. Segalés, N. Majó, K.
Kochanowski, J. Vergara-Alert Malaria: when the drugs don’t work Management of treatment failure in non-
O0224 Exploring the impact of acute lung hypoxia on CD8 endemic countries
T cell phenotypes following severe influenza Chairs Laura Nabarro (London, United Kingdom)
infection.B. Huckestein* (Memphis, United States), Caroline Rönnberg (Stockholm, Sweden)
P. Thomas
O0225 Virological characterisation of RSV after Nirsevimab
Breakthrough Infections in a Multicentre
Observational Real-world Study in FranceS. W0201 16:15 Malaria in the non-endemic setting: who to treat as
Fourati* (Créteil, France), A. Reslan, J. Bourret, Y. an outpatient and how to detect treatment
Rahou, L. Chollet, S. Pillet, P. Tremeaux, N. Candace failureEmmanuel Bottieau (Antwerp, Belgium)
Dossou, E. Gault, M. Salmona, B.M. Imbert, A. W0202 16:35 Malaria resistance mutations in the non-endemic
Mirand, S. Larrat, A. Moisan, S. Marot, A. setting: role of genomic surveillanceAnna Rosanas
Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, Urgell (Antwerp, Belgium)
A. Henry, V. Stephan, S. Brichler, V. Avettand-
W0203 16:55 How to manage Plasmodium Knowlesi infectionGiri
Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L.
Shan Rajahram (Kota Kinabalu, Malaysia)
Deroche, M.C. Jaffar, L. Mouna, C. François, A.
Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C. W0204 17:15 Epidemiology and control of Plasmodium
Rodriguez, G. Dos Santos, J. Buchrieser, O. KnowlesiKimberly Fornace (Singapore, Singapore)
Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, Co-organised with: British Infection Association (BIA)
M.A. Rameix-Welti
O0226 Baseline immunity to highly pathogenic avian
influenza viruses in a healthcare worker cohortC. SY065
Geurts Van Kessel* (Rotterdam, Netherlands), M.
16:15 - 18:15 Hall 4

Power, W. Rijnink, L. Gommers, T. Bestebroer, W. 2-hour Symposium

Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van
Nierop, R. Sikkema, A. Grifoni, A. Sette, M. Gram-positives, are they still going?
Koopmans, R. Fouchier, M. Richard, R. De Vries, C. Chairs Diederik Bathoorn (Groningen, Netherlands)
Geurtsvankessel Stefania Stefani (Catania, Italy)
O0227 Impact of reinfection on post-acute sequelae of
COVID-19 over multi-organ systemsJ.Y.J. Tan*
(Singapore, Singapore), J.T. Lim, L.E. Wee, C.
Chiew, B. Ong, D. Lye S0181 16:15 The vanco chronicles: enterococci's global
journeyGuido Werner (Wernigerode, Germany)
O0228 Clinical and economic burden of respiratory
syncytial virus in adults with acute respiratory S0182 16:45 Pitfall in susceptibility testing of Gram-
infections – a Danish nationwide cohort positivesHelena Zemlickova (Prague, Czech
studyStanislava Bratkovic (Copenhagen, Denmark) Republic)
O0229 The burden of respiratory syncytial virus in children S0183 17:15 Drivers for daptomycin and linezolid resistance in
<3 years old presenting to primary, secondary and Gram-positivesGlen Carter (Melbourne, Australia)
tertiary care in England: report from the STOP RSV S0184 17:45 What is new in treatment against MDR Gram-
prospective surveillance studyE. Carter* (Liverpool, positives?Alex Soriano (Barcelona, Spain)
United Kingdom), H. Hill, D. Ferreira, A. Collins, C.
Solórzano, L. Mclellan, L. Kerruish, F. Fyles, S.
Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. SY066
Crozier, P. Saunderson, R. Kramer, M. Bangert, N. 16:15 - 18:15 Hall 5

Vassilouthis, S. Messahel, B. Caroline, S. Brearey, J. 2-hour Symposium

Bernatoniene, S. Bhowmik, J. Perry, P. Mottram, P.
Mcnamara, D. Lewis, N. Van Kinnekan, A. Finn Biomarker testing to manage respiratory infections in primary care in low
O0230 Targeted metagenomic sequencing of influenza, resource settings
RSV, and symptomatic respiratory infections from Chairs Sonia Lewycka (Hanoi, Vietnam)
UK healthcare workersM. Knoll* (Hinxton, United Heiman Wertheim (Nijmegen, Netherlands)
Kingdom), L. Findlater, B. Katie, J. Wagner, T. Diego,
D. Rajan, S. Frances Field, S. Thurston, A. Wong, B.
Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin,
B. Blane, Y.L. Huang, K. Howe, M. Forbes, K. S0185 16:15 The Vietnamese experience with CRP testing in the
Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick- community settingThi Thuy Nga Do (Ha Noi, Vietnam)
ESCMID Global 2025 - Programme
S0186 16:45 The Nigerian experience with CRP testing in the E0260 Acute disseminated encephalomyelitis following
community settingAugustine Onwunduba (Awka, bacterial meningoencephalitis – Two Case reports &
Nigeria) Review of LiteratureM. Priyadarshi* (Delhi, India), M.
S0187 17:15 CRP testing in diagnosing tuberculosis in Zambia and Salunkhe, A. Mohan, P. Gupta, A. Agarwal, V. Goel, R.
South AfricaHelen Ayles (Lusaka, Zambia) Bhatia
S0188 17:45 The health economics of CRP testing in LMICsYoel E0261 Streptococcus equi Subspecies zooepidemicus
Lubell (Bangkok, Thailand) Endocarditis and Meningitis in a 62-Year-Old Patient:
A Case Report and Literature reviewD. Chemello*
(Modena, Italy), G. Franceschi, S. Alessandra, B.
Andrea, S. Mario, M. Marianna, M. Cristina
EF035
17:15 - 18:15 Arena 1
E0262 Breaking barriers: meropenem-vaborbactam as a
ePoster Flash Session game-changer for KPC central nervous system
infectionsF. Prataviera* (Udine, Italy), S. Giuliano, S.
Genomics in pathogen surveillance Flammini, J. Angelini, P.G. Cojutti, C. Tascini
Chair Vítor Borges (Lisbon, Portugal) E0263 Multidrug-Resistant Klebsiella pneumoniae
Meningitis in the Absence of Intracranial Devices: A
Case ReportM. Chumbita* (Barcelona, Spain), E.
Viñas Esmel, P. Castro, S. Herrera, C. Bastida, A.
E0250 Genomic Surveillance of Invasive Group A Soriano
Streptococcus in Argentina's 2023 Epidemic:
E0264 Triple Threat: Sequential Meningitis Infections in an
Unveiling Hypervirulent emm1 Lineages and Pediatric
Immunosuppressed Patient with Morganella
emm12 BurdenL. Cipolla* (Buenos Aires, Argentina),
morganii, Acinetobacter baumannii, and
A. Gianecini, T. Poklepovich, C. Giovacchini, M. Prieto
Vancomycin-resistant Enterococcus faeciumY. Çakir
E0251 Understanding the population structure of Moraxella Kiymaz* (Sivas, Türkiye), Y. Çakır Kıymaz, E. Kıymaz,
catarrhalis using core-genome multilocus sequence Z. Bulut, S.A. Büyüktuna, N. Elaldı
typingI. Yassine* (Oxford, United Kingdom), K.A.
E0265 Invasive pulmonary Arthrographis kalrae infection
Jolley, J.E. Bray, M.J. Jansen Van Rensburg, F. Patel,
with cerebral abscesses in an immunocompromised
A. Sheppard, H.J. Zar, V. Allen, L. Ah Tow, M.C.J.
childB. Winkel* (Utrecht, Netherlands), J. Jans, M.
Maiden, M.P. Nicol, A.B. Brueggemann
Luesink, R.J. Nievelstein, F. Hagen, J. Buil, T. Wolfs, T.
E0252 Impact of the COVID-19 pandemic on the Van Der Bruggen
Streptococcus pyogenes clones causing adult
E0266 Treatment of herpes simplex encephalitis with the
invasive infectionsM. Ramirez* (Lisbon, Portugal), A.
helicase-primase inhibitor pritelivir in an
Friães, J. Vermeiren, R. Mamede, C.R. Bettencourt,
immunocompromised patientA. Birkmann*
M.P. Bajanca-Lavado, J. Melo-Cristino, P. Group For
The Study Of Streptococcal Infections (Wuppertal, Germany), C. Lueck, C. Rautenberg, S.
Bonsmann, A. Marini, M. Sumner, T. Schroeder, S.
E0253 Unveiling the Hidden Complexity of Providencia: Voigt
Genomic Insights into Species Reclassification and
E0267 A case of influenza A (H1N1) encephalitis: Rare
Antibiotic ResistanceX. Dong* (Hangzhou, China)
neurological implication in a healthy adultN.K. Midha*
E0254 Genomic description of outbreak of VIM-1 carrying (Jodhpur, India), S. Bhat K S, S. Tiwari, D.S. Meena, D.
Enterobacter in Switzerland suggests plasmid Kumar, G.K. Bohra
transmission between sequence typesH. Seth-Smith*
(Zurich, Switzerland), M. Greutmann, C. Beckmann, E.
Gruner, R. Capaul, G. Greub, P.M. Keller, S. Tschudin-
Sutter, L. Berlinger, S.D. Brugger, T. Roloff, O. Nolte,
Sunday, 13 April 2025
L. Poirel, P. Nordmann, A. Egli
E0255 Genomic epidemiology of Klebsiella pneumoniae
bloodstream infections in a german tertiary centre: SY075
increased virulence in carbapenem-resistant strainsL. 08:30 - 10:30 Hall 15
Knegendorf* (Hannover, Germany), M. Lindenberg, 2-hour Symposium
C. Baier, J. Erdmann, S. Häußler, D. Schlüter
E0256 Phylogenetic mixing and undetected circulation of Diphtheria: from re-emergence to vaccine strategies
multiple Candida auris lineages following recognition Chairs Helena Seth-Smith (Zurich, Switzerland)
of imported cases in ItalyV. Di Pilato* (Genoa, Italy), Julie Toubiana (Paris, France)
E. Willison, L. Calabrese, L. Magnasco, C. Elisa, G.
Daniele Roberto, M. Mikulska, B. Matteo, M. Anna
E0257 Using Long-Read Sequencing for Core Plasmid
Multilocus Sequence Typing to Investigate Plasmid S0221 08:30 Diphtheria: from clinical picture to medical
Relationships Among Bacterial Species in German managementRegina Oladokun (Oyo, Nigeria)
Hospital WastewaterA.K. Bari* (Groningen, S0222 09:00 The epidemiology of diphtheria worldwide over the
Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, last half-century: more than one comebackAndreas
T.T. Severs, M.J. Cardoso, M. Savin Hoefer (Solna, Sweden)
E0258 Screening for rectal colonization with multidrug- S0223 09:30 There’s more than one toxigenic Corynebacterium:
resistant pathogens: usage of rapid metagenomic the current genomics landscape of diphtheria-
long-read technologyS. Purushothaman* (Zurich, associated strainsSylvain Brisse (Paris, France)
Switzerland), A.M. Rooney, S. Moser, A. Egli S0224 10:00 Diphtheria vaccination: a reappraisal Gayatri
Amirthalingam (London, United Kingdom)
EF036 Co-organised with: ESCMID Study Group for Epidemiological Markers
17:15 - 18:15 Arena 3
(ESGEM), ESCMID Vaccine Study Group (EVASG)
ePoster Flash Session

EF039
Heads up! CNS infections 08:30 - 09:30 Arena 1
Chair Jacob Bodilsen (Aalborg, Denmark) ePoster Flash Session

Novel approaches to antiviral therapy

E0259 Central Nervous System Involvement by Chair Pinyo Rattanaumpawan (Bangkok, Thailand)
Mycobacterium avium Complex in Advanced HIV: A
Rare and Underdiagnosed ChallengeE. Sienra
Iracheta* (Tlalpan, Mexico), M. Aranda Aurelio, A.
Camiro Zuñiga, D.H. Martínez Oliva, A. Llamas Lopez, E0288 Obeldesivir exhibits broad anti-RSV activity and a
A.P. Rodriguez Zulueta high barrier to resistance in vitro and is efficacious
in a non-human primate challenge model of RSV
ESCMID Global 2025 - Programme
infectionJ. Pitts* (Foster City, United States), J.L.R. Olgemöller
Zamora, S. Manhas, T. Aeschbacher, J. Chan, V. E0303 NADPH oxidase of the mosquitoes and the
Cutillas, V. Nair, N. Riola, A. Vijjapurapu, M. antioxidant genes repertoire of the bacteria
Vermillion, S. Eng, C. Richards, D. Han, J. Perry, S. coordinate mosquito-bacteria interaction in midgutB.
Chaudhuri, I. Liu, C. Martinez, N. Peinovich, K.H. Song* (Kowloon, Hong-Kong SAR, China), J. Zeb, N.
Sun, A. Cai, R. Martin, J. Moshiri, C. Hedskog, V. Buchon, O. Sparagano, P. Butaye
Avadhanula, P. Piedra, K. Stobbelaar, P. Delputte, T.
Cihlar, S. Fletcher, J. Bilello E0304 Molecular detection and sequencing of the genes
encoding the predicted enzymes; Amidase, NADH
E0289 EDP-323, a first-in-class, oral, RSV L-protein ubiquinone oxidoreductase, and sodium
inhibitor reduces disease severity (respiratory neurotransmitter symporter in Onchocerca
mucus production) and accelerates viral clearance volvulusA. Acheampong* (Sunyani, Ghana), J. Larbi,
in a human viral challenge studyJ. Devincenzo* P.C. Kudzordzi, P. Nyarko, K.B. Otabil
(Watertown, United States), A. Ahmad, S. Chen, B.
Löndt, A. Mann, J. Mori, A. Catchpole, S. E0305 Tuberculosis outcomes among international migrants
Rottinghaus living in Europe compared to the non-migrant
population: a systematic review and meta-analysisG.
E0290 A Combined In Silico and In Vitro Pipeline for Guido* (Bari, Italy), S. Cotugno, L. Frallonardo, R.
Optimizing Nanobodies Targeting Surface Proteins Papagni, V. Giliberti, F.V. Segala, C. Polizzotto, G. Di
of Pathogens: Applications to SARS-CoV-2, WNV, Franco, M. Affronti, E. Piccione, G. Gualano, F.
and Influenza A VirusC.L. Pierri* (Bari, Italy), G.C.M. Palmieri, M. Barbagallo, N. Veronese, A. Saracino, F.
Perrone, A.L. Francavilla, S. Todisco, M.N. Sgobba, Di Gennaro
V. Scaglione, D.I. De Luca, F. Mastropirro, S.
Spadone, L. Guerra, M. Volpicella, A. De Grassi
E0291 Bemnifosbuvir and Remdesivir exhibit potent EW079
antiviral activity against tick-borne encephalitis 08:30 - 10:30 Hall 11

virus in vitroD. Grandgirard* (Bern, Switzerland), S. Educational Session

Leoni, R. Dijkman, L. Eyer, D. Ruzek, S.L. Leib
E0292 Combinations of antiviral drugs demonstrating New guidelines for management of brain infections
synergistic inhibition of multiple respiratory RNA Chairs Jacob Bodilsen (Aalborg, Denmark)
virusesS. Ellis* (London, United Kingdom), A.I. Kartika Maharani (Jakarta, Indonesia)
Jacobs, M. Woodall, S. Zhang, J.F. Standing, J.
Breuer
E0293 The safety and pharmacokinetics of ABI-5366, a
W0237 08:30 Tuberculous meningitis: what can we learn from the
novel, oral, long-acting HSV helicase-primase
first global guidelines?Joseph Donovan (Ho Chi Minh
inhibitor: Interim results from a Phase 1a/1b study in
City, Vietnam)
healthy participantsA. Gaggar* (South San
Francisco, United States), E. Gane, C. Schwabe, G. W0238 08:50 WHO guidelines on bacterial meningitis: change of
Wang, J. Liu, S. Knox, K. Kitrinos, K. Zomorodi clinical practice?Matthijs Brouwer (Amsterdam,
Netherlands)
E0294 Efficacy of ganciclovir against CMV infection is
dependent on treatment initiation timeL. W0239 09:10 ESCMID encephalitis guidelines 2024: what’s
Sudarsono* (Leiden, Netherlands), X. Liu, J.G.C. new?Tom Solomon (Liverpool, United Kingdom)
Van Hasselt, A.G. Märtson W0240 09:30 WHO guidelines for cryptococcal meningitis: success
E0295 Efficacy of molnupiravir and baloxavir against stories and barriers to implementationNelesh
influenza A H1N1 infection in vitro and in vivoD. Liu* Govender (Johannesburg, South Africa)
(Hong Kong, Hong-Kong SAR, China), K.Y. Leung, R. Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain
Zhang, Y. Fan, K.H. Chan, F.N.I. Hung (ESGIB)
E0296 Human defensin derived peptide showing broad
antiviral activity against human adenovirusesX.
SY073
Wang* (Hongkong, China), H. Zhao 08:30 - 10:30 Hall 12

2-hour Symposium
EF040
08:30 - 09:30 Arena 3
Proxy indicators: bridging the gap between surveillance and antimicrobial
ePoster Flash Session stewardship
Chairs Bhanu Sinha (Groningen, Netherlands)
New frontiers in parasitic disease and migrant health research Annelies Verbon (Bosch En Duin, Netherlands)
Chair Miriam José Álvarez-Martínez (Barcelona, Spain)

S0213 08:30 A broad spectrum of possibilities: spectrum scores as

E0298 Targeting metabolic bioenergetics: the ‘Achilles' heel' a unifying metricCéline Pulcini (Nancy, France)
of LeishmaniaD. Sarkar* (Kolkata, India) S0214 09:00 Proxy indicators to estimate appropriateness of
E0299 Leishmaniasis in Southern Alicante (Spain): what is antibiotic prescriptionsDiane Ashiru-Oredope
the new patient profile?M.D. Hernández Rabadán* (London, United Kingdom)
(Orihuela, Spain), C. Bernal Alcaraz, M.B. Martínez S0215 09:30 How to bridge the gap between surveillance and
López, D. López Parra, J. Llenas García antimicrobial stewardshipMark G. J. De Boer (Leiden,
E0300 Schistosoma haematobium infection is associated Netherlands)
with oncogenic gene expression in cervical mucosa, S0216 10:00 Health economics, surveillance and antimicrobial
with enhanced effects following treatmentAnna stewardshipZhu Nina Jiayue (London, United
Mertelsmann (Zürich, Switzerland) Kingdom)
E0301 Associations between water and sanitation service, Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID
risk of intestinal schistosomiasis, infection intensity, Education Subcommittee, International Society for Infectious Diseases (ISID)
and liver fibrosis in selected households living near
Lake Albert: a descriptive cross-sectional study?G.
Lam* (London, United Kingdom), D. Dee, A. Edielu, E. SY074
Ohuma, V. Anguajibi, E. Webb, A. Wamboko, P. 08:30 - 10:30 Hall 13
Mawa, J. Friedman, A. Bustinduy 2-hour Symposium
E0302 Schistosomiasis detected by Screening of sub-
Saharan African Unaccompanied Minor Refugees in Difficile to treat: advanced management strategies in difficult to treat CDI
Berlin between 2023 and 2024G. Equihua Martinez* Chairs Frédéric Barbut (Paris, France)
(Berlin, Germany), A.K. Lindner, M.C. Moreno-Del Kerrie Davies (Leeds, United Kingdom)
Castillo, J. Hammer, M. Nürnberg, P. Pitzinger, T.
Geppert, F. Mockenhaupt, B. Kampmann, F.
ESCMID Global 2025 - Programme
S0217 08:30 Severe CDI: when standard protocols failHynek Mshana (Mwanza, Tanzania, United republic of)
Bartos (Prague, Czech Republic) S0227 09:30 A clinically-oriented AMR surveillance network: case-
S0218 09:00 Therapies for complicated CDIEmma Bishop (Clayton based surveillance and implementationPaul Turner
Vic, Australia) (Siem Reap, Cambodia)
S0219 09:30 Recurrent CDI: Breaking the cycleAndrea Marino S0228 10:00 National prescribing guidelines based on AMR
(Catania, Italy) surveillance dataVilada Chansamouth (Vientiane, Lao
S0220 10:00 Live biotherapeutic products for Clostridioides People's democratic republic)
difficile infectionSimon Goldenberg (London, United Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial
Kingdom) Resistance Surveillance (ESGARS)
Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD)

EW077
08:30 - 10:30 Hall 2
OS038
08:30 - 10:30 Hall 14
Educational Session
2-hour Oral Session
New tools in acute bacterial infections and sepsis: from machine learning to
Making fast for making better: AMR rapid diagnostics precision medicine
Chairs Giulia De Angelis (Rome, Italy) Chairs Benjamin Mcfadden (Perth, Australia)
Onur Karatuna (Växjö, Sweden) Rita Murri (Rome, Italy)

O0278 Point of care rapid lateral flow antibiotic resistance W0229 08:30 Differentiating acute infection, sepsis and sepsis
test to detect carbapenem resistance in lower mimics in the ED?Lisa Mellhammar (Lund, Sweden)
respiratory tract infectionsJ. Rogers* (Bedford, W0230 08:50 Machine learning for early recognition of
United Kingdom), A. Gregg, Q. Liu, S. Owen, C. Chen, sepsisKarsten Borgwardt (Martinsried, Germany)
M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch W0231 09:10 How to avoid common mistakes in randomised
O0279 Evaluation of a new rapid Lateral flow immunoassay clinical study designYin Mo (Singapore, Singapore)
for the detection of DHA-producing Gram-negative W0232 09:30 Improved clinical trials in community-acquired
bacteriaC. Moguet* (Guipry, France), S. Oueslati, A. pneumonia using precision medicineLennie Derde
Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas (Utrecht, Netherlands)
O0280 The NitroSpeed Taniborbactam NP test; easy Co-organised with: ESCMID Scientific Affairs Subcommittee, European
detection of β-lactamase sensitivity to Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study
taniborbactamO. Raro* (Fribourg, Switzerland), S. Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES),
Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poirel, P. European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro
Nordmann
O0281 Rapid detection of β-lactamase-mediated resistance
to aminopenicillins from urines.P. Nordmann* SY072
(Fribourg, Switzerland), N. Helsens, C. Duployez, L. 08:30 - 10:30 Hall 3

Poirel, R. Dessein 2-hour Symposium

O0282 Rapid detection of antibiotic resistance in direct urine
samplesM. Bot* (Arnhem, Netherlands), J. Flipse, S. Tackling the emergence of dengue and other Aedes-borne diseases in
Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim, Europe
M. Van Meer Chairs Fernanda Boulos (São Paulo, Brazil)
O0283 Next-Generation Utilizer Dipsticks for direct-from- Martin P. Grobusch (Amsterdam, Netherlands)
sample phenotypic Antibiotic Susceptibility Testing in
UTIsE. Iseri* (Stockholm, Sweden), W. Van Der
Wijngaart, V. Özenci, R. Santini, A. Nakama, O. S0209 08:30 How dengue, chikungunya and zika virus disease
Ekelund, A. Van Belkum became emerging threats to EuropeCeline Gossner
O0284 Screening for ceftriaxone-resistant Neisseria (Solna, Sweden)
gonorrhoeae with the Urogenital and Resistance kit S0210 09:00 Surveillance of dengue in urbanised tropical
(AusDiagnostic)A. Braille* (Paris, France), M.
regionsVincent Junxiong Pang (Singapore,
Mainardis, F. Meunier, M. Mathar, M. Mérimèche, B. Singapore)
Condamine, F. Caméléna, B. Berçot
S0211 09:30 Mosquito surveillance and control: opportunities and
O0285 Comparative evaluation of rapid antimicrobial
challengesDavid Roiz (Montpellier, France)
susceptibility testing assays for Gram-negative
bacteria from positive blood culturesD. Squitieri* S0212 10:00 Tracking autochthonous arboviral infectionLuisa
(Rome, Italy), G. Menchinelli, C. Magrì, T. D'inzeo, M. Barzon (Padua, Italy)
Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti Co-organised with: European Centre for Disease Prevention and Control
O0286 Rapid detection of Carbapenemases directly from (ECDC)
positive blood culture bottle: A tool for early shifting
from empirical to targeted therapyK. Chaudhary*
EW078
(New Delhi, India), H. Gautam, P. Batra, S. Mohapatra,
S. Sood, B. Dhawan, B. Das Kumar
08:30 - 10:30 Hall 4

Educational Session

SY076 Implementing metagenomics in my lab and mistakes to avoid

08:30 - 10:30 Hall 16
Chairs Hege Vangstein Aamot (Lørenskog, Norway)
2-hour Symposium Claudio Neidhöfer (Bonn, Germany)

AMR Surveillance in low resource countries: insights into clinical and policy
translation
Chairs Kwame Ohene Buabeng (Ho, Ghana) W0233 08:30 Is metagenomics right for my lab?Paula Mölling
H. Rogier Van Doorn (Hanoi, Vietnam) (Örebro, Sweden)
W0234 08:50 Understanding the experimental and certification
aspects of metagenomicsMads Albertsen (Aalborg,
Denmark)
S0225 08:30 New indicators in national monitoring and evaluation
W0235 09:10 Navigating tools, techniques, and procurementBasil
of AMR supported by improved data utilisationDirek
Britto Xavier (Groningen, Netherlands)
Limmathurotsakul (Bangkok, Thailand)
W0236 09:30 Setting realistic goals and outcomes for
S0226 09:00 Interdisciplinary investigation of the drivers and
metagenomics integrationClaire Bertelli (Lausanne,
burden of AMR in urinary tract infectionsStephen
ESCMID Global 2025 - Programme
Switzerland) Mezzogori, M. Bonaffini, L. Magnasco, F.
Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Centorrino, V. Di Pilato, E. Willison, F. Portunato,
Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association D.R. Giacobbe, A. Vena, A. Marchese, M. Mikulska,
of ESCMID (TAE) Steering Committee M. Bassetti
E0307 A pilot study of digital retinal photography (DRP)
and tele-ophthalmology of patients with
OS037 candidemia.C. Clancy* (Pittsburgh, United States),
08:30 - 10:30 Hall 5
C. Hadi, E. Waxman, J.A. Viehman, A. Eller, M.
2-hour Oral Session O'donnell, F. Silveira, P. Samantha, B. Smith, S.
Padival, V. Nauriyal, M.H.T. Nguyen
Whole genome sequencing: tracking transmission and reservoirs in E0308 Epidemiology and diagnosis of Pneumocystis
outbreaks pneumonia : a 11 years-surveillance in FranceA.
Chairs Eric Claas (Leiden, Netherlands) Alanio* (Paris, France), K. Boukris-Sitbon, M.
Paul G. Higgins (Cologne, Germany) Desnos-Ollivier, D. Garcia-Hermoso, F. Lanternier,
O. Lortholoary
E0309 Chronic pulmonary aspergillosis coexisting with
pulmonary cystic echinococcosis: a global
O0268 From outbreaks to outcomes: Harnessing WGS for
systematic reviewA. Adhikari* (Chame, Nepal), F.
IPC in a high-risk paediatric settingN. Storey*
(London, United Kingdom), E. Cloutman-Green, J. Bongomin, R. Olum, P. Baral, I. Osaigbovo, W.
Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J. Kibone, B. Ekeng, L. Atulinda, S. Katwal, B. Morgan,
Hatcher, J. Brown, J. Breuer N.V. Rhijn, D. Denning
E0310 Implementation and performance of a universal
O0269 Why do routine genome-oriented surveillance for
Mucorales PCR assay for diagnosis of
Pseudomonas aeruginosa?A. Rath* (Regensburg,
mucormycosisA. Haas* (Salt Lake City, United
Germany), L. Grancicova, B. Kieninger, A. Caplunik-
Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert States), K. Hanson
E0311 Blood cultures (BCs) contain populations of
O0270 TreeTime estimation depicts transmission dynamics
genetically diverse Candida strains that may differ
of clinical and environmental Pseudomonas
in antifungal resistance and toleranceC. Clancy*
aeruginosa from common reservoirs in healthcare
environment through whole genome sequencing
(Pittsburgh, United States), S. Cheng, H. Badrane,
(WGS)Ö. Yetis* (London, United Kingdom), Ö. Yetiş,
B. Hao, G. Fleres, E. Driscoll, D. Chris, E. Josh, M.H.
F. Dyrkell, S. Ali, P. Wilson Nguyen
E0312 Clinical validation of a urinary antigen test as an aid
O0271 Understanding Serratia transmission during a
to diagnose invasive aspergillosis in hematology
neonatal ICU outbreak: A combined genotyping and
patientsY. Vanbiervliet* (Leuven, Belgium), R. Aerts,
risk factor analysisK. Jaakkola* (Lyon, France), C.
Dananché, A. Fischer, J.C. Picaud, P. Cassier, M. T. Mercier, E. Boon, G. Gysembert, E. Houben, K.
Colomb-Cotinat, S. Haÿs, J.P. Rasigade Lagrou, J. Maertens
E0313 Genomic epidemiology of Greek Candida auris
O0272 Genomic Insights into the Regional Transmission of
clinical isolatesM. Siopi* (Athens, Greece), B.
KPC-Producing Bacteria: Clonal and Non-Clonal
Plasmid SharingC. Shankar* (Ann Arbor, United
Spruijtenburg, I. Anagnostakis, C. Anthoulaki, A.
States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Argyropoulou, S. Varveraki, C. Vossou, A. Votsi, P.
Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin Giannopoulou, K. Gartzonika, M. Damala, I.
Daskalakis, I. Dendrinos, V. Dimitriou, E. Dimitroulia,
O0273 Genome-oriented analysis of the first outbreaks L.P. Drosopoulou, O. Zarkotou, L. Zachariadou, V.
involving the novel Serratia sarumanii at a neonatal Ippa, A. Kampas, P. Karagiannidou, S. Karabela, A.
unitA. Rath* (Regensburg, Germany), B. Kieninger, Katsaka, A. Katsiaflaka, E. Kafkoula, M. Kimouli, I.
L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M. Lamprou, O. Legga, V. Mamali, M. Martsoukou, G.
Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik- Mouratis, C. Mparka, T. Biniari, A. Xanthaki, E.
Pratsch, M. Kabesch, J. Kalinowski, W. Schneider- Oikonomopoulou, M. Orfanidou, F. Paliogianni, E.
Brachert Palla, A. Pantazatou, K. Panteli, E. Papadogeorgaki,
O0274 Evaluating the Utility of Whole-Genome Sequencing M. Papadogianni, K. Papaefstathiou, P.
to Optimise Infection Prevention and Control in a Papanikolaou, J. Papaparaskevas, G. Parvouleskou,
Hospital Setting: Findings from the GENOTIPE E. Perivolioti, S. Pournaras, C. Silleli, T. Skalidis, E.
StudyJ. Price* (Brighton, United Kingdom), I. Sey, A. Souki, A. Spiliopoulou, C. Stergiou, S. Tsiplakou, P.
Yeoh, D. Wlazly, A. Davies, O. Makanjuola, J. Leach, S. Tsolakidou, N. Charalampaki, E. Chinou, G.S.
Mookerjee, M. Krutikov Christodoulatos, G. Chronopoulou, E. Chrysou, E.
Meijer, A. Tsakris, J. Meletiadis, G. Vrioni
O0275 Outbreak of Carbapenem-Resistant Acinetobacter
seifertii in a Neonatal Intensive Care Unit: Genomic
Characterization and Surveillance.D. Pereira* (Porto
EF042
Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, 09:30 - 10:30 Arena 4
G. De Oliveira, L. Lutz, M. Mott, C. Constante, C.
Wilhelm, L. Antochevis, R. Paiva, K. Tragnago, A. ePoster Flash Session
Barth, A. Martins
Prosthetic and device-associated infections
O0276 Unveiling the Clonal Dynamics and transmission
Chair Marjan Wouthuyzen-Bakker (Groningen,
mechanism of Carbapenem-Resistant Klebsiella
Netherlands)
pneumoniae in the ICU environmentX. Han*
(Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu
O0277 Survey of Infection Prevention staff perception of
WGS integration into routine IPC practiceD. Ling* E0315 Case series of gluteal Apophysomycosis post
(Melbourne, Australia), B. Baral, V. Madigan intramuscular injectionR. Sivasankaran* (Vellore,
India), R. Bandyopadhyay
E0316 MIGRATING mesh - an unusual cause of pyogenic
EF041
09:30 - 10:30 Arena 2 liver abscessM. Caris* (Leiden, Netherlands), J.
Rutgers, A. Inderson, S.M. Arend, L.M.F. Kuijpers
ePoster Flash Session
E0317 Ceftaroline salvage monotherapy: successful
Contemporary diagnostic approaches for fungal infections treatment of a cerebrospinal fluid drain infection
caused by a multidrug-resistant Staphylococcus
Chair Ilse D. Jacobsen (Jena, Germany) epidermidis strainM.D. Di Trapani* (Bozen, Italy), T.
Kamal Eldin, G. Spoladore, D. Drusiani, B. Ladinser, R.
Aschbacher
E0306 Evaluation of persistence of C. auris colonization in E0318 Timeline of early infections post porcine
a cohort of patients discharged from a C. auris xenothymokidney transplantH. Neumann* (New
endemic areaM. Bavastro* (Genoa, Italy), L. York, United States), M. Ringer, R. Alpizar-Rivas, J.
ESCMID Global 2025 - Programme
Stern, F. Zervou, V. Halpern-Cohen, J. Hogan, A. Sometimes it's hard to be a woman
Griesemer, R. Montgomery, S. Williams, S. Mehta Chair Debora Konopnicki (Brussels, Belgium)
E0319 Invasive Non-tuberculous mycobacteria Infection in
children undergoing Cardiac Surgery at the
specialized Cardiology Hospital of PeshawarM.
Khan* (Peshawar, Pakistan) E0354 Interleukins 17 and 18: Key players in Cervical
Cancer Progression in Indian PopulationP. Gupta*
E0320 Use of multiplex PCR assay analysis in patients with
(Bhopal, India), A. Vyas, A. Halder, S. Purwar
suspected implant-based breast reconstruction
infection: a single center experienceA. Pagotto* E0355 Risk evaluation of iatrogenic transmission of Human
(Udine, Italy), G.G. Caputo, A. Scarabosio, A. Sartor, Papillomavirus (HPV) during gynaecological
A. Colombo, P.C. Parodi, C. Tascini proceduresB. Casini* (Pisa, Italy), F. Chiovelli, Y.
Ferchichi, E. Esposito, M. Basile, G. Del Bravo, A.
E0321 PET CT controls and Dalbavancin therapeutic drug
Giannini, T. Simoncini
monitoring can help guiding Dalbavancin treatment
duration of complicated cardiovascular infectionsC. E0357 Rubella screening in pregnancy – Slovakian one-
Kujat* (Kiel, Germany), M. Jüptner, D. Pape, J. Frank, center retrospective analysis around COVID-19
A.T.D. Thiem, B. Panholzer, B. Steinborn, S. Ewering, pandemicZ. Paraličová* (Kosice, Slovakia), D.
A. Friedrichs Javorská
E0322 A complex case of pelvic bone infection caused by E0358 The impact of maternal influenza infection and
carbapenem-resistant Acinetobacter baumanii vaccination during pregnancy on birth outcomesB.
successfully treated with eravacyclineM. Zagarrigo* Goundappa* (Pittsburgh, United States), X. Zhang,
(Bologna, Italy), S. Tedeschi, M. De Paolis, G. Fornaro, B. Gk, H.E.A. D'agostino, H. Liu, A.M. Rick
A. Pozzi, E. Zamparini, P. Viale E0359 Use of valaciclovir therapy during pregnancy for the
E0323 Oritavancin in a patient with recurrent endocarditis by prevention of congenital cytomegalovirus infection:
Enterococcus faecalis: a new therapeutic option?M. a monocentric experienceG. Lorenzetti* (Rome,
Bongiovanni* (Lugano, Switzerland), B. Barda, E. Italy), S. Garattini, L. Romani, M. Di Giuseppe, M. De
Bernasconi Luca, L. Cursi, S. Bernardi, S. Chiurchiù, S.
Mercadante, C. Tripiciano, A. Krzysztofiak, C.
Vassallo, I. Fabietti, L. Caforio, L. Lancella, F.I. Calò
KN080 Carducci
09:30 - 10:30 Hall 1
E0360 Multi-systemic long-term sequelae following SARS-
Keynote Lecture CoV-2 Omicron infection in pregnancy: a
population-based cohort studyY.Y. Tan*
Infections after solid organ transplantation: past, present and future (Singapore, Singapore), E.X.H. Loy, A.T. Tay, J.T.
Chairs Nina Khanna (Basel, Switzerland) Lim, C.J. Chiew, D.C.B. Lye, L.E. Wee
Priscilla Rupali (Vellore, India) E0361 The Impact of OAS1 rs4766664 and OAS3
rs10735079 Polymorphisms on the Clinical Course
of COVID-19 in Pregnant WomenS. Kirik Yilmaz*
(Konya, Türkiye), S. Kırık Yılmaz, S. Sumer, N. Demir
K0241 09:30 Jay Fishman (Boston, United States) Aktug, O. Ural, E. Ozdemir Marzioglu, O. Secilmis, T.
Cora
E0362 Sex-stratified analysis of T cell activation,
SY082
11:00 - 12:00 Hall 6
exhaustion, proliferation and HIV reservoir among
1-hour Symposium PLWHL. Santinelli* (Rome, Italy), M. Andreotti, L.
Maddaloni, Z. Michelini, G. Bugani, F. Romano, E.
How to address anti-science in our community? Gentili Cacciola, G. Antonelli, C.M. Mastroianni, C.
Scagnolari, G. D'ettorre
Chairs Tuba Dal (Ankara, Türkiye)
Tyra Grove Krause (Copenhagen, Denmark)
EF050
11:00 - 12:00 Arena 3

S0243 11:00 The rise of anti-science: lessons for the future ePoster Flash Session
scientistMarion Koopmans (Rotterdam, Netherlands)
Expanding MALDI-TOF applications
S0244 11:30 Open science for public trustLisa Hansen (Ottawa,
Canada) Chair Belen Rodriguez-Sanchez (Madrid, Spain)

FO090
11:00 - 12:00 Arena 1 E0363 Application of MALDI-TOF Mass Spectrometry and
Machine Learning for the Detection of Vancomycin-
Open Forum Resistant Enterococcus faeciumM. Sánchez Cueto*
(Madrid, Spain), M. Sánchez-Cueto, M. Blázquez-
European CM/ID exam: going forward Sánchez, M. Marín, E. Cercenado, P. Muñoz, B.
Chair Siri Goepel (Tuebingen, Germany) Rodríguez-Sánchez, D. Rodríguez-Temporal
E0364 Early detection of ampicillin susceptibility in
Enterococcus faecium with MALDI-TOF MS and
machine learningT. Pichl* (Munich, Germany), L.
F0259 11:00 View from medical microbiologyMaeve Doyle
Miranda, N. Wantia, K. Borgwardt, J. Sattler
(Waterford, Ireland)
E0365 Rapid antifungal resistance prediction based on
F0260 11:10 view from infectious diseasesEoghan De Barra
MALDI TOF mass spectrometryD. Duroux* (Zurich,
(Dublin, Ireland)
Switzerland), Y. Yang, J. Sattler, A. Egli
F0261 11:20 view from trainees (TAE)Christian Kraef
E0366 Rapid prediction of fluconazole resistance by
(Copenhagen, Denmark)
machine-learning analysis of Candida parapsilosis
F0262 11:30 European exam - how to prepare?Annelies Verbon MALDI-TOF mass profilesC. Magri* (Rome, Italy), C.
(Bosch En Duin, Netherlands) Magrì, V. Ivagnes, M. Sanguinetti, E. De Carolis
Co-organised with: ESCMID Education Subcommittee, ESCMID Professional E0367 Optimizing pretreatment for MALDI-TOF MS:
Affairs Subcommittee, UEMS Section of Medical Microbiology, UEMS Section Evaluating the dispersion method for filamentous
of Infectious Diseases fungal identificationR. Huang* (Shenzhen, China), Y.
Li, Y. He, T. Ma, F. Lu
E0368 Rapid detection of colistin resistance in
EF049
11:00 - 12:00 Arena 2 Acinetobacter baumannii by a MALDI-TOF MS-based
assayE. Kırbaş* (Van, Türkiye), I.D. Nix, K. Sparbier,
ePoster Flash Session
O. Drews, B. Oberheitmann, M. Kostrzewa, G.
ESCMID Global 2025 - Programme
Hasçelik, B. Sancak
E0369 Discrimination of clinical Pseudomonas strains at the SY084
species level using a large-scale genomically 11:00 - 12:00 Hall 10
predicted protein mass database with MALDI-MSK. 1-hour Symposium
Teramoto* (Kyoto, Japan), Y. Sekiguchi, L. Sellami,
M. Tohya, T. Kirikae Sleeping sickness and Chagas: a tale of the two trypanosomes
E0370 Automatic differentiation of Clostridioides difficile Chairs Hanne Brekke (Oslo, Norway)
ribotypes using MALDI-TOF MS and web-based Irene Losada Galvan (Barcelona, Spain)
classification modelsM. Blazquez Sanchez* (Madrid,
Spain), M.C. Blazquez-Sanchez, J.M. Moreno, A.
Guerrero-López, G.P. Mark, V. Gómez-Verdejo, P.
Muñoz, M. Marín, L. Alcalá, D. Rodriguez-Temporal, S0247 11:00 Human African Trypanosomiasis: recent diagnostic
B. Rodriguez-Sanchez and medical practicesJean-Mathieu Bart (Conakry,
E0371 Identification of sepsis-causing bacteria using Guinea)
shotgun proteomicsL. Meekes* (Rotterdam, S0248 11:30 American Trypanosomiasis: Diagnosis, screening and
Netherlands), D. Rustad, C. Güzel, T.K. Jenssen, H. managementTba
Hauge, C. Klaassen, M. Bexkens, N. Strepis, T. Luider, Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)
W. Goessens

OS047
EF051
11:00 - 12:00 Arena 4 11:00 - 12:00 Hall 11

1-hour Oral Session

ePoster Flash Session
Clinical studies in UTI
The enemy of my enemy: From jumbo phages to cocktails for difficult to treat
infections Chairs Iva Butic (Zagreb, Croatia)
Paul Christoffer Lindemann (Bergen, Norway)
Chair Paul G. Higgins (Cologne, Germany)

O0344 Short versus long antibiotic treatment for

E0372 Anti-K2 recombinant phage depolymerases as anti- pyelonephritis and complicated UTIs: an updated
virulence agents against hypervirulent Klebsiella systematic review and meta-analysis of RCTsI.
pneumoniaeM. Roch* (Geneva, Switzerland), R. Zahavi* (Haifa, Israel), D. Kunwar, J. Olchowski, H.
Sierra, D. Andrey Dallasheh, M. Paul
E0373 Jumbo Klebsiella bacteriophage demonstrates O0345 Antibiotic treatment duration of complicated urinary
efficient multidrug-resistant Klebsiella pneumoniae tract infection patients in Europe: results from the
killing and significant clinical potentialY. Liu* Ecraid POS-cUTI studyC. Kats* (Utrecht,
(Singapore, Singapore), Y. Zhong, S. Thong, L.H.A. Netherlands), J.M. Bravo-Ferrer, T.T. Doesschate,
Kwa P.D. Van Der Linden, P. Martinez, O. Awwad, E. Rubio,
E0374 A new phage cocktail targeting at Klebsiella P. Clevenbergh, A. Barac, A. Cano, E. Merino, P.
pneumoniaeX. Yin* (Chengdu, China), Y. Feng, H. Andrade, L. Jacquin, B. Koprivica, R. Espindola, P.
Luo, Z. Zong Muñoz, T. Lafon, M. Mendris, J. Van Laethem, D.
E0375 Bacteriophages against pulmonary infection and Viglino, A. Ternhag, J. Rupp, A. Hernandez-Torres, D.
colonization of the gut by multidrug-resistant Chadwick, B. Carevic, M. Bonten, E. Tacconelli, J.
Klebsiella pneumoniae in murine modelsA.M. Örmälä- Rodríguez-Baño
Tiznado* (Stockholm, Sweden), S. Patpatia, J. O0346 Prevalence and impact of multidrug resistance in a
Bengoechea, C. Frantzen, A. Garcia Navarro, C. Giske cohort of patients admitted to emergency
E0376 A novel broad-spectrum phage cocktail effictive for department for urinary tract infections: the UTILITY
carbapenem resistant Acinetobacter baumannii of study, a prospective multicentre studyL. Onorato*
capsular type 104/2/7 in vitroL. Wei* (Chengdu, (Naples, Italy), E. Allegorico, M. Macera, C. Monari, B.
China), Y. Feng, Z. Zong Migliaccio, F.G. Numis, C. Nasta, M.T. Florio, R.
Sciorio, G. Guiotto, M. Giordano, R. Raucci, F. Dello
E0377 Proteomic and Genomic Characterization of a Novel Vicario, R. Nasti, A. Voza, N. Coppola
Bacteriophage of a New Genus Infecting
Pseudomonas aeruginosaS. Unlu* (Ankara, Türkiye), O0347 Weekly sequential antibioprophylaxis for UTI in
A. Uskudar Guclu neurogenic bladderR. Calin* (Paris, France), C.
Chesnel, C. Hentzen, M. Teng, F. Le Breton, V. Phe, F.
E0378 Phages as innovative adjuvants of antibiotics therapy Adda, C. Palacios, G. Amarenco, G. Pialoux
against S. aureus and P. aeruginosa in the context of
Cystic FibrosisA. Glorieux* (Brussels, Belgium), S. De O0348 Evidence for the duration of antibiotic therapy for
Soir, M. Merabishvili, J.P. Pirnay, D. De Vos, F. Van chronic bacterial prostatitis: a systematic reviewL.
Bambeke Cordes* (Geneva, Switzerland), A. Huttner, R. Calin,
K. Gupta, M. Lafaurie, M. Lambregts, V. Lavergne, B.
E0379 Evaluation of bacteriophages against Staphylococcus Trautner
aureus strains isolated from orthopaedic infectionsS.
Patpatia* (Helsinki, Finland), A. Camporeale, S.
Kiljunen, C. Giske, A.M. Örmälä-Tiznado OS048
E0380 Anti-Staphylococcus aureus phages: assessing the 11:00 - 12:00 Hall 12

risk of bacterial resistance emergence through 1-hour Oral Session

selective pressureM. Degreze* (Lyon, France), M.
Medina, F. Laumay, L. Blazère, E. Helluin, F. Laurent, Complexities of infections in solid organ transplantation
C. Kolenda Chairs Silvia Corcione (Turin, Italy)
Monica Slavin (Melbourne, Australia)
KN081
11:00 - 12:00 Hall 1

Keynote Lecture O0349 Solid Organ Transplants from donors with positive
blood cultures: watch out for carbapenem-resistant
The new frontiers in antimicrobial stewardship EnterobacteralesA. Cona* (Palermo, Italy), C.
Chairs Jose Ramon Pano-Pardo (Zaragoza, Spain) Curatolo, P. Giordani, F. D'andrea, M. Campanella, E.
Jeroen Schouten (Nijmegen, Netherlands) Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F.
Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N.
Coppola, A. Mularoni
O0350 Risk factors for carbapenem-resistant
K0242 11:00 Karin Thursky (Carlton, Australia) Enterobacteriaceae infection after orthotopic liver
ESCMID Global 2025 - Programme
transplant in a large cohort of pre-transplant CRE Chair Laurent Poirel (Fribourg, Switzerland)
carriersM. Rinaldi* (Bologna, Italy), B. Miani, M.
Freire, E. Girão, D. Yahav, M. Valerio, L.M. Parra, L.
Alagna, E. Franceschini, P. Burra, A. Mularoni, M.
Halpern, L. Camargo, R. Romagnoli, E. Graziano, N. S0253 11:00 Bacterial PROTACs: Do proteolysis-targeting
Caroccia, M. Di Chiara, P. Viale, M. Giannella degraders represent a viable strategy for new
antimicrobials?Morreale Francesca Ester (London,
O0351 Serologic follow up of solid organ transplant
United Kingdom)
recipients who receive organs from syphilis
seropositive donors.O. Fernandez Garcia* S0254 11:30 Activity-based protein profiling of bacterial
(Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. pathogens: new enzymes and their functions at the
Doucette host-microbe interfaceChristian Stephan Lentz
(Tromsø, Norway)
O0352 Prophylaxis strategies and risk of cytomegalovirus in
solid organ transplant recipientsA. Dahl* (KøbenhaVn
V, Denmark), M. Koller, O.J. Manuel, K.S. Moestrup,
ME088
J. Reekie, E. Tusch, C.G. Crone, M. Perch, F. 11:00 - 12:00 Hall 2
Gustafsson, S.S. Sorensen, N. Schultz, K. Schønning,
Meet-the-Expert
J. Lundgren, N. Mueller, M. Helleberg
O0353 Burden of non-microbiologically confirmed infections Global AMR Policy after UNGA: what do we do now!
in solid organ transplant recipientsM. Zou* (Basel,
Switzerland), M. Koller, O.J. Manuel, N. Mueller, K.
Boggian, C. Hirzel, C. Garzoni, N. Khanna, C. Van
Delden, D. Neofytos M0255 11:00 Gisela Robles Aguilar (Oxford, United Kingdom)
M0256 11:12 Mike Sharland (London, United Kingdom)
SY085
11:00 - 12:00 Hall 13
OS043
1-hour Symposium 11:00 - 12:00 Hall 3

Diagnosing the undiagnosed fraction: the final step towards viral hepatitis 1-hour Oral Session
elimination
Navigating disinfection challenges: resistance, outbreaks, and efficacy
Chairs Mojca Maticic (Ljubljana, Slovenia)
Snjezana Zidovec Lepej (Zagreb, Croatia) Chairs Hillary A. Craddock (Dublin, Ireland)
Stephanie J. Dancer (Glasgow, United Kingdom)

S0249 11:00 Role of reflex testing strategies in identifying patients

with chronic viral hepatitisOana Sandulescu O0324 Prolonged disinfectant exposure impacts the
(Bucharest, Romania) antimicrobial resistance of healthcare-associated
microorganisms: a systematic reviewÂ.R. Fernandes*
S0250 11:30 Management and elimination of hepatitis in hard-to- (Porto, Portugal), A. Gonçalves Rodrigues, L.
reach personsSuda Tekin (Istanbul, Türkiye) Cobrado
Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), O0325 Sink-associated outbreak of verona integron-
Romanian Society for Infectious Diseases and HIV/AIDS encoded metallo-??-lactamase-producing
carbapenem-resistant Pseudomonas aeruginosa in a
Dutch intensive care unitM. Van Den Bos Kromhout*
SY086
11:00 - 12:00 Hall 14 (Zwolle, Netherlands), S. Debast, M. Van Den Bos-
Kromhout, S. De Vries-Van Rossum, S. Abma-Blatter,
1-hour Symposium B. Immeker, K. Zuur, M. Hijmering, J.W.A. Rossen
O0326 Carbapenemase-producing Enterobacterales
Impact on including a measure of viability in molecular diagnostic tests
outbreak control by replacement of toilets or long-
Chairs Fusun Can (Istanbul, Türkiye) term disinfection? A real-life experience.A.L.
Denise O'sullivan (Teddington, United Kingdom) Engsbro* (Slagelse, Denmark), K.H. Hansen, M.F.J.
Larsen, N. Kling, H.T. Larsen, R. Kjølsen, B. Hansen,
L.K. Vejrum, A.L. Laugesen, M. Kemp
S0251 11:00 Viability markers in support of development of O0327 Tolerance of Klebsiella pneumoniae biofilms to
Chlamydia screening recommendationsPetra Wolffs disinfection with peracetic acidM. Arvand* (Berlin,
(Maastricht, Netherlands) Germany), A.M. Richter, D. Csertö, K. Konrat
S0252 11:30 Measuring viability to improve the correlation of AMR O0328 Bringing balance to the formulation: disinfection
markers and clinical outcomes in Neisseria efficacy and material compatibilityJ. Jennings*
gonorrhoeaeTatum Mortimer (Athens, United States) (Halifax, United Kingdom), T. Langford, H.
Mansbridge, E. Fraser, I. Poles, J. Clarke
Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia
Infections (ESGMAC)
LB002
11:00 - 12:00 Hall 4
ME089
11:00 - 12:00 Hall 15 1-hour Oral Session
Meet-the-Expert Investigation of intriguing outbreaks
How to teach Medical Mycology Chairs Ana Raquel Freitas (Porto, Portugal)
Marc J. Struelens (Saltsjobaden, Sweden)

M0257 11:00 Katrien Lagrou (Leuven, Belgium) L0006 Molecular surveillance of artemisinin and
M0258 11:12 Mihai Mares (Iasi, Romania) sulfadoxine-pyrimethamine resistance in Plasmodium
Co-organised with: European Confederation of Medical Mycology (ECMM) falciparum isolates from Uganda: results of ERASE
studyM. L'episcopia* (Rome, Italy), F.V. Segala, J.
Ictho, R. Papagni, I. Obua, E. De Vita, N. Olang, R.
SY087 Novara, V. Totaro, L. Olal, G. Patti, C. Bignom, C.
11:00 - 12:00 Hall 16
Agaro, G. Dall'oglio, B. Ngole, S. Okori, P. Lochoro, G.
1-hour Symposium Putoto, F. Di Gennaro, C. Severini, A. Saracino
L0007 Investigation of an international pseudo-outbreak
Innovating antimicrobial drug discovery and host-pathogen interaction involving Paraburkholderia fungorum blood culture
studies using chemical biology contaminationJ. Moran-Gilad* (Jerusalem, Israel),
ESCMID Global 2025 - Programme
J.L. Dale, A. Michael-Gayego, A. Gross, V. Temper, S. and Therapeutics Committee Members ???S.
Lim, C. Lees, K. Knowles, J. Strahilevitz, Y. Oster, D. Mahadevaiah* (Mysore, India), C. Es, K. Anil, Y.
Grupel, D. Reshef, B.A. Smith, B. Warren, E.L. Maheshwarappa, S.S. Sc, S. Srinivas, V. Swamy Gs,
Palavecino, P. Snippes Vagnone K. Gautam
L0008 Evolving cluster of severe infective endocarditis with O0336 Healthcare providers' perspectives on antibiotic use
non-toxigenic C. diphtheriae amongst people and resistance in pregnancy, childbirth, and children
experiencing homelessness and substance misuse in under five years of age across four levels of hospitals
the UKR. Cordery* (London, United Kingdom), T. in Lao PDR, 2024S. Vantava* (Vientiane Capital, Lao
Patel, T. Anwar, N. Utjesanovic, A. Aryee, E. People's democratic republic), K. Thilakoun, D.
Mavrogiorgou, N. Karogiannis, D.J. Litt, J. D'aeth, C. Sypaseuth, C. Khamla, I. Bounxou, P. Vanpheng, B.
Primus, S. Das, K. Paranthaman, G. Amirthalingham Phetsamone, S. Bangthong, K. Sengchanh, S.
L0009 AI-driven live cough rate tracking for public health Latsamy, S. Vanphanom, L. Annick, S. Somphou
surveillanceM. Kågebäck* (Göteborg, Sweden), E. O0337 High gender gap in female labour force participation
Carlsson and reduced gender inequality linked to high
antibiotic consumption: Evidence from a global
analysisD. Samria* (Bangalore, India), D. Batheja, A.
OS044 Nandi
11:00 - 12:00 Hall 5
O0338 Gender gaps in knowledge of antibiotics and
1-hour Case Session antimicrobial resistance: Evidence from IndiaD.
Batheja* (Delhi, India), S.R. Umenthala, S. Goel, D.
Unusual presentations of unusual parasites Samria, R. Bhagawati, B. Deepshikha
Chairs Emmanuel Bottieau (Antwerp, Belgium)
Marcelo Victor Radisic (Buenos Aires, Argentina)
OS046
11:00 - 12:00 Hall 9

1-hour Oral Session

O0329 Atypical neonatal cutaneous myiasis: a diagnostic
challenge mimicking pustular rash in a resource- Vaccines and prophylaxis against respiratory viral infections
limited settingD. Ekwem Amarachi* (Gulu, Uganda),
E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi, Chairs Ana Atti (London, United Kingdom)
R. Olum Sophie Schneitler (Homburg, Germany)
O0330 An itchy awakening due to Dermanyssus infestationJ.
Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales,
J.M. Bérenegr, S. Ranque O0339 Public health impact of universal prophylaxis with
O0331 Uterine Myiasis: A Rare Case of External nirsevimab for prevention of infant hospitalizations
Genitourinary MyiasisR.L. Johnson* (Birmingham, due to respiratory syncytial virus. Full 2023-24
United States), J.C.F. Nakazaki, P. Legua season analysis of the NIRSE-GAL study
(www.nirsegal.es/en)F. Martinón-Torres* (Santiago
O0332 Neurognathostomiasis Presenting with Cerebral De Compsotela, Spain), N. Mallah, J. Pardo-Seco, O.
Venous Sinus Thrombosis: A case report of rare Pérez-Martínez, M.I. Santiago-Pérez, M.T. Otero-
clinical manifestation.C. Norsungnern* (Bangkok, Barrós, N. Suárez-Gaiche, R. Kramer, J. Jing, L.
Thailand), J. Vinichanan, L. Paitoonpong Platero-Alonso, R.M. Alvárez-Gil, O.M. Ces-Ozores, V.
O0333 If at first, you don't succeed… Treatment-resistant Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo,
Fascioliasis: case reportW. Garr* (Leeds, United J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez,
Kingdom), K. Woods, L. Nabarro I. Rivero-Calle, Á. Manzanares-Casteleiro
O0340 Relative effectiveness of high-dose versus standard-
dose quadrivalent influenza vaccine against
SY083
11:00 - 12:00 Hall 7 hospitalizations and mortality according to Charlson
Comorbidity Index: A post-hoc analysis of the
1-hour Symposium DANFLU-1 randomized trialK. Feldballe Bernholm*
(Copenhagen, Denmark), N. Dyrby Johansen, C.
Lyme neuroborreliosis: challenges in diagnosis and treatment Espersen, D. Modin, K. Hyldekær Janstrup, J. Nealon,
Chairs Alexandra Mailles (Paris, France) S. Samson, M.M. Loiacono, R. Harris, C. Schade
Joanna Maria Zajkowska (Białystok, Poland) Larsen, A.M. Reimer Jensen, N.E. Landler, S. Tellerup
Nielsen, L. Russell, T. Skovsgaard Itenov, B.L.
Claggett, S.D. Solomon, M.J. Landray, G.H. Gislason,
L. Køber, P. Sivapalan, J.U. Stæhr Jensen, T. Biering-
S0245 11:00 Challenges in diagnosis of Lyme neuroborreliosisRick Sørensen
Dersch (Freiburg, Germany)
O0341 Relative vaccine efficacy of a SARS-CoV-2 spike
S0246 11:30 Challenges in treatment of Lyme receptor-binding and N-terminal domain COVID-19
neuroborreliosisAnne Marit Solheim (Kristiansand, vaccine versus mRNA-1273: subgroup analysesS.
Norway) Chalkias* (Cambridge, United States), C. Grassi, P.
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain Dennis, D. Petersen, K. Radhakrishnan, L. Vaughan, R.
(ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR) Handforth, N. Vicic, A. Rossi, R. Wahid, D. Edwards, J.
Feng, W. Deng, H. Zhou, E. De Windt, V. Urdaneta, B.
Girard, S. Faust, S. Walsh, C. Cosgrove, R. Das
OS045
11:00 - 12:00 Hall 8 O0342 Effectiveness of RSV vaccine in lung transplant
recipients: neutralizing antibody response against
1-hour Oral Session reference and seasonal strainsN. Shirin* (Ramat Gan,
Israel), L. Levy, D. Yahav, M. Benzimra, Y. Bezalel, T.
Social behavioural dynamics of antibiotic use and AMR Hoffman, T. Sinai, M. Jurkowicz, O. Deri, N. Matalon,
Chairs Sonia Lewycka (Hanoi, Vietnam) M. Saute, Y. Lustig, E. Nachum, M. Peled, I. Nemet, M.
Filippo Medioli (Milan, Italy) Mandelboim
O0343 Novavax investigational COVID-19 Influenza
Combination nanoparticle vaccine phase 2 study
safety evaluationC. Bennett* (Gaithersburg, United
O0334 Investigating the Knowledge, Attitudes, and Practices States), V. Shinde, S. Neal, J.S. Plested, T. Vincent, M.
around Antimicrobial Resistance and Stewardship Zhu, S. Cloney-Clark, Z. Cai, B. Riviers, A. Ahmed, F.
Among Syrian Healthcare Professionals: A Cross- Mahkhou, A.M. Marchese, I. Cho, L. Fries, W. Woo
Sectional SurveyA. Abbara* (London, United
Kingdom), H. Alhosni, F. Alahdab
O0335 Gamified Intervention to Enhance Antimicrobial SY093
Stewardship: Improving Knowledge and Practices on 13:30 - 14:30 Hall 11

the Rational Use of Antimicrobials Among Medicines

ESCMID Global 2025 - Programme
1-hour Symposium ePoster Flash Session

Immunosenescence and immune response to vaccination Beware the sink! Pathogen reservoirs in drains and waste water
Chairs Petar Velikov (Sofia, Bulgaria) Chair Stephan Juergen Harbarth (Geneva, Switzerland)
Dafna Yahav (Ramat-Gan, Israel)

E0391 Genomic Epidemiology to Investigate Healthcare

S0267 13:30 How immunosenescence impacts vaccine Environment as Reservoir for Carbapenem-
responseAndrea Cossarizza (Modena, Italy) Resistant Organisms in an Academic Hospital in
S0268 14:00 Strategies to tackle immunosenescence and improve Miami, Florida.A. Jimenez* (Miami, United States),
immune response to vaccination in the elderlyInna S. Hawken, S. Arenas, K. Mokoban, D. Pronty, O.
Ovsyannikova (Rochester, United States) Martinez, J. Colson, A. Richardson, T. Ferreira, B.
Shukla
Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE),
ESCMID Vaccine Study Group (EVASG) E0392 Two clusters of carbapenemase-producing
Enterobacterales linked to hospital wastewater
drainage in utility rooms – an outbreak
investigationI. Vock* (Basel, Switzerland), G.
EW096
13:30 - 15:30 Hall 15
Capoferri, P. Urwyler, P. Domene, D. Roy, S. Kuster,
Educational Session N. Gürtler, B. Ivan, P.M. Keller, S. Tschudin-Sutter
E0393 Assessing the burden of carbapenemase and
Tools for successful development as a medical educator colistin antimicrobial resistance genes in hospital
Chairs Giorgia Caruana (Sion, Switzerland) wastewaterE. Au* (Calgary, Canada), N. Acosta, B.
Yoav Keynan (Winnipeg, Canada) Waddell, J. Lee, K. Du, R.B. Weyant, B. Dalton, M.
Bautista, J. Mccalder, R. Clark, J. Pitout, J. Kim, B.
Missaghi, O. Larios, J. Vayalumkal, J. Leal, E.
Rennert-May, J. Kanji, P. Westlund, B. Lee, X.L.
W0273 13:30 Developing your educator professional identityTodd Pang, K. Frankowski, C. O'grady, J.M. Conly, C.R.
Cassese (Bronx, United States) Hubert, M. Parkins
W0274 13:50 What do IPC doctors need to learn to be E0394 Hospital wastewater as a reservoir for
preparedSimone Scheithauer (Göttingen, Germany) carbapenemase-producing organismsA.
Anantharajah* (Brussels, Belgium), C. Altintas, T.
W0275 14:10 Communities of practice: successful experience of a
Lavalleye, A. Delaunoy, I. Meyts, E. Dumitreasa, A.
transformative collaboration and roadmapErin
Bennert, C. Schirvel, A. Verroken, H. Rodriguez-
Bonura (Portland, United States)
Villalobos
W0276 14:30 The critical need for ongoing innovations in medical
E0396 Reversing and controlling microbial proliferation in
educationClémentine Schilte (Paris, France)
the water system of a high-risk hospital ward after
Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID extended closure and reconstructionD. Chaput*
Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) (Glasgow, United Kingdom), K. Clarkson, L.
Steering Committee, British Infection Association (BIA), Young Leader Circle Bagrade, A. Marek, D. Kelly, D. Watson, A. Leanord,
of the American Society of Microbiology T. Steele
E0397 Whole-genome sequencing as part of the tracking
and managing Carbapenemase producing
FO097
13:30 - 14:30 Arena 1 Enterobacterales transmission in an acute hospital
settingD. Coffey* (Cork, Ireland), R. Waldron, D.
Open Forum Neshev, M. Cormican, C. Clarke, L. Hayes
Essential diagnostics in Low-Resource Settings: why are we still talking? E0398 Is there a solution for hospital acquired infections
due to the aquatic reservoir in the near patient
Chair Truls Michael Leegaard (Lørenskog, Norway)
environment?H. Zayyad* (Poriya, Israel), R. Khouri,
N. Saleh, A. Peretz
E0399 Reducing Antimicrobial Resistance (AMR) across
F0277 13:30 Training skilled personnel in LMIC and brain drain: is the One Health Landscape: Diverse Perspectives on
the solution the problem?Sipho Kenneth Dlamini AMR risks and their mitigation in sinks, drains, and
(Observatory, South Africa) wastewaterH.A. Craddock* (Dublin, Ireland), A.
F0278 13:40 Leveraging surveillance networks to strengthen basic Kearney, F. Fitzpatrick, C. Finn, M.T. Pryce, D.
bacteriologyDissou Affolabi (Cotonou, Benin) Fitzgerald-Hughes
F0279 13:50 Clinical bacteriology laboratories in low-resource
settings: considerations for sustainabilityMakeda
EF055
Semret (Montreal, Canada) 13:30 - 14:30 Arena 4

Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch ePoster Flash Session
Society for Medical Microbiology (NVMM), ESCMID Parity
Commission,Federation of European Microbiological Societies (FEMS), The cutting edge in tuberculosis
ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge Chair Graeme Ayton Meintjes (Observatory, South Africa)
d'Infectiolo

FO098
13:30 - 14:30 Arena 2 E0400 Personalised risk predictions for incident TB and
preventive treatment uptake.R. Rose-Key* (London,
Open Forum United Kingdom), R. Gupta, M. Noursadeghi
E0401 Programmatic migrant screening for tuberculosis
Best of ID Week
identifies a spectrum of clinical phenotypes and
Chair Tina Tan (Chicago, United States) outcomes: cohort data from a national migrant
screening programmeM. Gohar* (Leicester, United
Kingdom), C. Martin, A. Ayobami, H. Patel, M. Patel,
L. Ahyow, B. Srini, G. Rishi, P. Mark, S. Nilesh, C.
F0280 , Seth Cohen (Seattle, United States), Erin Mccreary Trevithick, K. Pierun, M. Wiselka, L. Gray, I.
(Pittsburgh, United States), Ilan Youngster (Beer Abubakar, R. Baggaley, A. Cooper, P. Haldar, M.
Yaakov, Israel) Pareek
E0402 An investigation into the relationship between
EF054 human and animal Mycobacterium bovis isolates
13:30 - 14:30 Arena 3
using whole genome analysis.M. Mansfield*
(Dublin, Ireland), E. Roycroft, S. Mok, P. Flanagan,
ESCMID Global 2025 - Programme
M. Mc Elroy, B. Byrne, H. Cameron, D. Farrell, S.V.
Gordon, J. Wagener, M.M. Fitzgibbon, T.R. Rogers
LB003
E0403 Distinguishing relapse from reinfection in 13:30 - 14:30 Hall 13
tuberculosis patients from LithuaniaL. 1-hour Oral Session
Vasiliauskaite* (Vilnius, Lithuania), L. Vasiliauskaitė,
A. Zinola, F. Di Marco, V.E. Davidavičienė, B. New solutions for difficult-to-treat infection
Nakčerienė, A. Vaitulionytė, D.M. Cirillo, T.
Kačergius Chair Shampa Das (Liverpool, United Kingdom)
E0404 Rapid Resistance Profiling of Mycobacterium
tuberculosis from Clinical Specimens using
Targeted Next-Generation Sequencing: A Pilot L0011 Antimicrobial CRISPR-Cas9-based treatment against
Validation StudyP. Chheda* (Mumbai, India), S. antibiotic resistant extraintestinal pathogenic E. coli
Shivaprakash, T. Dama, G. Thandassery (ExPEC) ST131C. Morros-Bernaus* (Penryn, United
E0405 Inflammation precedes early respiratory worsening Kingdom), J. Westley, E. R. Wyrsch, S. P. Djordjevic,
in HIV-negative tuberculosis patients during A. F.C. Leonard, D. Sünderhauf, S. Van Houte
antituberculosis treatmentA. Van Laarhoven* L0012 Ultra-narrow spectrum antibiotic against multi-drug
(Nijmegen, Netherlands), L. Kurver, E. Klein resistant gonococci with novel mode of actionN.
Teeselink, A. Lemson, C. Bosteels, N. Carpaij, J. Van Nguyen* (Vienna, Austria), N. Nhung, A.K. Mix
Ingen, E. Ardiansyah, C. Van Arkel, R. Vullinghs, C. L0013 Multivalent OMV-based vaccine against Klebsiella
Magis Escurra, W. Hoefsloot, R. Van Crevel pneumoniaeB. Cano Castaño* (Madrid, Spain), B.
E0406 Impact of fluoroquinolone resistance on the cost- Cano-Castaño, A. Tajuelo Moreno-Palancas, S. Prieto
effectiveness of empiric treatment for multidrug- or Martin-Gil, D. Fousteris, L. Del Pozo Acebo, F.
rifampicin-resistant tuberculosisC. Kim* (London, Docando Sánchez, E. Gato, A. Pérez, M.J. Mcconnell
United Kingdom), S. Sweeney, H. Sohn, G.M. Knight, L0014 Epidermicin NI01, a first-in-class peptide antibiotic
C.F. Mcquaid candidate, has potent efficacy in a robust MRSA
E0407 A longitudinal study on the evolution of drug wound infection model and low allergic reaction
resistance during tuberculosis treatmentE. Danso* liabilitiesM. Upton* (Plymouth, United Kingdom), G.
(Accra, Ghana), P. Asare, P. Tetteh, A. Tetteh, A.A. Barker, V. Bennett, I. Fotheringham, S. Baxter, H.
Boadu, S. Osei-Wusu, A. Asante-Poku, Y. Klinogo, A. Curry
Sylverken, J. Afriyie-Mensah, A. Adjei, D. Yeboah- L0015 Minimum inhibitory concentrations of quabodepistat
Manu in Mycobacterium tuberculosis clinical isolates from
E0408 Phase 1, randomized, double-blind, parallel-group, patients with drug-susceptible pulmonary
dose-escalation safety and tolerability of PLGA tuberculosisI. Kontsevaya* (Munich, Germany), Y.
encapsulated first line antitubercular drugs Hayashi, D. Towle, N. Hariguchi, Y. Liu, S. Takuva
nanoparticles in healthy volunteersA.K. Pandey*
(Chandigarh, India), N. Shafiq, S. Malhotra, C.
Mothsara, G. Khuller, J. Verma, L. Verma SY094
13:30 - 14:30 Hall 14

1-hour Symposium
SEL
13:30 - 15:30 Hall 1
Farm to fork: food-borne antimicrobial resistance
Special Session Chairs Beatriz Guerra Román (Parma, Spain)
Joel Mossong (Luxembourg, Luxembourg)
Selective Pressure
Chairs Jacob Moran-Gilad (Beer Sheva, Israel)
Joshua Nosanchuk (Bronx, United States)
Jose Ramon Pano-Pardo (Zaragoza, Spain) S0269 13:30 Foodborne risk in meat and fishery products and
Jesús Rodríguez-Baño (Seville, Spain) impact on AMRAnders Dalsgaard (Frederiksberg C,
Anja Šterbenc (Ljubljana, Slovenia) Denmark)
Suzanne Van Asten (Nijmegen, Netherlands) S0270 14:00 Control challenges associated with food-borne
David Van Duin (Chapel Hill, Nc, United States) multidrug resistanceLuisa Maria Vieira Peixe (Porto,
Portugal)
Co-organised with: ESCMID Food- and Water-borne Infections Study Group
(EFWISG)

JS1
13:30 - 14:30 Hall 12
ME095
Journal Session 13:30 - 14:30 Hall 16

Late-breaker research from CMI and CMI Communications Meet-the-Expert

Local antimicrobials for deep infections

J001 13:30 Measuring the impact of hospitalization for infectious

diseases on the quality of life of older patients in four
European countries: the AEQUI longitudinal matched M0271 13:30 Karolina Akinosoglou (Patra, Greece)
cohort study (2020–2023)Gaetan Gavazzi (Grenoble, M0272 13:42 Pierre Tattevin (Rennes, France)
France) Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG),
J002 13:42 Long-term outcomes of passive immunotherapy for ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID
COVID-19: a pooled analysis of a large multinational Study Group for Infectious Diseases of the Brain (ESGIB)
platform randomized clinical trialThomas Holland
(Durham, United States)
OS052
J003 13:54 The long-term sustainability of a pharmacist-led 13:30 - 14:30 Hall 2
antimicrobial stewardship penicillin allergy
delabelling ward round: A prospective cohort 1-hour Oral Session
studyElise Mitri (Heidelberg, Australia)
AI in infectious diseases: the lab and beyond
J004 14:06 Efficacy and safety of mechanical thrombectomy in
acute ischemic stroke secondary to infective Chair Miranda Langendam (Amsterdam, Netherlands)
endocarditisGuillermo Cuervo (Barcelona, Spain)
J005 14:18 A randomised non-inferiority trial investigating
antibiotic adjustments based on blood culture in O0381 Accurate strain typing of key bacterial pathogens
acute cholangitisSang Hyub Lee (Seoul, Korea, through artificial intelligence analysis of MALDI-TOF
Republic of) mass spectraN. Macesic* (Melbourne, Australia),
ESCMID Global 2025 - Programme
H.A. Nguyen, A. Peleg, J. Song, J.A. Wisniewski, D.L. Chairs Michele Bartoletti (Milan, Italy)
Dowe Merel Lambregts (Leiden, Netherlands)
O0382 CarbaDetector: An Artificial Intelligence-Driven
Prediction Model for Detecting Carbapenemase-
Producing Enterobacterales Using Disk-DiffusionL.K. S0265 13:30 Sex impacts incidence, management, and outcome in
Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler, bacteraemiaAnnette Westgeest (Leiden,
O. Nolte, L. Dortet, R. Bonnin, A. Egli, A. Hamprecht Netherlands)
O0383 AI-Driven Early Infectious Disease Detection in Dutch S0266 14:00 The complex interplay between gender and
Primary Care: leveraging Bidirectional Encoder sepsisInes Lakbar (Montpellier, France)
Representations from Transformers (BERT) and Early
Recognition using Neural Information Encoding Co-organised with: ESCMID Study Group for Bloodstream Infections,
(ERNIE)G. Danoe* (Groningen, Netherlands), M. Endocarditis and Sepsis (ESGBIES)
Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A.
Hamprecht, M. Brilman, L.L. Peters, M.S. Berends
ME101
O0384 Predicting potentially infection-related findings in 14:45 - 15:45 Hall 14
structured radiology reportsJ. Xu* (Oxford, United
Meet-the-Expert
Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P.
Langlotz, D. Eyre How to master conflict management and negotiation in healthcare
O0385 Application of Artificial Intelligence in Assisting X-ray
Diagnosis of Pediatric Pulmonary InfectionsH. Zhang*
(Shanghai, China), X. Xu, J. Ai
M0285 14:45 Esther Calbo (Terrassa, Spain)
M0286 14:57 Jan A.J.W. Kluytmans (Utrecht, Netherlands)
OS053
13:30 - 14:30 Hall 3

1-hour Oral Session

FO102
14:45 - 15:45 Arena 1
Immune evasion and intracellular survival strategies
Open Forum
Chairs Juliane Bubeck Wardenburg (St. Louis, United States)
Giovanni Delogu (Rome, Italy) Navigating the future of pandemics across One Health
Chair Xavier Lescure (Paris, France)

O0386 Capsule-Dependent Modulation of Cell Death

Pathways and Immune Evasion in Acinetobacter
baumanniiH. Wang* (Beijing, China), C. Jiang F0287 14:45 Status of the One Health Joint Plan of Action by the
QuadripartiteChadia Wannous (Paris, France)
O0387 Intracellular lifestyle of Acinetobacter baumannii:
Role of phospholipase A2 and transcriptional factor F0288 14:55 Evidence review on One Health governance and
EB (TFEB)Y. Smani* (Seville, Spain), C. Atalaya Rey, I. implementation at the European level Tyra Grove
Molina Panadero, A. Lora González, A. Hmadcha Krause (Copenhagen, Denmark)
O0388 The role of peg344 of hypervirulent Klebsiella F0289 15:05 Long-term consequences of emerging viral
pneumoniae on suppressing autophagy responses of diseasesAlfonso J. Rodriguez-Morales (Pereira,
macrophagesZ.E. Kuloğlu* (Istanbul, Türkiye), Ö. Colombia)
Albayrak, D. Güllü, G. Ekinci, F. Can Co-organised with: ESCMID Emerging Infections Subcommittee, ESCMID
O0389 c-Myc Inhibits Macrophage Antimycobacterial Study Group for Public Health Microbiology (ESGPHM), Trainee Association
Response in Mycobacterium tuberculosis InfectionC. of ESCMID (TAE) Steering Committee, Brazilian Society of Infectious Diseases
Dollé* (Zurich, Switzerland), E. Sarti, R. (SBI), Latin American Society for Travel Medicine
Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M.
Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander,
EF059
G.S. Olson, J. Nemeth 14:45 - 15:45 Arena 2
O0390 Targeting neutrophil extracellular traps (NETs) ePoster Flash Session
prevents tuberculosis immunopathologyJ.
Kutschenreuter* (London, United Kingdom), D. Bacterial infections in the post pandemic era
Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman,
J.S. Friedland, D.L.W. Chong Chair Özlem Kurt Azap (Ankara, Türkiye)

SY091
13:30 - 14:30 Hall 4 E0424 Genomic epidemiology of invasive meningococcal
disease in Scotland: The impact of the COVID-19
1-hour Symposium pandemicN. Ahmad* (London, United Kingdom), C.
Rodrigues, A. Smith, C. Cameron, L. Macdonald, R.
Emerging infectious diseases: staying informed and prepared in a globalised Ure, M. Maiden
world
E0425 Targeted probe-capture culture-independent
Chairs Nitin Gupta (Manipal, India) sequencing identifies emergence of Macrolide-
Pikka Jokelainen (Copenhagen, Denmark) Resistant Bordetella pertussis in AustraliaW. Fong*
(Westmead, Australia), R. Rockett, K. Tam, T. Nguyen,
E. Sim, C. Suster, J. Agius, S. Chandra, A. Watt, D.
S0263 13:30 Lessons learnt from previous outbreaksTba Speers, M. Graham, T. Tran, C. Lim, M. Wehrhahn, A.
Ginn, D. Gray, J. Robson, L. Papanicolas, I. Gardner,
S0264 14:00 Disease X: preparedness for the next pandemicYee A. Howard-Jones, A. Outhred, K. Kennedy, L. Cooley,
Sin Leo (Singapore, Singapore) Q. Wang, N. Jeoffreys, S. Chen, K. Basile, T.
Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Golubchik, J. Kok, V. Sintchenko
Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, E0426 Invasive pneumococcal disease in Spanish adults.
Reisemedizin und Globale Gesundheit e.V. Multicenter analysis of serotypes and lineages in the
post-pandemic period.R. España Bonilla* (Barcelona,
Spain), R. España-Bonilla, A. González-Díaz, J.M.
SY092
13:30 - 14:30 Hall 5 Marímón, A. Manzanal, E. Cercenado, S. De La Villa,
B. Viñado, M. Bernat-Sole, M. Campos-Ruiz, M.D.
1-hour Symposium Quesada, A. Casabella, M.L. Machado, R. Tejero, M.Á.
Galán, S. Calvo-Silveria, D. Berbel, J. Yuste, S. Martí,
Sex differences in management and outcome of patients with serious J. Càmara, C. Ardanuy
bacterial infections
E0427 Group A streptococcal infections in Germany from
ESCMID Global 2025 - Programme
2017 to 2024: a post-pandemic rebound above Ricciuto, D. Richardson, C. Vermeiren, K. Hassan, M.
expected numbers?A. Von Laer* (Berlin, Germany), J. Lefebvre, A.X. Li, N. Malik, M. Pejkovska, A. Sultana,
Mutevelli, A. Dörre, S. Haller, M. Feig, S. Buda, A. T. Vikulova, C. Kandel, Z. Zhong
Hoffmann, I. Noll E0441 Antimicrobial resistance in Streptococcus
E0428 Invasive group A streptococcus infections is often pneumoniae in the Netherlands: an 11-year trend
preceeded by seasonal influenza.J. Westin* analysis of surveillance dataI. Nauta* (Bilthoven,
(Gothenburg, Sweden), M. Nygren, U. Snygg-Martin, Netherlands), W. Altorf-Van Der Kuil, D.W.
L. Gustavsson, N. Sundell Notermans, A.F. Schoffelen
E0429 Impact of the COVID-19 Pandemic on Tuberculosis
Transmission RatesA. Cannas* (Rome, Italy), V.
EF061
Antonelli, A. Navarra, O. Butera, A. Mazzarelli, C. Nisii, 14:45 - 15:45 Arena 4
E. Girardi, C. Fontana
ePoster Flash Session
E0431 Incidence of Invasive Escherichia coli Disease in the
Northwestern United States (2002–2022): Insights Infections in the immunocompromised: a multifaceted overview
from Electronic Health RecordsM. Blum* (Leuven,
Belgium), C. Onwuchekwa, M.A. Schmidt, J. Chair Effrossyni Gkrania-Klotsas (Cambridge, United
Poolman, T. Verstraeten, J. Geurtsen Kingdom)
E0432 A prospective controlled cross-sectional study
demonstrates significantly higher IgG seroprevalence
of leptospirosis among Munich's Eisbach river E0442 Impact of Donor Colonization or Infection, or
surfersF. Voit* (München, Germany), D. Schult- preservation fluid contamination with Multiresistant
Hannemann, M.H. Richter, L. Wagner, J. Ostermaier, Bacteria and Fungi in Solid Organ Transplantation.
K. Stollberg, E. Luge, P. Bahn, M. Lee, J. Ten-Pas, J. Multicenter registry of ArgentinaL. Barcan* (Buenos
Erber, M. Kosch, M. Mayr, C.D. Spinner, J. Schneider Aires, Argentina), A. Smud, P. Giorgio, R. Gago, N.
Pujato, M. Martinez, S. Villamandos, C. Niveyro, N.
Lasserre
EF060
14:45 - 15:45 Arena 3 E0443 Analysis of viral load kinetics and risk factors for
Epstein-Barr virus DNAemia and Post-transplant
ePoster Flash Session lymphoproliferative disorders in pediatric liver
transplant recipients - a single centre experienceB.
AMR in the community
Kasztelewicz* (Warsaw, Poland), K. Skrok, I.
Chair Camilla Wiuff Coia (Copenhagen, Denmark) Jankowska, P. Kaliciński, K. Dzierżanowksa-Fangrat
E0444 Impact of pre-transplant infection on post-transplant
morbidity and graft survival in liver transplant
E0433 Socio-demographic factors associated with recipients: a prospective cohort studyL. Mani-
community-acquired extended spectrum β- Perren* (Bern, Switzerland), S.F. Perrodin, A.
lactamase producing E. coli urinary tract infections at Berzigotti, V. Banz, C. Hirzel, L.N. Walti
intermunicipal level in FranceM. Prime* (Nantes, E0445 Risks of live-attenuated vaccines in children with
France), O. Lemenand, S. Thibaut, T. Coeffic, B. primary immunodeficiencyS. Frigui Ep Oueslati*
Perrot, J. Caillon, D. Boutoille, E. Batard, G. Birgand (Tunis, Tunisia), S. Ben Jaafar, S. Frigui, Y. Chebbi, M.
E0434 Prolonged community outbreak of OXA-48- Ouederni, W. Achour
producing Escherichia coli linked to a food premises: E0446 Chagas reactivation/ transmission in kidney
Lower Hutt, New Zealand, 2018-2022C. Thornley* transplantation.M. Radisic* (Buenos Aires,
(Lower Hutt, New Zealand), M. Kelly, M. Bloomfield, Argentina), N. Pujato, M.C. Lopez-Albizu, R. Del
A. Nesdale, R. White Grosso
E0435 Low rates of macrolide resistance found in E0447 Clinical presentation and treatment of tuberculosis in
Mycoplasma pneumoniae cases in AustraliaR. solid organ transplant recipients: a multicentric
Rockett* (Westmead, Australia), J. Kok, K.G. Tam, T. retrospective analysisJ. Moltó* (Barcelona, Spain), I.
Golubchik, C. Suster, W. Fong, V. Sivalingam, M.C. Los-Arcos, D. Ruiz Cabrera, L. López González, M.
Wehrhahn, A. Ginn, J. Robson, I. Gardner, L. Fayos Pérez, R. Rodríquez-Alvarez, M. Murga De La
Papanicolas, K. Kennedy, M. Graham, T. Tran, D. Fuente, V. Pomar, E. García Vázquez, T. Tórtola, J.
Speers, L. Cooley, J. Harbidge, S. Campbell, K. Basile, Espinosa, O. Len, A. Sánchez-Montalva
V. Sintchenko, S.C.A. Chen E0448 Clinical presentation, risk factors and outcome of
E0436 Epidemiology of antibiotic resistance associated with non-tuberculous mycobacteria infection in
E. coli/Klebsiella pneumoniae bloodstream infections hematopoietic stem-cell transplant recipients: a
in England 2012-2023S. Lipworth* (Oxford, United multinational case-control studyM. Fernandez Ruiz*
Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. (Madrid, Spain), M. Fernández-Ruiz, J.T. Silva, P.L.
Sanderson, C. Beck, R. Hope, C. Brown, T. Katy Carver, S. Rutjanawech, L.F. Aranha-Camargo, R.
E0437 The effect of long-term fluoroquinolone prophylaxis Fernandes, S. Belga, A. Alghamdi, N.J. Mueller, S.
on carriage of antimicrobial resistant organisms in Burkhard, N.M. Theodoropoulos, D.F. Postma, P.J.
children.C. Brand* (Cape Town, South Africa), R. Van Duijn, F. Arnaiz De Las Revillas, C. Pérez Del
Ocloo, D. Wilck, P. Dube, A. Hesseling, J. Seddon, A. Molino-Bernal, J. Hand, A. Lowe, M. Bodro, E. Vanino,
Demers, M. Newton-Foot, A. Whitelaw A. Fernández-Cruz, A. Ramos-Martínez, M.J. Makek,
R. Bou Mjahed, O. Manuel, N. Kamar, A. Calvo-Cano,
E0438 Risk factors and prevalence of AntiMicrobial L. Rueda-Carrasco, P. Muñoz, A. Álvarez-Uría, S.
Resistant microbes In the English Community Pérez-Recio, N. Sabé, R. Rodríguez-Álvarez, A.
(AMRIC)D. Lecky* (Gloucester, United Kingdom), Z. Mularoni, E. Vidal, J. Alonso-Titos, T. Del Rosal, A.Y.
Aiken, M. Joyce, A. Hawker, N. Zhu, L. Eastwood, S. Classen, C. Mejía-Chew, F. López-Medrano
Leaver, K. Hopkins, R. Hope, S. Eccles, S. Neilson, M.
Neilson, G. Edwards, S. Hopkins, C. Brown E0449 Impact of bronchoalveolar lavage results on clinical
decision-making among immunocompromised,
E0439 Risk factors for antimicrobial resistance in community critically ill patients.C. Fanelli* (Sassari, Italy), R.
commensal Staphylococcus aureus isolates, a sub- Mondaca, R. Colima, D. Prado, R.R. Abud, S. Morales,
analysis of the AMRIC project.M. Joyce* M.M. Vera, E. Kattan
(Manchester, United Kingdom), Z. Aiken, N. Zhu, A.
Hawker, L. Eastwood, S. Leaver, K.L. Hopkins, R. E0450 Campylobacter spp. bloodstream infections:
Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, preliminary results from a multicenter differential
S. Hopkins, C. Brown, D.M. Lecky clinical analysis in immunocompromised and
immunocompetent patients.M. Paniagua-García*
E0440 Prevalence and risk factors for antimicrobial (Seville, Spain), J.M. Bernal-Aznar, S. Herrera-
resistance in invasive pneumococcal disease in Espejo1, S. Salto-Alejandre, A. Valiente, M.C.
southern Ontario in the late post PCV13 era (2014- Domínguez, M.Á. López-Zúñiga, F. Cobo, L. Alsina-
2023)A. Mcgeer* (Toronto, Canada), A. Shigayeva, A. Manrique De Lara, C. Marti-Castellote, M. Monsonis-
Golden, I. Martin, G. Zhanel, H. Adam, K. Barker, W. Cabed, V. García-López, A. Polo, J. Laporte-Amargos,
Gold, R. Lovinsky, M. Muller, K. Ostrowska, D.
ESCMID Global 2025 - Programme
G. López De Egea, M.Á. Galán-Ladero, E. Ruiz De consequence?J. Sonnenberg* (Muenster, Germany),
Gopegui-Bordes, G. Sena-Corrales, J.A. Girón, F. K. Thiyagarajah, E. Görgülü, P. Lembeck, M. Glitscher,
Galán, M. Chávez-Caballero, M.O. Mohamed- F. Uschner, M. Brol, W. Gu, R. Schierwagen, S. Klein,
Balghata, S. Winderickx, J.M. García De Lomas, F.J. M. Schulz, T. Wiedemann, J. Reißing, J. Söhne, N.
Martinez-Marcos, M. Giannella, M. Garzaro, M. Kraus, M. Praktinjo, J. Fischer, H.P. Erasmus, J.
Fernández, M. Freire, M.L. Pedro-Botet Montoya, S. Vasseur, S. Zeuzem, H. Storf, C. Welsch, J. Trebicka,
López Cardenas, E. Cendejas, A.V. Halperin Benito, A. S. Ciesek, J. Chang, T. Bruns, E. Hildt, K.H. Peiffer
Romero Palacios, M. Navarro, C.A. Alonso, A. O0411 Delta in Denmark: current prevalence of hepatitis
Gimeno-Gascón, S. Jiménez Jorge, J. Pachón, M.E. delta virus infectionH. Watson* (Lyon, France), P.
Pachón-Ibáñez, E. Cordero-Matía Jepsen, H. Vilstrup, H. Krarup
O0412 RatHEV as an aetiological agent of acute hepatitis in
SY100 Europe: results from the ESGHV-RHEV StudyA.
14:45 - 15:45 Hall 12
Rivero-Juarez* (Córdoba, Spain), M. Casares, B.
1-hour Symposium Becerril, Á. Dencs, G. Gherlan, J. Caballero, L. Rios-
Muñoz, A.B. Pérez, A. Fuentes, C. Freyre, F. Franco-
The challenge of a healthy microbiota in neonates Álvarez De Luna, I. Viciana, M.D.C. Domínguez, M.
Altindis, G. Özkaya, A. Rivero, A. Rivero-Juárez
Chairs Maria Vehreschild (Frankfurt Am Main, Germany)
Walter Zingg (Zurich, Switzerland) O0413 Understanding the incidence and risk factors of low-
level viremia in chronic hepatitis B: A propensity-
matched comparison of tenofovir and entecavirI.
Hasanoglu* (Ankara, Türkiye), R. Guner, E. Zerdali, A.
S0283 14:45 Infant gut microbiome developmentDebby Bogaert Batirel, Y. Onlen, E. Parlak, B. Kurtaran, S. Tosun, I.
(Edinburgh, United Kingdom) Yilmaz Nakir, O. Gunal, N. Eser, H. Yaqoobi, O. Tabki,
S0284 15:15 Metagenomic signatures and antibiotic disruption of
T. Turunc, U. Balci, S. Komur, E.E. Tutuncu, L.N.
the gut microbiome in neonatesGautam Dantas (Saint
Altunal, N.D. Sari, D.S. Yildiz, H.D. Ozkaya, I.E. Yildiz,
Louis, United States) S. Kaya, O. Karabay, S. Alkan, F. Tabak
Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI),
European Society of Paedriatic Infectious Diseases (ESPID) OS057
14:45 - 15:45 Hall 3

1-hour Oral Session

OS058
14:45 - 15:45 Hall 16
Precision Medecine: from models to patient care
1-hour Case Session
Chairs Anouk Edwina Muller (The Hague, Netherlands)
In the field with fungi
Sebastian Wicha (Hamburg, Germany)
Chairs Beatriz L. Gomez (Bogota, Colombia)
Leonardo Nimrichter (Rio De Janeiro, Brazil)
O0414 Pharmacokinetics and pharmacodynamics of BPaLM,
BPaLC and BPaL regimens for treatment of RR-TBF.
Kloprogge* (London, United Kingdom), B.T.
O0419 Fosmanogepix expanded access in patients with Nyang'wa, I. Motta, R. Moodliar, V. Solodovnikova, S.
Fusarium infectionsS. Dadwal* (Duarte, United Rajaram, M. Rasool, Z. Huang, C. Berry, G. Davies, D.
States), A. Baluch, J. Dickter, J.R. Newman, M.H. Moore
Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner
O0415 Physiologically Based Pharmacokinetic Modeling for
O0420 Voriconazole's hidden toll: unveiling periostitis in a Nemonoxacin in Predicting the Respiratory System
heart transplant recipient and a hematologic Pharmacokinetic Profile: Based on Comprehensive
patient.G. Motoa* (Boston, United States), A. Preclinical and Clinical DataY. Chen* (Shanghai,
Woolley, N. Issa China), J. Zhao, J. Zhang
O0421 Unveiling the Uncommon: Managing Geotrichum O0416 Context-specific genome-scale metabolic modelling
candidum in Pancreatic NecrosisL. Kriegl* (Graz, reveals metabolic alterations in multidrug-resistant
Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Klebsiella pneumoniae in response to polymyxin
Schlager, G. Zollner, K. Dichtl, R. Krause B/zidovudine combinationJ. Zhao* (Melbourne,
O0422 Detection of siderophores as a superior non-invasive Australia), Y.W. Lin, J. Tao, Y. Zhu, T. Velkov, J. Li
diagnostic tool in unravelling mixed fungal O0417 Agent-based model predictions of polymyxin B
infectionsV. Havlicek* (Prague, Czech Republic), R. activity on Acinetobacter baumanniiH. Soeorg*
Dobias, M. Navrátil, R. Patil, D. Luptakova, D.A. (London, United Kingdom), Y. Yuan, J. Readman, J.F.
Stevens Standing
O0423 Efficacy of novel antifungal therapies in refractory O0418 Monthly dalbavancin dosing for suppressive therapy:
Candida and Aspergillus infections: insights from a case series and pharmacokinetic estimation
compassionate use and clinical trialsS. Sedik* (Graz, analysisC. Volk* (Madison, United States), W. Kufel,
Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. P. Hutson, R. Mahapatra, W. Rose
Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenigl,
J. Prattes
SY099
14:45 - 15:45 Hall 4

OS056
14:45 - 15:45 Hall 2 1-hour Symposium

1-hour Oral Session How innovations of AMR and HAI surveillance systems help the clinical
practice
Emerging trends in viral hepatitis across Europe
Chairs Pascal Astagneau (Paris, France)
Chairs Federico Garcia (Granada, Spain) Mandy Wootton (Cardiff, United Kingdom)
Neven Papic (Zagreb, Croatia)

S0281 14:45 The EUCAST system in surveillance of AMRSören G.

O0409 One of the largest outbreak of hepatitis A in the 21st Gatermann (Bochum, Germany)
century in EuropeI. Hockickova* (Košice, Slovakia), I. S0282 15:15 Insights into developments in the surveillance of
Hockicková, J. Hockicko, D. Javorská, Š. Zamba, A. HAIsDiamantis Plachouras (Solna, Sweden)
Vasiľová, M. Ševčík, A. Cehelská, D. Hudáčková, P.
Kristian Co-organised with: EUCAST Steering Committee, EUCIC Steering
Committee, European Centre for Disease Prevention and Control (ECDC)
O0410 Higher prevalence of Cytomegalovirus and Epstein–
Barr virus in acute-on-chronic liver failure – cause or
ESCMID Global 2025 - Programme

Movie Session high in vitro potency against KPC- and OXA-48-like-

15:00 - 18:30 Hall 5
producing Enterobacterales of meropenem in
Special Session combination with the novel diazabyciccloctane β-
Behind the scenes: Contagion lactamase inhibitor ANT3310L. Sánchez-Peña* (A
Coruña, Spain), S. Rodríguez-Pallares, T. Blanco-
Chairs William Hanage (Boston, United States) Martín, L. González-Pinto, M. Outeda-García, P. Aja-
Luigia Scudeller (Pavia, Italy) Macaya, I. López-Hernández, J.C. Vázquez-Ucha, G.
Bou, A. Beceiro, J. Arca-Suárez
E0476 Antibacterial potential of D-limonene and diallyl
disulfide and their interaction with gentamicin against
multidrug-resistant Pseudomonas aeruginosa in rat
SY107
16:15 - 17:15 Hall 15 pneumonia modelY. Almuhanna* (Shaqra, Saudi
Arabia), M. Asad
1-hour Symposium
E0477 In vivo pharmacokinetic/pharmacodynamic targets
of a novel macrolide antibiotic nafithromycin,
Communicating (your) ID science for policy and societal impact
determined in neutropenic murine lung infection
Chairs Leonard Leibovici (Petah-Tiqva, Israel) model of Streptococcus pneumoniaeA. Muller* (The
Ines Steffens (Solna, Sweden) Hague, Netherlands), R. Chavan, S. Takalkar, V. Zope,
K. Umarkar, P. Tayde, M. Tellis, S. Bhagwat, M. Patel,
B. Veeraraghavan
S0297 16:15 Communicating to policy makers and for societal E0478 NiPharmins: novel low resistance-inducing
impactBalázs Babarczy (Budapest, Hungary) antimicrobials with antibiofilm activity against
Staphylococcus aureusA. Nunes* (Lisbon, Portugal),
S0298 16:45 Influencing behaviour through the media and a B. Alves, J.P. Carrilho, N.R. Candeias
multichannel communications strategyCharlotte
Hutchinson (London, United Kingdom)
Co-organised with: CMI Board of Editors EF066
16:15 - 17:15 Arena 2

ePoster Flash Session

EW109
16:15 - 18:15 Hall 2
Modelling infectious disease burden and impact of vaccination
Educational Session Chair David Fisman (Toronto, Canada)
Infections in cancer patients: tips for daily practice
Chairs José Molina Gil-Bermejo (Seville, Spain)
Stefan Schwartz (Berlin, Germany) E0480 Evaluating the Impact of Re-vaccination on
Pneumococcal Disease in Individuals Previously
Vaccinated with PPSV23 in Germany: Comparative
ApproachO. Sharomi* (Rahway, Nj, United States), M.
W0301 16:15 Tailoring pharmacologic prophylaxis in patients with De Lepper, S. Mihm, T.C. Reuter, C. Solleder, G.
non-haematologic cancer: from viruses to fungiJanne Meleleo, T. Malik, K. Bakker, R. Oidtman
Vehreschild (Frankfurt, Germany) E0481 Modeling the public health impact of a 21-valent PCV
W0302 16:35 Pneumonitis or pneumonia? A practical approach to in the Canadian adult populationO. Sharomi*
lung infiltrates in patients with solid tumoursTba (Rahway, United States), R. Oidtman, M.C. Meilleur,
W0303 16:55 The diagnostic dilemmas and treatment challenges of S. Weinrich, K. Bakker
mycobacteria in cancer patientsŞiran Keske E0482 Estimating the health and economic burden of
(Istanbul, Türkiye) pneumococcal diseases attributable to PCV21 (V116)
W0304 17:15 HTLV-1 and T-cell lymphoma - predict & preventLucy vs. PCV20 or PPSV23 serotypes among adults in
Cook (London, United Kingdom) NorwayZ. Yi* (Rahway, United States), A.A. Tajik, S.T.
Klitkou, E. Tsoumani, K. Owusu-Edusei
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV),
International Immunocompromised Host Society (ICHS) E0483 Shifting from risk-based to age-based approach for
pneumococcal vaccination in adults in France: a
comprehensive evaluationO. Sharomi* (Mt Carmel,
EF065 United States), S. Oluwaseun, M. Breau-Brunel, F.
16:15 - 17:15 Arena 1
Gaëlle, B. Lionel, C. Jérémy, M. Giulio, N. Robert, O.
ePoster Flash Session Rachel, M. Tufail, B. Kevin
E0484 The socio-economic value of adult respiratory
The Antibiotic bakery: Novel compounds in the pipeline immunisation programmes in the United Kingdom –
Chair Susanne Haeussler (Braunschweig, Germany) Are we measuring what matters to society?C.
Harrison* (Tadworth, United Kingdom), T. Hu, J.
Yang, J. Vietri, D. Mendes, S. Chowdhury, C.
Theakston, S. Brassel, L. Steuten
E0471 In vitro activity and in vivo proof-of-efficacy of E0485 Improving Danish all-cause mortality monitoring by
epimutilin derivatives AR-7732, AR-7731, AR-9842 nowcasting weekly deathsA. Kalnæs* (Copenhagen,
and AR-10058 against AMR bacterial pathogensS. Denmark), J. Nielsen, L. Vestergaard, S. Nørgaard
Paukner* (Vienna, Austria), W.W. Wicha
E0486 Modelling to identify an optimal ring vaccination
E0472 SC5005 and DHA: A Novel, Rapid-Acting strategy to mitigate a smallpox outbreakV.
Combination Therapy for Biofilm Eradication in Costantino* (Sydney, Australia), M. Kunasekaran, T.
Catheter-Associated InfectionsY. Hui Hui* (Taipei, Leroyd, K. Yeo, R.C. Macintyre
Taiwan, China), H.H. Yeo, H.N. Huang, Y.T. Huang,
Y.S. Lu, H.C. Chiu E0487 The impact of introducing meningococcal C/ACWY
booster vaccination among adolescents in Germany:
E0473 In vitro potency of ceftibuten with xeruborbactam a dynamic transmission modelling studyF. Günther*
against β-lactamase-producing isolates of (Berlin, Germany), U. Reinacher, S. Chisholm, M.
Enterobacterales (ENT) from the SENTRY global Griskaitis, M. Höhle, S. Scholz, V. Schönfeld, O.
surveillance programmeO. Lomovskaya* (San Diego, Wichmann, T. Harder, F.G. Sandmann
California, United States), M. Castanheira, J. Lindley
E0488 Potential public health impacts of gonorrhoea
E0474 Effect of novel antimicrobial peptides SET-M33L and vaccination programmes under declining incidences:
SET-M33L-PEG on Pseudomonas aeruginosa biofilm a modelling analysisL. Geng* (Singapore, Singapore)
formation.A. Fontanot* (Rotterdam, Netherlands), W.
Unger, J. Hays, P. Croughs, A. De Bruijn, C. Falciani,
A. Pini, R. Ecker, I. Ellinger EF067
E0475 Broad spectrum coverage of serine β-lactamase and
16:15 - 17:15 Arena 3
ESCMID Global 2025 - Programme
ePoster Flash Session Gelormini
E0502 Global, regional, and national temporal trends in
Blood parasitology at its best mortality for carbapenem-resistant bacteria from
Chair Miriam José Álvarez-Martínez (Barcelona, Spain) 1990 to 2021: An age-period-cohort analysisC.
Zhihui* (Shanghai, China), Z. Mingchen, W. Jing, Y.
Xiangru, J. Jialin, Z. Wenhong
E0489 Unexepected P.malariae diagnosis in Italian woman E0503 Global Trends and Impact of Antimicrobial Resistance
with no history of travel to endemic areasA. Busni* in Paediatric Populations: An Analysis Using WHO
(Milan, Italy), L. Tartaglione, S. Torri, A. Longhi, E.M. AWaRe Classification and Priority PathogensJoseph
Zavaroni, F. Crippa, C.S. Vismara Harwell (North Melbourne, Australia)
E0490 A blue-hued mystery: Primaquine-induced E0504 Antibiotic resistance profile and comparative
methemoglobinemia in mixed infection with evaluation of WHO AWaRe Guidelines at the
Plasmodium vivax and Plasmodium falciparumU.A. Emergency's Children's Surgical Hospital in UgandaL.
Zainulabid* (Pahang, Malaysia), X.K. Cheong, P. Barcellini* (Milan, Italy), F. Riccaboni, V. Fabiano, F.
Periyasamy, A.F. Mohd Salleh, N. Ghazali, N.W. Forlanini, A. Banfi, E. Crivellaro, A. La Mendola, A.
Hassan, K. Sangaran, A. Mohd Yasin, Z.M. Idris Mohammed Zain, G.V. Zuccotti, L. Folgori, L.
Napolitano
E0491 Trick or Treat? An unrelenting malaria caseC.
Uhomoibhi* (Dublin, Ireland), E. De Barra, C. Leddy, E0505 Initiatives in antimicrobial resistance surveillance:
A. Brown Using automated bacteraemia surveillance for
hospital-wide multidrug resistance monitoringF.D.
E0492 "64% Parasitaemia in Falciparum Malaria: Ruether* (Berlin, Germany), L.A. Peña Diaz, M.
Challenges in Managing Severe Infection and Behnke, C. Geffers, S.J.S. Aghdassi
Delayed Haemolysis"F. Murphy* (Dublin, Ireland), A.
Albadi, P. Coakley, C. Mcnally E0506 Global and regional prevalence of antimicrobial
resistance in GLASS target bacterial pathogens for
E0493 Benznidazole treatment in Chagas Disease: a case bloodstream, urinary tract and gastrointestinal
series in Luigi Sacco Hospital, Milan (Italy)F. Sabaini* infections: a systematic review of the global literature
(Milan, Italy), A. Giacomelli, M. Beltrami, L.R. (2019-2024)B. Caddey* (Calgary, Canada), G.
Galimberti, S. Antinori Lazarus, S. Bertagnolio, D.B. Nobrega, R.L. Hamers,
E0494 The Challenge of Managing Visceral Leishmaniasis in A. Dean, V.K. Wangsaputra, F. Febrina, J.M. Conly,
Immunocompromised PatientsS. Vita* (Rome, Italy), H.W. Barkema, E. Van Kleef, O. Tosas-Auguet
A. D'abramo, A. Corpolongo, M.V. Tomassi, F.
Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G.
Maffongelli, E. Nicastri KN103
16:15 - 17:15 Hall 1
E0495 Diagnosis and management of visceral leishmaniasis
in children in France : a national retrospective studyJ. Keynote Lecture
De Larminat* (Paris, France), N. Dahane, N. Argy, M.
Rifai, O. Haas Ferrua, C. Pomares, N. Rasandisona Tuberculosis: where are we now and where should we be
Ravonjena, D. Dupont, J.P. Lemoine, T. Cesar, O. Chairs Jon S. Friedland (London, United Kingdom)
Pineau, P. Picherit Steinbrucker, S. Azohana, S. Delia Goletti (Rome, Italy)
Guilmon-Crepon, I. Allouche, C. Ravel, A. Faye
E0496 Chronic cutaneous leishmaniasis following visceral
leishmaniasis in a pediatric patient: a rare report of K0290 16:15 Guy Thwaites (Ho Chi Minh City, Vietnam)
extensive facial involvementA. Mohta* (Bikaner,
India)
E0497 Therapeutic challenges in the management of OS063
Disseminated leishmaniasis in a patient with HIV co- 16:15 - 17:15 Hall 11

infectionN. T R* (Jodhpur, India), T. Kanagiri, S. 1-hour Oral Session

Angirekula, N. Kaur, Y. Khatod, D. Kumar, A. Purohit,
G.K. Bohra Improving blood culture diagnostics: rethinking the basics
Chairs Direk Limmathurotsakul (Bangkok, Thailand)
Pilar Retamar Gentil (Seville, Spain)
EF068
16:15 - 17:15 Arena 4

ePoster Flash Session

O0461 Blood culture volume, guideline adherence and
A global perspective on antimicrobial resistance surveillance pathogen yield of 35,433 paediatric blood cultures in
Chair Mirfin Mpundu (Lusaka, Zambia) GermanyJ. Forster* (Würzburg, Germany), A.L. Sieg,
V. Rücker, H. Haefner, T. Bähr, S. Rössler, J. Held, V.
Le Saout – Chapot, M. Hogardt, B. Spielberger, E.A.
Idelevich, M. Christner, S. Zimmermann, S.
E0498 Global, regional and country-level prevalence of Schneitler, M. Mauritz, C.S. Stingu, M. Gerlach, U.
antimicrobial resistance in human bacterial infections Von Both, S. Schoeler, L. Marr, J. Zens, E. Komini, M.
under surveillance in WHO's Global Antimicrobial Krone
Resistance and Use Surveillance System (GLASS)E. O0462 Changing the paradigm: are two sets of blood
Van Kleef* (Geneva, Switzerland), O. Tosas Auguet, cultures always needed?R. Rosa* (Miami, United
S. Tolba, S. Eremin, D. Marcano, K.B. Pouwels, B.S. States), J. Somani, K. Manzanillo, H. Dinh, G. Rosello,
Cooper, A.S. Dean, S. Bertagnolio L. Abbo
E0499 Comparative analysis of antimicrobial resistance O0463 Evaluating clinical and economic empact of reducing
(AMR) burden across european countriesA. Dörre* blood culture incubation timings: Time to shift the
(Berlin, Germany), A. Meinen, S. Haller, G. Robles paradigm?R. Gupta (bagga)* (London, Canada), R.
Aguilar, T. Meštrović, M. Nahgavi, T. Eckmanns Gupta, J. Delport, T. Mazzulli
E0500 Setting up a regional AMR surveillance network in the O0464 Revolutionizing hospital workflows with blood
Netherlands: challenges and opportunitiesC. Van culture-free ultra-rapid antimicrobial susceptibility
Rossum* (Nijmegen, Netherlands), C. Meijer, P. testing: A clinical pilot studyS. Kwon* (Seoul, Korea,
Koopman, D. Van Der Vegt, T. De Groot, M. Nabuurs- Republic of), K. Sunghoon, K. Dong Young, J. Jisung,
Franssen, G. Heeren, M. Heuvelmans, J. Flipse, E. K. Tae Hyun, K. Junwon, J. Hyelyn, L. Gi Yoon, P. Wan
Bowles, A. Tostmann, C. Van Der Veer, S. Pas Beom
E0501 Bridging gaps in antimicrobial resistance O0465 Human in vivo footprints from blood plasma for
surveillance: the CAESAR network's first decadeR. improved diagnostics in sepsisM. Sonntag*
Janssen* (Bilthoven, Netherlands), S. Woudt, D. (Stuttgart, Germany), J. Mueller, A. Von Haeseler, Y.
Boudville, C. Ruesen, W. Van Den Reek, J. Monen, O. Vainshtein, S.O. Decker, T. Brenner, K. Sohn
Karatuna, A. Tambić-Andrašević, D. Lo Fo Wong, M.
ESCMID Global 2025 - Programme

ME108
16:15 - 17:15 Hall 12 SY106
16:15 - 17:15 Hall 14

Meet-the-Expert 1-hour Symposium

Navigating travel medicine: expert tips for safe international travel Strain dynamics in determining gut microbial colonisation resistance
Chairs Silvio Daniel Brugger (Zurich, Switzerland)
Li Yang Hsu (Singapore, Singapore)
M0299 16:15 Sophie Schneitler (Homburg, Germany)
M0300 16:27 Andreas Neumayr (Basel, Switzerland)
S0295 16:15 Strain dynamics in serious bacterial infections in
infantsDrew Schwartz (Saint Louis, United States)
OS062 S0296 16:45 Long-term colonisation dynamics of carbapenemase-
16:15 - 18:15 Hall 13
producing EnterobacteralesNiranjan Nagarajan
2-hour Oral Session (Singapore, Singapore)

Heterogeneity and complexity of sepsis

OS064
Chairs Despoina Koulenti (London, United Kingdom) 16:15 - 17:15 Hall 16
Sylvain Meylan (Lausanne, Switzerland)
1-hour Oral Session

Viral immune response - nature or nurture? Exploring the limits of immune

O0451 A consensus immune dysregulation framework for response
sepsis: results of the SUBSPACE consortiumA. Chairs Malin Flodström-Tullberg (Stockholm, Sweden)
Moore* (Emerald Hills, United States), T. Sweeney, Florian Krammer (New York, United States)
A. Rogers, P. Khatri, H. Zheng, A. Ganesan, Y. Hasin-
Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B.
Scicluna, E.J. Giamarellos-Bourboulis, A. Kotsaki, I.
Martin-Loeches, A. Garduno, J. Sevransky, D. O0466 Orthopoxvirus-specific antibody dynamics up to
Wright, R. Rothman, M. Atreya, L. Moldawer, P. two years after monkeypoxvirus infection or
Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. vaccinationC. Van Dijck* (Antwerp, Belgium), N.
Meyer Berens-Riha, L. Zaeck, I. Brosius, R. De Vries, J.
O0452 BLOODICU: Bloodstream infections and their Marien, L. Liesenborghs
outcomes in ICU patients - Insights from the O0467 DENG-VAC study: preliminary data on
PROSAFE StudyC. Genovese* (Milan, Italy), M. immunogenity and reactogenity of Qdenga vaccine
Offer, G. Tricella, G. Scaglione, E. Palomba, G. versus natural infectionA. D'abramo* (Rome, Italy),
Montrucchio, F. Agostini, F. Dore, G. Monti, B. S. Vita, F. Colavita, E. Cimini, P. De Marco, E. Lalle,
Viaggi, A. Gori, S. Finazzi, M. Colaneri G. Maffongelli, L. Rosa, S. Cammisa, G. Delia, M.
O0453 Deciphering the Dynamics of Klebsiella pneumoniae Fabrizio, N. Emanuele
Colonization and Infection: Genomic Insights and O0468 Long-Lasting Immunity Followed by Natural CCHFV
Microbiome Interactions in ICU PatientsW. Yu* InfectionH. Karakoc* (Trabzon, Türkiye), H.N.
(Beijing, China) Karakoç Parlayan, A. Aslanabadi, D. Yapar, Q.
O0454 Antibiotics with anti-anaerobe activity promote Murphy, G. Kaplan, O. Akdoğan, A. Çelikbaş, A.
enteric pathobionts in ICU patientsS. Taylor* Koroglu, F. Aksoy, E. Karaaslan, A. Abbasi, M.
(Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, Karimi, M. Hojabri, G. Yilmaz, S.M. Ciupe, S.D.
L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Pegan, É. Bergeron, G. Lewis, N. Baykam, M.M.
Papanicolas Sajadi
O0455 Association between blood culture time to positivity O0469 Why does rabies virus not induce an anti-viral
and 30-day bacteremia mortality differs for immune response : insights from experimental
bacterial groupsM.H. Øvre* (Herlev And Gentofte, models and a human cohortC. Geurts Van Kessel*
Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. (Rotterdam, Netherlands), C. Embregts, A. Gohar,
Hansen, T.S. Itenov, B.J. Holzknecht B. Verstrepen, J. Aijaz, N. Salahuddin, C.
Geurtsvankessel
O0456 Treatment patterns of patients with
sepsis/SIRS/septic shock treated with O0470 Establishing a human challenge model for human
ceftolozane/tazobactam – results from SPECTRAE. metapneumovirus: disease characteristics and
Yucel* (Rahway, United States), A. Soriano, F. immune responsesN. Noulin* (London, United
Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich, Kingdom), A. Mann, N. Veselinski, J. Mori, B. Löndt,
J. Levy, H. Yang, S. Kaul K. Bradley, M. Kalinova, S. Ascough, G. Boivin, C.
Chiu, A. Catchpole
O0457 Risk of myocardial infarction and stroke following
bloodstream infection: a population-based self-
controlled case seriesJ. Underwood* (Cardiff, SY104
United Kingdom), N. Reeve, V. Best, A. Akbari, H. 16:15 - 17:15 Hall 3
Ahmed 1-hour Symposium
O0458 Is transthoracic echocardiography required in all
patients with Staphylococcus aureus bacteremia? Targeted vs. standard perioperative prophylaxis in Solid Organ Transplant
Validating the VIRSTA and VIRSTA+ scores to with MDR Gram-negative colonisation
define the population at low risk of endocarditisM. Chairs Elda Righi (London, United Kingdom)
Verdejo Gómez* (Barcelona, Spain), D. Malano- David Van Duin (Chapel Hill, Nc, United States)
Barletta, M.Á. Verdejo, G. Cuervo, C. Pitart, M.
Hernández-Meneses, M. Bodro, S. Herrera, C.
Garcia-Vidal, P. Puerta, A. Del Rio, M. Espasa, J.A.
Martínez, L. Morata, A. Soriano S0291 16:15 Standard prophylaxisMaddalena Giannella (Bologna,
O0459 DNA methylation changes in Sepsis: Potential use Italy)
as biomarkersI. López-Cruz* (Valencia, Spain), J.L. S0292 16:45 Targeted approachesMaristela P. Freire (Sao Paulo,
García-Giménez, L. Piles, M. Madrazo, G. Judit, M. Brazil)
López-Torres, A. Artero Co-organised with: European Association for the study of the liver (EASL)
O0460 Host response plasma biomarkers and
transcriptomic alterations in critically ill patients
with suspected aspiration pneumoniaS. Doeleman* SY105
(Amsterdam, Netherlands), D. Susanne, E. Michels, 16:15 - 17:15 Hall 4

J. Butler, F. Uhel, O. Cremer, T. Van Der Poll 1-hour Symposium

ESCMID Global 2025 - Programme
Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and efavirenz-based antiretroviral therapy for patients
therapeutic approach coinfected with HIV and tuberculosis: a multicentre,
Chairs Robert A. Bonomo (Cleveland, United States) open-label, randomised trialY. Shen* (Shanghai,
Arjana Tambic Andrasevic (Zagreb, Croatia) China), X. Le
L0022 17:27 Initial vancomycin taper for the prevention of
recurrent Clostridioides difficile infection: the TAPER-
V randomised controlled trialE.G. Mcdonald*
S0293 16:15 Novel beta-lactams and beta-lactamase inhibitors: (Montreal, Canada), Y. Chen, B. Coburn, N. Daneman,
challenges for laboratory diagnosticsAnna Sramkova S. Hota, C. Frenette, C.E. Kandel, L. Kong, Y. Longtin,
(Pilsen, Czech Republic) V.G. Loo, D. Macfadden, M. Muller, T.S. Steiner, L.
S0294 16:45 Clinical perspectives of novel beta-lactams and beta- Valiquette, T.C. Lee
lactamase inhibitorsParikshit Prayag (Pune, India) L0023 17:39 Beneficial effects of a clinical metagenomics
Co-organised with: EUCAST Steering Committee intervention on clinical outcomes, healthcare
economics, and quality of life in patients with
sepsis/septic shock: results of the DigiSep-trialT.
LB004 Brenner* (Essen, Germany), A. Skarabis, S.J.
16:15 - 18:15 Hall 9
Schaller, T. Von Groote, C. Putensen, U. Günther, M.
2-hour Oral Session Sauer, S.O. Decker, F. Dusse, M. Weiss, K.
Suchodolski, T.P. Simon, P. Rosenberger, O. Moerer,
Trials in severe infections M. Unterberg, J.C. Schewe, H. Bracht, S. Hutzl, M.
Feißt, U. Marschall, P. Brandenburg, J. Englisch, P.
Chairs Lennie Derde (Utrecht, Netherlands)
Stevens, J. Schmidt, M.W. Pletz, J. Brands, A.
Steven Tong (Melbourne, Australia)
Antinoro, L.O. Warner, M.A. Weigand, D.M. Hart, G.
Marx, J. Mossanen, T. Breuer, H. Häberle, K.
Nitzsche, P. Thalmann, J. Brezinski, J. Saam, T.
L0016 16:15 Temocillin versus meropenem for the targeted Schwerhoff, S. Grumaz, M. Steinmann, M. Gaasch, B.
treatment of bacteraemia due to third-generation Pasieka, U. Jaekel, T. Brandenburger, F. Bach, H.
cephalosporin-resistant Enterobacterales (ASTARTÉ): Mutlak, S. Utzolino, M.M. Berger
a randomised, pragmatic trialF. Cogliati Dezza* L0024 17:51 Shortened antibiotic treatment for 5 days in patients
(Seville, Spain), L. Barrera Pulido, I. Borreguero hospitalised with community-acquired pneumonia
Borreguero, F. Docobo Peréz, V. Palomo Jiménez, S. (CAP5): a multicentre randomised controlled
De La Rosa Riestra, J. Bravo-Ferrer Acosta, M.A. noninferiority trialS. Bastrup Israelsen* (Hvidovre,
Lopez Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Denmark), L. Hagens Mygind, F. Al-Zergani, B.
Horcajada, E. Merino, M. Parra, J. Lopéz-Contreras, Lindegaard, A. Knudsen, S. Tingsgård, L. Thorlacius-
A. Rivera, D. Sousa Regueiro, M. Pampin Garcia, S. Ussing, I. S Johansen, H. Nielsen, P. Ravn, T. Benfield
Lopez Cardenas, M.C. Goméz Sanchez, I. Peréz L0025 18:03 High-dose rifampicin in the treatment of tuberculous
Camacho, S.M. Martin Ramos, E. Leon Jimenez, A.I. meningitis: results of the HARVEST phase III multi-
Aller García, M.T. Peréz-Rodríguez, A. Sousa, M.C. country randomised clinical trialR. Van Crevel*
Fariñas, A.D.L.R.A. Fracisco, L. Gisbert Pérez, J. (Nijmegen, Netherlands), D. Meya, R. Rovina, D.
Goikoetxea Agirre, A. Cano, F.J. Martínez-Marcos, Boulware, B. Dai, N. Engen, F. Cresswell, K. Naidoo, A.
M.J. García País, R. Escudero Sanchez, S. De La Villa, Rizal, D. Imran, R. Lessels, L. Tugume, R. Hamers, M.
J.R. Yuste Ara, M.A. Esteban-Moreno, A. Ruiz- Kabahubya, S. Marais, Y. Moosa, N. Bahr, E.
Sancho, M. Pedrosa Aragón, J. Alba Fernandez, A. Svensson, L. Te Brake, R. Aarnoutse
Barrios Blandino, H.H. Vilchez Rueda, R. Álvarez-
Marín, A. Romero Palacios, A.E. Roura Piloto, E. Nuño
Álvarez, Z.R. Palacios Baena, L. López Cerero, J.
EF074
Rodríguez-Baño 17:30 - 18:30 Arena 1

L0017 16:27 HRS-8427 versus imipenem-cilastatin for ePoster Flash Session

complicated urinary tract infections: a randomised,
double-blind phase 2 studyM. Ju* (Shanghai, China), New methods for rapid pathogen detection and typing
M. Wang, J. Yuan, H. Huang, G. Bi, J. Lyv, X. Lyv, L. Chair Sylvain Brisse (Paris, France)
Xue, H. Yang, D. Fan, H. Wu, X. Wang, J. Xu, X. Li, Q.
Zhang
L0018 16:39 Efficacy and safety in a Phase 2 study of intravenous
BV100 combined with polymyxin B versus best E0532 Rapid detection of Shiga toxin-producing Escherichia
available therapy in adult subjects with ventilator- coli (stx2a and stx2d) in korean diarrheal stool
associated bacterial pneumonia suspected or samples: a performance evaluationL. Hyeonji* (Seoul,
confirmed to be due to carbapenem resistant Korea, Republic of), H.J. Lee, H.J. Kim, S.S. Choi, H.J.
Acinetobacter baumanniiG. Dale* (Basel, Choo, H.J. Huh, E.J. Won
Switzerland), F. Fratzeskaki, I. Tsagkaris, A. E0533 Global prevalence of O-serotypes and antibiotic
Armaganidis, M. Katsiashvili, D. Kazaishvili, T. resistance among extraintestinal pathogenic
Gaphrindashvili, K. Japaridze, E. Mouloudi, M. Escherichia coli isolated from older adult patients
Kapanadze, T. Kachibaia, A. Sarkany, E. Zakynthinos, with bacteraemia (2011–2021)J. Geurtsen* (Leiden,
P. Delique, M. Davila, L. Husband, P. Timofeev, F. Netherlands), M. De Been, O. Go, M. Aitabi, C.
Jung, C. Kemmer Willame, E. Weerdenburg
L0019 16:51 Neutralising plasma versus placebo for hospitalised E0534 Strategy for the rapid typing of Salmonella spp using
patients with West Nile fever: a double-blind infrared spectroscopy: a one health perspectiveJ.
randomised controlled trialM. Canetti* (Tel Aviv, Jiménez* (Santiago, Chile), D. Fredes, A. Piña, I.
Israel), G. Regev-Yochay, N. Barda, Y. Shusterman, E. Mercado, J. Miranda, S. Henríquez, T. González, A.
Magiel, N. Baharav, A. Belkin, I. Margalit, V. Adell, A. Moreno-Switt, A. Wozniak, P. García
Indenbaum, E. Tomer, Y. Lustig, Y. Ottolenghi, G.
E0535 WGS-based surveillance as a paradigm shift in
Joseph, H. Yonath, E. Leshem, I. Levy, Y. Peretz, S.
outbreak detection, AMR monitoring and source
Amit, L. Miller, M. Misgav, N. Landa, M. Brod, A.
attribution in CampylobacterA. Nunes* (Lisbon,
Wieder-Finesod, N. Maggio, D. Yahav
Portugal), M.L. Lemos, S. Ortiz, I. Santos, S. Ramos,
L0020 17:03 Randomised placebo controlled trial of faecal M. Oleastro
microbiota transplantation to tackle antimicrobial
resistance: inducing bacteriophage network E0536 Prevalence of Staphylococcus aureus clonal complex
remodelling and enteric pathogen reductionL.A. 97 amongst BORSA isolates in a large UK hospitalH.
Edwards* (London, United Kingdom), B. Auch, T. Gareth* (Birmingham, United Kingdom)
Portlock, B.H. Mullish, B. Merrick, C. Woodhouse, T. E0537 The effectiveness of clinical laboratory tools in the
Tranah, J.M. Blanco, L. Meoli, A. Clavé Llavall1, V.T. surveillance of nontuberculous mycobacterium
Kronsten, A. Zamalloa, V.C. Patel, J.R. Marchesi, I. isolations within different counties in TaiwanH.W.
Liachko, S. Goldenberg, D.L. Shawcross Chu* (Taipei, Taiwan, China), T.F. Lee, C.C. Shu, Y.T.
L0021 17:15 Double-dose dolutegravir and lamivudine versus Huang
ESCMID Global 2025 - Programme
E0538 Rapid detection of oxazolidinone-resistance-related EF076
mutations in Enterococcus spp. by using High
17:30 - 18:30 Arena 3

Resolution Melting-qPCR-typing analysisR. ePoster Flash Session

Musumeci* (Monza, Italy), E. Giordano, M. Martinelli,
M. Oggioni, D. Oggioni, V. Marano, E. Arighi, C. Villa, Knowing me, knowing you: behaviour influencing AMS
C. Giubbi, G. Mannarà, F. Perdoni, S. Frugoni, P. Chair Elena Carrara (Verona, Italy)
Congedo, C.E. Cocuzza
E0539 An automated pipeline to genotype bacteriophages
using third generation sequencingZ. Halász*
(Debrecen, Hungary), E. Szoták, L. Dr. Laczkó, G. Dr. E0550 Exploring determinants in deciding the optimal
Kardos antimicrobial dose in patients recieving CRRT: a
mixed method studyT. Yanık Yalçın* (Ankara,
E0540 Novel approach for fast, automated strain typing and Türkiye), A. Pehlivanlı, İ. Yeşiler, H. Şahintürk, Ö.
source tracking by Fourier-transform infrared Azap, H. Arslan, B. Başgut, P. Zeyneloğlu
spectroscopyN. Mauder* (Bremen, Germany), M.
Cordovana, M. Kostrzewa E0551 Behaviour change vs policy change: Key drivers of
inappropriate antibiotic use among health care
professionals in LMICs – insights from Indian
EF075 community settingN. P Mathew* (Manipal, India), U.
17:30 - 18:30 Arena 2
B, M. Varma, V. K E, R. Ruiter, G. Thunga, C.
ePoster Flash Session Mukhopadhyay
E0552 Contextual determinants to antimicrobial
Healthcare (workers') safety revisited stewardship implementation in 16 hospitals: a four-
Chair Daniel Diekema (Harpswell, United States) country analysis in AsiaH. Vu Thi Lan* (Ha Noi,
Vietnam), R. Limato, H.Y. Duong, S. Manandhar, D.
Limmathurotsakul, A. Apisarnthanarak, N.T. Pham,
V.C. Nguyen, R.L. Hamers, E.J. Nelwan, S. Sakinah, A.
E0541 Preparedness and cooperation throughout the Karkey, M.K. Upadhyaya, E. Dodds Ashley, D.
chain of care during regional-level outbreaks with Anderson, H.R. Van Doorn, H. Vu
multidrug resistant organisms: a network analysis E0553 SpeakAB, a pilot study to encourage nurses to speak
and interview studyB. Beishuizen* (Bilthoven, up about antibiotic careM. Bos* (Nijmegen,
Netherlands), M. Stein, A. Tostmann, C. Rovers, A. Netherlands), J. Schouten, H. Vermeulen, M.
Timen Hulscher, C. De Bot
E0542 Preparing First-Line health care workers for 'Virus E0554 Understanding what matters to patients in
X' through targeted training (FiLi-Vi-X)A. antimicrobial stewardship in hospitals. PERSPEcT
Mondelaers* (Antwerp, Belgium), Y. Somers, K. study updateB. Jacob* (Dublin, Ireland), E. De Barra
Vanden Driessche, I. Brosius, L. Liesenborghs, C.
Rovers, L. Zweers, M. Wieland, E. Vlieghe E0555 Determinants of antibiotic prescribing in hospitals
from low, middle and high-income countries in AsiaS.
E0543 Analysis of the current situation of hospital Chhabra* (Singapore, Singapore), S. Nair, A.
inspection practices by German health authoritiesA. Bramley, J.Y. Chee, K. Vignesvaran, R.E.D. See, L.J.
Schwabe* (Bonn, Germany), J. Dannenberg, A.D. Sun, A.H. Ching, B.S. Cooper, E. Charani, Y. Mo
Wollkopf, F. Droop, S. Engelhart, N.T. Mutters
E0556 Riding "the antimicrobial rollercoaster": The
E0544 A nationwide survey on the status and behavioural and phenomenological science of
implementation of infection prevention and control antimicrobial use in haemato-oncology.C. Eades*
practice on behalf of INSIEME Project (Italian (London, United Kingdom), L. Byrne-Davis, R.
National project for contrast antibiotic resistance a Rautemaa-Richardson, T. Felton
cooperation between Simit (Italian society of
infectious diseases) E (&) Ministry of hEalth)M. E0557 Addressing Antimicrobial Resistance: Expert Insights
Meschiari* (Modena, Italy), F.V. Segala, E. Ricchizzi, and Policy Recommendations for Effective
A. Gallerani, V. Scaglione, R. Castoldi, F. InterventionsB. Madran* (Istanbul, Türkiye), F.
Almerigogna, I. Spalliera, A. Parente, S. Coladonato, Almeida, E. Carrara, D. Kofteridis, N. Rocha-Pereira,
P. Grimaldi, C. Camaioni, M. Abbott, A. Carretta, S. G. Pieve, N. Tziolos, İ. Kayı, Ş. Keske, E. Önder, S.
Audagnotto, A. Pan, C. Fanelli, S. Cicalini, P. Tanzili, Sakarya
E. Ponatali, I. Gentile, R.F. Del Vecchio, A. Oliva, A. E0558 Implementation of hospital antimicrobial stewardship
Mularoni, M. Lichtner, F. Di Gennaro, A. Marino, R. in Europe using a data-driven behaviour change
Murri, C. Mussini approach: insights from the drive-AMS EU projectI.
E0545 High level of measles immunity among Dutch Pauwels* (Antwerp, Belgium), R. Janssen, E. Iosifidis,
healthcare workers with self-reported “unknown” N. Milevska-Kostova, M. Lupşe, J.A. Paiva, E. Roilides,
measles immunity status.C. Meijer* (Nijmegen, T. Schoffelen, R. Valinteliene, A. Versporten, E.
Netherlands), J. Leijser, M. Mccall, C. Rovers, E. Vlieghe, J. Schouten
Bowles, N. Van Der Geest, A. Tostmann
E0546 Factors associated with positive latent TB screening
EF077
results in healthcare workers at two tertiary referral 17:30 - 18:30 Arena 4
hospitals in IrelandC. Anderson* (Dublin, Ireland), ePoster Flash Session
D. Mcgee, M. Coleman, A. Hehir, L. Dolan, N.
Noonan, V. Tormey, C. Bergin, C. Fleming, L. Viral aphrodites
Townsend
Chair Rémi Charrel (Marseille, France)
E0547 Systematic review of determinants of vaccine
hesitancy among healthcare workersV. Gabellone*
(Lecce, Italy), F. Nuccetelli, R. Prato, E. Gabrielli, P.L.
Lopalco E0559 Potential for international spread of Oropouche
E0548 Post-pandemic questions on vaccine usage: Two virus via commercial air travelM. Torres Portillo*
qualitative analyses of open-ended responses (Toronto, Canada), A. Marwah, M. Kraemer, A.
comparing hypothetical and novel vaccinesP. Thomas, K. Khan, I. Bogoch
Shamsrizi* (Hamburg, Germany), S. Eitze, D. E0560 Estimating mpox Clade Ib outbreak size in the
Heinemeier, A. Tänzer, M.A. Jenny Democratic Republic of the Congo to attenuate
E0549 Do healthcare professionals working in acute surveillance gaps during the early stages of the
healthcare settings identify infection prevention and 2024 outbreakM. Torres Portillo* (English, Canada),
control related knowledge deficits?A. Kearney* A. Marwah, A. Thomas-Bachli, I. Bogoch, K. Khan
(Dublin, Ireland), H. Humphreys, D. Fitzgerald E0561 Disparate epitope recognition between MPXV-
Hughes infected and Smallpox-vaccinated individualsA.
Otter* (Salisbury, United Kingdom), S. Jones, B.
Hicks, B. Hallis, C. Rowe
ESCMID Global 2025 - Programme
E0562 Diverse residual and late-onset symptoms of severe O0512 Global guideline for the diagnosis and management
fever with thrombocytopenia syndrome: insights of candidiasis: an initiative of the ECMM in
from a multicenter questionnaire study in Western cooperation with ISHAM and ASMR. Sprute*
JapanR.M. Sada* (Osaka, Japan), S. Yamamoto, T. (Cologne, Germany), O.A. Cornely, M. Bassetti, C.
Toyokawa, T. Takahashi, A. Yamanaka, M. Sharon, A. Groll, O. Kurzai, C. Lass-Flörl, L. Ostrosky-
Kawamura, K. Yokota, Y. Fukumori, T. Taniguchi, R. Zeichner, R. Rautemaa-Richardson, G. Revathi, M.E.
Tanizaki, K. Iwata, S. Kutsuna Santolaya, L. White, L.P. Zhu
E0563 Post-Acute Sequelae and Excess Healthcare O0513 Impact of achieving early mycological eradication
Utilization Following Dengue Infection: A with rezafungin on all-cause mortality and ICU length
Population-Based Cohort StudyJ.T. Lim* of stayM. Bassetti* (Genoa, Italy), G.R. Thompson, A.
(Singapore, Singapore), I. Wee, W.Z. Tan Soriano, S. Dickerson, I. Bielicka, O.A. Cornely
E0564 Challenges of dengue in haematological malignancy O0514 An open-label study of ibrexafungerp in patients with
patients: Analysis from the DANGO registry during refractory fungal infections (FURI)O.A. Cornely*
the 2023-2024 outbreak in ArgentinaG.A. Méndez* (Cologne, Germany), B.D. Alexander, P.G. Pappas,
(Posadas, Argentina), J. Salmanton-García, C. T.F. Patterson, M. Hoenigl, M.H. Miceli, P. Vergidis, A.
Niveyro, P.A. Villalba Apestegui, V.I. Martín, L.M. Spec, G.R. Thompson, L. Ostrosky-Zeichner, R.S.
Compañy Kec, M.C. Tomasino, M.D.C. Marull, H.I. Siebert, M. Middle, E. McKie, F. Lewis, D. Angulo
Bernard, C.P.L. Fernández, M.F. Tosin, M.F. O0515 Novel immunotherapy approach using pan-Candida
Hobecker, K.B. Duranona, A.D. Jara, O.A. Cornely monoclonal antibodies to treat life-threatening
E0565 Key predictors of critical illness and mortality in invasive candidiasis and tackle global AMRY. Zhao*
Crimean-Congo haemorrhagic feverD. Yigci* (Aberdeen, United Kingdom), C.A. Munro, S. Palliyil
(Istanbul, Türkiye), D. Güllü, N. Baykam, A. Kocagül O0516 Relative contribution of pharmacokinetics and
Çelikbaş, D. Yapar, Ö. Akdoğan, K. Özden, R. İnan immune signatures to clinical outcomes in patients
Sarıkaya, İ. Hasanoğlu, H.R. Güner, E. Doğan, F. with HIV-associated cryptococcal meningitis.K. Stott*
Karakeçili, H. Alay, Z. Türe Yüce, E. Eryılmaz Eren, A. (Liverpool, United Kingdom), D. Tembo, C. Kajanga,
Erbay, Ş.E. Gök, Ç. Kader, G. Ünüvar Kalın, A. A. Ahmadu, K.D. Ruwanthi, M. Moyo, D. Lawrence, T.
Yetişgen, M. Özgüler, A. Şenol, Ö. Gündağ, M. Harrison, J. Jarvis, D. Namakhwa, D. Lalloo, W. Hope,
Çağlar Özer, F. Soyak, B. Tanır, I.D. Alıravcı, G. H. Mwandumba
Çınar, B. Öztürk, E. Gürbüz, F. Pınarlık, M. Kuşkucu,
Ö. Ergönül
E0566 Kyasanur Forest Disease in 2024: A Retrospective OS071
Cohort Study from a tertiary care centre in South 17:30 - 18:30 Hall 14

IndiaP. Venkata Swathi Kiran* (Udupi, India), P.K. 1-hour Oral Session
Tirlangi, N. Gupta, R. Bhat, P. Ravindra, S.K.
Pothumarthy Intestinal parasitic uncovered: epidemiology and treatment success
E0567 Unravelling the aetiology of summer flu-like illness Chairs Kurt Hanevik (Bergen, Norway)
in CzechiaM.F. Kříha* (Ceske Budejovice, Czech Pavla Tůmová (Praha, Czech Republic)
Republic), V. Hönig, J. Kamiš, M. Dvořáková, L.
Tardy, D. Teislerová, A. Chrdle, M. Palus, D. Růžek
O0517 Giardia- Does the treatment work? The experience
SY112 from a national tertiary referral centreA. Boté
17:30 - 18:30 Hall 1
Casamitjana* (London, United Kingdom), A. Boté-
1-hour Symposium Casamitjana, S. Eisen, L. Nabarro, N. Longley, G.
Godbole
Year in public health O0518 Giardiasis: Who gets it? Experience from a Central
Chairs Ziad A. Memish (Riyadh, Saudi Arabia) London Teaching Hospital.A. Boté Casamitjana*
Catherine Moore (Cardiff, United Kingdom) (London, United Kingdom), A. Boté-Casamitjana, S.
Eisen, L. Nabarro, N. Longley, G. Godbole
O0519 Assessing the Effect of Antimicrobial Treatment on
the Accuracy of Serial Serum and Urine Testing for
S0309 17:30 Li Yang Hsu (Singapore, Singapore) Detecting E. histolytica cfDNAP. Datta* (Chandigarh,
S0310 18:00 Rita Oladele (Lagos, Nigeria) India), D. Rattan, A. Duseja, N. Sharma, N. Kalra, S.
Khurana
O0520 Longitudinal observation of Blastocystis sp. and
SY111
17:30 - 18:30 Hall 11 Dientamoeba fragilis in children: a very rare
occurrence in chronic diseases with gut dysbiosisJ.
1-hour Symposium Hurych* (Prague, Czech Republic), J. Havlova, V.
Neuman, K. Litosova, K. Hubackova, L. Hlinakova, M.
PK/PD in drug development: what’s in it for me? Kubat, O. Hradsky, J. Bronsky, K.L. Kolho, P.
Chairs Sandrine Marchand (Poitiers, France) Saavalainen, H. Malcova, D. Cebecauerova, P.
Sebastian Wicha (Hamburg, Germany) Dřevínek, Z. Sumnik, O. Cinek
O0521 High prevalence of the zoonotic Angiostrongylus
cantonensis in rats in SpainJ. Caballero Gómez*
S0307 17:30 PK/PD from the EUCAST/regulatory perspective:
(Córdoba, Spain), T. Fajardo-Alonso, I. García-
what tools do we need?Joseph Meletiadis (Athens,
Bocanegra, M. Gonzálvez, A. Beato-Benítez, R.
Greece) Cuadrado-Matías, M.Á. Quevedo, R. Guerra, R.
Martínez, A. Rivero-Juárez, J. Martínez, E. Martínez-
S0308 18:00 PK/PD for new anti-TB drugs Elin Svensson (Uppsala, Nevado, P. Soriano, D. Crailsheim, J. Lazpita, A.
Sweden) González, P. Foronda, J. Caballero-Gómez
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

OS072
OS070
17:30 - 18:30 Hall 15
17:30 - 18:30 Hall 12
1-hour Oral Session
1-hour Oral Session
Training models - a new model for training
What’s new in antifungal guidelines and management Chairs Erin Bonura (Portland, United States)
Chairs Sharon Chen (Sydney, Australia) Casandra Bulescu (Bucharest, Romania)
Helmut Salzer (Linz, Austria)

O0522 Can ChatGPT4o help build Objective Structured

ESCMID Global 2025 - Programme
Clinical Examination (OSCE) stations in infectious S0305 17:30 IRIS in HIV immunocompromised hosts: a failure of
diseases ?S. Villard* (Paris, France), Y. Guedj, L. successPaola Maria Cinque (Milan, Italy)
Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B. S0306 18:00 Dysregulated host responses to infectionMichal
Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. Holub (Praha, Czech Republic)
Mageau, T. Mirault, A. Pellat, C.A. Hobson, D. Bouzid,
M. Thy, N. Peiffer-Smadja
O0523 Large language model in real-world clinical infectious OS069
diseases: are we there yet?G. Carra* (Switzerland, 17:30 - 18:30 Hall 4

Switzerland), M. Van Singer, A. Cancela Costa, P.A. 1-hour Oral Session

Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y.
Fougère, T. Galpérine, E. Gauthiez, B. Guery, M. Determining new and revising old breakpoints
Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Chairs Jaroslav Hrabak (Plzen, Czech Republic)
Papadimitriou-Olivgeris, M. Plebani, V. Suttels, P. Erika Matuschek (Växjö, Sweden)
Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann,
N. Boillat-Blanco
O0524 Artificial Intelligence-Powered Transformation:
Enhancing Public Health Education at Tampere O0507 EUCAST disk diffusion testing of ten additional
University Towards Sustainable Development Goal species of anaerobic bacteriaJ. Ahman* (Växjö,
3S. Ahmad* (Tampere, Finland) Sweden), J. Åhman, E. Matuschek, B.J. Holzknecht,
P.C. Lindemann, H. Marchandin, S. Copsey-Mawer, T.
O0525 A Survey on Perceived Priorities for the
Morris, G. Kahlmeter
Implementation of Artificial Intelligence in Developing
ESCMID GuidelinesJ. Molina Gil-Bermejo* (Seville, O0508 Standardised antimicrobial susceptibility testing
Spain), J. Molina, J.R. Paño-Pardo, B. Nagavci, M. protocol for Legionella pneumophila validated across
Paul, T. Kostyanev, M.W. Langendam, J.P. Stahl, E. ten European reference laboratories.M. Sewell*
Tacconelli, S. Tschudin-Sutter, M. Zervos, L. (Cardiff, United Kingdom), C. Farley, A.V. Krøvel, M.
Scudeller Golob, D. Kese, U. Roisin, D. Lindsay, S. Nadarajah, B.
Afshar, V. Gaia, S. Paukner, C. Michel, E. Fedoua, J.M.
O0526 Expect the unexpected: Longitudinally extensive
González-Rubio, F. González-Camacho, M. Petzold,
transverse myelitis in a healthy young adult - a rare
M. Scaturro, C. Ginevra, G. Descours, S. Jarraud, L.
manifestation of tuberculosisS. Angirekula*
Jones, O.B. Spiller
(Jodhpur, India), R. Modi, R. Bora, R. Lohiya, S.K.
Shivtarkar, S. Jagennath, D. Kumar, S. Tiwari, G.K. O0509 Antimicrobial susceptibility testing of the
Bohra combination of aztreonam and avibactam in
carbapenem-resistant Enterobacterales: a practical
evaluation using the CLSI and EUCAST methodsL.
OS073 Chan* (Kennedy Town, Hong-Kong SAR, China),
17:30 - 18:30 Hall 16
D.Y.L. Lok, R.C.W. Wong, A.L.H. Lee, I.Y.Y. Cheung,
1-hour Case Session V.C.Y. Chow
O0510 Determination of optimal disk diffusion mass for
Still going viral zosurabalpinM. Castanheira* (North Liberty, United
Chairs Ursula Hofer (London, United Kingdom) States), J. Maher, Y. Edah, A. Trauner
Yee Sin Leo (Singapore, Singapore) O0511 The clinical significance of aminoglycoside
susceptibility breakpoints modificationO. Henig* (Tel
Aviv, Israel), M. Elbaz, N. Bishouty, Y. Yaakobi, R. Ben-
Ami
O0527 Clinical outcomes of adoptive cell therapy for EBV
reactivation and EBV-PTLD in primary
immunodeficiencies: prophylactic and therapeutic
applications of post-allo-HSCT memory T cell
Monday, 14 April 2025
infusions.A. Tessitore* (Trieste, Italy), N. Maximova,
S. Braidotti, M. Granzotto, R. Simeone
O0528 Histopathological proof of herpes simplex
SY116
pneumonitis in a patient with severe COVID-19 08:30 - 10:30 Hall 15
pneumoniaJ. Heylen* (Leuven, Belgium), B. Lopuhaa,
2-hour Symposium
L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K.
Lagrou, G. Hermans, M. Peetermans, E. Van Climate Change: changing risks and adaptation strategies for a world on the
Wijngaerden, P. Meersseman, A. Wilmer, G. De move
Hertogh, G. Verjans, J. Von Der Thüsen, J. Van
Kampen, J. Wauters Chairs Rachel Lowe (Barcelona, Spain)
Giacomo Stroffolini (Lausanne, Switzerland)
O0529 Transmission of dengue virus from donors to
recipient after solid organ transplantation. Case
series in Argentina.L. Barcan* (Buenos Aires,
Argentina), S. Villamandos, R. Gago, M. Aguirre, A. S0323 08:30 Vector-borne diseases in Europe and clinical
Martinoia, A. Patterer, M. Uranga, C. Sarkis, E. consequencesTuba Dal (Ankara, Türkiye)
Temporiti, N. Pujato, S. Claudia, D. Calfunao, C.
S0324 09:00 Rising temperatures and risks of fungal
Nyveyro, M. Martinez, A. Smud, P. Giorgio, L. Barcán
diseaseAnuradha Chowdhary (New Delhi, India)
O0530 Rash without borders: waning immunity in a travelling
S0325 09:30 Strategies for climate prevention and adaptation in a
physicianR. Ville Benavides* (Mexico City, Mexico),
moving worldKristie Ebi (Seattle, United States)
R. Ville-Benavides, I. Avendaño-Gutiérrez
S0326 10:00 AMR in climate change-affected countriesEsmita
O0531 A handful of Orf: a case of successful management
Charani (London, South Africa)
with cidofovir in a renal transplant recipientA. Kaya*
(Izmir, Türkiye), G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I. Co-organised with: ESCMID Study Group for Infections in Travellers and
Karaaslan, M. Taşbakan Migrants (ESGITM)

EF079
SY110
17:30 - 18:30 Hall 3 08:30 - 09:30 Arena 1

1-hour Symposium ePoster Flash Session

Immune reconstitution syndrome in infectious diseases: Who. Are. You? AMS around the world: what we can learn from each other
Chairs Elisa Borghi (Milan, Italy) Chair Benedikt Huttner (Geneva, Switzerland)
Justyna Kowalska (Warsaw, Poland)

E0578 Battlefield Stewardship: Implementing Antimicrobial

ESCMID Global 2025 - Programme
Management in the Ukrainian Trauma PathwayH. Kocer, T.K.L. Le, T.T. Tran, T.T. Nguyen, H.S. Le, T.P.
Uren* (Lviv, Ukraine), N. Aliieva, O. Voitovych Velavan
E0579 Evaluating a Tailored Antimicrobial Stewardship E0590 In vitro activity of nitroxoline among Acinetobacter
Strategy to Optimise IV to Oral Conversion: A Pre and baumannii and Stenotrophomonas maltophilia
Post-intervention StudyM. Alyazji* (Abudhabi, United clinical isolatesE. Wohlfarth* (Cologne, Germany),
Arab Emirates), A. Sadeq, J. Shamseddine, Z.O.E. P.G. Higgins, M. Kresken
Babiker, A. Almansoori, M. Alhindasi, A. Abadi, S. E0591 Assessing biocide resistance genes and
Alhebsi, S. Alawlaqi, F. Aljasmi, A. Aitamimi, S. susceptibility to biocides in carbapenem-resistant
Shaabani, A. Alhosani, S. Shawish, R. Ali Acinetobacter baumannii isolates from Thai
E0580 Antimicrobial stewardship program for antibiotic use hospitalsM.R.D. Wiradiputra* (Bangkok, Thailand),
in the community: impact of multidisciplinary local K. Thirapanmethee, P. Khuntayaporn, M.T.
guidelines during the 2023-2024 influenza a H1N1 Chomnawang
season in northern ItalyR. Corsini* (Reggio Emilia, E0592 Epidemiological and Genomic Characteristics of
Italy), P. Pavone, L. Donghi, S. Filippini, A. Valcavi, S. Acinetobacter baumannii in a Hospital in Zhejiang,
Filippi, F. Marchi, F. Violi, A. Gandolfi, E. Casini, M. China: A Study from 2015 to 2020Y. Zhang*
Bardaro, G. Russello, P. Nardini, G. Formoso, G. Dolci, (Hangzhou, China), X. Hua
S. Mezzadri
E0593 Evaluation of the susceptibility of Carbapenem-
E0581 Effectiveness of Clinical Algorithms combined with resistant Acinetobacter baumannii to sulbactam-
Point-of-Care testing to improve Antibiotic durlobactamJ. Caierão* (Porto Alegre, Brazil), L.
Prescribing practices of physicians in outpatient Silva Dornelles, G. Da Silva Collar, M. Preussler
setting of low middle-income countryS. Qureshi* Mott, A. Luís Barth
(Karachi, Pakistan), S. Ahmed, N. Nasir, F.N. Qamar
E0594 Clonal dissemination of Acinetobacter baumannii
E0582 Antibiotic prescribing behaviour in a public International Clone 2 Carrying ArmA and
Bangladeshi hospital: a snapshot from BALANCE emergence of OXA-23-NDM1 co-producers in
studyM.S. Kabir* (Dhaka, Bangladesh), R. Farzana, IndiaG. Nagaraj* (Bangalore, India), N. Geetha, S.
S.M.R. Islam, A. Monir, A. Sharmin, J.B. Joyee, F. Varun, K. Ravikumar
Humayra, M. Sultana, M.N. Haque, T.R. Walsh
E0595 Insight into Acinetobacter baumannii's phenotypic
E0583 Tailored response to antimicrobial resistance and genotypic traits in oncological patientsF. Sivori*
emergence: remote-created stewardship program in (Rome, Italy), I. Cavallo, M. Truglio, G. Fabrizio, M.
a low/middle-income country pediatric hospitalP. Francalancia, F. Fraticelli, E. Abril, E.G. Di Domenico,
Favier* (Valencia, Spain), M.A. Aguilera, G. Rapetti F. Pimpinelli
Salik, M. Quipildor, M.M. Maresca, I.A. Falco
E0584 Weekly interdisciplinary antimicrobial stewardship
rounds at two surgical wards show notable potential EW119
in optimising antimicrobial treatmentG. Brunhofer- 08:30 - 10:30 Hall 11

Bolzer* (Vienna, Austria), M. Krauss, C. Labut, G. Educational Session

Laml-Wallner, B. Unterkoefler, M. Andtisch, E.
Presterl, H. Burgmann, B. Willinger, I. Minichmayr, P. This bacterium might harbour AmpC, what should I do?!
Starzengruber, F. Loetsch, H. Lagler Chairs Sören G. Gatermann (Bochum, Germany)
E0585 Antimicrobial stewardship programmes may improve Pranita Tamma (Ellicott City, United States)
patients' outcome and hospitalization: a sub-analysis
of the CASAS (CArbapenem Sparing Antimicrobial
Stewardship) ProjectM. Bongiovanni* (Lugano,
Switzerland), B. Barda, L. Elzi, P. Bellini, C. Di W0335 08:30 Laboratory identification of AmpC and its impact on
Benedetto, N. Ramponi, M. Mombelli, N. Centemero, /i>in vitro resistanceAna Gales (Sao Paulo, Brazil)
A. Colombo, D. Destefani, M. Bissig, E. Bernasconi W0336 08:50 Divergent levels of AmpC expression in Gram-
E0586 “Prescribing antibiotics is a gamble…”: A mixed- negative pathogensAntonio Oliver (Palma De
methods approach to current practices and Mallorca, Spain)
implementation challenges of antimicrobial W0337 09:10 Rational choice of antimicrobial therapy against
stewardship in a Ugandan tertiary care hospitalL. AmpC-producing pathogensPatrick Harris (Herston,
Jung* (Leipzig, Germany), L. Atikoro, D. Owachi, A. Australia)
Schneider, S. Schönherr, A. Von Braun, C. Kabugo
W0338 09:30 Novel antimicrobials active against AmpC: what RCTs
tell us in support of their use?Amy Mathers
(Charlottesville, United States)
EF080
08:30 - 09:30 Arena 3

ePoster Flash Session

SY114
08:30 - 10:30 Hall 13
Acinetobacter baumannii, still a strong knight to be knocked
2-hour Symposium
Chair Parikshit Prayag (Pune, India)
Sepsis Global 2025
Chairs Brigitte Lamy (Bobigny, France)
E0587 Evaluation of the Antibacterial Activity of New Willem Joost Wiersinga (Amsterdam, Netherlands)
Dermaseptin Derivatives against Acinetobacter
baumanniiH. Haddad* (Sousse, Tunisia)
E0588 Clonal dissemination of highly resistant S0315 08:30 The ESCMID-ISF Sepsis Award LectureAndrew
Acinetobacter baumannii ST2: Insights from the Moore (Emerald Hills, United States)
BALANCE studyC. Abdellaoui* (Oxford, United
S0316 08:45 The WHO Global Maternal Sepsis StudyCarolina
Kingdom), R. Farzana, M.N. Haque, M. Sultana, A.
Carvalho Ribeiro Do Valle (Sao Paulo, Brazil)
Sharmin, R.I. Rony, T. Ahmed Rifat, Z.T. Chaity, S.
Afroj, S. Parvin, M. Ea De Kraker, S. Harbarth, N. S0317 09:15 Sepsis: year in reviewSylvain Meylan (Lausanne,
Hassoun-Kheir, M. Hamza, G. Jana, S. Jamshaid, R. Switzerland)
Yaseen, G. Fatima, M. Nawaz, S.N.Z. Rizvi, U. S0318 09:45 How to design and implement a Sepsis National
Ibrahim, K. Shafique, A. Naqvi, R. Zahra, B. Hassan, Action Plan (SNAP)Erika Vlieghe (Antwerp, Belgium)
E. Carretto, K. Sands, K.J. Hoog, T.R. Walsh
Co-organised with: ESCMID Study Group for Bloodstream Infections,
E0589 Prevalence and genomic characterization of Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)
Sulbactam-Durlobactam-resistant and
Carbapenem-resistant Acinetobacter baumannii in
ICU Patients in a tertiary hospital in Hanoi, Northern SY115
VietnamD. Nurjadi* (Luebeck, Germany), S. Boutin, 08:30 - 10:30 Hall 14
Q.T. Nguyen, A.M.P. Thi, N.M. Truong, T.K.P. 2-hour Symposium
Nguyen, T.S. Bui, V.T. Nguyen, L. Göpel, L. Huber, K.
ESCMID Global 2025 - Programme
Challenges in infection management, prevention and antimicrobial Disease in IndiaKavitha Saravu (Manipal, India)
stewardship in long-term care facilities S0313 09:30 Crimean Congo Haemorrhagic Fever: Newer insights
Chairs Gaetan Gavazzi (Grenoble, France) into pathogenesis leading to new vaccines and
Giusy Tiseo (Pisa, Italy) therapeuticsAli Mirazimi (Stockholm, Sweden)
S0314 10:00 Venezuelan Equine Encephalitis: Impact of newer
strategies for vector controlCarlos Seas (Lima, Peru)
S0319 08:30 The burden of nosocomial infections in long-term
facilities Virginie Prendki (Genève-Thônex,
OS078
Switzerland) 08:30 - 10:30 Hall 5
S0320 09:00 Pneumonia in the elderly: management and 2-hour Oral Session
preventionMarcos Restrepo (San Antonio, United
States) Trending topics in tuberculosis
S0321 09:30 Challenges in the clinical diagnosis of infection in the Chairs Delia Goletti (Rome, Italy)
elderlyMaheen Abidi (Denver, United States) Sean Wasserman (London, United Kingdom)
S0322 10:00 Challenges in implementing antimicrobial
stewardship in long-term care facilitiesElena Carrara
(Verona, Italy)
O0568 Lineage-specific immune responses to
Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), Mycobacterium tuberculosis: insights into L4 and
ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering L6 pathogenesisM. Silva* (Porto, Portugal), J.
Committee Couto, M. Cardoso, B. Cá, M. Saraiva
O0569 Deciphering the functional role of distinctive
SY117
Mycobacterium tuberculosis peptidoglycan
08:30 - 10:30 Hall 16
modifications in modulating antibiotic resistance
2-hour Symposium and the immune responseC. Silveiro* (Lisbon,
Portugal), F. Olivença, M. Mandal, D. Pires, E. Anes,
Survival of the parasites: is treatment failure due to antimicrobial resistance? M.J. Catalão
Chairs Hanne Brekke (Oslo, Norway) O0570 Increased innate immune and neutrophil blood
Jaco J. Verweij (Tilburg, Netherlands) transcriptomic signatures associate with poor
outcome in HIV-1 tuberculous meningitisJ.
Barnacle* (London, United Kingdom), A. Davis, R.J.
Wilkinson, K. Wilkinson, C. Stek, M. Maxebengula,
S0327 08:30 Nitroimidazole refractory Giardia intestinalis N. Bangani, G. Kelly, M. Rodriguez-Lopez, R. Lai, S.
infectionPavla Tůmová (Praha, Czech Republic) Wasserman, G. Meintjes, A. O' Garra
S0328 09:00 Treatment failure in scabiesFrancisco Bravo (Lima, O0571 Subpopulations in clinical samples of
Peru) Mycobacterium tuberculosis can give rise to
rifampicin resistance and shed light on how
S0329 09:30 Recurrent Enterobius infectionsSarah Eisen (London,
resistance is acquiredV. Brunner* (Oxford, United
United Kingdom)
Kingdom), P. Fowler
S0330 10:00 Recent advances in the treatment of Visceral
O0572 A systematic comparison of automated
Leishmaniasis and PKDLShyam Sundar (Varanasi,
Mycobacterium tuberculosis complex whole
India)
genome sequencing analysis pipelinesR. Spies* (Ho
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP) Chi Minh City, Vietnam), D. Crook, T. Peto, P.
Fowler, R. Turner, H. Thai, J. Watson, T. Walker
O0573 Lung ultrasound for the detection of pulmonary
EW118
08:30 - 10:30 Hall 2 tuberculosis using expert and AI-guided
interpretationVeronique Suttels (Lausanne,
Educational Session
Switzerland)
How can we infer and track plasmid outbreaks? O0574 Nanomotion Technology for Rapid Antimicrobial
Susceptibility Testing of Mycobacterium
Chairs Alessandra Carattoli (Rome, Italy)
tuberculosis: Evaluating Novel Benzothiazinone
Jacob Moran-Gilad (Beer Sheva, Israel)
Derivatives.A. Vocat* (Lausanne, Switzerland), A.
Luraschi-Eggemann, C. Antoni, G. Cathomen, D.
Cichocka, G. Greub, O. Riabova, V. Makarov, O.
W0331 08:30 Evolutionary modelling of plasmidsManuel Ares Opota, A. Mendoza, S. Cole, A. Sturm
Arroyo (Paris, France) O0575 Rapid drug susceptibility testing of Mycobacterium
W0332 08:50 How plasmids shape the emergence of nosocomial tuberculosis directly from clinical samples using
pathogensJukka Corander (Oslo, Norway) targeted next-generation sequencingE. Rosendal*
(Lisbon, Portugal), J. Isidro, S. Carneiro, R. Macedo
W0333 09:10 Understanding the complexity of plasmid outbreaks
using bioinformaticsTorsten Seemann (Melbourne O0576 Enhancing cerebral tuberculosis therapy with an
(VIC), Australia) innovative particulate nose-to-Brain drug delivery
system: Insights from pharmacokinetic and
W0334 09:30 Plasmid transmission at the One Health pharmacodynamic studiesK. Jadhav* (Sas Nagar,
interfaceNicole Stoesser (Oxford, United Kingdom) India), K. Sudhakar Jadhav, A.K. Singh, R.K. Verma
Co-organised with: ESCMID Study Group for Epidemiological Markers O0577 Multi-drug resistant tuberculosis among migrants
(ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM) in EuropeS. Hayward* (London, United Kingdom),
K. Rustage, L.B. Nellums, J.S. Friedland, S.
Hargreaves
SY113
08:30 - 10:30 Hall 3

2-hour Symposium SY120

09:30 - 10:30 Hall 1
Haemorrhagic viral infections 1-hour Symposium
Chairs Önder Ergönül (Istanbul, Türkiye)
Catherine Houlihan (Porton Down, United Kingdom) Year in clinical microbiology
Chairs Fidelma Fitzpatrick (Dublin, Ireland)
Maurizio Sanguinetti (Rome, Italy)
S0311 08:30 Filovirus disease: evolving therapeutic strategiesIan
Crozier (Frederick, United States)
S0312 09:00 Jack in the box: Re-emergence of Kyasanur Forest S0339 09:30 Mario Ramirez (Lisbon, Portugal)
ESCMID Global 2025 - Programme
S0340 10:00 Anna Papa-Konidari (Thessaloniki, Greece) FO129
11:00 - 12:00 Arena 1

Open Forum
EF081
09:30 - 10:30 Arena 2
Predatory journals in CM/ID: from symptoms to cure
ePoster Flash Session Chair Emily G. Mcdonald (Montreal, Canada)
Clinical features and outcome of invasive fungal infections
Chair Marcus De Melo Teixeira (Brasília, Brazil)
F0356 11:00 The genesis of predatory journals: symptoms and
root problemsLeonard Leibovici (Petah-Tiqva, Israel)
F0357 11:10 The role of editors and publishers of ‘reputable
E0596 Management, outcomes and predictors of mortality journals’: what can they do to stop predatory
of Cryptococcus infection in patients without HIV: a journals?Till Bärnighausen (Heidelberg, Germany)
multicentre study in 46 hospitals from Australia and
New ZealandJ. Coussement* (Melbourne, Australia), F0358 11:20 The roles of authors and academic institutions:
C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. towards governance and regulation Luigia Scudeller
Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. (Pavia, Italy)
Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. F0359 11:30 Bibliometric literacy in scientific publicationLauren
Crawford, S.J. Crawford, B.J. Smith, A.P. Gador- Maggio (Chicago, United States)
Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B. Co-organised with: CMI Communications Board of Editors
Walls, G.M. O’kane, M.T. Broom, C.L. Keighley, O.
Bupha-Intr, L. Cooley, J.A. O’hern, J.D. Jackson, A.J.
Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade,
EF089
V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A. 11:00 - 12:00 Arena 2
Slavin, S.C.A. Chen ePoster Flash Session
E0597 Incidence of invasive fungal infections in hospitalised
paediatric patients in EnglandA. Warris* (Exeter, Emerging Infectious Diseases, Zoonoses and Outbreaks
United Kingdom), L. Ferreras-Antolin, G. Kiely, Z. Riaz,
M. Czachorowski, M. Gerino, K.K. Rai, Z. Akhter, J.
Owczarek, C. Castillo, I. Jimenez
E0598 Invasive fungal disease in critically ill patients with E0640 Seasonality of Influenza and Respiratory Syncytial
cirrhosis: an autopsy studyL. Maessen* (Leuven, Virus related hospital contacts in Denmark (1999-
Belgium), A. Wilmer, P. Meersseman, J. Wauters, J. 2021)O. Rezahosseini* (Hillerod, Denmark), C.L.
Heylen, S. Feys, C. Jacobs, H.M. Lauwers, K. Lagrou, Burrett, M.F. Eiberg, M.P. Andersen, M.F. Howitz, C.
M. Peetermans, G. Hermans, Y. Debaveye, E. Van Roed, J.G. Holler, B. Lindegaard Madsen, D.M.
Wijngaerden, S. Van Der Merwe, G. De Hertogh Weinberger, T.K. Fischer, C. Torp-Pedersen, Z.B.
Harboe
E0599 Non-Aspergillus mould infections in Australia and
New Zealand: a multi-centre study on epidemiology E0641 Are we serologically prepared against an avian
and clinical outcomesC.F. Neoh* (Melbourne, influenza pandemic and could seasonal flu vaccines
Australia), S.C.A. Chen, A.J. Morris, C.H. Heath, S.J. help us?I. Sanz-Muñoz* (Valladolid, Spain), J.
Tan, R. Lane, S.Y. Tio, M.B. Roberts, S.Y. Tay, K. Sánchez-Martínez, C. Rodriguez-Crespo, I. Arroyo-
Kennedy, S. Van Hal, H. Murray, R. Pickles, A. Hernántes, C.S. Concha-Santos, M.L. De Dlego, S.
Douglas, K. Urbancic, M. Menon, A. Stewart, P. Rojo-Rello, M. Domíguez-Gil, M. Hernández-Pérez, A.
Simos, N.M. Vaselli, J. Howard, C. Keighley, S. Martín-Toribio, A. Mostafa, L. Martínez-Sobrido, J.M.
Miyakis, R. Beresford, L. Cooley, O. Smibert, M. Sehu, Eiros, A. Nogales
K.Y. Yong, A. Crowe, M. England, O. Robinson, S. E0642 The UK Imported Fever Service (IFS): National VHF
Lynar, K. Daveson, C. Halliday, S. Kidd, D.C.M. Kong, testing 2023-2024A. Belfield* (Salisbury, United
T. Spelman, L. Worth, M. Slavin Kingdom), A. Thompson, H. Umpleby, B. Hack, S.
E0600 Leveraging natural language processing (NLP) for Poole, J. Furneaux, J. Owen, J. Osborne, C. Petridou,
early detection of aspergillosis: A retrospective T. Brooks, N.C. Gordon, T. Rampling, C. Houlihan, C.E.
studyL. Nwankwo* (London, United Kingdom), N. Warrel
Pinnock, A. Shek, C. Hemsley, J. Periselneris, S. E0643 Reemergence of Poliovirus in Pakistan: Challenges
Schelenz, D. Armstrong-James and Implications for Global Health SecurityS. Ahmad*
E0601 How often does Mucormycosis (MCM) contribute to (Tampere, Finland)
mortality in Hematologic Malignancy (HM) patients? E0644 Preparing an emerging infectious diseases unit for
Analysis of 103 patients over 20 yearsS. Wurster* high-consequence infectious diseasesA. Silva-Pinto*
(Houston, United States), T.M. John, J. Ying, D.P. (Porto, Portugal), C. Silva, A.S. Santos, M. Teixeira, L.
Kontoyiannis Santos
E0602 Emergence of Wickerhamomyces anomalus invasive E0645 Correlation between clinical and wastewater measles
infections in injecting drug usersM. Lefranc* positivity rate in three towns of karachi, pakistanF.
(Bordeaux, France), M. Desnos-Ollivier, P. Baudino, K. Naz Qamar* (Karachi, Pakistan), F.N. Qamar, S.
Boukris-Sitbon, C. Plaisant, F. Dalle, F. Lanternier, S. Qureshi, M. Larik, F. Kabir, J. Iqbal, K. Begum, J.
Imbert Gauld, S. Kroiss, J. Giles
E0603 Prevalence and risk-factors for secondary E0646 Salmonella serovars in wild European hedgehogs
localizations during candidemia in intensive care unit (Erinaceus europaeus): an over 12-year monitoring in
patients: the French CandidICU multicenter studyJ.P. the Ferrara Province, ItalyE. Massella* (Piacenza,
Gangneux* (Rennes, France), F. Reizine, J. Henry, L. Italy), M. Munari, S. Russo, L. Cirasella, C.
Desmedt, C. Camus, V. Coirier, F. Arrive, E. Burban, Torreggiani, R. Taddei, A. Luppi, S. Rubini
G. Eustache, T. Belleville, A. Marc, J. Malherbe, P.
E0647 Clinico-epidemiological and Microbiological
Bouju, P. Jaubert, O. Lesieur, M. Leclerc, P. Fillâtre, A.
Investigation of Diphtheria Outbreak in Odisha, India,
Frérou, R. Prével, A. Cady, F. Morio, M. Pihet, G.
2024I. Praharaj* (Bhubaneswar, India), S. Panda, S.
Nevez, L. Delhaes, S. Imbert, H. Guegan, J.
Subhadra, J. Sabat, S. Mallik, S. Xalxo, N. Manisha, S.
Bonhomme, E. Perraud, C. Dupin, D. Du Cheyron, Y.
Priyadarshini, S. Nayak, N. Ray, S. Mallick, S. Pati
Launey, C. Aubron
E0648 Seroprevalence of nine causes of acute febrile illness
E0604 Population-based longitudinal study over two
in rural Cambodia and Thailand using a multiplex
decades of Candida and Candida-like species
assayM. Zhang* (Bangkok, Thailand), R. Tripura, L.
bloodstream infection reveals gender and species
Dysoley, C. Perrone, E. M. Batty, J. Wongsantichon,
differences in mortality, recurrence and resistanceA.
S. D. Blacksell, S. S. Y. Kang, N. P. J. Day, R. J. Maude,
Stewart* (Boston, United States), K. Laupland, F.
S. J. Lee, Y. Lubell, T. J. Peto
Edwards, S. Koo, S. Hammond, P. Harris, D. Paterson,
M. Slavin, S. Chen
ESCMID Global 2025 - Programme

EF090 O0622 Molecular epidemiological characterization of

11:00 - 12:00 Arena 3
enterotoxigenic and enteroaggregative Escherichia
ePoster Flash Session coli causing traveller's diarrhoea and their
relationship with clinical featuresP. Oliveras Julia*
Addressing the need for speed: advances in point-of-care testing (Barcelona, Spain), P. Oliveras, E. Riera, L. Horvath,
Chair Jennifer Dien Bard (Los Angeles, United States) R.M. Albarracín, M.E. Valls, M.J. Álvarez-Martínez, M.
Alguacil, E. Guiral, M. Espasa, D. Camprubi-Ferrer, J.
Vila
O0623 Bites and bytes – can digital surveillance of travellers'
E0649 Rapid respiratory microbiological POCTs and illness predict outbreaks?N. Hedrich* (Zürich,
antibiotic use in primary care: the RAPID-TEST RCTE. Switzerland), T. Lovey, P. Schlagenhauf
Brown* (Bristol, United Kingdom), A.D. Hay, S. Abbs,
M. Ridd, S. Granier, A. Lane, P. Muir, J. Taylor, G. O0624 Travel-associated infections and diseases: a
Young, K. Eastwood, H. Dash, L. Bradshaw, R. Clarke, retrospective cross-sectional studyM. Trojanek*
M. Lui, E. Bridgeman, R. Brierley, H. Thornton, P. (Prague, Czech Republic), M. Trojánek, V. Grebenyuk,
Mitchell, L. Zhu, L. Yardley, C. Metcalfe V. Jegorova, P. Hubacek, A. Briksi, J. Havlova, K.
Dundrova, L. Kolarik, I. Zicklerova, L. Richterova, O.
E0650 Evaluation of the prototype BIOFIRE® nasal HR panel Beranek, T. Ernestova, L. Kohout, G. Meseznikov, A.
(nHRP) in children with acute respiratory illness, a Nycova, B. Pisova, R. Šindlerová, M. Tulach, Z.
nasal swab-based rapid hoSt gene expression testG. Uhříková, M. Vidlička, M. Štefan, F. Stejskal
Storch* (Saint Louis, Missouri, United States), M.
Wallendorf, C. Rindlisbacher, J. Jackson, M. Hockin
E0651 Evaluation of the analytical performance of the OS086
Biosynex AMPLIQUICK Fecal Bacteriology kit in the
11:00 - 12:00 Hall 11

diagnossis of bacterial intestinal infectionsP. 1-hour Oral Session

Lehours* (Bordeaux, France), Q. Beaufils, L. Benejat,
A. Ducournau, J. Aptel, A. Chevalier, M. Jauvain Marker based diagnostics: forget the pathogen
E0652 Development and Validation of a Novel Rapid Antigen Chairs Virginie Prendki (Genève-Thônex, Switzerland)
Test for Norovirus Detection: A Comparative Suzanne Van Asten (Nijmegen, Netherlands)
Performance AnalysisN. Younes* (Doha, Qatar), G.
Nasrallah
E0653 A Rapid Molecular POCT System for Detection of O0625 A 29-mRNA molecular host response test
Carbapenem-Resistant Enterobacterales (CRE)S.Y. demonstrates enhanced accuracy compared to a
Choi* (Daejeon, Korea, Republic of), C. Lee, H.O. Park protein-based host response test for the diagnosis of
E0654 Validation of an ultra-rapid, point-of-care, antibiotic bacterial and viral infectionsN. Whitfield* (Sunnyvale,
susceptibility testing deviceA. Van Der Linden* United States), C. Lu, O. Liesenfeld
(Eindhoven, Netherlands), Y. Deurloo, N. Doomen, D. O0626 Diagnostic accuracy of a bacterial versus viral host-
Kreft, J. Hays, H. Stapert, A. Van Belkum, S. Shanko protein test for pediatric inpatients with acute
E0655 Development of a frugal multiplexed paper sensor for infectionT. Gottlieb* (Tirat Carmel, Israel), L. Bont, A.
rapid detection of sepsis-causing pathogensC. Klein, M. Stein, M. Mor, I. Srugo, R. Navon, E. Eden,
Singhal* (Faridabad, India), S. Chatterjee, S. Gupta, B.P. Muller
M. Yadav, C. Sharma, S. Pandey, D. Kumar, P. Joshi, O0627 Diagnostic accuracy of combined urine lipocalin 2
J. Jaya, R. Dwivedi, S. Tanwar, S. Sharma, S. Shamsi, and copper test in acute pyelonephritis or cystitisV.
A. Tyagi, N. Kumar, S. Chaudhuri Havlicek* (Prague, Czech Republic), J. Hrbacek, T.
E0656 Multianalyte POCT device for a sample-to-result Pluhacek, J. Houst, A. Palyzova, D. Luptakova, D.A.
detection of nucleic acid and proteinL. Pommiès* (Gif Stevens, J. Novak, R. Dobias, R. Zachoval
Sur Yvette, France), H. Boutal, D. Fras, H. Volland O0628 Diagnostic Performance of Whole-Blood RNA
E0657 A smartphone app for point-of-care quantification of Signatures for Tuberculosis Diagnosis in a Cohort of
lateral flow assaysR. Armiger* (London, United Patients with Non-Tuberculous Mycobacterial Lung
Kingdom), R. Reid, P. Georgiou, A. Holmes, J. Herberg DiseaseP. Escalante* (Rochester, Mn, United States),
B. Piatkowski, B. Pathakumari, V. Van Keulen, N.
Fadra, P. Arias-Sanchez, L. Gutierrez, S. Karnakoti, T.
KN121 Peikert
11:00 - 12:00 Hall 1
O0629 Diagnostic utility of MxA and MxA/CRP ratio in
Keynote Lecture differentiating viral and bacterial infections: a
prospective cohort studyO. Beránek* (Prague, Czech
HIV: from needle parks to injectables Republic), R. Prusa, M. Trojánek, O. Beranek, Z.
Chairs Mary Horgan (Dublin, Ireland) Uhříková, J. Illner, P. Lehnert, P. Bukovska, M. Štefan,
Gülsen Özkaya Sahin (Lund, Sweden) V. Jegorova, T. Ernestova, L. Kohout, G. Meseznikov,
A. Nycova, R. Šindlerová, M. Tulach, M. Vidlička, V.
Grebenyuk
K0341 11:00 Huldrych Günthard (Zürich, Switzerland)
PM2
11:00 - 12:00 Hall 12

OS085
11:00 - 12:00 Hall 10 Panel Discussion
AMR and vaccines
1-hour Oral Session
Chairs Charlotte Vernhes (Brussels, Belgium)
Planes, Pains, and Pathogens: The Perils of Travel Medicine Ghada Zoubiane (London, United Kingdom)
Chairs Anu Kantele (Helsinki, Finland)
Carlos Seas (Lima, Peru)
L005 11:00 Overview of the current evidence of the impact of
vaccines on AMRAdam Cunningham (Birmingham,
O0620 Fever in returning travelers from tropical regions: United Kingdom)
what not to miss in an evolving epidemiologyS. L006 11:20 Panel discussion: gaps, needs, and opportunities to
Caronni* (Milan, Italy), M. Pieruzzi, A. Rizzo, A.H. leverage vaccines against AMR, Adam Cunningham
Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, (Birmingham, United Kingdom), Sipho Kenneth
A. Mancon, D. Mileto, S. Antinori Dlamini (Observatory, South Africa), Erin Duffy
O0621 Tracing the itch: A spatiotemporal analysis of scabies (Boston, United States), Mateusz Hasso-Agopsowicz
rates and its risk factors using the Global Burden of (Geneva, Switzerland)
Disease dataS. Gupta* (Auckland, New Zealand), S.
Thornley, G. Sundborn, C. Grant
ESCMID Global 2025 - Programme

SY126 O0636 Viral metagenomics in patients with persistent

11:00 - 12:00 Hall 13
unexplained neutropenic fever- some clues to the
1-hour Symposium cause of fever?A. Douglas* (Melbourne, Australia),
L. Caly, M.A. Slavin, I. Savic, J. Moselen, A. Aziz, G.
Why is the concept of complicated UTI so complicated? Papadakis, G. Ng, J. Druce, K. Thursky
Chairs Gernot Bonkat (Basel, Switzerland) O0637 Results of Optifil study: 18F-FDG-PET/CT guided
Maeve Doyle (Waterford, Ireland) antifungal stewardship in invasive pulmonary
aspergillosisF. Lanternier* (Paris, France), C.
Maunoury, F. Montravers, F. Marquant, S. Poiree, C.
Elie, C. Robin, A. Thiebaut, F. Ader, F. Suarez, E.
S0350 11:00 The concept of complicated UTI: underlying Blanchard, O. Lortholary
conditions matterSuzanne Geerlings (Amsterdam,
Netherlands) O0638 Long-term immunogenicity and boostability of the
5-dose pneumococcal vaccination schedule
S0351 11:30 The concept of complicated UTI: the site of infection following allogeneic hematopoietic stem cell
matters mostJesús Rodríguez-Baño (Seville, Spain) transplantation: a prospective cohort studyS.
Co-organised with: ESCMID Education Subcommittee Haggenburg* (Amsterdam, Netherlands), J.
Schnyder, H. Garcia Garrido, M. Schoordijk, A.
Reiners, B. Meek, M. Hazenberg, A. Goorhuis
ME128
11:00 - 12:00 Hall 14 O0639 Humoral and cellular immune response to
adjuvanted respiratory syncytial virus vaccine
Meet-the-Expert RSVPreF3 in adults after allogeneic hematopoietic
cell transplantationJ. Lötscher* (Basel,
How to apply organoid models to study infectious disease Switzerland), C.S. Walti, J. Halter, N. Khanna, S.
Heller, S. Schmid, K. Leuzinger

M0354 11:00 Jennifer Rohn (London, United Kingdom) OS082

M0355 11:12 Nathalie Sauvonnet (Paris, France)
11:00 - 12:00 Hall 2

1-hour Oral Session

OS087 New insights in bloodstream infections and endocarditis

11:00 - 12:00 Hall 15
Chairs Barbara Hasse (Zurich, Switzerland)
1-hour Oral Session José M. Miro (Barcelona, Spain)

Antimicrobial resistance around birth

Chairs Julia Anna Bielicki (London, United Kingdom)
O0605 Different from the start – Sex differences in
Surbhi Malhotra-Kumar (Antwerp, Belgium)
Staphylococcus aureus bacteremia mortalityA.
Westgeest* (Leiden, Netherlands), M. Lambregts, F.
Ruffin, V.G. Fowler, J.T. Thaden
O0630 Prevalence and risk factors of antibiotic resistance O0606 Tracking evolution in action during invasive
genes in breastmilk and neonatal oral cavity of Staphylococcus aureus infections: the BARISTA
preterm mother-infant pairsA. Sharma* (Chandigarh, studyS. Giulieri* (Melbourne, Australia), D. Daniel, M.
India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Duarte Aguilera, D. Velasquez-Reyes, R. Guérillot, A.
Ray Gador-Whyte, F. James, E. Goodall, P. Fuge-Larsen,
O0631 Effect of maternal peripartum antibiotic exposure on M. Henri, J. Trubiano, M. Leroi, K. Bond, T. Stinear, S.
the microbial diversity, relative abundance of taxa, Tong, J. Kwong, B. Howden
and resistome in breastmilkA. Chakraborty* O0607 Identifying heterogeneity of treatment effect for
(Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. antibiotic duration in bloodstream infection – an
Kumar, P. Kumar, A. Pal, A. Arora exploratory post-hoc analysis of the BALANCE
O0632 Dynamics of gastrointestinal colonisation by randomized clinical trialS. Ong* (Melbourne,
antibiotic-resistant bacteria in high-risk infants in Australia), R. Pinto, A. Rishu, S. Tong, R. Commons,
Swiss and Greek neonatal intensive care unitsA. J.M. Conly, G. Evans, M. Fralick, C. Kandel, P. Lagacé-
Braspenning* (Antwerp, Belgium), L. Timbermont, L. Wiens, T. Lee, S. Lother, D. Macfadden, J. Marshall, V.
Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, Martel-Laferrière, M. Mayette, E. Mcdonald, J. Neary,
C.H. Van Werkhoven, J. Bielicki, S. Malhotra-Kumar J. Prazak, E. Raby, A. Regli, B.A. Rogers, S. Smith, L.
Taggart, H.T. Wang, T. Wuerz, D. Yahav, P. Young,
O0633 Harnessing functional omics to decipher how R.A. Fowler, N. Daneman
probiotics reduce antibiotic resistance gene carriage
in infants' gutV. Pettersen* (Tromsø, Norway), A. O0608 Bloodstream infection pathogen diversity and clinical
Bargheet, G.H. Bø, C. Klingenberg impact revealed through unbiased whole genome
sequencing: a prospective genomic epidemiology
O0634 Dynamics of gut resistome and mobilome in early life: studyN. Macesic* (Melbourne, Australia), J. Hawkey,
A meta-analysisV. Pettersen* (Tromsø, Norway), A. J.A. Wisniewski, A. Peleg
Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K.
Korpela, M. Valles-Colomer, J. Debelius, A. O0609 Risk of infection of intracardiac devices in patients
Kurilshikov with valvular infective endocarditis who carry
cardiovascular implanted electronic devices. Analysis
on a national cohortA. Blanco Arévalo* (Barcelona,
OS088 Spain), A. Blanco-Arevalo, E. Calbo, P. Muñoz, D.
11:00 - 12:00 Hall 16
Monzón, M. Valerio, M. Hernandez Meneses, J.M.
1-hour Oral Session Miró, M. Cobo Belastegui, A. De Alarcón, R.
Rodríguez, I. Villanueva Benito, J.C. Lopez-Azor, L.
Advancing diagnostics and preventive measures in hemato-oncological Garcia-Alvarez, L. Boix
patients
Chairs Dina Averbuch (Jerusalem, Israel)
SY122
Malgorzata Mikulska (Genoa, Italy) 11:00 - 12:00 Hall 3

1-hour Symposium

O0635 Prediction of bacterial and fungal bloodstream Chronic infections in the era of CFTR modulators: what is going on in cystic
infections using machine learning in patients fibrosis lungs these days?
undergoing chemotherapyM. Freire* (Sao Paulo, Chairs Pavel Drevinek (Prague, Czech Republic)
Brazil), A. Villani. Jr, M. P. Freire, F. Lazzar Neto, L.A. Helle Krogh Johansen (Copenhagen, Denmark)
De Padua Covas Lages, M. Salaroli De Oliveira, E.
Abdala, F. L.S. Nunes, A.S. S. Levin
ESCMID Global 2025 - Programme

S0342 11:00 The lung microbiome of people with cystic fibrosis

receiving modulator therapySebastien Boutin SY125
(Lübeck, Germany) 11:00 - 12:00 Hall 7

S0343 11:30 Tackling chronic infections in people with cystic 1-hour Symposium
fibrosis receiving modulator therapy: is it still
necessary?Alessandra Bragonzi (Milano, Italy) Cutting edge methods in mycology
Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society Chairs Katrien Lagrou (Leuven, Belgium)
for Medical Microbiology Antonio Vena (Genova, Italy)

SY123
11:00 - 12:00 Hall 4
S0348 11:00 Imaging for diagnosing mycoses: focus on 18F-FDG
1-hour Symposium PET/CTAna Fernández-Cruz (Majadahonda (Madrid),
Spain)
Infection prevention and control and intensive care: challenges and solutions S0349 11:30 Exploring the intersection of fungal metagenomics
Chairs Antonios Katsounas (Bochum, Germany) and medical mycologyMarcus De Melo Teixeira
Claire Roger (Nimes, France) (Brasília, Brazil)
Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID
Education Subcommittee, Medical Mycology Study Group (GEMICOMED)
within the SEIMC (Spanish Society of Infectious Diseases and Clinical
S0344 11:00 Intensive care unit (ICU) and infection: two sides of a Microbiology), ESCMID Study Group for Critically Ill Patients (ESGCIP),
coinReto Schuepbach (Zurich, Switzerland) Società Italiana per la Terapia Antinfett
S0345 11:20 Ventilator- associated pneumonia (VAP) and ICU
enviroment: how can we improve practices?Despoina
Koulenti (London, United Kingdom) OS084
11:00 - 12:00 Hall 8
Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP),
EUCIC Steering Committee 1-hour Case Session

Weird and unusual infections

OS083 Chairs Murat Akova (Ankara, Türkiye)
11:00 - 12:00 Hall 5
Muge Cevik (St Andrews, United Kingdom)
1-hour Oral Session

Don't 'rash' it
O0615 Vertical Transmission of Clade Ib monkeypoxvirus
Chairs Heli Harvala (Turku, Finland) during Pregnancy: Clinical and Histopathological
Catherine Moore (Cardiff, United Kingdom) description of 3 casesE. Hasivirwe Vakaniaki*
(Kinshasa, Congo, the Democratic Republic of the),
N.R. Swar Kuispond, H. Yuichiro, S. Tadaki, R. Bulakali
Chirimwami, L. Liesenborghs, P. Mbala-Kingebeni, E.
O0610 Current Prevalence of Parvovirus B 19 Infections:
Bangwen, I. Brosius, T. Wawina-Bokalanga, S. Sabiti
Ankara Bilkent City Hospital Experience 2019-
Nundu
2024B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kırca,
A. Toyran, S. Aydoğan, B. Dinç O0616 First case of Oropouche fever in the South of SpainI.
Pérez Hernández* (Málaga, Spain), I.A. Pérez-
O0611 Managing an outbreak of parvovirus B19 infection in
Hernández, E. Basallote Leal, M.A. Sempere Alcocer,
pregnancy: clinical outcomes from a single-centre
B. O´donell Cortés
studyM. Melchio* (Genoa, Italy), E. Ricci, E. Cristina,
E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. O0617 Wild hippopotamus bite and Aeromonas spp.
Mesini, M. Mariani, C. Russo Artimagnella, C. infection: a treatment challenge. First case report.J.
Saffioti Alza Arcila* (Medellín, Colombia), N.M. Daza Alarcon,
M.V. Montoya Garcia, A. Múnera-Echeverri, F.F.
O0612 The dark side of the „fifth disease” endemic: human
Jiménez Quiroz, J. Alza-Arcila
parvovirus B19 infections transmitted through blood
transfusions in adults with malignant hematological O0618 From the sea to the land: an emerging speciesK.
diseasesB.G. Szabo* (Budapest, Hungary), D. Rodríguez Martínez* (Santo Domingo, Dominican
Korozs, P. Remenyi, J. Sinko Republic), K. Rodríguez, A. Fernández, K. Espaillat, J.
Cruz, X. Rodríguez, T. Flores
O0613 Key learnings from a measles outbreak with
multiple hospital exposures in Ireland, May-July O0619 The first findings of Wohlfahrtiimonas chitiniclastica
2024A.M. Murray* (Dublin, Ireland), G. Larkin, D. and Ignatzschineria species bacteremia in two cases
Hickey with maggot infested wounds in ScandinaviaA.L.
Engsbro* (Slagelse, Denmark), C. Mortensen, R. Jul,
O0614 Measles virus in the context of subacute sclerosing
W. Cebula, A.L. Laugesen, J.T. Møller, M. Kemp
panencephalitis (SSPE)J. Dina* (Caen, France), S.
Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous
ME127
11:00 - 12:00 Hall 9
SY124
11:00 - 12:00 Hall 6
Meet-the-Expert
1-hour Symposium
EUCAST: What's new in susceptibility testing
Antimicrobial prescribing: myths or pearls?
Chairs Massimo Fantoni (Roma, Italy)
Spyros Pournaras (Athens, Greece) M0352 11:00 Erika Matuschek (Växjö, Sweden)
M0353 11:12 Rafael Canton (Madrid, Spain)
Co-organised with: EUCAST Steering Committee
S0346 11:00 Why treat IV when PO is possible?Bradley Spellberg
(Los Angeles, United States)
ME134
S0347 11:30 De-escalation of antibiotic therapy to narrow-
spectrum IV drugsFlaminia Olearo (Hamburg,
13:30 - 14:30 Hall 16

Germany) Meet-the-Expert
Co-organised with: CMI Communications Board of Editors, ESCMID AMR
The older solid organ transplant recipient: between frailty,
Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship
immunosenescence and infection
(ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID
Scientific Affairs Subcommittee
ESCMID Global 2025 - Programme
Bernasconi
M0367 13:30 Maheen Abidi (Denver, United States)
E0669 Assessment of HIV-DNA, immune activation and
M0368 13:42 Alaa Atamna (Petah-Tikva, Israel) senescence biomarkers during injectable
Co-organised with: ESCMID Study Group for Infections in Compromised cabotegravir/rilpivirine treatmentM. Mazzitelli*
Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE) (Padua, Italy), M.R. Petrara, C. Cozzolino, L. Sasset,
D. Leoni, S. Gardin, E. Ruffoni, A. De Rossi, A. Cattelan
E0670 Impact of Cabotegravir plus Rilpivirine Long-Acting
SY131
13:30 - 14:30 Hall 2 on Body Composition: Results from a Prospective
StudyA. De Vito* (Sassari, Italy), A. Marongiu, A.
1-hour Symposium Cano, M. Puci, A. Colpani, A. Mura, M.G. Catte, M.A.
Deledda, S. Uzzau, S. Babudieri, G. Sotgiu, F. Deriu, A.
Vaccines and antimicrobial resistance Spanu, G. Madeddu
Chairs Iva Butic (Zagreb, Croatia) E0671 Real-World Efficacy and Tolerability of Long-Acting
Zitta Barrella Harboe (Hillerød, Denmark) Cabotegravir/Rilpivirine in Older Woman with
Polypharmacy and ComorbiditiesM. Rosas Cancio-
Suárez* (Madrid, Spain), A. Moreno, S. Del Campo
Terrón, M.J. Vivancos, A. G. García De Morales, J.
S0361 13:30 The impact of current and future vaccines on AMR:
Martínez-Sanz, M.D. Corbacho, M. Suárez, C. Cano,
from pneumococcal to COVID-19Mateusz Hasso-
R. Ron, M.J. Cárdenas-Isasi, M. Vélez-Díaz-Pallarés,
Agopsowicz (Geneva, Switzerland)
S. Moreno, M.J. Pérez-Elías
S0362 14:00 Can vaccines against AMR be translated into
E0672 Two-year comparative analysis of lipid profile
policy?William Hausdorff (Washington DC, United
changes between INSTI-based single tablet regimens
States)
in treatment-naïve people living with HIV: real-world
Co-organised with: ESCMID Study Group for Antimicrobial Resistance evidence from South KoreaS.Y. Lim* (Seoul, Korea,
Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG) Republic of), B. Chin, M.K. Kim, Y. Kim, G. Kim, J.
Bang
E0673 Long-acting antiretroviral therapy in PLWH with prior
EW135
13:30 - 15:30 Hall 3 HBV exposureJ. Mateo Gonzalez* (Valencia, Spain),
J.I. Mateo-Gonzalez, M. Plaza-De-La-Torre, D.
Educational Session
Martinez-Perez, J. Martinez-Andres, V. Abril-Lopez-
De-Medrano, E. Ballester-Belda, M. Garcia-
Transforming your research idea into an appropriate study design
Rodriguez, C. Ricart-Olmos, M. Garcia-Deltoro
Chairs Casandra Bulescu (Bucharest, Romania)
E0674 Protease inhibitors in today's antiretroviral
Mary Horgan (Dublin, Ireland)
landscape: are we tracking resistance?J. Ciscar
Soriano* (València, Spain), J. Ciscar-Soriano, M.D.
Gómez-Ruiz, A. Hernández-Cabezas, A. Valentín-
W0369 13:30 Designing high-quality research studies: Martín, M. Montero-Alonso, J.L. López-Hontangas
methodological skills and knowledgeMical Paul E0675 Effect after Switching from Efavirenz to Rilpivirine on
(Haifa, Israel) Liver Steatosis Among People Living with HIV with
W0370 13:50 How to design and run scientific studies using AI Non-Alcoholic Fatty Liver Disease: A Randomized
agents as research assistantsAlyssa Bilinski Controlled TrialL. Srikham* (Sakon Nakhon,
(Cambridge, United States) Thailand), S. Sriphoosanaphan, O. Putcharoen
W0371 14:10 Designing your first study: how to construct a E0676 Impact of maternal dolutegravir on growth outcomes
workable project when your work environment may of HIV-exposed uninfected children: A prospective
not helpThomas Tängdén (Uppsala, Sweden) studyE. Yoram* (Morongoro, Tanzania, United
republic of), E. Luoga, S. Glanzman, F. Vanobberghen,
W0372 14:30 Bridging early-career professionals with partners and M. Weisser, E. Dotto, G.J. Mollel, G. Sigalla, E.
seniorsGiorgia Caruana (Sion, Switzerland) Nyenza, L. Moshi, L. Wilson, J. Okuma, D. Paris
Co-organised with: CMI Board of Editors, CMI Communications Board of
Editors, Trainee Association of ESCMID (TAE) Steering Committee
EF094
13:30 - 14:30 Arena 3

FO136 ePoster Flash Session

13:30 - 14:30 Arena 1

Open Forum Speed, convenience and performance of virus diagnostic methods

Chair Hans H. Hirsch (Basel, Switzerland)
Diversity in CM and ID: gender gaps and policy traps
Chair Andre Fuchs (Augsburg, Germany)
E0677 Prospective evaluation of a rapid diagnostic test in a
tertiary hospital and prospects for reinforced
F0373 13:30 How to avoid parity traps in ID/CM research?Muge dengue surveillance in Catalonia (Northeastern
Cevik (St Andrews, United Kingdom) Spain)L. Horvath* (Barcelona, Spain), L. Horvath
F0374 13:40 Gender gaps in visibility at scientific Ruiz, J. Navero, M. Navarro, M. Pujada, A. Navarro,
conferencesSarah Delliere (Paris, France) M. Garrido, B. Herrerías, P. Rodríguez, N. Zancada,
B. Escudero-Perez, M.J. Martinez
F0375 13:50 Psychological determinants of empowerment at
individual and societal levelTba E0678 Sequence-Independent Single-Primer Amplification
(SISPA) followed by Next-Generation Sequencing
Co-organised with: ESCMID Education Subcommittee, ESCMID Parity for Diagnosing Viral Respiratory Tract InfectionsP.
Commission Trindade* (Santa Maria, Brazil), B.C. Casarin, T.R. Y
Castro, B.C. Piccoli, V.T. Santos, L.F. Tessele, A.V.
Schwarzbold
EF093
13:30 - 14:30 Arena 2
E0679 Seasonal trends and co-infection dynamics of
ePoster Flash Session respiratory pathogens: insights from a yearlong
studyZ. Tsinaris* (Thessaloniki, Greece), A. Tychala,
Real world experience with modern HIV treatment: the art of ART G. Meletis, A. Greco, T. Chatziantoniou, R.
Dimitriadou, C. Chantzi, E. Georgiadou, G. Kagkalou,
O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou
E0680 Speed meets reliability in respiratory infections
E0668 Use of long-acting cabotegravir/rilpivirine in HIV- diagnosis with a new nucleic acid extraction
viraemic individuals: a metanalysisM. Bongiovanni* workflowL. Pastor-Bernad* (San Mateo De Gállego,
(Lugano, Switzerland), B. Barda, G. Barilaro, E. Spain), B. Santos Da Silveira, E. Lucia, M.C. Gil-
Rodríguez, H. Alonoso, C. Giménez-Rota
ESCMID Global 2025 - Programme
E0681 Pathobiome characterization and role in disease
severity in children under 5-years with respiratory
OS092
infection symptomsL. Terranova* (Milan, Italy), L. 13:30 - 14:30 Hall 14
Corneo, G. Di Pietro, R. Pinzani, M. Bolis, L. Alagna,
M. Caruso, F. Giorgetti, N. Hejazifar, E. Furchì, M. 1-hour Case Session
Carnevale Schianca, P. Bono, C. Tagliabue, F.B.A.
Blasi, A. Callegaro, A. Bandera, S. Bosis, C. Alteri Mycobacterial mayhem

E0682 Viral viability markers of SARS-CoV-2: A Chairs Seif Al-Abri (Muscat, Oman)
Comparison of cell culture genomic RNA RT-PCR Linda Aulin (Leiden, Netherlands)
and subgenomic RNA RT-PCRC. Cuesta Chasco*
(Barcelona, Spain), S. Alex, M. Mª Ángeles, C.C.
Genoveva, A. Francesco, R. Cristina, V. Anna, H. O0663
Juan Carlos, F.A. Francesc, R.L. Luis Gerardo, N. Limitations of the Xpert® MTB/RIF assay: A series of
Mireia, G. Ignacio, B. Marta, G.V. Carolina four clinical casesA. Haas* (Salt Lake City, United
States), A. Ma, J. Pham, P. Verma, U. Malhotra, E.C.
E0683 Diagnostic performance of Hepatitis B virus surface Church, M. Narita, V. Escuyer, S. Shakir
antigens in the Netherlands using type-specific
external quality assessmentE. Vanhulle* (Bilthoven, O0664 Pharmacokinetic analysis of blood and cerebrospinal
Netherlands), M. Simões, H. Ten Bruin, G. Boland, A. fluid contezolid concentrations in a patient with
Brandenburg, K. Benschop tuberculous meningoencephalitisW. Nie* (Beijing,
China), N. Chu
E0684 Low utility of parallel testing by multiplex and
individual real-time PCR assays for the diagnosis of O0665 Is this the first case of Mycobacterium
viral meningitis and encephalitis at a large public stephanolepidis infection in humans?S. Pérez-Recio*
hospital in the United States.A. Cuber* (Los (Barcelona, Spain), M.D. Grijota-Camino, A. Lérida, A.
Angeles, United States), S. Butler-Wu Bauer, L. Fernández-Delgado, M.J. Luque, N. Sabé
Fernández, F. Alcaide, M. Santin
E0685 Plasma Separation Card as an alternative sampling
method for quantitative HCV RNA testing with high O0666 Diagnostic Aspects of a Bacillus Calmette-Guërin
comparability to EDTA plasmaF. Garcia* (Granada, Infection Following Intravesical Treatment for Bladder
Spain), A. Fuentes López, A. Rando Segura, R. CancerK.J. Kim* (Seoul, Korea, Republic of), J.H. Cha,
Carracedo, A. Kessler, A. De Salazar González, S.Z. S.G. Yoon, M.H. Nam, G.I. Lee, Y. Cho
Gebreab, E. Molina, N. Parajó, S. Pereira, J. Romero O0667 Mycobacterium abscessus: Is Shorter Antibiotic
Vico, E. Ruiz Escolano, M. Vila, L. Viñuela González, Therapy Combined with Surgery Sufficient?M.J.
A. Carrasco Durán, A. Aguilera, F. García, M. Buti Lopes* (Amadora, Portugal), C. Paulo, D. Trigo, M.
Ferret Caixeiro, M. Alves, R. Macedo, P. Pacheco

SY133
KN130
13:30 - 14:30 Hall 1
13:30 - 14:30 Hall 15

Keynote Lecture 1-hour Symposium

Infectious disease challenges in an ever-changing environment
Probiotics in infectious diseases: current state-of-play
Chairs Jacob Moran-Gilad (Beer Sheva, Israel)
Annelies Zinkernagel (Zurich, Switzerland) Chairs Nicolas Benech (Lyon, France)
Silvia Corcione (Turin, Italy)

K0360 13:30 Pamela Rendi Wagner (Stockholm, Sweden)

S0365 13:30 Probiotics in infectious diseases: the perfect
complement to antimicrobial therapies?Lena Biehl
(Cologne, Germany)
PM3
13:30 - 14:30 Hall 12
S0366 14:00 The horizon of next generation probiotics for
Meet-the-Innovators infectious diseasesCormac Gahan (Cork, Ireland)
Future prospects of electronic clinical decision support systems in Co-organised with: ESCMID Study Group for Host and Microbiota Interaction
stewardship programs (ESGHAMI)

OS091
L007 13:30 Opportunities for clinical decision support systems in
13:30 - 14:30 Hall 5

infectious disease managementNathan Peiffer- 1-hour Oral Session

Smadja (Paris, France)
Genomic and molecular drivers of bacterial virulence and resistance
L008 14:00 CDSS and AMS programs: the Lumed
exampleValiquette Louis (Sherbrooke, Canada) Chairs Ecaterina Noroc (Chisinau, Moldova, Republic of)
Guido Werner (Wernigerode, Germany)

SY132
13:30 - 14:30 Hall 13
O0658 Characterization of the virulence shaping and
1-hour Symposium
adaptability in the methicillin-resistant
Staphylococcus aureus ST9 lineage.Y. Chen*
Predicting antibiotic susceptibility profiles from whole genome sequences:
(Hangzhou, China), L. Sun
state-of-the-art
O0659 Elucidating molecular mechanisms of bacterial
Chairs Werner Ruppitsch (Vienna, Austria)
conjugation: towards an improved understanding of
Balaji Veeraraghavan (Vellore, India)
plasmid evolution and epidemiologyS. David*
(Oxford, United Kingdom), C. Seddon, J. Wong, N.
Ishimoto, S. He, J. Bradshaw, W.W. Low, D.
S0363 13:30 Impact of the WHO’s developed catalogue of Aanensen, G. Frankel, K. Beis
mutations on rapid TB diagnosis and O0660 Clinical carbapenem-resistant Klebsiella pneumoniae
treatmentThomas Schön (Kalmar, Sweden) (CRKP) strains carrying a mutH mutation are
S0364 14:00 Antimicrobial resistance prediction using whole hypermutators that have heightened virulence and
genome sequencingPatricia Simner (Rochester, readily develop β-lactam/β-lactamase resistanceS.
United States) Cheng* (Pittsburgh, United States), C. Clancy, M.H.
Nguyen, B. Hao, G. Liu
Co-organised with: ESCMID Study Group for Antimicrobial Resistance
Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers O0661 Genomic insights into the new prophages of MDR
(ESGEM), EUCAST Steering Committee Pseudomonas aeruginosa: an example of phage-
host-phage interactionA. Uskudar Guclu* (Ankara,
ESCMID Global 2025 - Programme
Türkiye), S. Unlu (Greifswald, Germany), L. Guardabassi, K. Schaufler,
O0662 Genome-wide association study (GWAS) reveals J.U. Müller, B. Jana, M. Schwabe, Y. Ma, M. Pirolo
importance of vaginal epithelium associated genes in E0717 Resistance profiles of Carbapenemase-producing
case of recurrent vaginitisR. Mändar* (Tartu, Enterobacterales in a large centre in England: are we
Estonia), E. Mutli, K. Koort, A. Salumets, T. Laisk already losing cefiderocol?I. Baltas* (London, United
Kingdom), T. Patel, A.L. Soares
E0718 Impact of cefiderocol therapy on patient survival
EF099
14:45 - 15:45 Arena 1 across different multi-drug resistant Gram-negative
bacilli infections: insights from the SUSANA cohort.N.
ePoster Flash Session Corti* (Monza, Italy), M. Faltoni, L. Mezzadri, E. Ricci,
M. Fois, A. De Vito, A. Bandera, P. Maggi, D. Bavaro,
Infection Prevention in Action: Innovations, Insights, and Global Intervention S. Rusconi, A. Mastroianni, M.A. Carleo, G.
Chair Allison Mcgeer (Toronto, Canada) Cenderello, L. Bisi, G. Madeddu, P. Bonfanti
E0719 Decoding resistance: investigating cefiderocol's
battle against carbapenem-resistant Acinetobacter
E0706 A Candida auris cgMLST Scheme for Enhanced
baumanniiY.T. Lee* (Taipei, Taiwan, China)
Outbreak Surveillance and Global Epidemiological E0720 Long-read sequencing reveals novel genetic factors
TrackingC. Harless* (Silver Spring, United States), J. in cefiderocol resistance in Pseudomonas aeruginosa
Stam, B. Corey, E. Horishny, A. Ong, Y. Kwak, J. ATCC 27853: A stepwise adaptive evolution studyM.
Bennett, P. Mcgann, F. Lebreton Cardoso* (Groningen, Netherlands), B.B. Xavier, B.
E0707 Machine Learning-Augmented Clinical Scoring
Sinha, J. W. A. Rossen, A. Kumar Bari, T. T. Severs
System for Predicting KPC Infections in Healthcare E0721 Activity of cefiderocol against carbapenem-resistant
Crisis ScenariosA. Rearte* (Buenos Aires, Argentina), and molecularly characterized Enterobacterales
F. Herrera, E. Temporiti, J. Smayevski, P. Bonvehi clinical isolates causing infection in hospitals in
Europe and adjacent regionsR. Mendes* (North
E0708 Incident infections with respiratory syncytial virus in a
hospital-based healthcare worker cohort, 2023-2024
Liberty, United States), A. Scullin, D. Beekman, Z.
winter seasonC. Savulescu* (Paris, France), M. Rojas,
Kockler, J.M. Maher, H.S. Sader, M. Castanheira
K. Brolin, A. Uusküla, C. Bergin, C. Fleming, V. E0722 Cefiderocol activity against planktonic and biofilm
Zvirbulis, D. Zavadska, V. Gaio, C.P. Popescu, R.M. forms of β-lactamase-producing Pseudomonas
Hrisca, M. Cisneros, M. Latorre-Millán, J. Mcgrath, L. aeruginosa from people with cystic fibrosisG.
Lohur, L. Ferguson, I. Abolina, D. Gravele, A. Fabrizio* (Rome, Italy), M. Truglio, I. Cavallo, F. Sivori,
Machado, S.A. Florescu, S.M. Pohrib, P. Subirats, L. M. Francalancia, R. Riveros Cabral J, S. Petrolo, L.
Clusa Cuesta, J. Sui, C. Kenny, D. Krievins, E.A. Pamparau, M. Comar, D. Compagnino, M.
Barzdina, C. Valadas Henriques, A.G. Kosa, M. Lazar, Trancassini, G. Antonelli, F. Ascenzioni, G. Cimino, F.
C. Muñoz-Almagro, A.M. Milagro, S. Bacci, A. Pimpinelli, E.G. Di Domenico
Nardone E0723 Activity of cefiderocol against clinical isolates of
E0709 Evaluation of the efficiency of reusable terminal filters Pseudomonas aeruginosa collected from five
for showers for nosocomial legionellosis prevention European countries as part of SENTRY antimicrobial
in a French university hospitalN. Khanafer* (Lyon, surveillance program 2020-2023C. Longshaw*
France), A. Regard, L. Beraud, R. Sintes-Tissot, Q. (London, United Kingdom), J. Maher, R. Mendes, H.
Barriot, J.C. Saurin, M. Chuzeville, P. Vanhems, M. Yamashiro, Y. Yamano
Chaboud
E0711 Emerging uncommon non-fermenters and their
EF101
decreasing antibiotic susceptibility in patients with 14:45 - 15:45 Arena 3
prolonged hospital stayV. Khillan* (New Delhi, India),
V.G. Nag P, P. Kale, A. Paul, A. Saran ePoster Flash Session
E0712 Air and surface sampling around mpox Clade 1b in Immunology of bacterial pathogens
hospitals in the UKS. Gould* (Liverpool, United
Kingdom), B. Atkinson, B. Hack, T. Williams, J. Otter,
Y. Ceesay, A. Alsonso, G. Nebbia, S. Blundell, W.
Newsholme, G. O'hara, M.G. Semple, T. Fletcher, J. E0724 Serotype 38 Streptococcus pneumoniae emerges as
Dunning one of the dominant serotypes causing invasive
E0713 Utilization of a healthcare facilities rapid assessment pneumococcal disease in Germany and Poland, but
tool to define infection prevention and control and not in the NetherlandsK. Hajji* (Bilthoven,
Water, Sanitation and Hygiene baseline criterion met Netherlands), I. Wróbel-Pawelczyk, J. Van
during Democratic Republic of Congo mpox outbreak Veldhuizen, K. Maruhn, W. Miellet, M. Rob, A. Steens,
from August to November 2024A. Baller* (Geneva, N. Van Sorge, K. Trzciński, M. Van Der Linden, A.
Switzerland), N.R. Okum, G. Nsambi, K. Kabamba, Skoczyńska, L. Visser
Y.L. Soro, L. Kabego, V. Willet, N. Usman, H. Hamilton E0725 Cross reactivity within pneumococcal serogroups 6
Hurwitz, M. Moon and 15 following adult vaccination with
E0714 The REACT study: Exploring the BSI Potential of KPC, pneumococcal conjugate vaccine V116: a secondary
NDM, VRE, and CRAB rectal colonizationM. Colaneri* analysis of five phase 3 studiesM. Esteves Jaramillo*
(Milano, Italy), P. Giordani, S. Lerta, A. Sangani, V.A. (Rahway, United States), J. Li, H. Platt, W. Hu, W. Xu,
Villano, A. Gori, M. Rettani, S. Milanesi, G. De Nicolao, T. Chapman, K. Nolan, J. Hartzel, U. Buchwald
R. Bruno E0726 Baseline serotype-specific IgG responses to
pneumococcal vaccines in type 2 diabetes:
implications for vaccine strategy in vulnerable
EF100
14:45 - 15:45 Arena 2 populationsS. Mettingal Ramakrishnan* (Bsk 2nd
Stage,Bangalore, India), V. Govindan, M.M. Akhila, N.
ePoster Flash Session Geetha, K.L. Ravikumar
Cefiderocol: an efficient Trojan horse? E0727 Protection against invasive meningococcal disease
and gonorrhoea, 5 years post introduction of a
Chair Anna Sramkova (Pilsen, Czech Republic) 4CMenB immunisation program in infants and
adolescents in South AustraliaH. Marshall* (Adelaide,
Australia), B. Wang, L. Giles, P. Andraweera, M.
E0715 Acceleration of Emergence of Cefiderocol Resistance
Mcmillan, S. Almond, R. Beazley, J. Mitchell, J.
in Microfluidic Evolution SystemB. Li* (Beijing, China),
Sisnowski, C. Bell, L. Flood, J. Ward
S. Shen, Q. Wang, S. Wang, W. Wang, H. Wang E0728 Molecular epidemiology and correlates of protection
among group B Streptococcus from carriage and
E0716 The hidden link between cefiderocol resistance and
disease: assessing vaccine coverage in BrazilT.
increased virulence in Klebsiella pneumoniae:
Insights from a TraDIS-based investigationE. Eger*
Pinto* (Rio De Janeiro, Brazil), L. Oliveira, N. Costa, E.
Bressan, A. Rio Tinto, S. Fracalanzza, L. Teixeira
ESCMID Global 2025 - Programme
E0729 Impact of BCG vaccination on adaptive immune O0698 Shiga toxin-producing Escherichia coli O26 as an
responses to mycobacterial and non-mycobacterial increasingly common cause of haemolytic uraemic
antigens in HIV-exposed, uninfected infants.R. syndrome in England: A fifteen-year analysis of
Namakula* (Bergen, Norway), V. Nankabirwa, S. national enhanced surveillance dataL. Mcgeoch*
Cose, O. Namugga, M.G. Netea, H. Steinsland, H. (London, United Kingdom), O. Quinn, C. Sawyer, A.
Sommerfelt, K. Hanevik Douglas, C. Jenkins, S. Balasegaram
E0730 Immune signature against Klebsiella pneumoniae O0699 Incidence, clinical presentation, and outcomes of
proteins in a mother-baby cohort from Blantyre, Pasteurella infections: a population-based Danish
MalawiE. Heinz* (Glasgow, United Kingdom), J. studyL. Øbo Larsen* (8200, Denmark), L.Ø. Larsen,
Campo, O. Pearse, A. Zuza, A. Teng, J. Pablo, A. H.L. Nielsen, K.K. Søgaard
Oberai, J. Edgar, A. Shandling, K. Kawaza, N. Feasey O0700 Natural history of latent brucellosis and efficacy
E0731 A comprehensive computational mapping of B-cell evaluation of B-spot in active and latent cases: A 12-
epitopes in the Klebsiella pneumoniae porinomeS. month prospective cohort studyH. Wang* (Shanghai,
Prieto Martin Gil* (Madrid, Spain), S. Prieto Martín China), G. Yuan, D. Li, H. Liu, J. Ai, W. Zhang
Gil, E. Gato, A. Pérez, M.J. Mcconnell, A.J. Martín
Galiano
OS098
E0732 Chronic infection induces a broadly neutralizing 14:45 - 15:45 Hall 15
antibody response to Elastase B of Pseudomonas
aeruginosaA. Albus* (Cologne, Germany), D. Kolling, 1-hour Case Session
K. Rox, D. Holzmann, K. Mundry, M. Sánchez Agut, C.
Meyer, R. Brock, J. Kutschera, K. Schmitt, J.A. Wilms, Opportunistic infections in the Immunocompromised
L. Ullrich, C. Kreer, M. Meyer-Willerscheidt, M. Hallek, Chairs Aleksandra Barac (Belgrade, Serbia)
E. Rietschel, S. Van Koningsbruggen-Rietschel, F. Olivier Lortholary (Paris, France)
Klein, J. Koehnke, J. Rybniker, A. Simonis

KN137 O0701 Dog scratch disease? A case of Vibrio vulnificus in a

14:45 - 15:45 Hall 1
liver transplant patientE. Kim* (Galveston, United
Keynote Lecture States), A. Covington
O0702 Mpox infection among solid organ transplant
Staphylococcus aureus host-microbe interaction: ecology, disease, and recipients: a single center experience at a U.S.
vaccine development Tertiary Care Facility.J. Bini Viotti* (Miami, United
Chairs Werner Ruppitsch (Vienna, Austria) States), J. Bini
Annelies Zinkernagel (Zurich, Switzerland) O0703 Histoplasmosis in Hansen's Disease: Thalidomide for
TNF-alpha Inhibition in ENL with a Risk of
Opportunistic InfectionsK.K. Vaitheeswaran* (Delhi,
India), M. Soneja, N. Bhari, R. M., G. K. V., S. Agarwal,
K0376 14:45 Juliane Bubeck Wardenburg (St. Louis, United States) R. Kumar, Y. Dharmashaktu
O0704 Nocardiosis in a kidney transplant recipient: pros &
ME140 cons of tedizolidM. Pellegrino* (Modena, Italy), V.
14:45 - 15:45 Hall 11
Todisco, S. Generoso, L. Benassi, E. Franceschini, F.
Meet-the-Expert Damiano, G. Donati, C. Mussini, A. Cervo
O0705 Mycobacterium genavense-Associated IRIS with
Bioinformatic tools from start to finish Macrophage Activation Syndrome: A Case Report
Highlighting Diagnostic ChallengesM. Meroi*
(Verona, Italy), M. Morra, M.E. De Rui, E. Tacconelli, F.
Soldani
M0381 14:45 Vítor Borges (Lisbon, Portugal)
M0382 14:57 Clare Sloggett (Melbourne, Australia)
SY139
14:45 - 15:45 Hall 16

1-hour Symposium
ME141
14:45 - 15:45 Hall 13
How to manage bacterial meningitis in low resource settings
Meet-the-Expert
Chairs Joseph Donovan (Ho Chi Minh City, Vietnam)
AI use in antimicrobial stewardship Christina Obiero (Kilifi, Kenya)

S0379 14:45 Bacterial meningitis diagnosis and surveillanceDivya

M0383 14:45 Shruti Gohil (Irvine, United States)
Deodhar (Muscat, Oman)
M0384 14:57 Jose Ramon Pano-Pardo (Zaragoza, Spain)
S0380 15:05 Clinical presentation and management of CNS
infectionsKartika Maharani (Jakarta, Indonesia)
OS097 Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain
14:45 - 15:45 Hall 14
(ESGIB), ESCMID Study Group for Forensic and Postmortem Microbiology
1-hour Oral Session (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF)

Update on zoonotic and enteric infections

OS095
Chairs Steen Ethelberg 14:45 - 15:45 Hall 2
Kavitha Saravu (Manipal, India)
1-hour Oral Session

Community respiratory tract infections: latest trends and approaches

O0696 A large-scale epidemiological study of Chairs Catia Cilloniz (Barcelona, Spain)
Campylobacter employing whole genome analysis Aurélien Dinh (Garches, France)
reveals the evolution of highly virulent and multidrug-
resistant clones in the UK.B. Lopes* (Middlesbrough,
United Kingdom), A.S. Boaitey-Biko
O0697 Population dynamics and evolution of multidrug
O0686 Mycoplasma pneumoniae increase in 2023/24
causes disease in adults in EuropeB.M.M. Streng*
resistant clones of Shigella sonnei in Metropolitan
FranceC. Silva Nodari* (Paris, France), I. Carle, M.
(Utrecht, Netherlands), C. Prat Aymerich, L. Bont, P.
Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M. Meyer Sauteur, M. Bonten, A. Van Rossum
Pardos De La Gandara, F.X. Weill O0687 Serotype distribution of pneumococcal community-
ESCMID Global 2025 - Programme
acquired pneumonia in hospitalized adults in Herrera-Yela
GermanyD. Karssen* (Utrecht, Netherlands), L.
Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T.
Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. SY144
Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U. 16:15 - 17:15 Hall 14

Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. 1-hour Symposium

Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten,
C. Prat-Aymerich What's the role of infant and maternal immunisation for paediatric RSV
O0688 Community-acquired pneumonia identification from prevention?
electronic health records in the absence of a gold Chairs Joanne M. Langley (Halifax, Canada)
standard: a Bayesian latent class analysisJ. Wei* Peter Openshaw (London, United Kingdom)
(Oxford, United Kingdom), K. Yuan, A. Luk, S. Walker,
D. Eyre
O0689 Causes of death and risk factors for 90-day mortality
S0391 16:15 Pros and cons of passive infant immunisation with
and readmission in community-acquired
mAb before their first RSV seasonFederico Martinón-
pneumonia.F. Al-Zergani* (Hvidovre, Denmark), C.
Torres (Santiago De Compostela, Spain)
Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard,
L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. S0392 16:45 Pros and cons of maternal vaccination in preventing
Benfield severe RSV infections in infants.Anne Vergison
(Luxembourg, Luxembourg)
O0690 Oropharyngeal carriage of gut-derived
Enterobacterales increases RTI risk in long-term aged
care residentsS. Miller* (Adelaide, Australia), F.
EF104
Zhang, S. Taylor, A. Shoubridge, E. Vasil, R. 16:15 - 17:15 Arena 1
Woodman, L. Papanicolas, G. Rogers
ePoster Flash Session

Cutting-edge technologies to improve viral diagnostics

SY138
14:45 - 15:45 Hall 4
Chair Patricia Alvarez (Rio De Janeiro, Brazil)
1-hour Symposium

Global clones and evolving resistance mechanisms towards newer beta-

lactams: Where are we heading? E0743 How straightforward is the switch from qPCR to
dPCR in a routine lab setting for quantification of
Chairs Yesim Besli (Istanbul, Türkiye) Varicella-zoster virus in CSF samplesA.
Spyros Pournaras (Athens, Greece) Baumhögger* (Bochum, Germany), T. Bähr, G. Geis,
S. Gatermann
E0744 A novel biosensor for the detection of RSV infectionC.
S0377 14:45 Carbapenemase-producing Enterobacterales: the not Zannella* (Naples, Italy), F. Passeggio, F. Napolitano,
so good, the bad and the ugly.Arjana Tambic A. De Filippis, F. Arcadio, C. Marzano, I. Tavoletta, L.
Andrasevic (Zagreb, Croatia) Zeni, M. Galdiero, G. Portella, N. Cennamo
S0378 15:15 The P. aeruginosa frightening cocktail: high-risk E0745 Insufficient sexual health bloods don't always need
clones, horizontally-acquired resistance and evolving throwing away!S. Hutchings* (Bristol, United
mutational resistomeKaty Jeannot (Besançon, Kingdom), R. Hopes, P. North, W. Stoate, M. Murphy,
France) G. Beckley, J. Gabb
Co-organised with: ESCMID Study Group for Antimicrobial Resistance E0746 A comparison of 4 HAV serology assays: the value of
Surveillance (ESGARS) consensus results as a reference standardT. Chin*
(Ghent, Belgium), E. Padalko
E0747 Advancing herpesvirus diagnostics: clinical
OS096
14:45 - 15:45 Hall 5 evaluation of a high-performance real-time PCR
assayH. Alonso-Ezcurra* (Zaragoza, Spain), S. Lucea,
1-hour Oral Session C. Escolar, H. Alonso
E0748 Evaluation of microbiological techniques for the
Trends in antifungal resistance
diagnosis of West Nile Virus in the Virgen del Rocío
Chairs Alexandre Alanio (Paris, France) hospital area (Sevilla, Spain).M. Aznar Fernandez*
Ana Alastruey-Izquierdo (Madrid, Spain) (Seville, Spain), M. Aznar, C. Lozano, L. Merino, M.J.
Pérez, J.L. Garcia, C. Cintora, J.A. Lepe
E0749 Development of Non-Cross-Reactive Monoclonal
O0691 Turning resistance into vulnerability: leveraging Antibodies Against West Nile Virus and Usutu Virus
genetic insights to predict collateral sensitivity and Non-Structural Protein 1 to Improve Early
synergism for effective multidrug therapiesK. DiagnosisM. Ceconi* (Antwerp, Belgium), K. Ariën, P.
Schmidlin* (Tempe, United States), K. Geiler- Delputte
Samerotte E0750 Enhancing Diagnostics and Global Standards through
O0692 Role of the C2585G substitution in the MRR1 gene in the QCMD Viral Metagenomics EQAG. Sutton*
the development of azole resistance in Candida (Glasgow, United Kingdom), D. Montgomery, E.
parapsilosis sensu strictu.I. Franconi* (Pisa, Italy), P. Mcculloch, A. Ricketts
Noemi, A. Tavanti, A. Lupetti, R. Cosmeri, L. Maltinti, E0751 Analysis of HIV-1 drug-resistence in newly diagnosed
M. Falcone subjects using Next Generation SequencingV.
O0693 Fungaemia in a tertiary Madrid hospital from 2007 to Micheli* (Milan, Italy), F. Bracchitta, L. Morelli, A.
2024: changes in species epidemiology, increase in Cavallo, S. Giubileo, A. Tamoni, A. Lombardi, A. Dolci
echinocandin resistance and low patient-to-patient
transmission in recent yearsJ. Guinea* (Madrid,
EF105
Spain), P. Escribano, G. Jesús, M. Machado, A. 16:15 - 17:15 Arena 2
Burillo, P. Muñoz
ePoster Flash Session
O0694 A multicentre study for determination of
epidemiological cutoff values for rezafungin and four New data in non-tuberculous mycobacterial disease
comparators against Candida auris with EUCAST
broth microdilution reference methodologyJ. Chair Lorenzo Guglielmetti (Paris, France)
Meletiadis* (Haidari, Greece), J. Guinea, S. Arikan-
Akdagli, E.F.J. Meijer, J. Meis, M.C. Arendrup
O0695 Decoding Candida auris Resistance in Latin America: E0752 Deciphering genotypic resistance to amikacin in
Candida.app vs. PathogenwatchJ. Acosta España* Mycobacterium abscessus using whole genome
(Quiro, Ecuador), P. Eduarda, J.D. Acosta-España, A. sequencing and a specific pipeline (GenoMAB)C.
ESCMID Global 2025 - Programme
Allam* (Paris, France), S. Agsous, P. Baylac, K. La, E0765 The inappropriate use of antibiotics for blood culture
N. Godron, F. Mougari, Z. Awad, E. Cambau contamination and colonisation by multidrug-
E0753 Pseudomonas aeruginosa rapidly kills resistante microorganisms: the role of counselling on
Mycobacterium abscessus in dual-species biofilms antibiotic prescriptionR.R. Peña-Zalbidea* (Palma
in vitroM. Mcdaniel* (Nijmegen, Netherlands), J. (balearic Islands), Spain), L. Martin, H. Vilchez, L.
Scoffield, J. Van Ingen Periañez, E. Rojo, M. Peñaranda, M. Garcia, M. Riera,
X. Mulet, A. Oliver, J. Murillas
E0754 Distribution of contezolid in different tissues of mice
and human patients infected with Mycobacterium E0766 Factors influencing meropenem prescription
abscessusW. Nie* (Beijing, China), N. Chu following the 2020 EUCAST « I » definition update : a
multicentric observational study in Belgian
E0755 Exploration of clofazimine and bedaquiline activity hospitalsL. Catteau* (Brussels, Belgium), L. Bonacini
against clinical strains of Mycobacterium abscessus
to advance innovative therapeutic strategiesC. E0767 Impact of an Antimicrobial Stewardship Mobile
Maria* (Madrid, Spain), M. Cano-Fernández, J. Application on Antimicrobial Prescribing, Length of
Esteban, P. López-Roa, A. Ruedas-López, J.J. Hospital Stay, and Cost SavingsZ.O.E. Babiker* (Abu
Aguilera-Correa, M.C. Muñoz-Egea Dhabi, United Arab Emirates), L. Bukasa, A. Sadeq, J.
Shamseddine, R. Ali
E0756 Leveraging stem cell technology to identify new
treatment options for nontuberculous E0768 Evaluation of a model-based clinical decision support
mycobacteriaS. Sarkar* (Parkville, Australia), K. system for empirical antimicrobial therapyM.L.
Strumila, S. Yu, R. Werder, T. Johanssen, A. Hidalgo Mogensen* (Aalborg, Denmark), S.N. Søgaard, L.
Gonzalez, E. Stanley, S. Ranganathan Ward, H. Skjøt-Arkil
E0757 Recovery of Non-Tuberculous Mycobacteria and E0769 A rapid systematic review of criteria to facilitate
Detection of Dominant Circulating Clones in Indoor prompt intravenous-to-oral antimicrobial switch in
Water Samples from GermanyN. Wetzstein* children and young people in England.R. Oettle*
(Frankfurt, Germany), M. Diricks, D. Frank, I. (London, United Kingdom), S. Patel, A. Demirjian, M.
Friesen, S. Niemann, T. Wichelhaus Mcleod, C. Jamieson, G. Damant, K. Hand, D. Ashiru-
Oredope
E0758 Deciphering the Epidemiology of Mycobacterium
chimaera: Genetic Lineages, Environmental
Sources, and Infection Prevention InsightsG. EA
Lorenzin* (Trento, Italy), M. Sandei, P. Fassan, A. 16:15 - 17:30 Hall 1
Casadei, C. Scarparo Awards
E0759 Evaluation of a novel media for susceptibility testing
of Mycobacterium avium-intracellulare complex Excellence Award Lectures
isolatesT. Grams* (Salt Lake City, United States), S. Chairs Jon S. Friedland (London, United Kingdom)
Shakir Robert Leo Skov (Copenhagen, Denmark)
E0760 Emerging cases of Mycobacterium chelonae
endocarditis associated with BioIntegral
bioprosthesesJ. Kikhney* (Berlin, Germany), F.
Pfäfflin, L. Kursawe, K. Sarbandi, I. Friesen, M. A006 16:15 Towards pandemic prevention, moonshot or utopia?
Stegemann, R. Schwarzer, D. Von Schöning, V. Falk, Marion Koopmans (Rotterdam, Netherlands)
A. Moter A007 16:50 Can global warming bring new infectious
diseases?Arturo Casadevall (Baltimore, United
States)
EF106
16:15 - 17:15 Arena 3

ePoster Flash Session SY143

16:15 - 17:15 Hall 11

The ABC (allergy, bloodstream infections and clinical decision support) in 1-hour Symposium
AMS
Chair Céline Pulcini (Nancy, France) ESCMID guidelines for the vaccination of immunocompromised individuals:
solid organ transplant recipients
Chairs Elisa Cordero Matia (Seville, Spain)
Zitta Barrella Harboe (Hillerød, Denmark)
E0761 Evaluation of the allergy fact checker, a clinical
decision support system to promote non-invasive
delabeling of incorrect penicillin allergy labels: a
mixed-methods studyD. Wets* (Leuven, Belgium), R. S0389 16:15 Vaccination against respiratory pathogensAlbert
Schrijvers, I. Spriet, G. Van De Sijpe, L. Gilissen, C. Vollaard (Bilthoven, Netherlands)
Breynaert, T. Ieven, P. De Munter S0390 16:45 Other vaccinesOlivier Epaulard (Grenoble, France)
E0762 Penicillin allergy assessment pathway versus usual
Co-organised with: ESCMID Study Group for Infections in Compromised
clinical care for primary care patients with a penicillin
Hosts (ESGICH), ESCMID Vaccine Study Group (EVASG)
allergy record to assess safety, de-labelling and
antibiotic prescribing: The ALABAMA randomised
controlled trial.J. Sandoe* (Leeds, United Kingdom),
EW146
S. Ahmed, K. Armitage, C. Bates, R. Bestwick, B. 16:15 - 18:15 Hall 13
Jenny, C. Butler, J. Cook, F. Joanne, U. Galal, P.
Educational Session
Howard, D. Howdon, S. Mort, R. Mujica-Mota, A.
Negut, C. Porter, N. Powell, M. Santillo, R. Sargur, S. How to detect, manage and communicate hospital outbreaks
Savic, S. Tonkin-Crine, M. Wanat, R. West, M. Yang, Chairs Margaret Ip (Shatin, Hong-Kong SAR, China)
L.M. Yu, S. Pavitt Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)
E0763 Stewardship interventions reduced blood culture
utilization by 40% during BD BACTEC™ Blood
Culture media shortageX. Li* (Toronto, Canada), K.
Katz, A. Ceentavida, R. Kozak, C. Vermeiren, P. W0395 16:15 How to detect hospital outbreaksDavid Fisman
Sheldrake, S. John, A. Belhaj, S. Hsieh, S. Patel, R. (Toronto, Canada)
Lovinsky W0396 16:35 How to confirm hospital outbreaks using
E0764 Prescriptive Impact of Rapid Microbiological genomicsJohn W. A. Rossen (Groningen,
Diagnostics in Bloodstream Infections Caused by Netherlands)
Escherichia coli, Klebsiella pneumoniae, and W0397 16:55 How to rapidly respond to an ongoing hospital
Staphylococcus aureus (PRIMEKA): A Retrospective outbreakErmira Tartari (Msida, Malta)
Single-Center Cohort Study.F. Salvati* (Rome, Italy), W0398 17:15 How to communicate hospital outbreaks via scientific
F. Giovannenze, G.M. Leanza, M. Chiuchiarelli, A. publicationInes Steffens (Solna, Sweden)
Frater, M.L. Colombo, F. Iannarelli, B. Fiori, T. D'inzeo,
R. Murri, C. Torti
ESCMID Global 2025 - Programme

ME145 L0026 Genome-wide association study identifies ABCG1 as

16:15 - 17:15 Hall 15
a susceptibility locus for tick-borne encephalitisP.
Meet-the-Expert Gampawar* (Graz, Austria), M. Sagmeister, D. Ruzek,
N. Schweintzger, E. Hofer, B. Kohlmaier, V. Švendová,
Fungal meningitis: recognition and current status of management P. Bogovicˇ, J. Zajkowska, L. Krbková, V. Štruncová,
A. Mickiene, D. Kohlfürst, A. Sonnleitner, A. Fořtová,
M. Berankova, M. Pychova, D. Zavadska, N. Sallah, A.
Pichler, D. Sedlácek, A. Chrdle, C. Haudum, B.
M0393 16:15 Olivier Lortholary (Paris, France) Obermayer-Pietsch, P. Hoffmann, M. Nöthen, M.L.
Tammesoo, A. Metspalu, P. Husa, K. Stiasny, A.
M0394 16:27 Janis Blair (Phoenix, United States)
Binder, A. Berghold, F. Strle, M. Hibberd, W. Zenz
L0027 First detection of tick-borne encephalitis virus in
JS2 Belgian ticks, May 2024E. Portell-Buj* (Stockholm,
16:15 - 17:15 Hall 16
Sweden), C. Philippe, S. Terryn, S. Van Gucht, F.
Journal Session Dufrasne
L0028 Spread of a fusidic acid and methicillin-resistant
Late-breaker research from the Lancet group: new interventions for familiar Staphylococcus aureus clone causing impetigo in
and new infectious diseases EuropeA.R. Larsen* (Copenhagen, Denmark), A.
Chairs Syeda Saleha Hassan (London, United Kingdom) Petersen, L. Roer, K. Vendrik, R. Zwittink, D.
Ursula Hofer (London, United Kingdom) Notermans, N. Yin, M. Perrin, K. Khonyongwa, A.
Tristan, B. Youenou, F. Layer-Nicolaou, G. Werner, H.
Enger, E.C.H. Eikrem, J. Darenberg, B. Mäkitalo, M.
Paulsson, H. Fang, E. Tång Hallbäck, L. Lindholm, K.
J011 16:15 Phase 3 randomised trial of oral gepotidacin for the Moganeradj, B.J. Holzknecht, H.B. Eriksen, M. Hoppe,
treatment of uncomplicated gonorrhoea (EAGLE- M.D. Bartels, J.A. Samaniego Castruita
1)Janet Wilson (London, United Kingdom) L0029 Increase of PVL-positive livestock-associated MRSA
J012 16:30 The spatio-temporal ecology of Oropouche virus: a in the Netherlands: a growing concern beyond
laboratory-based modelling study across Latin livestock settingsK. Vendrik* (Bilthoven,
AmericaJan Felix Drexler (Berlin, Germany) Netherlands), S. Witteveen, D.W. Notermans, S.C. De
J013 16:45 The WHO Bacterial Priority Pathogens List: guiding Greeff, C.C. Wielders, E. Van Duijkeren, A.S.
research and development, and informing innovative Schoffelen, A.P. Hendrickx, R.D. Zwittink
public health strategies to address antimicrobial L0030 H5N1 human infection in the United Kingdom: a One-
resistanceHatim Sati (Geneva, Switzerland) Health approachN. Hamzaoui* (London, United
J014 17:00 Efficacy, safety, and immunogenicity of the AS01E- Kingdom), S. Hayward, W. Proto, E. Booth, C.
adjuvanted respiratory syncytial virus prefusion F Kennedy, C. Beck, A. Lackenby, K. Spence, M.
protein vaccine (RSVPreF3 OA) in older adults over Beadsworth, N. Wong, M. Samuel, A. Singanayagam,
three RSV seasons: a randomized trialAlberto Papi K. Hoschler, N. Groves, D. Kumar, O. Olufon, W. Cook,
(Ferrara, Italy) N. Watkins, D. Ready, S. Makki, K. Marston, S. Collins,
C. Arevalo, D. Blackman, L. Guiness, C. Chatt, M.
Co-organised with: The Lancet group Mcgivern, A. Edwards, A. Banyard, R. Jorquera, K.
Saville, S. Van Helvoort, R. Benee, E. Brown, L.
Leighton Mcteague, M. Chand, S. Rokadiya, S.
OS102
16:15 - 17:15 Hall 2 Hopkins, H.I.M. Team, N. National Response Center
Team, R. Puleston
1-hour Oral Session

AI tools empowering AMR prediction in WGS and MALDI-TOF

SY142
Chairs Oliver Nolte (Zürich, Switzerland) 16:15 - 18:15 Hall 4

Patricia Simner (Rochester, United States) 2-hour Symposium

Precision genomics to improve infectious diseases management

O0733 A scalable machine learning approach to predict Chairs Jacob Moran-Gilad (Beer Sheva, Israel)
antimicrobial susceptibility from whole genome Nicole Stoesser (Oxford, United Kingdom)
sequencing dataY. Zhong* (Liverpool, United
Kingdom), A. Gerada, A. Howard, P. Green, W. Hope
O0734 Machine Learning-Based Antimicrobial Resistance S0385 16:15 Human genomics approaches to infection
Prediction of 11 antibiotics for Klebsiella pneumoniae immunityFergus Hamilton (Bristol, United Kingdom)
from Clinical NGS DataQ. Yang* (Beijing, China), X. S0386 16:45 Applying bacterial GWAS to uncover new
Jia, J. Zhang, J. Chen mechanisms of antibiotic resistanceMarco Galardini
O0735 AI-Powered Real-Time Plasmid Prediction Using (Hannover, Germany)
Nanopore SequencingE. Sauerborn* (Munich, S0387 17:15 Evolution in action: large-scale within-host evolution
Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. analyses of persistent bacterial infectionsStefano
Foster-Nyarko, L. Urban Giulieri (Melbourne, Australia)
O0736 MALDI-TOF Prediction model based on machine S0388 17:45 Machine learning in bacterial genomics and
learning algorithm for the detection of ST23 high- metagenomicsFrancesco Asnicar (Trento, Italy)
virulence K. pneumoniaeL. Dortet* (Le Kremlin-
Bicêtre, France), L. Mancera Pascual, M.J. Arroyo
O0737 Predicting rifampicin resistance in Mycobacterium OS103
tuberculosis complex with a machine learning based 16:15 - 17:15 Hall 5

MALDI-TOF MS approcheY.W. Sun* (Taichung, 1-hour Oral Session

Taiwan, China), P. Huang, B. Tsou, S.C. Chang, C.W.
Lu, C.C. Chen, J. Yu Polymicrobial interactions and competition
Chairs Alessandra Bragonzi (Milano, Italy)
Kimberly Kline (Genéve, Switzerland)
LB005
16:15 - 17:15 Hall 3

1-hour Oral Session

O0738 The Klebsiella pneumoniae type VI secretion system
Emerging pathogens in humans, animals and vectors effector Tle4 facilitates adaptation survival by
Chair Anna J Henningsson (Jönköping, Sweden) damaging the cell membrane of competing
bacteriaW. Li* (Shanghai, China), J. Zhang
O0739 Candida albicans promotes TSST-1 production in
ESCMID Global 2025 - Programme
Staphylococcus aureus by depleting glucose and Funk* (Brooklyn, United States), I. Khan, J. Li, J.
lifting carbon catabolite repressionM. Carriou* (Lyon, Cusumano
France), C. Badiou, A. Soulard, K. Chikh, O. Vitalis, A. E0793 Risk factors for in- hospital mortality in 500 cases of
Frugier, K. Dufresne, G. Lina infective endocarditisC. Lamas* (Rio De Janeiro,
O0740 Understanding polymicrobial biofilm dynamics: focus Brazil), G. Pompeo, T. De Almeida, M. De Carvalho,
on Pseudomonas aeruginosa and its molecular N. Feijoó, R. Garrido, G. Barbosa, B. Zappa, C.
interactionsS. Kansal* (Chandigarh, India), U. Dutta, Weksler, M. Correia, W. Golebiovski
A. Angrup, P. Ray
O0741 Intra- and interspecific antagonism inhibits growth of
EF111
Staphyloccous aureus in human nasal microbial 17:30 - 18:30 Arena 2
communitiesL. Brülisauer* (Zurich, Switzerland), M.
Boumasmoud, S. Brugger, A.R. Hall ePoster Flash Session
O0742 Combination therapy against drug resistance Don't blink: STIs are everywhere
biomimetic dual-species biofilm model of
Pseudomonas aeruginosa and Staphylococcus Chair Mathew Beale (Hinxton, United Kingdom)
aureusP. Mojarrad* (Helsinki, Finland), P. Tammela,
T. Laaksonen, Z. Gounani
E0794 Neurosyphillis and Mpox co-infection mimic HIV
encephalitisL. Mejdoubi* (Vienna, Austria), A. Nader,
EF110
17:30 - 18:30 Arena 1 L. Mautner, A. Bahrami, F. Hofer
ePoster Flash Session E0796 An unusal cause of transverse myelitisJ. Koleri*
(Doha, Qatar), M. Samawi, M. Maslamani
Advancing diagnostics and treatment of endocarditis E0798 Ocular Syphilis, an uncommon presentation form of
Chair Benoît Guery (Lausanne, Switzerland) syphilis: two casesR. Kardashi* (Dresden, Germany),
A. Frenz, K. De With
E0799 Case report of a severe skin infection in a young man
on PrEP and DoxyPEPM. Zlámal* (Prague, Czech
E0785 18F-FDG-PET/CT improves source control of extra- Republic), Z. Bartovská, B. Lacmanová, M. Holub
cardiac complications in infective endocarditisJ.M.
Prins* (Amsterdam, Netherlands), S. Douiyeb, W. E0800 Serowaffling in PrEP Users: The Difficulty of HIV
Van Gameren, D. Buis, T. Van Der Vaart, M. Diagnosis – A Case Report.P. Pillado Alonso*
Boekholdt, J. Selder, D. Robbers-Visser, H. (Badalona, Spain), G. Fernández Rivas, A. Rivero
Verberne, H. Van Werkhoven, K. Sigaloff Calaf, Á. Hernández-Rodríguez, R. Peña, J. Prado, J.
Martínez-Picado
E0786 Comparing Duke criteria updates: Advancing IE
diagnosis in patients with prosthetic intracardiac E0801 Severe disseminated mpox in a patient with
materialsM. Papadimitriou Olivgeris* (Sion, advanced HIV: A case reportM.A. Quadros Flores*
Switzerland), M. Papadimitriou-Olivgeris, B. (Lisbon, Portugal), R. Diogo, F. Gonçalves, T.
Ledergerber, N. Fourré, V. Zimmermann, N. Marques, S. Paulo, F. Cota Medeiros, D. Mendes
Ianculescu, P. Monney, M. Frank, G. Tzimas, G. Pedro
Domenichini, P. Tozzi, M. Kirsch, M. Van Hemelrijck, E0802 Sensorimotor polyneuropathy in a patient affected by
O. Dzemali, J. Epprecht, B. Guery, B. Hasse HIV-1: an atypical presentation of neurosyphilis
E0787 In vivo Dalbavancin efficacy against methicillin- associated to anti-SOX-1 antibodiesA. Lippi* (Siena,
resistant Staphylococcus aureus (MRSA) and high- Italy), L. Ancillotti, M. Fabbiani, L. Migliorini, S.
level aminoglycoside resistant (HLAR) Bartalini, F. Ginanneschi, M. Tumbarello, F. Pippi, C.
Enterococcus faecalis (EFAE) experimental Puttini, F. Montagnani
endocarditis model.C. Garcia De La Maria*
(Barcelona, Spain), C. García De La Mària, M.A.
EF112
Cañas, M. Brunet, J. García-González, G. Cuervo, M. 17:30 - 18:30 Arena 3
Espasa, M. Hernandez-Meneses, C. Falces, A.
Perissinotti, B. Vidal, J.M. Tolosana, E. Sandoval, J. ePoster Flash Session
Llopis, A. Moreno, J.M. Miro
Clinical considerations in resistant organisms
E0788 Identification and validation of clinical phenotypes
in Staphylococcus aureus blood stream infection Chair Divya Deodhar (Muscat, Oman)
and their association with mortality (FEN-AUREUS
study)J. Rodríguez-Baño* (Seville, Spain), B.
Gutiérrez-Gutiérrez, B. Gallego, A.J. Kaasch, M.
E0803 Clinical characteristics, therapy and outcome of
Riediger, S. Rieg, M. Trigo, S. Sonsoles, F. Anguita-
bloodstream infections caused by vancomycin-
Santos, Á. Cano, R. Palacios, S. López-Cárdenas,
resistant enterococci: a multicenter clinical
M.T. Pérez-Rodríguez, F.J. Martínez-Marcos, E.
experienceF. Serapide* (Catanzaro, Italy), R.
Merino-Lucas, B. Anaya-Baz, A. Aizcorreta, A. Plata-
Serraino, L. Spadafora, M. Bernardi, G. Brucci, G.
Ciézar, M. Piscaglia, A. Aceituno, E. Ruiz-Gutiérrez,
Cattardico, S. Corcione, I. De Benedetto, M. Del
L. Romero-Calderón, A. Alemán-Rodríguez, E.
Monte, A. Limongelli, D.R. Giacobbe, E. Graziano, M.
Recacha, J. Torre-Cisneros, N. Merchante, Á.
Meschiari, S. Mornese Pinna, M. Peghin, G. Tiseo,
Pascual, L.E. López-Cortés
A. Vena, F. Romeo, G. Sarto, M. Bassetti, G. Biondi-
E0789 Enterococcal Infective Endocarditis: demographics, Zoccai, F.G. De Rosa, M. Falcone, P.A. Grossi, C.
comorbidities, diagnostic evaluation and mortality Mussini, A. Russo
outcomesM. Singh* (London, United Kingdom), C.
E0804 Clinical outcomes of MSSA bacteremia exhibiting
Watkins, H. Bristowe, M. Gunning, J. Galloway, R.
the cefazolin inoculum effect and development of a
Dworakowski, M. Arias
novel diagnostic methodS. Yoshizawa* (Ota-Ku,
E0790 Health related quality of life of patients with Japan), T. Sato, K. Komori, K. Yamada, T.
infective endocarditis – preliminary data of the Yamaguchi, K. Tateda
DERIVE cohortC. Meyer-Schwickerath* (Cologne,
E0805 Third- and fourth-generation cephalosporins for the
Germany), K. Schmidt-Hellerau, J. Camp, K. Last, I.
treatment of infections due to OXA48
Joost, S. Rieg, N. Jung
carbapenemase-producing EnterobacteralesA.
E0791 The optimal management of Enterococcus faecium Blanco Arévalo* (Barcelona, Spain), A. Blanco-
catheter-related bloodstream infections: a gap to Arevalo, E. Sastre-Escolà, J. Camara Mas, F. Tubau
bridgeI. Rancan* (Florence, Italy), M. Rinaldi, F. Quintano, R. Costa, A. Padulles, E. Shaw, C. Gudiol,
Malerba, B. Profiti, L. Ancillotti, M. Tumbarello, P. M. Puig-Asensio
Viale, M. Giannella
E0806 Are meropenem or imipenem-cilastatin effective
E0792 Ceftobiprole alone versus in combination with therapies for patients with invasive ertapenem-
ampicillin against borderline penicillin-resistant, resistant infections?A. Peters* (Santiago, Chile), S.
vancomycin-resistant Enterococcus faecalisO. Fiawoo, L. Diaz, J.R. Martínez, M. Spencer-Sandino,
ESCMID Global 2025 - Programme
L. Rivas, M.P. Riquelme, P. Rojas, L. Rojas, M.L. Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft
Rioseco, J. Moreno, R. Araos, P. Garcia, P.D. für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group
Tamma, J.M. Munita for Infections in Travellers and Migrants (ESGITM)
E0807 Oral Fosfomycin after Carbapenems as de-
escalating therapy in Complicated Urinary Tract
OS109
Infection: A randomized controlled trialK. 17:30 - 18:30 Hall 16
Angkanavisan* (Bankgkok, Thailand), B.
Sakboonyarat, C. Ungthammakhun 1-hour Oral Session
E0808 Oral switch vs. intravenous antibiotics treatment for Training CM/ID - a global view
serious carbapenem-resistant Enterobacterales and
Pseudomonas aeruginosa infections on hospital Chairs Mihai Mares (Iasi, Romania)
discharge: the next frontier for oral switch?C. Priya Nori (New York, United States)
Arena* (Detroit, United States), A. Abed, R. Kenney,
G. Suleyman, A. Shallal, S. Davis, M. Veve
E0809 Metallo-β-lactamase colonization and subsequent O0780 Specialist training in infectious diseases in EuropeJ.
risk of infection: a retrospective study.C. Lee Luna Salmanton-Garcia* (Cologne, Germany), J.
Fernandes* (Sao Paulo, Brazil), C. Vaiana, C. Amato, Salmanton-García, A. Guerra Maio, J.P. Stahl, E. De
S. Castelbuono, G. Di Martino, F. Cardinale, F. Barra, S. Jensen-Fangel, C. Torti, C. Kraef, J.M. Miró,
Monaco, A. Cona, A. Mularoni A. Verbon, O.A. Cornely, N. Beeching
E0810 Polymyxin including therapy versus colistin O0781 Infectious Diseases Residency Training over the
including therapy in the therapy of carbapenem- WorldP. Irkören* (Zeytinburnu/istanbul, Türkiye), P.
resistant Gram-negative infections: A retrospective Irkoren, C. Cimen, S. Keske, Ö. Ergönül
matched cohort studyM. Mert Vahabi* (Van,
O0782 Five years of experience with the virtual International
Türkiye), D. Akyol Seyhan, B. Kenanoğlu, Ş. Yeniyol, Postgraduate Diploma in Infection Prevention and
G. Şanlıdağ İşbilen, Ş. Dirik, D. Dağ, B. Özkara, M. Control from the Infection Control Africa Network.A.
Ceylan, C. Bulut Avşar, U. Önal, S. Ketentzi, A. Uyan Tostmann* (Nijmegen, Netherlands), E. Schoeman, B.
Önal, A. Kaya, O. Acet, D. Kaya, N. Yalcin, G. Du Toit Ludick, E. Ruizendaal, Y. Gouws, J. Hopman,
Vatansever, C. Tol, Ş. Aydemir, D. Akdağ, H.A. C. Azzouz, S. Mehtar
Erdem, T. Yamazhan, H. Sipahi, B. Arda, O.R. Sipahi
O0783 Combatting challenges in laboratory capacity
E0811 Prognostic factors and role of clinical management
through an innovative, longitudinal Gram stain
in carbapenem-resistant Acinetobacter baumannii
training programme for blood culture specimens in
bacteraemia: results from a prospective,
Zimbabwe.T. Mwaturura* (Harare, Zimbabwe), D.
international, multicentre cohort (EURECA)F.
Hettle, F. Makoga, A. Mudungwe, B. Sado, K. Kranzer
Cogliati Dezza* (Seville, Spain), J.M. Bravo-Ferrer
Acosta, B. Gutiérrez-Gutiérrez, B. Carevic, G. O0784 Benefit of the implementation of Entrustable
Dragovac, G.L. Daikos, M. Akova, L. Raka, A. Professional Activities (EPA) as an assessment tool in
Hristea, P. Viale, E. Shaw, E. Roilides, M. Antonelli, the Laboratory of clinical bacteriology: a study
H. Akalin, A. Komnos, J.M. Reguera, A. Vince, M. focused on the improvement of residents' skills and
Mašanovic, L. Radulović, C. Kirakli, C. Gogos, A. feelings.H. Pailhoriès* (Angers, France), H. Pailhories,
Bartoloni, C. Dan, P. Kapisyzi, M.E. Falagas, A. Vata, C. Zins, R. Chenouard, M. Kempf, M. Eveillard
S. Benea, D. Tomescu, A. Meda Vasiesiu, L.
Bukarica, N. Lukic, A. Cano, V. Pintado, A. Azap, H.
ME149
Goosens, M.J.M. Bonten, J. Rodríguez-Baño 17:30 - 18:30 Hall 2

Meet-the-Expert
SY147
17:30 - 18:30 Hall 11
How to perform molecular surveillance of multidrug resistant bacteria
1-hour Symposium

Avian influenza in mammals: jumps under the radar

Chairs Patricia Antunes (Porto, Portugal) M0403 17:30 Martina Lengerova (Brno, Czech Republic)
Ana Vale (Dublin, Ireland) M0404 17:42 Henrik Hasman (Copenhagen, Denmark)

OS107
S0399 17:30 Threat of highly pathogenic avian influenza to non- 17:30 - 18:30 Hall 3
traditional hosts, including humansThijs Kuiken 1-hour Oral Session
(Rotterdam, Netherlands)
S0400 18:00 Recent changes in the epidemiology of avian Novel vaccines in clinical development
influenza in relation to human health risksRon Chairs Mateusz Hasso-Agopsowicz (Geneva, Switzerland)
Fouchier (Rotterdam, Netherlands) Hanna M. Nohynek (Helsinki, Finland)
Co-organised with: ESCMID Food- and Water-borne Infections Study Group
(EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM),
ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific
Working group on Influenza (ESWI) O0770 Safety and immunogenicity of a seasonal booster
dose of the 6-valent, OspA-based Lyme borreliosis
vaccine candidate VLA15 in a healthy population aged
5-65 yearsM. Messier* (Vienna, France), L. Wagner,
SY148
17:30 - 18:30 Hall 15
R. Hochreiter, J. Larcher-Senn, E. Lamberth, R.
Simon, C. Clarkin, J. Stark, S. Eder-Lingelbach
1-hour Symposium
O0771 Safety and immunogenicity of mRNA mpox vaccine
Echinococcosis: neglected but expanding candidate mRNA-1769: Interim analysis results from a
Chairs Daniel Grupel (Jerusalem, Israel) Phase 1/2 TrialH. Hiruy* (Cambridge, United States),
Francesca Tamarozzi (Negrar-Verona, Italy) R. Lazarus, K. Mccafferty, K. Cohen, R. Dhar, T. Rizk,
A. Adeniji, X. Chang, L. Siquel, H. Bennett, B. Leav
O0772 Development of a Rapid-Acting Oral Cholera Vaccine:
Phase I Clinical TrialA. Hannaford* (Boston, United
S0401 17:30 Expansion and diversity of cystic States), D. Leitner, M. Waldor, L. Baden, M.
echinococcosisPedro Legua (Lima, Peru) Desjardins, M. Suzuki, L. Carr, D. Slater, H. Levine, H.
S0402 18:00 Management of echinococcosis: evidence, eminence Kaul, J.B. Park Chang, A. Piermatti, N. Puri, B.
and new developmentsBeate Grüner (Ulm, Germany) Piantadosi, J. Harris, S. Piantadosi, A. Sherman, S.
Walsh
Co-organised with: Österreichische Gesellschaft für Antimikrobielle
Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, O0773 Safety and immunogenicity of a Group B
ESCMID Global 2025 - Programme
Streptococcus vaccine in participants aged 55-75 2-hour Symposium
yearsL. Oostvogels* (Frederiksberg, Denmark), A.
Alhatemi, S. De Gussem, E. Englev, B. Jacobs, B. Breaking new ground in febrile neutropaenia management
Johansson-Lindbom, G. Kitson, G. Waerlop, I. Leroux- Chairs Murat Akova (Ankara, Türkiye)
Roels Stefan Schwartz (Berlin, Germany)
O0774 Aggregated summary of immunogenicity and safety
for the chikungunya virus virus-like particle (VLP)
vaccine development programmeL. Tindale*
(Toronto, Canada), J. Richardson, D. Anderson, J. S0417 08:30 Do we need to redefine the concept of febrile
Mendy, S. Muhammad, T. Loreth, V. Jenkins, P. neutropaenia in the era of immunotherapy?Manuela
Ajiboye, L. Bedell Aguilar-Guisado (Seville, Spain)
S0418 09:00 Should some patients be empirically treated with
combination therapy?Dina Averbuch (Jerusalem,
OS108 Israel)
17:30 - 18:30 Hall 5
S0419 09:30 Role of new antibiotics in febrile
1-hour Oral Session neutropaeniaMalgorzata Mikulska (Genoa, Italy)
Novel approaches to preventing device-related infections S0420 10:00 Can treatment strategies be personalised using AI or
new diagnostic tools?Carolina Garcia Vidal
Chairs Natividad Benito (Barcelona, Spain) (Barcelona, Spain)
Preeti Malani (Ann Arbor, United States)
Co-organised with: ESCMID Study Group for Infections in Compromised
Hosts (ESGICH), European Conference on Infections in Leukemia (ECIL)

O0775 Clinical and microbiological impact of antibiotic-

impregnated catheters in ventriculoperitoneal shunt EW156
infections in adults.M. Sanz De Mena* (Barcelona, 08:30 - 10:30 Hall 5

Spain), I. Pelegrín Senent, J. Gómez Junyent, J. Educational Session

Poblet Florentin, C. Iglesias, A. Siverio Parés, S.
Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. The rules of the game: how to tackle the peer-review and publication process
Horcajada Chairs Christian Kraef (Copenhagen, Denmark)
O0776 Reducing drainage-associated meningitis by using an Oana Sandulescu (Bucharest, Romania)
antiseptic dressing: A randomized controlled trial
AntiRedMenS. Scheithauer* (Goettingen, Germany),
O. Moerer, V. Rohde, N. Srivastava, T. Asendorf, K.
Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich, W0429 08:30 Communicating with journals, editors and
A. Beste, N. Kucheryava, M. Baehr reviewersAngela Huttner (Geneva, Switzerland)
O0777 Efficacy of antimicrobial envelopes in preventing W0430 08:50 The Wild West of predatory journalsUrsula Hofer
cardiac implantable electronic device infections – (London, United Kingdom)
systematic review and meta-analysisA. Mahajan* W0431 09:10 Communicating your publications on social mediaNeil
(Melbourne, Australia), C. Robson Stone (London, United Kingdom)
O0778 A bundled approach to reducing central line W0432 09:30 Re-imagining peer reviewAmelia Joseph
associated blood stream infections (CLABSI) in (Nottingham, United Kingdom)
hemodialysis (HD) patientsJ. Guerrero*
Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie,
(Scarborough, Canada), A. Garga, S. Paramalingam,
CMI Communications Board of Editors, ESCMID Parity Commission, CMI
R. Lovinsky, F. Go
Board of Editors
O0779 Increased long-term mortality in patients with
prosthetic joint infection after primary total hip
arthroplasty – a cohort study with 89'709 patientsN. EF114
Imhasly* (Lucerne, Switzerland), A. Widmer, C. 08:30 - 09:30 Arena 1

Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M. ePoster Flash Session

Wicki, M. Beck, R. Sommerstein
Innovations and insights in diagnosing parasitic infections
Chair Pikka Jokelainen (Copenhagen, Denmark)
Tuesday, 15 April 2025

E0822 Evaluation of a multiplex beads assay for the

SY152 simultaneous detection of serum antibodies in
08:30 - 10:30 Hall 12
neurocysticercosis patients.A. Lopez Alva* (Lima,
2-hour Symposium Peru), P.D.S. Nakazaki Aza, L.M. Toribio Salazar, H.H.
Garcia Lescano
Out of the spotlight or out of reach? Vaccination of hard-to-reach groups E0823 Development and evaluation of real-time loop
Chairs Olivier Epaulard (Grenoble, France) mediated isothermal amplification assay for rapid
Justyna Kowalska (Warsaw, Poland) detection of hookworm (Ancylostoma duodenale) in
human fecal samplesM. Thakur* (Chandigarh, India),
S. Khurana, A. Mewara, L. Pvm
E0824 Exploring Genotypic Prevalence and Transmission of
S0413 08:30 Ukrainian war refugees and vaccination attitudes:
Cryptosporidium and Giardia in
experience from PolandMaria Ganczak (Zielona Gora,
Immunocompromised Patients: A Dual Approach with
Poland) Modern Molecular Methods: MLST & nested real-
S0414 09:00 Vaccination in migrants in Latin America: The time HRMP. Rani* (Chandigarh, India), P. Datta, S.L.
challenges of transit through Darien, PanamaAlfonso Bhasin, P. Malhotra, S.S. Rana, R. Sehgal
J. Rodriguez-Morales (Pereira, Colombia) E0825 Prevalence and diagnostic accuracy of different
S0415 09:30 Are penitentiary systems ready for introducing diagnostic tests for Chagas disease in the
vaccination programmes?Lara Tavoschi (Pisa, Italy) Paraguayan ChacoS. Ardiles Ruesjas*
S0416 10:00 HPV and other essential vaccinations for sex (Saarbruecken, Germany), S. Ardiles-Ruesjas, V.
workersDebora Konopnicki (Brussels, Belgium) Lesmo, V. González-Romero, Z. Cubilla, L. Chena, C.
Huber, M.J. Rivas, P. Saldaña, A. Carrascosa, S.
Co-organised with: ESCMID Vaccine Study Group (EVASG) Méndez, S. Sanz, S.L. Becker, J. Alonso-Padilla, I.
Losada
SY153 E0826 Development and validation of an artificial
08:30 - 10:30 Hall 13
intelligence model for detection of gastrointestinal
parasites from concentrated wet-mount stool
ESCMID Global 2025 - Programme
examinationsM.R. Couturier* (Salt Lake City, Ut, Clinical Grand Round
United States), B. Mathison, K.A. Knight, J.R. Potts, F. Chairs Robert C. Read (Southampton, United Kingdom)
Markow, A.E. Wood, K.W. Dixon, J.F. Walker, D.L. Robert C. Read (Southampton, United Kingdom)
Bess, W. Hymas
E0827 Evaluation of KU-F40 automated microscope for Experts Nina Khanna (Basel, Switzerland)
diagnosis of intestinal parasitic infections : will AI Dimitrios P. Kontoyiannis (Houston, Tx, United States)
rescue old-time microscopy ?A. Aupaix* (Hornu, Lior Nesher (Beersheba, Israel)
Belgium), L. Filippin, I. Mansoor, M. Chemais, D. David L. Paterson (Singapore, Singapore)
Martiny, V.Y. Miendje Deyi, M. Deffontaine, C. Priscilla Rupali (Vellore, India)
Deckers, V. Verbelen, J. Brauner Monica Slavin (Melbourne, Australia)
E0828 Improving vector surveillance: evaluating a real-time
PCR assay for Leishmania DNA detection in CGR01 Case 1Kruthi Malur Kumaraswamy (Mumbai, India)
sandfliesH. Alonso-Ezcurra* (Zaragoza, Spain), M.P.
Peris, I. Ruiz-Arrondo, J.A. Castillo, D. Martínez- CGR02 Case 2Christopher Wong (Victoria, Australia)
Durán, S. Delacour, I. Ruiz-Zarzuela, I. De Blas, C. CGR03 Case 3Filipa Ferreira (Porto, Portugal)
Cervera-Acedo, J.A. Oteo, F. Collantes, B. Dehesa, H.
CGR04 Case 4Jia Arng Lee (Zhongzheng Dist, Taipei City,
Alonso
Taiwan, Taiwan, China)
E0829 Assessment of a new immunochromatographic assay
CGR05 Case 5Lorenzo Bertolino (Naples, Italy)
for serological diagnosis of amoebic liver abscessR.
Fleury* (Besançon, France), M.P. Brenier-Pinchart, P. CGR06 Case 6Armani Hawes (Baltimore, United States)
Tirard-Collet, F. Gabriel, E. Pretot, F. Touafek, A. CGR07 Case 7Sima Sharara (Baltimore, United States)
Marteau, S. Houze, C. Amiot, T.G. Nguyen, D. Dupont,
Co-organised with: Infectious Diseases Society of America (IDSA)
A. Moreno-Sabater, F. Grenouillet
E0830 Human piroplasmosis: diagnostic lessons from a
national parasitology reference laboratory in South OS113
Africa.C. Sriruttan-Nel* (Johannesburg, South Africa), 08:30 - 10:30 Hall 11
J. Frean 2-hour Oral Session

Knockin' on Science's Door: New Antimicrobial Solutions

EF115
08:30 - 09:30 Arena 3 Chairs Sandrine Marchand (Poitiers, France)
Ursula Theuretzbacher (Vienna, Austria)
ePoster Flash Session

New genomic methods in clinical microbiology

Chair Natacha Couto (Oxford, United Kingdom) O0812 Chimerbactin: a hybrid antibiotic for persistent
Gram-positive infections that overcomes resistance
developmentR. Lee* (Memphis, United States), Y.
Zhao, A. Arya, M. Lafleur, R. Conlin, G. Phelps, C.
E0831 Prediction of antimicrobial minimum inhibitory Dunn, E. Griffith, J. Portelinha, N. Chumbler, V.
concentration from Escherichia coli whole genome Loudon, I. Lister, S. Zia, K. Urish, K. Lewis
sequence data using machine learningA. Gerada*
O0813 A Novel Klebicin Cocktail to Treat Lung Infection
(Liverpool, United Kingdom), N. Harper, Y. Zhong, A.
Caused by Klebsiella pneumoniaeV.D. Paul*
Howard, P.L. Green, W. Hope
(Bangalore, India), A. Ambady, U. Chopra
E0832 Dynamically Optimized Reference Adaptive Sampling
O0814 Thiophene derivatives: A promising solution against
(DORAS) to streamline bacterial Multi-Locus
MDR Gram-negative bacilliY. Smani* (Seville,
Sequence TypingA. Ramette* (Bern, Switzerland), L.
Spain), I. Molina Panadero, Á. Rey Hidalgo, M.
Borcard, M.A. Terrazos Miani, S. Gempeler, S.
Morales-Tenorio, A. García-Rubia, T. Samernate, P.
Neuenschwander
Nonejuie, A. Martínez, A. Hmadcha, A. De Alarcón,
E0833 Prediction of antibiotic resistance in Pseudomonas C. Gil
aeruginosa, Escherichia coli and Klebsiella
O0815 Molecular insight into non-lytic polyproline peptide
pneumoniae from genomic data using machine
disruption of Klebsiella pneumoniae biofilmsR.
learning and deep learning approachesE. Denakpo*
Fleeman* (Orlando, United States), R. Beckman Iv,
(Gif-Sur-Yvette, France), N. Dias, F. Jay, B. Iorga
B. Victoria, L. Suits, P. Eswara
E0834 Machine learning pipeline accelerates identification
O0816 Reverting cefotaxime resistance in CTX-M-15-
of diagnostic targets for Neisseria gonorrhoeaeA.
producing Escherichia coli using Targeted-
Verich* (Sydney, Australia), T. Applegate, D. Bauer, P.
Antibacterial-Plasmids (TAPs): a CRISPR-Cas9
Ramarao-Milne, L. Sng, E. Trembizki, E. Mokany
approach.N. Roson Calero* (Barcelona, Spain), N.
E0835 Reliable bacterial genomic genotyping from Oxford Roson-Calero, E. Derollez, P. Rouze, A. Dedieu-
Nanopore Technologies data – the ONT cgMLST Berne, S. Bigot, C. Ballesté-Delpierre, J. Vila, P.
PolisherN. Scherff* (Muenster, Germany), J. Bogaerts, C. Lesterlin
Rothgänger, D. Harmsen
O0817 Structural and functional characterization of
E0836 Developing a core genome MLST (cgMLST) for LysSM5: An innovative endolysin from Salmonella
Mycoplasma pneumoniaeC. Dixon* (Cardiff, United Phage vB_SenA_SM5K. Sharma* (Chandigarh,
Kingdom), R. Mamede, M. Ramirez, H. Milton, P.M. India), H. Kaur, N. Chaudhary, S. Prajapati, B.
Meyer Sauteur, G. Greub, N. Couto, M.L. Beeton Mohan, N. Taneja
E0837 Voyager: real-time taxonomic characterization of O0818 Rational step-by-step design of a two-phage
long-read mixed-species sequencing samples in cocktail against a contemporary A. baumannii strain
sorted motif distance spaceS. Branders* (Hamar, recovered from a burned patient at CHUV.G.
Norway), M. Grabherr, R. Ahmad Resch* (Lausanne, Switzerland), H. De Villiers De La
E0838 VCP: a signature protein-based tool for accurate and Noue, G. Golliard, X. Vuattoux
rapid profiling of human gut viromeJ. Li* (Shenzhen, O0819 A novel antibiotic class targeting the enolase of
China), F. Yang, L. Xiong, X. Feng, H. Zhong Acinetobacter baumanniiI. Molina Panadero*
E0839 Genomic Data-Driven Machine Learning for (Seville, Spain), A. Moreno Rodríguez, Á. Rey
Predicting Antimicrobial Resistance in ESCAPEE Hidalgo, L. Tomás Gallardo, M. De La Cruz, P.
PathogensA. Skoulakis* (Lamia, Greece), K. Sánchez, T. Samernate, A.J. Pérez Pulido, S. Glisic,
Daniilidis, S. Digenis, A. Hatzigeorgiou O. Genilloud, P. Nonejuie, A. Hmadcha, Y. Smani
O0820 Reviving antibiotic potency: Pharmacological
Assessment of JS238 a newly designed potentiator
CGR
08:30 - 10:30 Hall 1 against P. aeruginosaP. Rasouli* (Brussels,
Belgium), J.M. Brunel, J.H. Lorent, F. Van Bambeke
Special Session
O0821 Advancements in combating tularemia: Novel
therapeutic strategies targeting Francisella
ESCMID Global 2025 - Programme
tularensisS. Guillier* (Brétigny-Sur-Orge, France),
M. Gâchon, C. Lemoigne, C. Rougeaux, V. Lourde,
C. Demeure, J. Pizarro Cerda, G. Guichard, G. S0405 08:30 How can we recognise and deal with adverse events
Compain, D. Burnouf, O. Gorgé, J. Wagner of Faecal Microbiota Transplantation?Serena Porcari
(Roma, Italy)
S0406 09:00 What to check? – An attempt at evidence-based
SY154 donor screeningElisabeth Terveer (Leiden,
08:30 - 10:30 Hall 14
Netherlands)
2-hour Symposium S0407 09:30 What are the right bugs – Developing LBPs out of
FMTsLena Biehl (Cologne, Germany)
Using mathematical and epidemiological models to identify the drivers of
AMR S0408 10:00 What’s up next? – Hot LBP candidatesIlan Youngster
(Beer Yaakov, Israel)
Chairs Marc J.M. Bonten (Utrecht, Netherlands)
Sarah Tschudin Sutter (Basel, Switzerland) Co-organised with: ESCMID Study Group for Host and Microbiota Interaction
(ESGHAMI), The European Faecal Microbiota Transplantation Network of
academics (EurFMT), European Helicobacter & Microbiota Study Group
(EHMSG)
S0421 08:30 Quantifying the drivers of antiviral resistance: what
does it take to prevent resistance evolution?Roger
Kouyos (Zürich, Switzerland) SY151
08:30 - 10:30 Hall 4
S0422 09:00 Inferring the determinants of AMR dynamics across
bacterial pathogensLulla Opatowski (Paris, France) 2-hour Symposium
S0423 09:30 Modelling the evolution of resistanceErida Gjini News in endocarditis care
(Lisbon, Portugal)
Chairs Michele Bartoletti (Milan, Italy)
S0424 10:00 Assessing the associations of microbiome and socio- Pilar Retamar Gentil (Seville, Spain)
demographic dynamics on AMRKatariina Pärnänen
(Helsinki, Finland)

S0409 08:30 Endocarditis guidelines: what is new?Siegbert Rieg

EW157 (Freiburg, Germany)
08:30 - 10:30 Hall 15
S0410 09:00 Oral therapy and outpatient careLaura Escolà-Vergé
Educational Session (Barcelona, Spain)
Endemic mycoses and mycetoma: underdiagnosed and underreported fungal S0411 09:30 PK/PD aspects of endocarditis antibiotic
diseases therapyFekade Bruck Sime (Brisbane, Australia)
Chairs Ana Alastruey-Izquierdo (Madrid, Spain) S0412 10:00 The Endocarditis Team: there is no way to work
Rita Oladele (Lagos, Nigeria) aloneBarbara Hasse (Zurich, Switzerland)
Co-organised with: ESCMID Study Group for Bloodstream Infections,
Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Antimicrobial
stewardship (ESGAP), Sociedad Espanola de Infecciones Cardiovasculares
W0433 08:30 Advances and gaps in the diagnosis and treatment of (SEICAV)
histoplasmosisDiego Rodrigues Falci (Porto Alegre,
Brazil)
W0434 08:50 Paracoccidioidomycosis: an update on diagnostic EF116
challengesBeatriz L. Gomez (Bogota, Colombia) 09:30 - 10:30 Arena 2

W0435 09:10 What is new in TalaromycosisBrown Lottie (London, ePoster Flash Session
United Kingdom)
Sepsis revolutions: from machines to molecules
W0436 09:30 Mycetoma: treatment challenges of a unique
neglected tropical diseaseBorna Nyaoke-Anoke Chair Pierluigi Del Vecchio (Roma, Italy)
(Nairobi, Kenya)

E0840 Machine learning enabled prediction of blood

EW155
08:30 - 10:30 Hall 2 stream infection in emergency department
attendees.C. Rosato* (Liverpool, United Kingdom),
Educational Session S. Aston, A. Velluva, A. Howard, W. Hope
An update on arboviral disease challenges E0841 Utilizing Automation to Streamline the Blood Culture
Process: Enhancing Efficiency and Patient
Chairs Misa Korva (Ljubljana, Slovenia) OutcomesJ. Qin* (Shanghai, China), M. Li, Z. Shen
Anna Papa-Konidari (Thessaloniki, Greece)
E0842 Implementation of a bundle for Gram-negative
bloodstream infection: impact on mortality and
MDT/DTT carriageC. Bonazzetti* (Bologna, Italy), A.
W0425 08:30 The global epidemiology of arboviral diseasesChantal Grechi, D. Gibertoni, L. Mangione, F. Todisco, N.
B.E.M. Reusken (Bilthoven, Netherlands) Caroccia, M. Rinaldi, R. Pascale, B. Tazza, A. Toschi,
W0426 08:50 Arboviral diseases transmitted by mosquitoesLuisa A. Amicucci, C. Campoli, Z. Pasquini, F. Calo', P.
Barzon (Padua, Italy) Viale, M. Giannella
W0427 09:10 Aboviral diseases transmitted by ticksJoanna Maria E0843 A matter of time: impact of time to first follow-up
Zajkowska (Białystok, Poland) blood cultures in patients with candidemia and
Staphylococcus aureus bacteremia from a
W0428 09:30 Arboviral diseases transmitted by sandfliesRémi retrospective cohortP. Valsecchi* (Pavia, Italy), E.
Charrel (Marseille, France) Bono, A. Valeretto, S. Resuli, M. Corbella, P.
Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Cambieri, E. Seminari, R. Bruno
Infectiologists E0844 Characteristics of infections and outcomes in
patients with left ventricular assist devicesN. Sarı*
(Ankara, Türkiye), E. Ateş, Ç. Sarıkaş, Ö. Kurt Azap,
SY150
08:30 - 10:30 Hall 3 Ç. Erol, A. Sezgin
2-hour Symposium E0845 Nb2(Sn0.7Cu0.3)C MAX phase for anti-Infection
therapy via hyperthermia-mediated bacterial
Faecal microbiota transplantation and live biotherapeutic products: scientific metabolic interferenceM. Yang* (Chengdu, China)
and regulatory challenges E0846 Age-Dependent Plasma Lipidomic Alterations and
Chairs Lindsey Ann Edwards (London, United Kingdom) Immune Correlations in Sepsis: Insights into
Ed J. Kuijper (Leiden, Netherlands) Disease Severity and Biomarker PotentialY. Sun*
ESCMID Global 2025 - Programme
(Shanghai, China), K. Lin, L. Wang, J. Ai, J. Zhao, X. M0451 11:12 Jani Sormunen (Turku, Finland)
Cheng, Y. Wan, P. Cui, S. Wang, J. Wu, J. Jin Co-organised with: European Centre for Disease Prevention and Control
E0847 Aberrant integrin activation causes transmigration (ECDC)
defects in S100A9-/- neutrophils during sepsisS.
Mülder* (Münster, Germany), N. Ludwig, J.
SY164
Rossaint, T. Vogl 11:00 - 12:00 Hall 15
E0848 Efficacy of dimercaptosuccinic acid in combination
1-hour Symposium
with imipenem in a murine model of experimental
sepsis due to metallo-ß-lactamase-producing dsDNA virus infections in immunocompromised patients
Pseudomonas aeruginosa.S. Herrera-Espejo*
(Seville, Spain), M. Bouvier, J. Findlay, L. Ceballos- Chairs Lior Nesher (Beersheba, Israel)
Romero, J. Pachón, J.M. Cisneros, M.E. Pachón- Michelle Yong (Melbourne, Australia)
Ibáñez, P. Nordmann

S0448 11:00 Challenges of diagnosis: do we need to treat all

EF117
09:30 - 10:30 Arena 4 patients with detectable dsDNA virus PCR?Hans H.
Hirsch (Basel, Switzerland)
ePoster Flash Session
S0449 11:30 The role of CRISPR-Cas9-edited antiviral T cells
C. diff challenges: insights into treatment, monitoring, and infection against dsDNA virus infectionsTba
prevention
Chair Kerrie Davies (Leeds, United Kingdom)
FO167
11:00 - 12:00 Arena 1

Open Forum
E0849 Epidemiology, risk factors, and outcomes of
nosocomial Clostridioides difficile infections: a cohort Vaccine rollout in low resource settings
study in a tertiary hospital.L. Ruiz Salazar* (Madrid, Chair Asma Nasim (Karachi, Pakistan)
Spain), T. Mata Forte
E0850 Long-read or short-read sequencing in Clostridioides
difficile infection surveillance?M. Brajerová* (Prague,
F0454 11:00 Typhoid vaccine roll outNginache Nampota
Czech Republic), M. Brajerova, P. Kinross, P.
(Baltimore, United States)
Drevinek, M. Krutova
F0455 11:10 Introduction of malaria vaccines to countries in sub-
E0851 “Beyond C. difficile Colitis”: Exploring the Role of
Saharan Africa: acceptance and barriersBernhards
Fidaxomicin in preventing concomitant and
Ogutu Ragama (Nairobi, Kenya)
secondary bloodstream infections in patients with
Clostridioides difficile colitis.D.F. Bavaro* (Milan, F0456 11:20 The story of COVID-19 vaccines in LMICPaul Adepoju
Italy), D. Schumann, A. Cilli, L. Diella, D. Barbanotti, D. (Perton, United Kingdom)
Mondatore, F. Medioli, M. Casana, A. Belati, L. Co-organised with: ESCMID Ethics Advisory Committee (EEAC)
Bussini, V. Cento, R. Epis, M. Bartoletti
E0853 Comparison of bezlotoxumab versus no-
bezlotoxumab on recurrence in high-risk patients EF123
with Clostridioides difficile infectionC. Arena*
11:00 - 12:00 Arena 2

(Detroit, United States), A. Abed, R. Kenney, A. ePoster Flash Session

Shallal, S. Davis, M. Veve
Advancing antimicrobials: trials and therapies for resistant infections
E0854 Exploring bacterial contributors to C. difficile
colonization resistance: comparative effects of Chair Ursula Theuretzbacher (Vienna, Austria)
vancomycin and fidaxomicin in humanised miceE.
Montenegro-Borbolla* (Lausanne, Switzerland), L.
Beldi, S. Hapfelmeier, G. Greub, C. Bertelli, B. Guery
E0888 11:00 Efficacy of High Dose Tigecycline-Containing
E0855 An optimised vancomycin dosing regimen is effective Regimens for the Combination Treatment of
against C. difficile, reduces gut microbiota impact Carbapenem Resistance Enterobacterales
and prevents recurrent C. difficile infection in a Bacteremia: a propensity score-matched studyV.
human in vitro gut model.J. Freeman* (Leeds, United Vasikasin* (Bangkok, Thailand), W. Nasomsong, P.
Kingdom), C. Normington, E. Clark, K. Bentley, J. Wanloptaree
Altringham, A. Berry, W. Spittle, D. Ewin, A. Kirby, M.
Wilcox, K. Davies E0883 11:06 Evaluation of CRS3123 compared to vancomycin for
the treatment of Clostridioides difficile infection
E0856 Cost and resource utilization of fidaxomicin in risk (CDI)J. Bruss* (Pagosa Springs Co, United States),
patients with recurrent or refractory Clostridioides M.A. Degroote, L. Boccumini, W. Ribble, J. Day, C.
difficile infectionM. Engelhard* (Cologne, Germany), Mason, X. Sun, J. Freeman, N. Seema, N. Janjic, T.
I. Alram, S.M. Wingen-Heimann, N. Pfeiffer, J.J. Jarvis, U. Ochsner, M. Wilcox, T. Louie
Vehreschild, M.J.G.T. Vehreschild, S.M. Hopff
E0884 11:12 Phase 2/3, open-label, randomized, active-controlled
E0857 Impact of a cohorting intervention on the incidence of clinical trial evaluating the safety and efficacy of
hospital-acquired Clostridioides difficile infection imipenem/cilastatin/relebactam (IMI/REL) in
(CDI): an interrupted time series analysisC.D. paediatric patients with gram-negative bacterial
Moschopoulos* (Athens, Greece), M. Tsakona, S. infectionJ. Bradley* (San Diego, United States), C.T.
Grigoropoulou, P. Kazakou, M. Kostoula, I. Kliani, C. Norice, E. Roilides, A. Shevelev, B. Jurkiewicz, J.A.
Filis, K. Thomas, I. Grigoropoulos, K. Protopapas, E. Piedrahita, S. Koseoglu, I. Masih, P. Nair, K. Young,
Kalogeropoulou, S. Pournaras, N.V. Sipsas, G.L. D.W. Hilbert, G.T. Nieddu, J.A. Huntington, C.J. Bruno
Daikos, F. Kontopidou, A. Papadopoulos, S. Tsiodras,
D. Kavatha E0885 11:18 A Phase I, Randomized, Double-Blind, Placebo-
Controlled, Dose Escalation Study to Evaluate the
Safety and Tolerability of Intravenous Ertapenem
(ERT) with Zidebactam (ZID) in Combination (WCK
ME165
11:00 - 12:00 Hall 12
6777) in Healthy Adult SubjectsT. Lodise* (Albany,
Meet-the-Expert United States), R. Chavan, A. Patel, R. Yeole, S.
Bhagwat, M. Patel, G. Saviolakis, K. Gu, V. Ghazaryan,
How to use citizen science for public health M. Kankam, A. Jaunarajs, E. Hammett, H. Howell, R.A.
Bonomo
E0886 11:24 Head-to-head: meropenem/vaborbactam versus
ceftazidime/avibactam in ICUs patients with KPC-
M0450 11:00 Anna Noel-Storr (Leamington Spa, United Kingdom) producing K. pneumoniae infections – Results from a
retrospective multicentre studyA. Marino* (Catania,
ESCMID Global 2025 - Programme
Italy), A.E. Maraolo, M. Mazzitelli, A. Oliva, N. diversity and antimicrobial resistance hub in the
Geremia, A. De Vito, C. Gullotta, V. Scaglione, E. urinary tract ecosystemE. Cappelli* (Porto, Portugal),
Vania, S. Lo Menzo, P. Navalesi, L. Volpicelli, A. Fiori, A. Morais, T. Ribeiro, L. Peixe
P. Prestifilippo, A. Cattelan, C.M. Mastroianni, G. E0900 Active surveillance in the diagnosis of sexually
Madeddu, B. Cacopardo, G. Nunnari transmitted infections: performing PCR in negative
E0887 11:30 Phase 3 study of oral gepotidacin for the treatment of urine culturesA. Castellano Verdasco* (Lleida, Spain),
uncomplicated urinary tract infection in Japanese E. Sánchez Báscones, E. López González, A.
female participants (EAGLE-J)Y. Kayama* (Tokyo, Blanquero-Porras, M. Riesgo Magaña, A. Bernet
Japan), S. Yamamoto, K. Fujii, A. Nimura, T. Maenaka, Sánchez, S. Mormeneo Bayo, I. Prats Sánchez, A.
M. Ramirez, R. Banerjee, N.E. Scangarella-Oman, S. Bellés-Bellés, M. García González
Mozzicato, S. Ura
E0889 11:36 Efficacy of Ceftolozane/Tazobactam vs.
EF125
Ceftazidime/Avibactam in the Treatment of 11:00 - 12:00 Arena 4
Nosocomial Pneumonia Caused by Pseudomonas
aeruginosa: a multicentric retrospective study from ePoster Flash Session
the SUSANA cohort.A. Bitti* (Sassari, Italy), A. De
Vito, M. Fois, E. Ricci, A. Bandera, A. Maccaro, S. Bugs breaking the blood-brain barrier
Piconi, P. Maggi, G. Cenderello, M. Merli, G.V. De Chair Markus Zeitlinger (Vienna, Austria)
Socio, P. Morelli, P. Bonfanti, G. Madeddu
E0890 11:42 Experience of dalbavancin use for unlicensed
indications in a UK tertiary infectious diseases
E0901 Pharmacologic depletion of meningeal macrophages
settingC. Darlow* (Liverpool, United Kingdom), J.
worsens disease in a mouse model of meningitisU.
Parsons, D. Lucy, N. Wong Koedel* (Munich, Germany), S. Dyckhoff-Shen, I.
E0891 11:48 Investigator-driven randomised controlled trial of Masouris, H.W. Pfister, M. Klein
cefiderocol versus standard therapy for healthcare-
E0902 Pgm1 modulates the inflammatory response of
associated and hospital-acquired gram-negative
macrophages in experimental pneumococcal
bacterial bloodstream Infections (BSI) : Hierarchical
meningitisD. Bakker* (Amsterdam, Netherlands), R.
composite endpoint analysis with DOOR and
Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Van
generalised pairwise comparisonsM. Hardy*
De Beek
(Maroochydore, Australia), D.L. Paterson, M.
Chatfield, H. Bin Sulaiman, L. Po-Yu, M. Yilmaz, Z.N. E0903 Heparin-binding protein in cerebrospinal fluid as a
Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, biomarker for bacterial meningitis: a study of
D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, diagnostic accuracyS. Olie* (Amsterdam,
V. Thamlikitkul, Y.T. Lee, Y.T. Lin, W.N.W. Ramli, H.C. Netherlands), S.L. Staal, A.C. Da Cruz Campos, J.
Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Bodilsen, H. Nielsen, D. Van De Beek, M.C. Brouwer
Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. E0904 Efficacy Analysis of Intraventricular/Intrathecal
Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, Polymyxin B sulphate Injections in the Treatment of
P.Y. Chia, B. Forde, H. Wright, A. Stewart, K. Ramsay, Post-neurosurgical CNS Infections in Neurocritical Ill
W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris Patients:a prospective observational studyL. Yang*
(Shanghai, China), J. Song, M. Wang, H. Yuan, Q.
Yuan, Z. Du, G. Wu, J. Hu, W. Chen
EF124
11:00 - 12:00 Arena 3 E0905 Ventriculitis characteristics and outcomes (VELCRO):
an international retrospective cohort studyD. Luque
ePoster Flash Session Paz* (Rennes, France), B. Díaz Pollán, M. Boyer-
Besseyre, F. Djanikian, A.L. Munier, F. Cunha, L.
Thinking outside the box in urinary tract infection
Escaut, G. Martin-Blondel, B. Sarton, P. Jaquet, F.
Chair Özlem Kurt Azap (Ankara, Türkiye) Arrivé, R. Wolf, V. Legros, M. Willig, O.R. Sipahi, L.
Flurin, A. Bianchi, B. Balança, J. Puel, R. Lino, B.
Soyer, T. Leveque, A. Salomon, A. Serris, R. Larcher,
F. Bruneel, N. Mongardon, A. Mazeraud, M. Wolff, R.
E0892 Targeted NGS: a promising approach for pathogen Sonneville, F. Valour, P. Tattevin
detection of urinary tract infectionW. Gao* (Beijing,
China), P. Li, W. Han, D. Chen, L. Huang, P. Chen, B. E0906 Clinical Features and Outcomes of Staphylococcus
Cheng, Y. Gu, C. Hu, J. Chen, Z. Zhang aureus Brain AbscessE. Eriksen* (Aalborg, Denmark),
M. Bijlsma, S. Olie, L. Larsen, M. Storgaard, H. Mens,
E0893 Turnaround time of just four hours from sample L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau,
collection to informed decision-making for H. Nielsen, M. Brouwer, J. Bodilsen
complicated urinary tract infections in a urology
ward, using culture-independent metagenomicsA.B. E0907 Epidemiology of Adult Intracranial Bacterial Abscess
Bellankimath* (Hamar, Norway), S. Branders, J. Ali, F. in the Republic of Ireland (2010-2021)S. Kilgarriff*
Asadi, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. (Cork, Ireland), E. Glynn, D. Murray, C. Lim, C. Hickey,
Wagenlehner, R. Ahmad S. O Donnell, B. Dinesh, C. O Connor, A. Doherty
E0894 Identification of Microorganism Types in Urinary E0908 Corticospinal tract involvement in Neuromelioidosis:
Tract Infections Using Machine Learning and Flow A Retrospective cohort Study from South India and a
CytometryE. Flores* (Alicante, Spain), I. Gutierrez, R. Systematic Review of LiteratureP.K. Tirlangi*
Torrreblanca, A. Blasco, R. Carbonell, M. Lopez- (Manipal, India), N. Gupta, V. Muralidhar, C.
Garrigós Mukhopadhyay
E0895 A New Approach In Diagnosis Of Urinary Tract E0909 A multicenter prospective study to develop and
InfectionsB. Dinc* (Ankara, Türkiye), F. Kırca, S. validate clinical prediction models for diagnosis of
Kazcı, Ö. Uslu, N. Çöplü scrub typhus and treatment with doxycycline in
children with acute encephalitis syndrome in
E0896 Diagnosis of urinary tract infections: from machine southern IndiaT. Damodar* (Bangalore, India), L.
learning to clinical practiceE. Flores* (Alicante, Turtle, R. Kolamunnage-Dona, M. Jose, U. Kinhal, B.
Spain), R. Torrreblanca, I. Gutierrez, R. Carbonell, L.G. Singh, A. L, S. Marate, N. Prabhu, L. A V, F.S. D'souza,
Maite, A. Blasco S.V. Sajjan, K. Mallesh, R.S. Mani, T. Solomon, V.K.
E0897 Strategic testing optimisation practices for urinary Gowda, R. Vasanthapuram, R. Yadav
tract infections (STOP-UTI): findings from LMIC
hospital settingS. Sarika* (Chennai, India), B. Rithik
Dharan KN158
11:00 - 12:00 Hall 1
E0898 Rapid culture-independent mass spectrometry based
proteomics methods for improving urinary tract Keynote Lecture
infection diagnosticsS. El-Ali* (Gothenburg, Sweden),
L. Acha Alarcon, G. Alves, Y.K. Yu, R. Karlsson, E. What genomics brought to the knowledge of tuberculosis, leprosy and buruli
Moore ulcer
E0899 Unraveling the complexity: Corynebacterium Chairs Emmanuelle Cambau (Paris, France)
ESCMID Global 2025 - Programme
Kathryn Holt (London, United Kingdom) Nevers, A. Gagneux-Brunon
O0881 ‘The Sepsis Olympics': Raising awareness of the
Sepsis 6 care bundle in an Irish Hospital through a
K0437 11:00 Stewart T. Cole (Paris, France) clinical challenge game.C. Uhomoibhi* (Dublin,
Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra
O0882 Improvement of learners' confidence in antibiotic
SY162 management by an interdisciplinary annual multi-
11:00 - 12:00 Hall 11
centred webinarA. Friedrichs* (Kiel, Germany), E.
1-hour Symposium Kramme, T. Koch, J. Jochum, A. Van Der Linde, H.
Gerth, F. Jahn, A. Neubert
Antimicrobial stewardship across the lifespan from paediatrics to geriatrics
Chairs Lucy Catteau (Brussels, Belgium)
SY159
Priya Nori (New York, United States) 11:00 - 12:00 Hall 2

1-hour Symposium

S0444 11:00 Antimicrobial Stewardship in paediatrics across Beat the cancer by beating the infections
different settingsTaylor Morrisette (Charleston, Chairs Daniela Maric (Novi Sad, Serbia)
United States) Mojca Maticic (Ljubljana, Slovenia)
S0445 11:30 Stewardship in geriatrics: an exceedingly important
targetDafna Yahav (Ramat-Gan, Israel)
S0438 11:00 Prevention of infection-associated cancer: learning
from each otherCatharina Alberts (Amsterdam,
ME166
11:00 - 12:00 Hall 13
Netherlands)
Meet-the-Expert S0439 11:30 Test and treat early to prevent cancer: hepatitis B and
hepatitis CFrancesco Negro (Geneva, Switzerland)
Implementing AI in microbiological diagnostics: practical steps and quality
control
SY160
11:00 - 12:00 Hall 4

1-hour Symposium
M0452 11:00 Oliver Nolte (Zürich, Switzerland)
Personalised patient management and infection prevention: Current evidence
M0453 11:12 Jennifer Dien Bard (Los Angeles, United States) and future perspectives
Co-organised with: ESCMID Study Group for Genomic and Molecular
Chairs Agnes Hajdu (Budapest, Hungary)
Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)
Iris K. Minichmayr (Vienna, Austria)

SY163
11:00 - 12:00 Hall 14
S0440 11:00 The dosing perspective: towards individualised
1-hour Symposium treatment strategiesThomas Tängdén (Uppsala,
Sweden)
People-centred approach to strengthening the AMR response at primary care
S0441 11:30 The infection control perspective: advancing patient-
Chairs Benedikt Huttner (Geneva, Switzerland) centred approachesAlessia Savoldi (Verona, Italy)
Mirfin Mpundu (Lusaka, Zambia)

SY161
11:00 - 12:00 Hall 5
S0446 11:00 Implementation of WHO’s people-centred
1-hour Symposium
interventionsNienke Van De sanDe Bruinsma
(Geneva, Switzerland) Emerging fungal diseases in children: Global challenges and approach to
S0447 11:30 Opportunities for strengthening AMR interventions in management
primary healthcareSholpan Kaliyeva (Karaganda City, Chairs Andreas H. Groll (Münster, Germany)
Kazakhstan) Adilia Warris (Exeter, United Kingdom)
Co-organised with: World Health Organisation (WHO)

OS122 S0442 11:00 Emerging fungal infections in immunocompromised

11:00 - 12:00 Hall 16
and geographically exposed childrenLaura Ferreras-
1-hour Oral Session Antolin (London, United Kingdom)
S0443 11:30 Best available treatments and options for children in
Serious games - a serious business resource-limited settingsFabianne Carlesse (Sao
Chairs Christian Kraef (Copenhagen, Denmark) Paulo, Brazil)
Galadriel Pellejero-Sagastizábal (Zaragoza, Spain) Co-organised with: ESCMID Fungal Infection Study Group (EFISG), German-
Speaking Mycological Society (DMykG)

O0878 The development process, impact and

OS118
implementation of an educational VR-module in 11:00 - 12:00 Hall 6
infection prevention and control for medical students
1-hour Oral Session
and healthcare workers in The Netherlands.A.
Tostmann* (Nijmegen, Netherlands), O. Coenen- Plasmids as a powerful tool of antibiotic resistance spread
Bouwman, B. Schippers, F. Luk, M. Graner, F. Van
Hoek, N. Stikkelbroeck, M. Dronkers Chairs Monika Dolejska (Pilsen, Czech Republic)
Guido Werner (Wernigerode, Germany)
O0879 Impact of Professional Background on Performance
in ToREIMC: A Gamified Medical Knowledge
PlatformA. Blanco-Di Matteo* (Pamplona, Spain), M.
Morante Ruiz, M. Riesgo Magaña, M. Martín García O0858 Co-anchorage of antibiotic resistance genes and
O0880 Serious games and storytelling to enhance mobile genetic elements on bacterial plasmids
adolescents' capabilities for decision-making boosts horizontal gene transfer across sewage
regarding meningococcal vaccination: a monocenter interfacesM. Shafiq* (Shantou, China)
studyT. Morris* (Saint-Etienne, France), S. Essalim, K. O0859 The emergence of tet(X4) and mcr co-harbored on
Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho- the same plasmid and its clinical significanceN.
ESCMID Global 2025 - Programme
Rakhi* (Oxford, United Kingdom), A. Lankapalli, T. Using Differential AnalysisT. Vashist* (Chandigarh,
Lanyon-Hogg, P. Niumsup, K. Thomson, K. Sands, T. India), N. Rana, D. Nair, A. Angrup, V. Sharma, C.
Walsh Tandup, P. Ray, A. Arora
O0860 The plasmidome of a global collection of convergent O0871 Unveiling the hidden virulence of Acinetobacter
K. pneumoniae and its impact on virulenceF. baumannii: how the lipooligosaccharide core
Lebreton* (Silver Spring, United States), M. Martin, modulates immune responses and enhances
A.P. Sapre, T. Luo, U. Carolino-Macdonald, E. Mills, B. interferon-β productionY.T. Lee* (Taipei, Taiwan,
Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. China), Y.C. Wang
Russo, P. Mc Gann O0872 Platelets drive neutrophil-mediated
O0861 Factors that affect plasmid transfer in multispecies neuroinflammation in tuberculous meningitisK.
biofilmsH.Y. Liu* (Norwich, United Kingdom), M. Skolimowska* (London, United Kingdom), R.
Yasir, E. Trampari, G. Langridge, M. Webber Wilkinson, J.S. Friedland, D. Kirwan, T. Reid, D. De
O0862 Identification of the czc metal efflux operon on a new Swardt, D.L.W. Chong, J. Kutschenreuter, M. Saeed,
plasmid type in a Pseudomonas aeruginosa clinical A. Davis, S. Wasserman, R. Goliath, Q. Kakana, P.
isolate belonging to ST357 O11A. Valcek* (Brussels, Renner, M. Panchoo, C. Stek, R. Johnson, M.
Belgium), D.I. Costescu Strachinaru, P. Soentjens, A. Maxebengula
Stoefs, C. Van Der Henst
OS121
11:00 - 12:00 Hall 9
OS119
11:00 - 12:00 Hall 7
1-hour Oral Session
1-hour Case Session
Shaping the future of IPC - digitalisation of surveillance
Looking inside endovascular infections Chairs Diamantis Plachouras (Solna, Sweden)
Chairs Claus Moser (Copenhagen, Denmark) Maaike S.M. Van Mourik (Utrecht, Netherlands)
Matthaios Papadimitriou Olivgeris (Sion, Switzerland)

O0873 11:00 PRAISE hospital-onset bacteraemia and fungaemia

O0863 A Case of Persistent Legionella micdadei Aortitis with algorithm as novel automated surveillance indicator:
Endocarditis: Diagnostic and Therapeutic results from four European university hospitalsS. Van
ChallengesV. Zwart* (Breda, Netherlands), E. Der Werff* (Stockholm, Sweden), S.J.S. Aghdassi, M.
Kayabasi, H. De Groot, R. Bentvelsen Behnke, M.S.M. Van Mourik, G. Catho, M.
Brekelmans, L.A. Peña Diaz, N. Buetti, F.D. Rüther, D.
O0864 Management and Prognosis of Vascular Endograft Dinis Teixeira, D. Sjöholm, P. Nauclér
Infections: Case SeriesN. Scarpulla* (Napoli, Italy), F.
Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. O0874 11:12 Transforming hospital-onset bacteremia and
Gallo, E. Durante-Mangoni fungemia data to the OMOP common data modelH.
Düsseldorf* (Vienna, Austria), G. Duftschmid, E.
O0865 Fungal frenzy: handling an uncommon etiology in Presterl
prosthetic valve endocarditisI. Cafarella* (Naples,
Italy), R. Gallo, F. Patauner, F. Luciano, L. Bertolino, O0876 11:24 Dutch Electronic Health Records in primary care: the
A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante- Nivel general practisioners databaseF.F. Stelma*
Mangoni (Utrecht, Netherlands), J. Van Summeren, M.
Hooiveld, C. Baliatsas, V. Sankatsing, J. Schmitz, S.
O0866 Successful Use of Oritavancin as Consolidation Van Beusekom
Therapy for Infective Endocarditis Caused by
Enterococcus spp.: Experience from Seven Cases in a O0877 11:36 Local signs at catheter insertion sites: Insights from
Referral CenterF. Frondizi* (Rome, Italy), G.M. the multicenter DeepCath cohort study with 4,256
Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. picturesN. Buetti* (Geneva, Switzerland), S. Ruckly,
Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. A. Byczko, L. Gallay, A. Nguyen, H. Slimani, J.R. Zahar,
Taddei, G. Scoppettuolo, C. Torti J.F. Timsit
O0867 Clinical Features and Outcomes of Gram-Negative O0875 11:48 Prospective evaluation of a machine learning-based
Bacterial Endocarditis: A Case Series from a real-time multidrug-resistant organism prediction
University HospitalG. Oliva* (Rome, Italy), F. systemV. Vasikasin* (Bangkok, Thailand), W.
Giovannenze, G.M. Leanza, F. Frondizi, M. Nasomsong, A. Holmes, R.L. Peach, K. Bhangananda,
Chiuchiarelli, B. Liguoro, B. Andriolo, E. Taddei, G. A. Myall, C.H. Yoon, D. Changpradub, S. Mookerjee,
Scoppettuolo, C. Torti J. Price, B. Mauricio, T.M. Rawson

EF131
OS120
11:00 - 12:00 Hall 8 13:30 - 14:30 Arena 1

1-hour Oral Session ePoster Flash Session

Exploring Host-Pathogen Interactions and Immune Dynamics in Bacterial The current landscape of carbapenem resistance: from genotype to
Virulence phenotype and virulence determinants
Chairs Giovanni Delogu (Rome, Italy) Chair Amy Mathers (Charlottesville, United States)
Simon Foster (Sheffield, United Kingdom)

E0940 Molecular Insights into the Growing Threat

O0868 Bacteria and host responses in both mice and human Carbapenem-Resistant Hypervirulent Klebsiella
lung organoid model revealed the role of a novel pneumoniae and the Rising Challenge of Ceftazidime-
plasmid pvirhs1 in hypervirulent Carbapenem- Avibactam ResistanceC. Vatansever* (Istanbul,
resistant Klebsiella pneumoniaeY. Zhang* (Shanghai, Türkiye), A. Akpinar, J. Boral, S. Belge, N. Kardan, B.
China), W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang Tanyolaç, G. Shahrokhi, G. Ekinci, E. Ural, B. İşler, Ö.
Ergönül, F. Can
O0869 Presence and role of hypervirulence-associated
markers in Klebsiella pneumoniae groups based on E0941 Global large-scale genomic snapshot on the diversity
LD50 value in mouse septic modelA. Avdeeva* of carbapenem-resistant and hypervirulent Klebsiella
(Saint-Petersburg, Russian Federation), D. Kandina, pneumoniae strainsR. Elias* (Lisboa, Portugal), T.
E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Clark, I. Portugal, J. Perdigao
Sopova, V. Lomonosova, V. Galushka, A. E0942 Carbapenem-resistant Enterobacter cloacae
Afinogenova, V. Shapovalova, O. Sulian, I. Ageevets, complex: genetic determinants of resistance and
V. Ageevets, S. Sidorenko molecular epidemiologyD. Pinheiro De Sousa Santos*
O0870 Meta-transcriptomic Insights into Host-Pathogen (Lisbon, Portugal), D. Santos, A. Bruschy-Fonseca, E.
Interactions in Necrotizing Soft Tissue Infections Gonçalves, D. Ranhel, C. Conceição, A. Pedrosa, A.C.
ESCMID Global 2025 - Programme
Silva, A. Duarte, L. Méndez, C. Toscano, J. Melo- System infection in an Immunocompromised Patient
Cristino, C. Caneiras from MexicoE. Sienra Iracheta* (Tlalpan, Mexico), A.
E0943 Molecular epidemiology of carbapenemase- Magallanes Lopez, J.P. Venzor Castellanos, M.J.
producing Escherichia coli in HungaryA. Hanczvikkel* Corredor Nassar, A.P. Rodriguez Zulueta
(Budapest, Hungary), D. Göbhardter, E. Ungvári, N.
Derzsy, A. Darab, L. Jánvári, L. Buzgó, L. Holub, K.
EF133
Papp, K. Kristóf, L. Majoros, K. Kamotsay, M. Käfer, G. 13:30 - 14:30 Arena 3
Jakab, Á. Sonnevend, Á. Tóth
ePoster Flash Session
E0944 Genomic multicentre surveillance of VIM-producing
Enterobacterales shows spread driven by bacterial Viral infections in special populations
clones and plasmids in Germany from 2015 to 2021A.
Wendel* (Cologne, Germany), J. Sattler, B. Bader, J. Chair Federico Garcia (Granada, Spain)
Müller, A. Hamprecht, S. Peter
E0945 Three distinct routes of virulence-resistance
convergence in ST-395 K. pneumoniae from Eastern E0958 ORCHESTRA Delphi Consensus: Therapeutic and
Europe over the last decade.A. Sapre* (Silver Spring, Diagnostic Management of SARS-CoV-2 Infection in
United States), E. Nguyen, T. Luo, E. Mills, B. Corey, R. Rheumatological PatientsM.G. Caponcello* (Seville,
Maybank, A. Ong, V. Kondratiuk, V. Kovalchuk, M. Spain), P. Olivares Navarro, J. Rodríguez Baño, Z.R.
Metreveli, N. Trapaidze, Y. Kwak, T. Musich, J. Palacios Baena, C. Bonazzetti, C. Campoli, A.
Bennett, P. Mc Gann, M. Martin, F. Lebreton Savoldi, E. Gentilotti, G. Marchetti, S. Lo Caputo, L.
E0946 Carbapenemases in Germany in 2024: Report of the Otero-Varela, I. Castrejón, E. Tacconelli
German National Reference Centre for Multidrug- E0959 Immunogenicity, reactogenicity and safety of
resistant Gram-negative BacteriaN. Pfennigwerth* booster vaccinations with BNT162b2 or full-dose
(Bochum, Germany), S. Möller, J. Eisfeld, F. Pankok, mRNA-1273 in adults ≥75 years (EU-COVAT-1-
A. Anders, S. Gatermann AGED) – final reportJ. Stemler* (Cologne,
E0947 Unravelling divergent genomic modes of Germany), L. Yeghiazaryan, C. Stephan, R. Cox, K.
transmission of Carbapenemase-Producing Greve-Isdahl Mohn, A.J. Carcas-Sansuan, E.
Organisms in a single hospital in Singapore between Romero Rodriguez, J. Moltó, I. Vergara
2019 and 2022V. Koh* (Singapore, Singapore), Z.Q. Mitxeltorena, T. Welte, B. Zablockienė, M. Akova, U.
Lim, S.Q.D. Loy, N.M. Thevasagayam, S.R.S. Prakki, Bethe, S. Grimm, J. Salmanton-García, J. Jakobs, L.
P.Y. Hon, X. Huan, Z.L. Kyaw, A.Y. Lin, P. Rao, P.P. De, Tischmann, M. Zarrouk, A. Cüppers, L.M. Biehl, J.
S. Vasoo, K. Marimuthu, O.T. Ng Grothe, S.C. Mellinghoff, J.A. Nacov, J.M. Neuhann,
R. Sprute, J. Frías-Iniesta, R. Negi, C. Gaillard, G.
E0948 2011-2017 vs 2018-2024: comparison of carbapenem Saini, A. García León, P.W.G. Mallon, C. Lammens,
non-susceptibility trends among bloodstream A. Hotterbeekx, L. Katherine, S. Malhotra-Kumar, H.
Klebsiella pneumoniae, Acinetobacter baumannii and Goossens, S. Kumar-Singh, F. König, M. Posch, P.
Pseudomonas aeruginosa isolates from Greek Koehler, O.A. Cornely
hospitals: data from the Electronic System for the
AMR surveillance-WHONET-GreeceM. Polemis* E0960 Effectiveness of adjuvanted recombinant zoster
(Vari, Greece), A. Vatopoulos, K. Tryfinopoulou vaccine in adults aged ≥50 years in the United
StatesL. Qian* (Pasadena, United States), L.S. Sy,
B.K. Ackerson, E. Rayens, J. Wu, Y. Luo, Y. Cheng,
EF132 J.H. Ku, L.I. Vega Daily, H.S. Takhar, J. Song, R.A.
13:30 - 14:30 Arena 2
Cohen, H. Yun, D. Oraichi, H. Seifert, H.F. Tseng
ePoster Flash Session E0961 Differential SARS-CoV-2 RNAemia features and
humoral immune response analysis of acute COVID-
Difficult-to-treat cases in the immunocompromised 19 in solid organ transplant recipients and patients
Chair Nicolas Mueller (Zurich, Switzerland) with hematological malignancies.A. Ruiz-Molina*
(Seville, Spain), J. Martín-Escolano, C. Infante-
Domínguez, Z.R. Palacios-Baena, I. Tallón-Ruiz, F.
Martín-Dominguez, G. Bernal-Blanco, B. Villacorta-
E0949 A case of IRIS nocardiosisS.K. Dlamini* (Cape Town, Linaza, G. Suárez-Artacho, C. Cepeda-Franco, D.
South Africa), P. Namale, P. Arnab Rangel-Sousa, C. Rodríguez-Urbistondo, B.
E0951 Concurrent invasive disseminated Nocardia farcinica Gutiérrez-Gutiérrez, M. Carretero-Ledesma, N.
and Candida infections in a patient undergoing long- Maldonado, S. Salto-Alejandre, B. Gallego, L.
term glucocorticoid therapy for autoimmune Merino, J. Rodríguez-Baño, J.M. Cisneros, J.A.
thrombocytopenia: A case reportN. Zhang* (Bengbu, Pérez-Simón, E. Cordero, J. Pachón, M. Aguilar-
China) Guisado, R. Álvarez-Marín, J. Sánchez-Céspedes
E0952 Subcutaneous paeohyphomycosis due to Alternaria E0962 Prevalence of and risk factors for persisting COVID-
infectoria in an immunosuppressed renal transplant 19 in patients with B-cell malignanciesA. Toschi*
recipient: successful multidisciplinary (Bologna, Italy), Z. Pasquini, A. Amicucci, N.
managementM. Arias* (London, United Kingdom), E. Caroccia, M. Di Chiara, F. Simone, B. Casadei, C.
Vetsiou, E. Rudd, S. Rai, K. Ahmed, S. Rao- Pellegrini, A. D'abramo, P. De Marco, L. Bussini, M.
Merugumala, A. Wasif, C. Shaw, A. Abdolrasouli Ciccone, A. Visentin, G. Caponcello, M. Bartoletti, E.
Nicastri, M. Krampera, P.L. Zinzani, J. Rodriguez
E0953 Lung nodules in a patient with breast cancer history… Baño, E. Tacconelli, M. Giannella
Not everything is cancer.E. Muñoa Hernández*
(Tuxtla Gutierrez, Mexico), E. Muñoa E0963 Clinical characteristics and predictors of severe
outcome among older adults hospitalized with
E0954 Treatment of fulminant Clostridioides difficile respiratory syncytial virus (RSV) infection– a
infection using bacteria-free stool supernatant in retrospective study from IsraelM. Jurkowicz* (Tel
adult hematological patients during chemotherapy- Aviv, Israel), I. Margalit, I. Harris, D. Mazar, A. Teper,
induced aplasiaB.G. Szabo* (Budapest, Hungary), D. I. Royzman, S. Uppal, C. Liang, E. Begier, I. Ganiel,
Korozs, A. Hardi, K. Jeszenszky, P. Remenyi, J. Sinko M. Mandelboim, D. Yahav
E0955 Eradication of multidrug resistant Pseudomonas E0964 RSV and bronchiolitis associated primary care and
aeruginosa pneumonia in acute lymphoblastic emergency department visit rates in children under
leukemia patient with broad host-range phageP. 5 years: Estimates for Europe and other high-
Gadea* (Montevideo, Uruguay), J. Puig, M. Gómez, I. income countries.F.F. Stelma* (Utrecht,
Ferrés, A. Galiana, F. Grill, G. Iraola Netherlands), S. Heemskerk, L. Van Heuvel, P.
E0956 An Emerging fungal pathogen in Spreeuwenberg, L. Bont, J. Van Summeren
immunocompromised hosts: A rare case of E0965 Higher incidence of post-transplant EBV infection in
subcutaneous abscess caused by Chondrostereum pediatric liver transplant recipients compared to
purpureumP. Kitjacharoenchai* (Bangkok, Thailand), pediatric kidney transplants: a retrospective
A. Thammahong, J. Vanichanan analysis from a tertiary pediatric transplant centerS.
E0957 Unveiling a Rare Simultaneous Central Nervous Mercadante* (Rome, Italy), L. Romani, A.
ESCMID Global 2025 - Programme
Pietrobattista, I. Guzzo, R. Labbadia, A. Cappoli, A.
Mosca, L. Lancella, M. De Luca
E0966 Insights from a single center's experience in W0481 13:30 Artificial Intelligence to predict VAPMiia Jansson
hepatitis C treatment across four prisons in (Oulu, Finland)
SlovakiaI. Hockickova* (Košice, Slovakia), I. W0482 13:50 Metagenomic approach to VAP diagnosisJacques
Hockicková, J. Hockicko, M. Novotný, Z. Paraličová, Schrenzel (Geneva, Switzerland)
P. Kristian W0483 14:10 Viruses in VAP and HAP: should we worry about
them?Catia Cilloniz (Barcelona, Spain)
EF134 W0484 14:30 Optimising antibiotic therapy in VAPPinyo
13:30 - 14:30 Arena 4
Rattanaumpawan (Bangkok, Thailand)
ePoster Flash Session

SY170
Infection Controller's Daily 13:30 - 15:30 Hall 13
Chair Cansu Cimen (Oldenburg, Germany)
2-hour Symposium

Novel strategies for eliminating the ‘worst films ever’

E0967 Mortality and length of stay associated with Chairs Elisa Borghi (Milan, Italy)
antimicrobial-susceptible and resistant hospital- Markus Zeitlinger (Vienna, Austria)
onset bloodstream infections at a tertiary referral
hospital in Melbourne, AustraliaA. Stewardson*
(Melbourne, Victoria, Australia), S.J. Curtis, S.L.
Lee, B.S. Cooper, J.M. Bell, G.W. Coombs, D. Daley, S0465 13:30 What answers can biofilm PK/PD modelling
A.C. Cheng, D.W. Spelman, A.Y. Peleg provide?Coen Van Hasselt (Leiden, Netherlands)
E0968 MRSA on the rise in neonatal care departmentsE. S0466 14:00 subMIC antibiotic effects to improve biofilm PK/PD
Herkes* (Amsterdam, Netherlands), A. Schoffelen, parameters – still relevant?Francoise Van Bambeke
R. Zwittink, J. Kluytmans, D. Notermans (Brussels, Belgium)
E0969 Risk factors for OXA-carbapenemase-producing S0467 14:30 PK/PD-based optimisation of antibiotic treatments to
Enterobacteriaceae acquisition in Israel: a suppress resistance in dynamic biofilm modelsMaria
retrospective case control studyM. Amar* (Haifa, Dolores Macia Romero (Palma De Mallorca, Spain)
Israel), R. Najjar-Debbiny, G. Weber, R. Yasin, A. S0468 15:00 Giving antibiotics an upper hand in the treatment of
Arbel, S. Shehade, I. Greenfeld, O. Salah, P. Shaked- biofilm infections – antibiotic augmenting
Mishan, O. Barnett-Griness strategiesClaus Moser (Copenhagen, Denmark)
E0970 Experience providing a rapid, reactive nanopore Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID
isolate sequencing service for bacterial outbreak Scientific Affairs Subcommittee
investigation for hospitals in London, UKS.
Raharison* (Nice, France), A. Alcolea-Medina, L.B.
Snell, M. Tan, G. Humayun, R. Chang, D. Ward, V. SY171
Enne, V. Patel, C. Alder, L. Sowole, R. Batra, S. 13:30 - 15:30 Hall 14

Goldenberg, J. Edgeworth, J. Otter 2-hour Symposium

E0971 Duration of colonization and time to de-isolation in
patients with extended-spectrum beta-lactamase Enhancing efficiency and reducing cost in microbiological diagnostics using
producing non-Escherichia coli EnterobacteralesJ. pool testing
Männer* (St.Gallen, Switzerland), V. Steinacher, T. Chairs Mauricio Farfan (Santiago, Chile)
Dörr, M. Schlegel, P. Kohler Chiara Minotti (Basel, Switzerland)
E0972 A tale of three cities: The comparative longitudinal
epidemiology of vancomycin-resistant
Enterococcus faecium from bloodstream infections
at three tertiary care hospitals in Bavaria, S0469 13:30 Congenital cytomegalovirus detection by pool testing
GermanyA. Rath* (Regensburg, Germany), B. in salivaGiannina Izquierdo (Santiago, Chile)
Neumann, V. Rauschenberger, B. Kieninger, A. S0470 14:00 Detection of blood-corne pathogens in asymptomatic
Eichner, J. Steinmann, S. Kampmeier, W. Schneider- blood donors by pool testingPatricia Alvarez (Rio De
Brachert Janeiro, Brazil)
E0973 Molecular epidemiology and transmission S0471 14:30 Large-scale pooled testing to increase rapid
dynamics of vancomycin-resistant Enterococcus molecular diagnostic test coverage for
faecium in Belgian hospitals (2022-2023)S. De tuberculosisMelissa Sander (Bamenda, Cameroon)
Koster* (Edegem, Belgium), S. Van Kleef-Van S0472 15:00 Pool testing for screening of bacterial sexually
Koeveringe, H. Jansens, S. Vandamme, T. transmitted infectionsTba
Demuyser, M. Vanden Driessche, Y. Glupczynski, S.
Malhotra-Kumar, V. Matheeussen
E0974 Increasing Prevalence of Linezolid-resistant OS130
Enterococci: Outbreak or Overuse?R. Traynor*
13:30 - 14:30 Hall 16

(Cork, Ireland), G. Brennan, I. O Callaghan, E. Keily, 1-hour Oral Session

E. Skelton, E. Kennedy, B. O Connell, J. Walsh, A.
Doherty, C. Hickey Advances in fungal diagnostics
E0975 Continuous 2-year surveillance for airborne fungi at Chairs Sarah Delliere (Paris, France)
hospitals in the same city: Impact of season, Lisa Marie Kriegl (Graz, Austria)
construction, a construction accident and HEPA-
filtered/positive pressure roomsM.H. Nguyen*
(Pittsburgh, United States), C. Clancy, Z. Wilkins, Y.
Cho, B. Hao, E. Driscoll, S. Cheng, A. Sundermann, O0935 BAL galactomannan dynamics predict survival in
A. Ayres, S. Graham critically ill patients with virus-associated pulmonary
aspergillosisV. Delanote* (Leuven, Belgium), J.
Wauters, S. Feys, J. Heylen, H.M. Lauwers, C. Jacobs,
EW174 L. Maessen, Y. Debaveye, P. Frederiks, G. Hermans,
13:30 - 15:30 Hall 11
P. Meersseman, M. Peetermans, E. Van Wijngaerden,
Educational Session A. Wilmer, K. Lagrou
O0936 Retrospective Assessment of a New
Best practices and emerging strategies in the management of ventilator- and Chemiluminescence Immunoassay for Serum (1, 3)-
healthcare-associated pneumonia β-D-Glucan Levels in Patient with Invasive Fungal
Chairs Fusun Can (Istanbul, Türkiye) InfectionsZ. Zhou* (Tianjin, China), K. Yuan, L. Ye, S.
Jeroen Schouten (Nijmegen, Netherlands) Liu, A. Huang, Z. Chen, W. Yan, S. Niu, K. Hua, Q.
ESCMID Global 2025 - Programme
Wang, G. Zhang, H. Wang, Y. Zhao, G. Li EnterobacteralesSasheela Ponnampalavanar (Kuala
O0937 Evaluation of a multiplex PCR assay using barcoded Lumpur, Malaysia)
magnetic bead technology for detection of fungal S0462 14:00 Non-fermenters still important globally: a review of
pathogens in bronchoalveolar lavage fluid: a spread and resistanceAnupa Thampy (Vellore, India)
diagnostic aid for invasive fungal infectionsS. Zhang* S0463 14:30 Innovative rapid diagnostic methodologies for Gram-
(Baltimore, United States) negative pathogensLaurent Dortet (Le Kremlin-
O0938 Combined use of (1,3)-β-D-glucan and PCR in oral Bicêtre, France)
wash for Pneumocystis jirovecii pneumonia diagnosis S0464 15:00 Tailoring treatment to resistant Gram-negative
in non-HIV populationA. Falcó Roget* (Mataró, bacteria: newer therapeutic approachesJuan P.
Spain), A. Falcó-Roget, A. Albasanz-Puig, A.B. Pérez, Horcajada (Barcelona, Spain)
S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, O. Len,
I. Ruiz-Camps, M.T. Martín-Gómez Co-organised with: ESCMID Study Group for Antimicrobial Resistance
Surveillance (ESGARS)
O0939 Iron levels in bronchoalveolar lavage fluid of
hematological patients with suspected invasive
pulmonary aspergillosis and their association with 12-
EW173
week mortality: a retrospective cohort studyH. 13:30 - 15:30 Hall 5
Lamberink* (Amsterdam, Netherlands), J. Heijmans, Educational Session
A. Wagemakers, K. Van Dijk
Tropical dermatology: a case-based approach

SY168 Chairs Pedro Legua (Lima, Peru)

13:30 - 15:30 Hall 2
Bobbi Pritt (Rochester, United States)
2-hour Symposium

Staphylococcus aureus: its expansion dynamics and interactions with its pals
W0477 13:30 Parasitic diseases: dermatological manifestations in
Chair Barbara C. Kahl (Münster, Germany) the tropicsKirti Sabnis (India)
W0478 13:50 Madura foot and other implantation mycosesM
Ramam (New Delhi, India)
S0457 13:30 S. aureus and its special relationship to S. W0479 14:10 MycobacteriaFrancisco Bravo (Lima, Peru)
epidermidis Andreas Peschel (Tübingen, Germany) W0480 14:30 Approach to rash in the returning travellerFrank O. D.
S0458 14:00 Computational and in vitro evaluation of probiotic Pettersen (Oslo, Norway)
treatments for nasal S. aureus decolonizationSilvio
Daniel Brugger (Zurich, Switzerland)
OS127
S0459 14:30 Clonal population expansion of S. aureus occurs due 13:30 - 14:30 Hall 6
to escape from a finite number of intraphagocyte
nichesSimon Foster (Sheffield, United Kingdom) 1-hour Oral Session
S0460 15:00 How bacteriophages and pathogenicity islands drive The good, the bad and the itchy: update on STIs
the evolution of S. aureus John Chen (Singapore,
Singapore) Chair Tatum Mortimer (Athens, United States)
Co-organised with: ESCMID Study Group for Staphylococci and
Staphylococcal Diseases (ESGS)
O0920 High frequency of Nichols-like strains of Treponema
pallidum subsp. pallidum circulating in Barcelona,
EW172 SpainP. Nadal-Baron* (Barcelona, Spain), P. Nadal-
13:30 - 15:30 Hall 3
Barón, J. Trejo-Zahinos, M. Arando, A. Barberan-
Educational Session Masegosa, M. Bernat-Sole, A. Perez-Ugarte, M.
Valverde Espinal, A. Canals Quintana, J.J. González-
Beyond the gift of life: viral infection during pregnancy López, A. Antón, M. Alberny, O. Mitjà, N. Larrosa, Y.
Chairs Gülsen Özkaya Sahin (Lund, Sweden) Hoyos-Mallecot
Simona Ruta (Bucharest, Romania) O0921 Doxycycline post-exposure prophylaxis (doxy-PEP)
use and outcomes in metropolitan DetroitC. Arena*
(Detroit, United States), N. Everson, R. Kenney, I. Brar,
S. Gudipati, N. Yared, S. Davis, M. Veve
W0473 13:30 Hepatitis B during pregnancy: diagnosis,
management and outcomeTba O0922 The Gonococcus Bacterial Load Measured by the
Cycle Threshold (Ct) in Urinary Samples Correlates
W0474 13:50 RSV and Influenza during pregnancy: management with SymptomatologyG. Beraud* (Orleans, France),
and outcomeMonika Redlberger-Fritz (Vienna, T. Prazuck, L. Barhoum, H. Meyjonnade, J. Effa, L.
Austria) Hocqueloux, A. Seve, J. Guinard, K. Kochbati, E.
W0475 14:10 Prenatal screening and prevention of congenital Carbonelle, C. Guillaume
CMV: shifting concepts and consensus O0923 STI pathogen interactions and viability in men who
guidelineMarianne Leruez-Ville (Paris, France) have sex with men (MSM)E. Rayo* (Zurich,
W0476 14:30 Novel methods of vaccine administration to Switzerland), D. Onorini, C. Leonard, H. Marti, T.
newbornsTba Pesch, B. Hampel, N. Low, N. Borel
Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), O0924 Epidemiology of bacterial genitourinary infections
European Society for Infectious Diseases in Obstetrics and Gynaecology among women with recurrent vulvovaginal
(ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Candidiasis (RVVC) in Nigeria.S. Fayemiwo* (Ibadan,
Hepatology Association of SubSaharan Africa (GHASSA) Nigeria), L. Novak-Frazer, I. Adewole, R. Rautemaa-
Richardson

SY169
13:30 - 15:30 Hall 4
OS129
2-hour Symposium
13:30 - 14:30 Hall 7

1-hour Oral Session

Molecular epidemiology, resistance mechanisms and management of Gram-
negative bacteria Biofilm biology and control
Chairs Agnes Maria Sonnevend (Pécs, Hungary) Chairs Margherita Cacaci (Rome, Italy)
Kyriaki Xanthopoulou (Cologne, Germany) Laura Escolà-Vergé (Barcelona, Spain)

S0461 13:30 Globally emerging resistance patterns of O0930 Influence of non-coding small RNA00203 in biofilm
ESCMID Global 2025 - Programme
cells of Acinetobacter baumannii: Transcriptomic and Finland)
phenotypicD. Gebrelibanos* (Hong Kong, China), P. O0918 Building a screening protocol for the detection of
Leung, A.M. Shenkutie, F. Chow Orthobunyavirus oropoucheense infectionG.
O0931 Sub-MIC antibiotic effects on Pseudomonas Gagliardi* (Milan, Italy), D. Mileto, A. Mancon, L.
aeruginosa biofilm streamer formationA. Di Claudio* Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli,
(Pieve Emanuele, Italy), R. Rusconi, E. Secchi, G. A. Lombardi, A. Dolci
Savorana O0919 Substantial viral diversity in bats and rodents from
O0932 Regulation of Novel Genes and Their Downstream East Africa: insights into conservation,
Functions in the AI-2-Mediated Quorum Sensing recombination, and co-circulationD. Wang*
System of Klebsiella pneumoniaeX. Chu* (Beijing, (Shenzhen, China)
China), Q. Yang
O0933 Exploring structural differences in biofilms of smooth
OS128
and rough Mycobacterium abscessus clinical strains 13:30 - 14:30 Hall 9
through confocal laser scanning microscopyC.
Maria* (Madrid, Spain), M. Cano-Fernández, J. 1-hour Oral Session
Esteban, P. López-Roa, A. Ruedas-López, M.C.
Muñoz-Egea AI Aiding AMS
O0934 Antibacterial and biofilm eradication of mupirocin- Chairs Marlieke De Kraker (Geneva, Switzerland)
loaded nano-emulsionsZ. Najmi* (Novara, Italy), A.C. Bhanu Sinha (Groningen, Netherlands)
Scalia, A. Cochis, J. De Souza Nunes, J. Alkorta, L.
Rimondini, D. Dupin
O0925 Using natural language processing to understand
free-text antibiotic prescriptionsA. Martin*
OS126
13:30 - 15:30 Hall 8 (Middlesbrough, United Kingdom), L. Christopher
2-hour Oral Session O0926 Enhancing Antimicrobial Stewardship Through
Collaboration Between an Intelligent System and
Emerging viruses, diverse threats Infectious Disease ExpertsH.M. Wei* (Taichung,
Taiwan, China), Y.L. Hsu, Y.W. Chang, I.C. Chen, K.P.
Chairs Luisa Barzon (Padua, Italy) Hwang
Karin Stiasny (Vienna, Austria)
O0927 Augmented Intelligence in Infectious Diseases (AI2D)
as an antimicrobial stewardship tool for early
antibiotic discontinuation in suspected lower
O0910 Epidemiological and clinical features of mpox respiratory tract infectionsJ.L. Lim* (Singapore,
during the clade Ib outbreak in South-Kivu, Singapore), P.Z.B. Cherng, P.M. Chlebicki, L.S.C. Gan,
Democratic Republic of the Congo: a prospective S.Y. Thien, S.L.S. Tang, L.X.T. Lee, Y.C.D. Yii, P.Y.
cohort studyI. Brosius* (Antwerp, Belgium), E. Zhou, Y. Wang, S.J. Chung, L.H.A. Kwa
Hasivirwe Vakaniaki, S. Sabiti Nundu, L.
Liesenborghs, P. Mbala-Kingebeni, G. Mukari, P. O0928 Virtual antimicrobial stewardship ward rounds:
Munganga, J.C. Tshomba, E. De Vos, E. Bangwen, predicting antibiotic course stopping decisions in
Y. Mujula, A. Tsoumanis, C. Van Dijck, A. Alengo, L. hospitals using machine learningK. Yuan* (Oxford,
Mutimba-Mambo, F. Mweshi Kumbana, J. United Kingdom), J. Wei, C.H. Yoon, Q. Gu, W. Walker,
Babingwa Muunga, D. Mazambi Mambo, J. T. Zhu, D. Eyre
Wakilongo Zangilwa, S. Bilembo Kitwanda, S. O0929 Prospective evaluation of a machine learning-based
Houben, N. Hoff, J.C. Makangara-Cigolo, E. decision support system for intravenous-to-oral
Kinganda-Lusamaki, M. Peeters, A. Rimoin, J. antibiotic switching.W. Bolton* (London, United
Kindrachuck, N. Low, P. Katoto, E. Bwenge Kingdom), R. Wilson, P. Georgiou, A. Holmes, T.M.
Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Rawson, M. Gilchrist
Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka,
S. Ahuka-Mundeke, K. Vercauteren, T. Wawina-
Bokalanga, J.J. Muyembe-Tamfum
O0911 Tracing the origin, spread and molecular evolution
of Dengue type 1 cases occurred in Northern Italy in
2023G. Romano* (Pavia, Italy), G. Ferrari, A.M.G.
Pitrolo, F. Rovida, A. Piralla, F. Baldanti
O0912 Dengue Country Risk Estimation: Vector Suitability
and Imported Activity 2024.M. Torres Portillo*
(Toronto, Canada), K. Williams, R. Lababidi, A.
Thomas, K. Khan
O0913 Rat HEV in humans in Germany: presence but low
detection rate, a screening study 2022 - 2023L.
Mueller* (Berlin, Germany), M.L. Schmidt, T.
Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J.
Jansen, J. Melchert, T. Mauno, C. Drosten, R.
Johne, V.M. Corman
O0914 Emergence of new enterovirus D68 lineage in
Europe in 2023 associated with distinct amino acid
substitutions in VP1 proteinA. Hirvonen* (Vantaa,
Finland), C.K. Johannesen, P. Simmonds, T.K.
Fischer, H. Harvala, K.S.M. Benschop
O0915 Health-economic impacts of chikungunya
vaccination in 34 countriesJ. Zhou* (Oxford, United
Kingdom), N. Salant, D. Smith, D. Hollingsworth, K.
Pouwels, S. Radoykova, J. Lord, K. French
O0916 Clinical importance of a new tick-borne flaviviridae
virus, Alongshan Virus: retrospective serologic and
molecular study in SwitzerlandF. Tagini* (Lausanne,
Switzerland), O. Opota, A. Eggermann, A. Coste, G.
Greub
O0917 From Trade Routes to Transmission Routes: Risk
Assessment of Japanese Encephalitis Outbreak in
Pakistan under China-Pakistan Economic Corridor
Using One Health ApproachS. Ahmad* (Tampere,